Treatment of cancer
Transcription factors like MYT1L are used to suppress glioblastoma states and induce neuronal differentiation, addressing therapy resistance and improving survival by targeting non-genetic mechanisms in glioblastoma treatment.
Patent Information
- Application Number
- PCT/GB2026/050830
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-05-13
- Publication Date
- 2026-11-19
AI Technical Summary
Current treatments for glioblastoma, particularly those using temozolomide, often fail due to therapy resistance and limited understanding of non-genetic mechanisms like epigenetic plasticity, leading to poor clinical responses and high mortality.
Utilization of specific transcription factors, such as MYT1L, ST18, and others, to suppress alternate glioblastoma states and induce neuronal-like differentiation, reducing tumor cell plasticity and enhancing survival outcomes through nucleic acid constructs, vectors, and oncolytic viruses.
The identified transcription factors effectively reduce therapy resistance and enhance survival in glioblastoma by promoting neuronal-like differentiation and reducing cellular plasticity, even under therapeutic pressure.
Smart Images

Figure GB2026050830_19112026_PF_FP_ABST
Abstract
Description
[0001] TREATMENT OF CANCER
[0002] Field of the invention
[0003] The invention relates to the treatment of gliomas, in particular glioblastoma.
[0004] Introduction
[0005] The capacity of cancer cells to switch phenotypic states, also called cellular plasticity, is an emerging hallmark of cancer involved in tumor initiation and progression, including therapeutic resistance, tumor relapse, and metastasis1. Glioblastoma (GB), the most common and lethal primary brain tumor in adults, is characterized by profound cellular heterogeneity and dismal prognosis23. Although extensive sequencing efforts have catalogued its genomic landscape, actionable genetic drivers remain scarce, and clinical responses to targeted therapies have been minimal4-6. Longitudinal studies have underscored the limited contribution of therapy-induced genetic evolution in GB, revealing remarkable clonal stability despite treatment78. These findings suggest that non-genetic mechanisms, such as epigenetic plasticity and transcriptional reprogramming, may be central to the adaptive potential and treatment resistance in GB.
[0006] Temozolomide (TMZ), either used alone or in combination with radiotherapy, has become the standard-of-care chemotherapeutic drug for the treatment of glioblastomas on the basis of moderately prolonging survival. Unfortunately, most glioblastoma patients are, or become, resistant to TMZ.
[0007] There is an ongoing need for improved treatments of glioblastomas. The invention is aimed at addressing this need.
[0008] Summary of the Invention
[0009] The inventors have identified transcription factors that are capable of suppressing alternate GB states. In particular, the inventors have identified transcriptional repressors that are capable of regulating complex morphological and molecular features of GB cells towards Neuronal-like states away from hyperconnected states linked to therapy resistance. Further,the transcription factors (also termed transcriptional repressors herein) are capable of reducing tumor cell plasticity and improving survival outcomes in animal models.
[0010] In particular, these features mean that the transcription factors can be used in therapy, in particular for therapy of treatment of resistant GB and for administration together with another anti-cancer therapy, e.g. a chemotherapeutic agent. Further, the transcriptional repressors they can also be used to target different subtypes of GB and stages of GB.
[0011] Thus, the invention relates to an isolated nucleic acid construct comprising a nucleic acid encoding one or more human transcription factor (TF) polypeptide selected from MYT1L, ST18, NR3C2, POU2F2, PKNOX2, BACH2, S0X4, S0X11, TET1, EBF1, TFDP2, KLF12, NPAS2, LEF1 or BCL11B, a fragment or homolog of any of these TFs or a sequence having at least 90% sequence identity to any of these TFs as well as various methods and uses as further described herein.
[0012] In one aspect, the invention relates to an isolated nucleic acid construct comprising a nucleic acid encoding a polypeptide selected from MYT1L (SEQ ID NO. 1) or a fragment thereof or a sequence having at least 90% sequence identity thereto, ST18 (SEQ ID NO. 2) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NR3C2 (SEQ ID NO. 3) or a fragment thereof or a sequence having at least 90% sequence identity thereto, POLI2F2 (SEQ ID NO. 4) or a fragment thereof or a sequence having at least 90% sequence identity thereto, PKNOX2 (SEQ ID NO. 5) or a fragment thereof or a sequence having at least 90% sequence identity thereto, BACH2 (SEQ ID NO. 6) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX4 (SEQ ID NO. 7) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX11 (SEQ ID NO. 8) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TET 1 (SEQ ID NO. 9) or a fragment thereof or a sequence having at least 90% sequence identity thereto, EBF1 (SEQ ID NO. 10) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TFDP2 (SEQ ID NO. 11) or a fragment thereof or a sequence having at least 90% sequence identity thereto, KLF12 (SEQ ID NO. 12) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NPAS2 (SEQ ID NO. 13) or a fragment thereof or a sequence having at least 90% sequence identity thereto, LEF1 (SEQ ID NO. 14) or a fragment thereof or a sequence having at least 90% sequence identity thereto and / or BCL11B (SEQ ID NO. 15) or a fragment thereof or a sequence having at least 90% sequence identity thereto. Also covered is an isolated nucleic acid construct comprising a nucleic acid encoding a homolog polypeptide, e.g. MYT 1 (SEQ ID NO. 129) or a fragment thereof or a sequence having at least 90% sequence identity thereto.
[0013] In one embodiment, the nucleic acid encoding the polypeptide as defined in the aspects above comprises one or more of SEQ ID NO. 16-30 or SEQ ID NO. 130, a fragment thereof or a nucleic acid sequence having at least 90% sequence identity thereto.
[0014] In one embodiment, the nucleic acid construct further comprises a nucleic acid encoding a tumour specific enhancer, for example a tumour specific enhancer comprising a sequence as selected from Table 1.
[0015] The invention also relates to a vector or plasmid comprising a nucleic acid construct as above. In one embodiment, the vector is viral vector.
[0016] In one embodiment, the vector is a recombinant adeno-associated vector (rAAV) or lentiviral vector.
[0017] In one embodiment, the rAAV is an AAV2, AAV5, AAV8 or AAV9 serotype.
[0018] In one embodiment, the vector is a recombinant oncolytic virus.
[0019] In one embodiment, the oncolytic virus is a herpes simplex virus, a polio virus, a vaccinia virus, a measles virus, a vesicular stomatitis virus, an orthomyxovirus, a parvovirus, a maraba virus or a coxsackievirus.
[0020] The invention also relates to a rAAV comprising a nucleic acid construct as above.
[0021] The invention also relates to an oncolytic virus comprising a nucleic acid construct as above.
[0022] The invention also relates to a host cell comprising a vector, a rAAV or oncolytic virus as described above.
[0023] The invention also relates to a pharmaceutical composition comprising a nucleic acid construct, a vector or plasmid, a rAAV or an oncolytic virus as above and a pharmaceutically accepted carrier.
[0024] The invention also relates to a nucleic acid construct, a vector or plasmid, a rAAV, an oncolytic virus or a pharmaceutical composition as above for use in the treatment or prevention of glioma, in particular glioblastoma.
[0025] In one embodiment, the tumor is resistant to treatment with an anti-cancer therapy, e.g. a chemotherapy.
[0026] In one embodiment, a chemotherapy, radiation, and / or surgical resection is administered to the subject. Adminstraiton may be before, after or concurrent with administration of a nucleic acid construct, a vector or pharmaceutical composition of the invention.
[0027] In one embodiment, the chemotherapy comprises temozolomide, lomustine, etoposide, doxorubicin, cisplatin, paclitaxel, carmustine, ceramide or phosphorylcholine or a derivative or a pharmaceutically acceptable salt of any of the recited compounds or a combination thereof. In one embodiment, at least two nucleic acid constructs are administered, each nucleic acid construct comprising a different nucleic acid encoding a different protein, wherein the proteinis selected from MYT1L (SEQ ID NO. 1) or a fragment thereof or a sequence having at least 90% sequence identity thereto, ST18 (SEQ ID NO. 2) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NR3C2 (SEQ ID NO. 3) or a fragment thereof or a sequence having at least 90% sequence identity thereto, POLI2F2 (SEQ ID NO. 4) or a fragment thereof or a sequence having at least 90% sequence identity thereto, PKNOX2 (SEQ ID NO. 5) or a fragment thereof or a sequence having at least 90% sequence identity thereto, BACH2 (SEQ ID NO. 6) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX4 (SEQ ID NO. 7) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX11 (SEQ ID NO. 8) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TET 1 (SEQ ID NO. 9) or a fragment thereof or a sequence having at least 90% sequence identity thereto, EBF1 (SEQ ID NO. 10) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TFDP2 (SEQ ID NO. 11) or a fragment thereof or a sequence having at least 90% sequence identity thereto, KLF12 (SEQ ID NO. 12) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NPAS2 (SEQ ID NO. 13) or a fragment thereof or a sequence having at least 90% sequence identity thereto, LEF1 (SEQ ID NO. 14) or a fragment thereof or a sequence having at least 90% sequence identity thereto and / or BCL11B (SEQ ID NO. 15) or a fragment thereof or a sequence having at least 90% sequence identity thereto or and / or MYT 1 (SEQ ID NO. 129) or a fragment thereof or a sequence having at least 90% sequence identity thereto.
[0028] In one embodiment, the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition induces neuronal cell like differentiation of glioma cells.
[0029] In one embodiment, the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition reduces cell plasticity of glioma cells.
[0030] In one embodiment, the tumor is of the classical (CL) subtype, mesenchymal (MES) subtype, proneuronal (PN) subtype or neural (NL) subtype.
[0031] In one embodiment, the glioblastoma cell is a progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte- 1 ike (AC-like) and mesenchymal-like (MES-like) cell (also described as gliosis and hypoxic cells).
[0032] In one embodiment, the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition is administered by oral delivery, parenteral delivery, intracerebral or intrathecal delivery.
[0033] In one embodiment, parenteral delivery is via intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular delivery.
[0034] In one embodiment, intrathecal delivery is via lumbar injection, cisternal magna injection or intraparenchymal injection.
[0035] The invention also relates to a nucleic acid construct, a vector or plasmid, a rAAV, an oncolytic virus or a pharmaceutical composition as above for use in a method to reduce the resistance of glioma, in particular glioblastoma to treatment with a chemotherapy, induce neuronal cell like differentiation and / or reduce cell plasticity of glioma cells.
[0036] The invention also relates to a combination therapy comprising a nucleic acid construct, a vector or plasmid, a rAAV, an oncolytic virus or a pharmaceutical composition as above and another anti-cancer therapy, for example a chemotherapeutic agent.
[0037] In one embodiment, the chemotherapeutic agent is temozolomide, lomustine, etoposide, doxorubicin, cisplatin, paclitaxel, carmustine, ceramide or phosphorylcholine or a derivative or a pharmaceutically acceptable salt of any of the recited compounds or a combination thereof. The invention also relates to a method of treating or preventing glioma, in particular glioblastoma comprising administering a nucleic acid construct, a vector or plasmid, a rAAV, an oncolytic virus or a pharmaceutical composition as above to a patient in need thereof.
[0038] The invention also relates to a method of inducing neuronal cell like differentiation and / or reducing cell plasticity of glioma cells comprising administering a nucleic acid construct, a vector or plasmid, a rAAV, an oncolytic virus or a pharmaceutical composition as above to a patient in need thereof.
[0039] In one embodiment of the methods, the tumor is resistant to treatment with standard anticancer therapy, e.g. a chemotherapy, radiation, and / or surgical resection.
[0040] In one embodiment of the methods, the methods comprise administering a chemotherapy, radiation, and / or surgical resection to the subject.
[0041] In one embodiment of the methods, the chemotherapy comprises temozolomide, lomustine, etoposide, doxorubicin, cisplatin, paclitaxel, carmustine, ceramide or phosphorylcholine or a derivative or a pharmaceutically acceptable salt of any of the recited compounds or a combination thereof.
[0042] In one embodiment of the methods, the methods comprise administering at least two nucleic acid constructs each nucleic acid construct comprising a different nucleic acid encoding a different protein selected from MYT1L (SEQ ID NO. 1) or a fragment thereof or a sequence having at least 90% sequence identity thereto, ST18 (SEQ ID NO. 2) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NR3C2 (SEQ ID NO. 3) or a fragment thereof or a sequence having at least 90% sequence identity thereto, POLI2F2 (SEQ ID NO. 4) or a fragment thereof or a sequence having at least 90% sequence identity thereto, PKNOX2 (SEQ ID NO. 5) or a fragment thereof or a sequence having at least 90% sequence identity thereto, BACH2 (SEQ ID NO. 6) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX4 (SEQ ID NO. 7) or a fragment thereof or a sequencehaving at least 90% sequence identity thereto, S0X11 (SEQ ID NO. 8) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TET1 (SEQ ID NO. 9) or a fragment thereof or a sequence having at least 90% sequence identity thereto, EBF1 (SEQ ID NO. 10) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TFDP2 (SEQ ID NO. 11) or a fragment thereof or a sequence having at least 90% sequence identity thereto, KLF12 (SEQ ID NO. 12) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NPAS2 (SEQ ID NO. 13) or a fragment thereof or a sequence having at least 90% sequence identity thereto, LEF1 (SEQ ID NO. 14) or a fragment thereof or a sequence having at least 90% sequence identity thereto and / or BCL11B (SEQ ID NO. 15) or a fragment thereof or a sequence having at least 90% sequence identity thereto and / or MYT1 (SEQ ID NO. 129) or a fragment thereof or a sequence having at least 90% sequence identity thereto.
[0043] In one embodiment of the methods, the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition induces neuronal cell like differentiation of glioma cells.
[0044] In one embodiment of the methods, nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition reduces cell plasticity of glioma cells.
[0045] In one embodiment of the methods, the tumor is of the classical (CL) subtype, mesenchymal (MES) subtype or proneuronal (PN) subtype.
[0046] In one embodiment of the methods, the glioblastoma cell is a progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte- 1 ike (AC-like) and mesenchymal-like (MES-like) cell.
[0047] In one embodiment of the methods, the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition is administered by oral delivery, parenteral delivery, intracerebral or intrathecal delivery.
[0048] In one embodiment of the methods, parenteral delivery is via intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular delivery.
[0049] In one embodiment of the methods, intrathecal delivery is via lumbar injection, cisternal magna injection or intraparenchymal injection.
[0050] The invention also relates to a method of modulating the physiological response of a mammalian glioma cell to a chemotherapeutic agent comprising administering the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition as above to a patient in need thereof.
[0051] The invention also relates to a method of treating a resistant glioma, in particular glioblastoma, comprising administering the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition as above to a patient in need thereof.
[0052] The invention also relates to a kit comprising the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition as above and optionally instructions for use.
[0053] The invention also relates to a nucleic acid construct comprising a nucleic acid as defined in SEQ ID NO. 31 to 126. These sequences relate to tumour specific enhancers.
[0054] Figures
[0055] The invention is further described in the following non-limiting figures.
[0056] Figure 1. Heterogeneity of Epigenetic Plasticity in Glioblastoma Revealed by Multi-ome Analysis
[0057] (A) Left: Experimental setup. Right: LIMAP projection and annotation of the RNA component of 368,054 TME and 657,275 GB cells from 12 patients processed for snRNA-ATAC multi-ome analysis. Colors and labels denote states of indicated malignant GB and TME cells.
[0058] (B) Workflow schematic to assess epigenetic plasticity of cells. We compared the ability of a linear classifier to predict cell states based on gene expression and gene accessibility. Cells with uncertain or ambiguous predictions based on gene accessibility exhibited higher epigenetic plasticity.
[0059] (C) Epigenetic plasticity score determined as in B, reflecting uncertainty of cell state predictions based on gene accessibility, visualised for all cells on LIMAP in A.
[0060] (D) Confusion matrix showing percentage of cells from a given expression-defined state (columns) assigned to different cell states (rows) based on gene accessibility profiles. Off-diagonal values correspond to incorrect predictions. Malignant cell types (yellow box) exhibited lower prediction accuracy, indicating elevated epigenetic plasticity.
[0061] (E) Average epigenetic plasticity score for indicated cell states across patients. Malignant states exhibit varying degrees of epigenetic plasticity, with N PC-neuronal-like and OPC-neuronal-like cells displaying the lowest levels (p=6.7x10-6, two-sided t-test).
[0062] (F) Variance component analysis of epigenetic plasticity scores across cells, assessing the contribution of patient, cell type, and unmodelled residual factors.
[0063] Figure 2. Epigenetic and Transcriptional Gene Regulatory Programs of GB
[0064] (A) Outline of the scDORI model architecture. Top: scATAC-RNA multi-ome data is used as autoencoder input to infer continuous eGRNs referred to as Topics. scDORI computes Topics via mechanistically constrained decoding tasks, modelling individual cells as a linear combination of co-active Topics. Bottom: Mechanistic constraints in scDORI, implemented as auxiliary decoding tasks incorporating information on co-accessible peak, TF binding, CRE-gene linkages, and TF-gene expression correlations.
[0065] (B) Activity of selected Topics in malignant cells visualised on the LIMAP representation of Fig.
[0066] 1A.
[0067] (C) Activation patterns of selected Topics across GB states, showing that GB cell states are associated with multiple Topics. Top: Hierarchical clustering of GB states based on Topic activation patterns, revealing five distinct regulatory states. Color denotes average Topic activation scaled across states.
[0068] (D) Accessibility of Topic-associated ATAC peaks (blue) and expression of predicted c / s-linked genes (orange) across cell states. Individual rows correspond to peaks (left) and c / s-linked genes (right), grouped by the Topic with the highest association score for each peak.
[0069] (E) Enriched pathways in scDORI Topics, based on gene set enrichment analysis (GSEA) of Topic genes ranked by Topic-association score. Shown are the normalized enrichment scores (NES) of two representative pathways significantly enriched in each Topic (p-adj<0.05).
[0070] Figure 3. Cell-state Specific eGRNs Inform Transition Potentials of GB cell states
[0071] (A) Topic regulators (TRs) across GB cells, defined as the TFs with the highest cumulative activation of genes in each Topic-specific GRN. Shown are cumulative activation scores for selected TRs and Topics. The bar on the left indicates TFs previously reported as GB cell state markers or as highly expressed in developmental cell types (Neuroblasts, NSC / NPCs, OPCs, astrocytes).
[0072] (B) Mean chromatin accessibility (color intensity) and mean expression (dot size) of TRs from (A) across selected Topics. The bar on the right highlights highly accessible TRs (>0.75 scaled accessibility) in Topics of an alternate state, suggesting potential priming fortransition.
[0073] (C) The Topic Activation Potential (TAP) from source Topic A to target Topic B (TAPa,p) integrates: (i) predicted activation links from TFs in Topic A towards TRs of Topic B, (ii) epigenetic priming of Topic B TRs in Topic A cells, and (iii) the downstream activity scores of these TRs in Topic B.
[0074] (D) TAP links between selected malignant Topics determined using the approach in C, visualised on LIMAP representation of malignant cells in Fig. 1A. Nodes correspond to Topics; edge color indicates source Topic, and edge width TAP values.
[0075] (E) Number of TAP links from selected source Topics towards Topics active in the same state (yellow) or alternate states (orange). Neuronal-like Topics display limited potential to activate alternate-state Topics, contrasting with OPC-N PC-like and AC-like Topics.
[0076] Figure 4. Activation and Repression Dictate Hierarchical State Transitions That Follow GB Spatio-temporal Logic
[0077] (A) The Topic repression score (TRS) from source Topic A to target Topic B integrates: (i) predicted repression links from TFs in Topic A towards TRs of Topic B, (ii) epigenetic barriersof Topic B TRs in Topic A cells, and (iii) the downstream activity scores of these TRs in Topic B.
[0078] (B) TRS values between indicated pairs of Topics highlight that Neuronal-like Topics exert the highest repressive effects towards alternate state Topics. Asterisks label significant TRS links. The bar on the right shows the aggregated repression of each Topic towards alternate Topics, which inversely correlates with the epigenetic plasticity of the same Topic (derived as in Fig.
[0079] 1C).
[0080] (C) Activating (TAP) and repressive (TRS) interactions from selected state-specific Topics towards indicated target Topics. Neuronal-like Topic 24 showed the highest degree of repression, while Topics 9, 34, and 19 mainly displayed activation and little repression towards other Topics.
[0081] (D) State transition potential calculation, which considers the net effect of activating (TAP) and repressive (TRS) interactions between Topics active in the source state towards those in the target state, a and p denote the proportional activation of Topics in source and target states, respectively.
[0082] (E) GB state transition networks derived as described in (C), visualised over LIMAP of malignant cells from Fig. 1A. Unlike other states, Neuronal-like cells exhibited dominant repressive interactions against alternate states, considerably limiting state transitions.
[0083] (F) Topic-driven plasticity, defined as the cumulative effect of activating (TAP) and repressive (TRS) interactions towards all Topics active in an alternate state. Topic plasticity patterns positively correlated with the global epigenetic plasticity score of associated cell populations, derived as in Fig. 1C.
[0084] (G) Schematic of spatial analysis to estimate transition probabilities based on Topic spatial organization on matching tumor sections using Visium spatial transcriptomics.
[0085] (H) Representative Visium sections of GB tumors depicting the spatial distribution of dominant Topics from each GB state.
[0086] (I) Average spatial distances between cell populations with different Topic activations in GB sections (N=97). OPC-NPC-like and AC-like Topics are spatially closer on average compared to Neuronal-like Topics. The bar on the right shows the correlation between the spatial distances and the net regulatory interactions (TAP-TRS) between Topics, indicating that Topic pairs with high net activation potential tend to be spatially proximal.
[0087] (J) Average spatial distance between GB state-associated Topics across all sections (N=97), computed by aggregating the distance between state-specific Topics in (H), weighted by the proportional activity of each Topic within a respective state. Neuronal-like cells are the most spatially segregated in GB tumors.
[0088] (K) GB states temporally preceded by Neuronal-like cells within pseudotime-aligned clonal cell populations (N=60). Values reflect temporal co-occurrence between the Topics of each state.
[0089] (L) Pseudotemporal ordering of a clonal cell population transitioning from Neuronal-like towards AC-like / Gliosis-Hypoxia states via Proliferative state. Sequential Topic activation patterns define distinct transition stages 1-4. Matched chromatin accessibility and expression of trajectory-relevant TFs are shown across pseudotime. Transitions out of Neuronal-like state are accompanied by marked chromatin accessibility rearrangements.
[0090] (M) Predicted gene regulatory interactions of transcription activators and repressors along the trajectory in (L), inferred based on active Topics at each stage. Links going opposite to the current trajectory are shaded for clarity. Stage 1 shows dominant repressive links targeting TFs of alternate states, followed by their shutdown through active repression as the trajectory progresses.
[0091] (N) Expression of top repressor TFs in Neuronal-like state in TME neurons (left) or GB states (right) from Fig. 1A. Colors indicate average expression, and dot sizes show the percentage of cells with expression per state. MYT1L is exclusively expressed in Neuronal-like GB cells and at comparable levels to TME neurons.
[0092] (O) Repression of alternate state genes by top repressor TFs in Neuronal-like cells. Color denotes repression of state marker genes and dot size denotes repression of expressed TFs in alternate states. The bar on the left labels expression in healthy neurons and neuroblasts (CellxGene Portal). MYT1L shows the broadest and strongest repression of alternate state genes.
[0093] Figure 5. MYT1L Promotes Neuronal-like GB Identity by Repressing Alternate States
[0094] (A) Schematic depiction of repressor-mediated decreased plasticity regulation in Neuronal-like GB states and experimental hypothesis that targeted manipulation of Neuronal-like statespecific repressors enables reprogramming of GB cell plasticity and identity.
[0095] (B) MYT 1 L expression and repression patterns, (top) Repression of alternate state genes by MYT 1 L. Color denotes repression of state marker genes and dot size denotes repression of expressed TFs in alternate states. (Bottom) MYT1L expression in TME neurons or GB states from Fig. 1A. Colors indicate average expression, and dot sizes show the percentage of cells with expression per state. MYT1L is exclusively expressed in Neuronal-like GB cells at comparable levels to TME neurons and exhibits strong repression towards all alternate states.
[0096] (C) Differential chromatin accessibility determined by ATAC-seq following 3 days of MYT1L overexpression (OE) or knockout (KO) in S24 or BG5 patient-derived GB cells (PDGCs) compared to controls, respectively (N=3 per condition, FDR<0.05). The total number of differentially closed or opened peaks and their overlap with top-scoring peaks per Topic (>0.95Topic-association score) are shown. Chromatin is predominantly closed in the presence of MYT1L, and opened upon MYT1L deletion. MYT1 L closed peaks associated with Topics from all other GB states.
[0097] (D) Selected TRs bound by MYT1L as determined by CUT& RUN sequencing (day 8 posttransduction, N=3 per condition) whose chromatin is differentially opened (red) or closed (blue) upon MYT1L OE in S24 PDGCs. Dot colors denote Topics of activity, and TRs whose regulation was predicted by scDORI are circled in yellow. MYT1L repressed TRs from all alternate GB states.
[0098] (E) Normalised enrichment score (NES) of indicated state and Topic signatures in bulk RNA sequencing data 3 weeks following MYT 1 L OE (S24, p3xx) or MYT 1 L KO (BG5) compared to controls (N=3 per condition). The epigenetic plasticity of each state and Topic is displayed as determined in Fig. 1C. Neuronal-like identity at the level of state markers and Topic-defining genes is enriched upon MYT1L OE and depleted upon MYT1L KO, respectively.
[0099] (F) Quantification of tumour microtube (TM) interconnectivity within 2D monocultures of S24 PDGCs with or without MYT1L OE (n = 48 ROIs (Ctrl) and 37 ROIs (MYT1L OE) of 3 independent experiments). The average length of TMs is significantly reduced upon MYT1L OE, leading to significantly less connected morphologies. (Right) total number of cells per region of interest (ROI) with comparable numbers of cells in all areas. P values of two-sided t-test are shown. Scale bar = 200 pm.
[0100] (G) Average number of primary branches (left) and total neurite-like projections (right) in S24 PDGCs with and without MYT 1 L OE upon co-culture with primary mouse hippocampal neurons for 7 days (14 days post-transduction, N=3 per condition). The presence of MYT 1 L significantly increased the number and complexity of neurite-like projections. P values of two-sided t-test are displayed. Scale bar = 100 pm.
[0101] (H) Proliferation time-course quantification of S24 PDGCs with or without MYT1L OE determined by Alamar blue assay normalized to day 0. N=50 per condition (10 technical replicates x 5 independent experiments). MYT1L OE significantly reduced cell proliferation, p values denote two-way ANOVA Tukey test.
[0102] (I) Spheroid growth of S24 PDGCs upon doxycycline-induced OE of indicated MYT1L constructs for 7 days, normalized to uninduced controls. OE of full-length MYT1L (N>27) and MYT1L DNA-binding domain (DBD) fused to a repressor (EnR; N>21) reduced spheroid growth, while an MYT1L DBD activator (VP64; N>13) fusion enhanced growth. Data from 3-4 independent experiments, p values of two-sided t-test are reported.
[0103] (J) Representative micrographs of mouse cortices 3 weeks after injection with S24 PDGCs with or without MYT1L OE captured with 2-photon live imaging. PDGCs are labelled with
[0104] tdTomato (red) and blood vessels with intravenously injected dextran-FITC (green). Tile scanned region (5000x5000 m2) around injection site (white arrow) and zoomed-in image shows decreased migration and increased complexity upon MYT 1 L OE. Scale bars = 500 pm (left), 50 pm (right).
[0105] (K) Quantification of the total number of S24 PDGCs with or without MYT 1 L OE from (J). The cell count comprises two tile-scanned regions (5000x5000 pm2), including the injection site at different depths (200 and 300 pm), per mouse. Mice injected with MYT1L OE PDGCs exhibit significantly less tumor cells (two-sided t-test). N =3 (MYT1L OE) vs 2 (control).
[0106] (L) Kaplan-Meier survival curve of mice injected as in (J) with S24 PDGCs with or without MYT1L OE (N=7 vs 6), showing a significant survival advantage in the presence of MYT1L (log-rank test, p=0.015).
[0107] Figure 6. Proof-of-concept validation of cell-state-specific GBM enhancers in patient-derived glioblastoma cells.
[0108] (A) Chromatin accessibility heatmap of 96 cell-state-specific candidate enhancers identified by scDORI from our single-cell multiomic GBM dataset (~1M cells). Columns: enhancers; rows: GBM cell states and TME cell types. Accessibility is higher in GBM than in TME, consistent with GBM-specific activity. Highlighted: SEQ ID 97 and SEQ ID 102 (AC-like-specific, validated in E-l); SEQ ID 89 and SEQ ID 79 (O PC- N PC- 1 ike), which become accessible upon MYT1L overexpression (panel C).
[0109] (B) Cell-state composition of three patient-derived GBM cell lines (PDGCs: BG5, S24, P3), shown as the fraction of cells per state (0-1). S24 has the highest AC-like fraction.
[0110] (C) Bulk ATAC-seq accessibility of the same 96 enhancers in S24 cells, 72 h after control or MYT1L overexpression (n = 3 biological replicates). SEQ ID ID 89 and 79 (OPC-NPC-like) show marked increases in accessibility upon MYT1L overexpression.
[0111] (D) Schematic of the enhancer reporter constructs: candidate GBM enhancer (500 bp) upstream of a minimal CMV promoter driving GFP, in an AAV-compatible backbone. E_Shf (shuffled) and E_SV40 serve as negative and positive controls.
[0112] (E) Representative immunofluorescence of S24 cells 72 h after electroporation with E_Shf, E_SV40, SEQ ID 97 or SEQ ID 102. Top: GFP; bottom: DAPI. Scale bar, 30 pm.
[0113] (F) Percentage of GFP-positive S24 cells across enhancer conditions, quantified by fluorescence microscopy. Bars: mean of two biological replicates; error bars: SD; points: perreplicate values.
[0114] (G) Mean GFP intensity from (E), as fold change vs. E_Shf. Pooled from two biological replicates (E_Shf, n = 574; E_SV40, n = 85,095; SEQ ID 97, n = 21,178; SEQ ID 102, n = 1,370). Box plots: median, IQR; whiskers: 1.5 x |QR (Tukey); outliers shown individually.
[0115] (H) Percentage of GFP-positive HEK293T cells 48 h after transfection with the same constructs. E_SV40 reaches -70%, confirming transfection efficiency; SEQ ID 97 and 102 are comparable to E_Shf. Bars: mean of two biological replicates; error bars: SD.
[0116] (I) Mean GFP intensity in HEK293T from (H), as fold change vs. E_Shf. Pooled from two biological replicates, seq ID 97 and 102 are comparable to E_Shf, supporting GBM-specific activity. Combined with (F), this indicates SEQ ID 97 and 102 are inactive in HEK293T and selectively active in GBM cells.
[0117] Figure 7. Experimental validation of transcriptional repressors that drive Neuronal-like state in patient-derived glioblastoma cells.
[0118] (A) Differentially accessible and expressed genes after 3-day overexpression (OE) of 8 Neuronal-like regulator TFs in monocultured S24 PDGCs, by ATAC- and RNA-seq (n = 3 per condition, p-adj < 0.05). All TFs induce broad transcriptional changes; chromatin remodeling, predominantly closure, is driven mainly by alternate-state repressors.
[0119] (B) Percentage of Topic-associated peaks closed upon OE of Neuronal-like TFs in (A). Significance: hypergeometric test, FDR < 0.05. Predicted repressors show widespread closure of non-neuronal Topics.
[0120] (C) Enrichment of Topic signatures in genes differentially expressed upon OE of Neuronal-like TFs in (A), by GSEA. Dot color: normalized enrichment score; dot size: significance. Predicted repressors show predominant negative enrichment of non-neuronal Topics (gene silencing); predicted activators selectively enrich Neuronal-like programs (gene induction).
[0121] Figure 8. Ability of predicted transcriptional repressors to reprogram patient-derived glioblastoma cells when co-cultured with primary neural cells.
[0122] (A) Schematic of a pooled TF overexpression screen. PDGCs were infected with a lentiviral pool of barcoded Tet-ON OE vectors, co-seeded with primary neural cells, and induced with doxycycline. After 5 days, PDGCs were isolated and sequenced to map the TF-induced cell identity.
[0123] (B) Effects of scDORI-predicted TFs on GB cell-state identity upon OE. For each TF: Iog2 fold change, number of OE cells, and state-identity changes. Significance of changes in state probability (A state score, OE vs. control) across four coarse GB states assessed by Cohen's d with permutation testing and Benjamini-Hochberg FDR correction. Filled circles: significance in pooled analysis across all cell lines; asterisks: number of individual lines with an independently significant effect (* 1, ** 2, *** 3; n = 3; FDR < 0.05). Black boxes: odds ratio > 1.5. Rightmost columns: consistency with scDORI prediction. Four TFs (MYT1L, SOX4, SOX11, ST18) significantly induce Neuronal-like identity.
[0124] Figure 9. MYT1L plasticity suppression activity is retained under chemotherapy and radiation.
[0125] (A) Differentially closed and opened genes linked to the indicated GBM states in PDGCs upon the indicated treatment vs. unmanipulated controls, by ATAC-seq (n = 2-3 per condition, FDR < 0.05). Cells were untreated or pre-exposed to ionizing radiation or temozolomide, ± MYT1L overexpression (OE), 6 days after co-culture with primary neural cells. MYT 1 L gain-of-function predominantly closes non-Neuronal-like and opens Neuronal-like genes under all conditions, indicating that MYT 1 L can suppress plasticity even under therapeutic pressure.
[0126] (B) Overlap of differentially accessible genes (DAGs) from (A): MYT 1 L OE alone (green), pretreatment alone (red), or both (orange). Over 50% of MYT1L-only DAGs overlap with therapy DAGs, supporting preserved MYT1L function under therapeutic pressure.
[0127] Detailed description
[0128] The present invention will now be further described. In the following passages, different aspects of the invention are defined in more detail. Each aspect so defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.
[0129] Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, pathology, oncology, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art. The methods and techniques of the present disclosure are generally performed according to conventional methods well-known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. (2013)). Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, immunology, molecular biology, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.
[0130] Nucleic acid constructs
[0131] In one aspect, the invention relates to a nucleic acid construct comprising a nucleic acid encoding one or more polypeptide selected from MYT1L (SEQ ID NO. 1) or a fragment thereof or a sequence having at least 90% sequence identity thereto, ST18 (SEQ ID NO. 2) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NR3C2 (SEQ ID NO. 3) or a fragment thereof or a sequence having at least 90% sequence identity thereto, POLI2F2 (SEQ ID NO. 4) or a fragment thereof or a sequence having at least 90% sequence identity thereto, PKNOX2 (SEQ ID NO. 5) or a fragment thereof or a sequence having at least 90% sequence identity thereto, BACH2 (SEQ ID NO. 6) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX4 (SEQ ID NO. 7) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX11 (SEQ ID NO. 8) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TET 1 (SEQ ID NO. 9) or a fragment thereof or a sequence having at least 90% sequence identity thereto, EBF1 (SEQ ID NO. 10) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TFDP2 (SEQ ID NO. 11) or a fragment thereof or a sequence having at least 90% sequence identity thereto, KLF12 (SEQ ID NO. 12) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NPAS2 (SEQ ID NO. 13) or a fragment thereof or a sequence having at least 90% sequence identity thereto, LEF1 (SEQ ID NO. 14) or a fragment thereof or a sequence having at least 90% sequence identity thereto and / or BCL11 B (SEQ ID NO. 15) or a fragment thereof or a sequence having at least 90% sequence identity thereto.
[0132] A nucleic acid as used herein may comprise DNA or an RNA and may be wholly or partially synthetic or recombinantly produced. Reference to a nucleotide sequence as set out herein encompasses a DNA molecule with the specified sequence, and encompasses an RNA molecule with the specified sequence in which II is substituted for T, unless context requires otherwise. A nucleic acid sequence or construct may be isolated, that is isolated from its natural environment.
[0133] Within the scope of the invention are also sequences that have at least 90% sequence identity to a full length sequence selected from SEQ ID Nos. 1-15 for amino acid sequences and SEQ ID Nos. 16-30 for nucleotide sequences. In one embodiment, sequence identity to the reference sequence (reference sequences are SEQ ID Nos. 1-15 and 129 for amino acid sequences and 16-30 and 130 for nucleotide sequences) is at least 90%, 91%, 92%, 93%,
[0134] 94%, 95%, 96%, 97%, 98% or 99%. Thus, the polypeptide or nucleic acid may be a functional variant of the reference sequence which retains the biological functions as referred to herein.
[0135] As used herein, the term “sequence identity” generally refers to the percentage of amino acid residues or nucleic acid residues in a sequence that are identical with the residues of the reference polypeptide with which it is compared, after aligning the sequences and in some embodiments after introducing gaps, if necessary, to achieve the maximum percentage homology, and not considering any conservative substitutions as part of the sequence identity. Thus, the percentage homology between two amino acid sequences is equivalent to the percentage identity between the two sequences. Neither N- or C-terminal extensions, tags or insertions shall be construed as reducing identity or homology. Methods and computer programs for the alignment are well known. The percentage identity between two amino acid sequences can be determined using well known mathematical algorithms.
[0136] Also within the scope of the invention are fragments of any one of SEQ ID NOs 1-15 and SEQ ID NOs16-30. The term fragment as used herein refers to a functional fragment, for example encoding a DNA binding domain. In one embodiment, the fragment of MYT1L is the DNA binding domain as shown in SEQ ID NOs. 127 and 128 below or a sequence having at least 90% sequence identify thereto.
[0137] Also within the scope of the invention are chimeric proteins comprising SEQ ID Nos. 1-15 or fragments thereof or a sequence having at least 90% sequence identify thereto.
[0138] In one embodiment, the nucleic acid construct comprises or consists of a nucleic acid encoding a polypeptide selected from MYT1L (SEQ ID NO. 1) or a fragment thereof or a sequence having at least 90% sequence identity thereto, ST18 (SEQ ID NO. 2) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NR3C2 (SEQ ID NO. 3) or a fragment thereof or a sequence having at least 90% sequence identity thereto, POLI2F2 (SEQ ID NO. 4) or a fragment thereof or a sequence having at least 90% sequence identity thereto, PKNOX2 (SEQ ID NO. 5) or a fragment thereof or a sequence having at least 90% sequence identity thereto, BACH2 (SEQ ID NO. 6) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX4 (SEQ ID NO. 7) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX11 (SEQ ID NO. 8) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TET1 (SEQ ID NO. 9) or a fragment thereof or a sequence having at least 90% sequence identity thereto, EBF1 (SEQ IDNO. 10) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TFDP2 (SEQ ID NO. 11) or a fragment thereof or a sequence having at least 90% sequence identity thereto, KLF12 (SEQ ID NO. 12) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NPAS2 (SEQ ID NO. 13) or a fragment thereof or a sequence having at least 90% sequence identity thereto, LEF1 (SEQ ID NO. 14) or a fragment thereof or a sequence having at least 90% sequence identity thereto and / or BCL11B (SEQ ID NO. 15) or a fragment thereof or a sequence having at least 90% sequence identity thereto.
[0139] Thus, the nucleic acid construct can comprise one or more nucleic acids, e.g. selected from the nucleic acids above.
[0140] In one embodiment, combinations of the nucleic acids encoding the polypeptides recited above are included in the construct, for example 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14 or 15 nucleic acids.
[0141] Thus, in one embodiment, the nucleic acid construct comprises or consists of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14 or 15 nucleic acids encoding a polypeptide selected from M YT 1 L (SEQ I D NO. 1) or a fragment thereof or a sequence having at least 90% sequence identity thereto, ST18 (SEQ ID NO. 2) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NR3C2 (SEQ ID NO. 3) or a fragment thereof or a sequence having at least 90% sequence identity thereto, POLI2F2 (SEQ ID NO. 4) or a fragment thereof or a sequence having at least 90% sequence identity thereto, PKNOX2 (SEQ ID NO. 5) or a fragment thereof or a sequence having at least 90% sequence identity thereto, BACH2 (SEQ ID NO. 6) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX4 (SEQ ID NO. 7) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX11 (SEQ ID NO. 8) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TET 1 (SEQ I D NO. 9) or a fragment thereof or a sequence having at least 90% sequence identity thereto, EBF1 (SEQ ID NO. 10) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TFDP2 (SEQ ID NO. 11) or a fragment thereof or a sequence having at least 90% sequence identity thereto, KLF12 (SEQ ID NO. 12) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NPAS2 (SEQ ID NO. 13) or a fragment thereof or a sequence having at least 90% sequence identity thereto, LEF1 (SEQ ID NO. 14) or a fragment thereof or a sequence having at least 90% sequence identity thereto and / or BCL11B (SEQ ID NO. 15) or a fragment thereof or a sequence havingat least 90% sequence identity thereto. A skilled person would appreciate that any combinations are covered.
[0142] In one embodiment, the construct comprises a nucleic acid encoding a MYT1L polypeptide (SEQ ID NO. 1) or a fragment thereof or a sequence having at least 90% sequence identity thereto) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13 or 14 nucleic acids selected from a nucleic acid encoding a polypeptide selected from ST18 (SEQ ID NO. 2) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NR3C2 (SEQ ID NO. 3) or a fragment thereof or a sequence having at least 90% sequence identity thereto, POLI2F2 (SEQ ID NO.
[0143] 4) or a fragment thereof or a sequence having at least 90% sequence identity thereto, PKNOX2 (SEQ ID NO. 5) or a fragment thereof or a sequence having at least 90% sequence identity thereto, BACH2 (SEQ ID NO. 6) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX4 (SEQ ID NO. 7) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX11 (SEQ ID NO. 8) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TET1 (SEQ ID NO. 9) or a fragment thereof or a sequence having at least 90% sequence identity thereto, EBF1 (SEQ ID NO. 10) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TFDP2 (SEQ ID NO. 11) or a fragment thereof or a sequence having at least 90% sequence identity thereto, KLF12 (SEQ ID NO. 12) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NPAS2 (SEQ ID NO. 13) orafragmentthereof ora sequence having at least 90% sequence identity thereto, LEF1 (SEQ ID NO. 14) or a fragment thereof or a sequence having at least 90% sequence identity thereto and / or BCL11B (SEQ ID NO. 15) or a fragment thereof or a sequence having at least 90% sequence identity thereto.
[0144] Also covered a is a combination of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14 or 15 nucleic constructs, each construct comprising a nucleic acid encoding a polypeptide selected MYT1L (SEQ ID NO. 1) or a fragment thereof or a sequence having at least 90% sequence identity thereto, ST18 (SEQ ID NO. 2) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NR3C2 (SEQ ID NO. 3) or a fragment thereof or a sequence having at least 90% sequence identity thereto, POLI2F2 (SEQ ID NO. 4) or a fragment thereof or a sequence having at least 90% sequence identity thereto, PKNOX2 (SEQ ID NO. 5) or a fragment thereof or a sequence having at least 90% sequence identity thereto, BACH2 (SEQ ID NO. 6) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX4 (SEQ ID NO. 7) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX11 (SEQ ID NO. 8) or a fragment thereof or a sequence having at least 90% sequenceidentity thereto, TET 1 (SEQ I D NO. 9) or a fragment thereof or a sequence having at least 90% sequence identity thereto, EBF1 (SEQ ID NO. 10) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TFDP2 (SEQ ID NO. 11) or a fragment thereof or a sequence having at least 90% sequence identity thereto, KLF12 (SEQ ID NO. 12) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NPAS2 (SEQ ID NO. 13) or a fragment thereof or a sequence having at least 90% sequence identity thereto, LEF1 (SEQ ID NO. 14) or a fragment thereof or a sequence having at least 90% sequence identity thereto and / or BCL11B (SEQ ID NO. 15) or a fragment thereof or a sequence having at least 90% sequence identity thereto.
[0145] In one embodiment of the construct above, the nucleic acid comprises one or more of SEQ ID NOs. 16-30 or a sequence having at least 90% sequence identity thereto.
[0146] A nucleic acid construct as described above may be an expression cassette or nucleic acid expression cassette.
[0147] The term “expression cassette” or "nucleic acid expression cassette" generally refers to nucleic acid molecules that include one or more transcriptional control elements including, but not limited to promoters, enhancers and / or regulatory elements, introns and polyadenylation sequences. The enhancers and promoters typically function to direct gene expression in one or more desired cell types, tissues or organs. In one embodiment, it further comprises one or more regulatory elements, introns and polyadenylation sequences.
[0148] The term "regulatory sequences" is used interchangeably with "regulatory elements" herein refers to a segment of nucleic acid, typically but not limited to DNA or RNA or analogues thereof, that modulates the transcription of the nucleic acid sequence to which it is operatively linked, and thus act as transcriptional modulators. Regulatory sequences modulate the expression of gene and / or nucleic acid sequences to which they are operatively linked. Regulatory sequences are nucleic acid sequences that are transcription binding domains and are recognized by the nucleic acid-binding domains of transcriptional proteins and / or transcription factors, repressors or enhancers etc. Typical regulatory sequences include, but are not limited to, transcriptional elements, a sequence encoding suitable mRNA ribosomal binding sites and sequences to control the termination of transcription and / or translation. Regulatory sequences can be a single regulatory sequence or multiple regulatory sequences or modified regulatory sequences or fragments thereof. Modified regulatory sequences areregulatory sequences where the nucleic acid sequence has been changed or modified by some means, for example, but not limited to, mutation, methylation etc. Regulatory sequences that can be included are for example tumour specific enhancers as further explained below.
[0149] As used herein, a "promoter" or "promoter region" or "promoter element" used interchangeably herein, refers to a segment of a nucleic acid sequence, typically but not limited to DNA or RNA or analogues thereof, that controls the transcription of the nucleic acid sequence to which it is operatively linked. The promoter region includes specific sequences that are sufficient for RNA polymerase recognition, binding and transcription initiation. This portion of the promoter region is referred to as the promoter. In addition, the promoter region includes sequences which modulate this recognition, binding and transcription initiation activity of RNA polymerase. These sequences may be cis-acting or may be responsive to trans-acting factors. Promoters, depending upon the nature of the regulation, may be constitutive or regulated.
[0150] Thus, in one embodiment, the nucleic acid construct further comprises a regulatory sequence, e.g. a promoter useful for regulation of the expression of the desired nucleic acid sequence.
[0151] In one embodiment, the nucleic acid construct further comprises one or more nucleic acid encoding a tumour specific enhancer. In one embodiment, the nucleic acid construct comprises one nucleic acid encoding a tumour specific enhancer. In another embodiment, the nucleic acid construct comprises two nucleic acids, each encoding a tumour specific enhancer. Examples of such tumour specific enhancers that can be used in the nucleic acid construct are shown in Table 1 below. Also within the scope of thew invention are variants of the tumour specific enhancers listed in Table 1 below, e.g. having a sequence that has at least 90% or 95% sequence identity to one of the sequences in Table 1.
[0152] Table 1
[0153]
[0154]
[0155]
[0156]
[0157]
[0158]
[0159]
[0160]
[0161]
[0162]
[0163]
[0164]
[0165]
[0166]
[0167]
[0168]
[0169]
[0170] Vectors
[0171] The invention also relates to a vector or plasmid comprising a nucleic acid or nucleic acid construct encoding a transcriptional repressor as described above.
[0172] The vectors can be suitable for replication and integration eukaryotes. Typical cloning vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the desired nucleic acid sequence.
[0173] In one embodiment, the vector further comprises a nucleic acid encoding a tumour specific enhancer, e.g. as in Table 1 or a variant thereof. Other aspects of the invention also relate to a vector comprises a nucleic acid encoding a tumour specific enhancer as in Table 1 or a variant thereof.
[0174] In one embodiment, the vector according to any aspect of the invention is an in vitro transcribed vector, e.g., a vector that transcribes RNA of a nucleic acid molecule described herein. Such an expression vector may be provided to a cell in the form of a viral vector. Viral vector technology is well known in the art and is described, for example, in Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 2013). A number of viral based systems have been developed for gene transfer into mammalian cells.
[0175] The term "viral vectors" refers to the use as viruses, or virus-associated vectors as carriers of the nucleic acid construct into the cell. Constructs may be integrated and packaged into nonreplicating, defective viral genomes like Adenovirus, Adeno-associated virus (AAV), or Herpes simplex virus (HSV) or others, including reteroviral and lentiviral vectors, for infection or transduction into cells. The vector may or may not be incorporated into the cells’ genome. The constructs may include viral sequences for transfection, if desired. Alternatively, the construct may be incorporated into vectors capable of episomal replication, e.g. EPV and EBV vectors.
[0176] In one embodiment, the vector is viral vector. In one embodiment, the vector is a non-viral vector.
[0177] Thus, one embodiment, the vector is a viral vector, including but not limited to recombinant adeno-associated viral (rAAV) vectors, retroviral vectors, adenoviral vectors, herpes-simplex viral vectors, lentiviral vectors and retrotransposon-based vector systems.
[0178] rAAV vectors have limited packaging capacity of the vector particles. The length of the transgene and the length of the regulatory nucleic acid sequences comprising enhancer(s) and promoter(s) are taken into consideration when selecting a regulatory region suitable for a particular transgene and target tissue.
[0179] In one embodiment, the vector is a AAV vector, for example a rAAV vector. A rAAV is engineered to deliver its DNA cargo into the nucleus of a cell.
[0180] The term “AAV” or “adeno-associated virus” refers to a Dependoparvovirus within the Parvoviridae genus of viruses. The AAV can be an AAV derived from a naturally occurring “wild-type” virus, an AAV derived from a rAAV genome packaged into a capsid comprising capsid proteins encoded by a naturally occurring cap gene and / or from a rAAV genome packaged into a capsid comprising capsid proteins encoded by a non-naturally occurring capsid cap gene. An example of the latter includes a rAAV having a capsid protein comprising a peptide insertion into or modification of the amino acid sequence of the naturally-occurring capsid.
[0181] In some embodiments, a recombinant AAV has an AAV genome in which part or all of the rep and cap genes have been replaced with heterologous sequences. The term “rep-cap helper plasmid” refers to a plasmid that provides the viral rep and cap gene function and aids the production of AAVs from rAAV genomes lacking functional rep and / or the cap gene sequences. The term “cap gene” refers to the nucleic acid sequences that encode capsid proteins that form or help form the capsid coat of the virus. For AAV, the capsid protein may be VP1, VP2, or VP3. The term “rep gene” refers to the nucleic acid sequences that encode the non- structural protein needed for replication and production of virus.
[0182] In one embodiment, the vector is a recombinant adeno-associated vector (rAAV).
[0183] In one embodiment, the rAAV is an AAV2, AAV5, AAV8 or AAV9 serotype.
[0184] The recombinant adenovirus can be a first generation vector, with an El deletion, with or without an E3 deletion, and with the expression cassette inserted into either deleted region. The recombinant adenovirus can be a second generation vector, which contains full or partial deletions of the E2 and E4 regions. A helper-dependent adenovirus retains only the adenovirusinverted terminal repeats and the packaging signal (phi). The transgene generally is inserted between the packaging signal and the 3’ITR, with or without stutter sequences to keep the genome close to wild-type size of approximately 36 kb.
[0185] Nucleic acid sequences of AAV-based viral vectors, and methods of making recombinant AAV and AAV capsids are well known in the art.
[0186] In an embodiment, the AAV vector comprises inverted terminal repeat (ITR) sequences. In an embodiment, the AAV vector comprises a TATA box. In an embodiment, the vector comprises a translation initiation sequence, for example a Kozak sequence.
[0187] The rAAV may be a mosaic or pseudotype AAV composed of a mixture of viral capsid proteins from different serotypes of AAV. The rAAV may comprise a capsid containing a capsid protein chimeric of two or more AAV serotypes.
[0188] In one embodiment, the vector is a recombinant oncolytic virus.
[0189] In one embodiment, the oncolytic virus is a herpes simplex virus, a polio virus, a vaccinia virus, a measles virus, a vesicular stomatitis virus, an orthomyxovirus, a parvovirus, a maraba virus or a coxsackievirus.
[0190] In one embodiment, the vector is a lentiviral vector.
[0191] The invention also relates to a rAAV comprising a nucleic acid construct as above.
[0192] The invention also relates to an oncolytic virus comprising a nucleic acid construct as above.
[0193] The invention also relates to a lentiviral vector comprising a nucleic acid construct as above.
[0194] Host cells
[0195] According to one aspect, the invention relates to a host cell comprising a nucleic acid construct or a vector according to the invention.
[0196] The host cell may be a mammalian cell, e.g. HEK cells, e.g. HEK-293 cells, CHO cells, HELA cells, bacterial cell or insect cell, e.g. SF9 cells.
[0197] Methods of making rAA V vectors
[0198] Another aspect of the present invention involves making rAAV vectors, AAV particles or expression cassettes disclosed herein.
[0199] The capsid protein, coat, and rAAV particles may be produced by techniques known in the art. In some embodiments, the viral genome comprises at least one inverted terminal repeat to allow packaging into a vector. In some embodiments, the viral genome further comprises a cap gene and / or a rep gene for expression and splicing of the cap gene. In certain embodiments, the cap and rep genes are provided by a packaging cell and not present in the viral genome.
[0200] In some embodiments, the nucleic acid encoding the capsid protein is cloned into an AAV Rep-Cap helper plasmid in place of the existing capsid gene. When introduced together into host cells, this plasmid helps package an rAAV genome into the capsid protein as the capsid coat. Packaging cells can be any cell type possessing the genes necessary to promote AAV genome replication, capsid assembly, and packaging.
[0201] In some embodiments, a recombinant expression cassette according to the invention, a vector according to the invention or a rAAV particle according to the invention may be manufactured using host cells, e.g., mammalian host cells, including host cells from humans, monkeys, mice, rats, rabbits, or hamster cells. Non-limiting examples include: A549, WEHI, 10T1 / 2, BHK, MDCK, COS1, COS7, BSC 1, BSC 40, BMT 10, VERO, W138, HeLa, HEK-293, Saos, C2C12, L, HT1080, HepG2, CHO, primary fibroblast, hepatocyte, and myoblast cells. Alternatively, baculovirus expression systems in insect cells, e.g. SF9 cells, may be used to produce AAV vectors. Typically, the host cells are stably transformed with the sequences encoding the transgene and associated elements (i. e., the vector genome), and genetic components for producing viruses in the host cells, such as the replication and capsid genes (e.g., the rep and cap genes of AAV).
[0202] Provided are methods of manufacturing a rAAV particle comprising culturing a host cell capable of producing a rAAV described herein under conditions appropriate for production ofthe rAAV comprising a vector as described herein. In one embodiment, the method provides (1) culturing a host cell a vector comprising the expression cassette comprising a nucleic acid as described herein and (2) recovering recombinant AAV encapsidating the vector comprising the expression cassette from the cell culture.
[0203] Virions may be recovered, for example, by CsCh sedimentation. In vitro assays, e.g. cell culture assays, can be used to measure transgene expression from a vector described herein, thus indicating, e.g., potency of the vector.
[0204] In particular, methods of manufacturing a recombinant AAV comprise culturing a host cell capable of producing a recombinant AAV described herein under conditions appropriate for production of the recombinant AAV comprising an artificial genome with an expression cassette described herein, e.g. comprising a synthetic promoter operably linked to the nucleic acid.
[0205] Pharmaceutical compositions
[0206] In another aspect of the present invention, there is provided a pharmaceutical composition comprising a nucleic acid construct or combination of nucleic acid constructs, a vector or plasmid, a rAAV or an oncolytic virus as above and a pharmaceutically accepted carrier.
[0207] " Pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable, and includes that which is acceptable for veterinary as well as human pharmaceutical use.
[0208] The pharmaceutically acceptable carrier or vehicle can be particulate, so that the compositions are, for example, in tablet or powder form. The term "carrier" refers to a diluent, adjuvant or excipient, with which a drug antibody of the present invention is administered. Such pharmaceutical carriers can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The carriers can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents can be used. In one embodiment, when administered to an animal, the nucleic acid construct or vector of the present invention or compositions and pharmaceutically acceptablecarriers are sterile. Water is a preferred carrier when the drug antibody of the present invention are administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
[0209] The pharmaceutical composition of the present invention can be administered by any convenient route, including parenteral administration.
[0210] Compositions can take the form of one or more dosage units.
[0211] In one embodiment, pharmaceutical composition is formulated for parenteral delivery, intracerebral or intrathecal delivery.
[0212] In one embodiment, parenteral delivery is via intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular delivery.
[0213] In one embodiment, intrathecal delivery is via lumbar injection, cisternal magna injection or intraparenchymal injection.
[0214] The composition of the invention can be in the form of a liquid, e.g., a solution, emulsion or suspension. The liquid can be useful for delivery by injection, infusion (e.g., IV infusion) or subcutaneously. The liquid compositions of the invention, whether they are solutions, suspensions or other like form, can also include one or more of the following: sterile diluents such as water, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides, polyethylene glycols, glycerin, or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; and agents for the adjustment of tonicity such as sodium chloride or dextrose. A composition can be enclosed in an ampoule, a disposable syringe or a multiple-dose vial made of glass, plastic or other material.
[0215] In one embodiment, pharmaceutical composition is formulated for oral delivery. When intended for oral administration, the composition is preferably in solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.
[0216] As a solid composition for oral administration, the composition can be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form. Such a solid composition typically contains one or more inert diluents. In addition, one or more of the following can be present: binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, corn starch and the like; lubricants such as magnesium stearate; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent. When the composition is in the form of a capsule (e. g. a gelatin capsule), it can contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol, cyclodextrin or a fatty oil.
[0217] The composition can be in the form of a liquid, e. g. an elixir, syrup, solution, emulsion or suspension. The liquid can be useful for oral administration or for delivery by injection. When intended for oral administration, a composition can comprise one or more of a sweetening agent, preservatives, dye / colorant and flavor enhancer. In a composition for administration by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent can also be included.
[0218] The amount of the therapeutic that is effective / active in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the compositions will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Factors like age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease shall be taken into account.
[0219] The invention also relates to a device, such as a pre-filled syringe which comprises a nucleic acid construct or vector or composition of the invention.
[0220] For administration by injection, the composition can comprise from about typically about 0.1 mg / kg to about 250 mg / kg of the subject’s body weight, preferably, between about 0.1 mg / kg and about 20 mg / kg of the subject’s body weight, and more preferably about 1 mg / kg to about 10 mg / kg of the subject’s body weight. In one embodiment, the composition is administered at a dose of about 1 to 30 mg / kg, e.g., about 5 to 25 mg / kg, about 10 to 20 mg / kg, about 1 to 5 mg / kg, or about 3 mg / kg. The dosing schedule can vary from e.g., once a week to once every 2, 3, or 4 weeks.
[0221] The pharmaceutical compositions can be prepared using methodology well known in the pharmaceutical art. For example, a composition intended to be administered by injection can be prepared by combining a nucleic acid construct or vector of the present invention with water so as to form a solution. A surfactant can be added to facilitate the formation of a homogeneous solution or suspension.
[0222] Kits
[0223] The invention also provides a kit comprising a nucleic acid construct or combination of nucleic acid constructs, vector or pharmaceutical composition of the invention.
[0224] Combination therapies
[0225] The invention also relates to a combination therapy comprising a nucleic acid construct, a vector or plasmid, a rAAV, an oncolytic virus or a pharmaceutical composition of the invention and a chemotherapeutic agent.
[0226] Methods of treatment and medical uses
[0227] The invention also relates to a nucleic acid construct, a vector or plasmid, a rAAV, an oncolytic virus or a pharmaceutical composition according to the invention for use as a medicament, e.g. in treating cancer.
[0228] The invention also relates to a nucleic acid construct, a vector or plasmid, a rAAV, an oncolytic virus or a pharmaceutical composition according to the invention for use in the treatment or prevention of glioma, in particular glioblastoma.
[0229] The invention also relates to a nucleic acid construct, a vector or plasmid, a rAAV, an oncolytic virus or a pharmaceutical composition according to the invention for use in a method to reduce the resistance of glioma, in particular glioblastoma, to treatment with a chemotherapy, induce neuronal cell like differentiation and / or reduce cell plasticity of glioma cells.
[0230] The invention also relates to a method of treating or preventing glioma, in particular glioblastoma, comprising administering a nucleic acid construct, a vector or plasmid, a rAAV, an oncolytic virus or a pharmaceutical composition according to the invention to a patient in need thereof.
[0231] The invention also relates to a method of inducing neuronal cell like differentiation and / or reducing cell plasticity of glioma cells comprising administering a nucleic acid construct, a vector or plasmid, a rAAV, an oncolytic virus or a pharmaceutical composition according to the invention to a patient in need thereof.
[0232] Gliomas are cancerous brain tumours that start in glial cells. Glioblastoma (GB), also known as glioblastoma multiforme or GBM, is a type of glioma and the most commonly occurring malignant tumour of the central nervous system and is a deadly disease with extremely poor prognosis. Based on the 2021 5th edition of the WHO Classification of Tumors of the Central Nervous System glioblastoma are classified as WHO CNS Grade 4.
[0233] In one embodiment, the glioma, e.g. glioblastoma is metastatic.
[0234] As used herein, "treat", "treating" or "treatment" means inhibiting or relieving a disease or disorder. For example, treatment can include a postponement of development of the symptoms associated with a disease or disorder, and / or a reduction in the severity of such symptoms that will, or are expected, to develop with said disease. The terms include ameliorating existing symptoms, preventing additional symptoms, and ameliorating or preventing the underlying causes of such symptoms. Thus, the terms denote that a beneficial result is being conferred on at least some of the mammals, e.g., human patients, being treated. Many medical treatments are effective for some, but not all, patients that undergo the treatment.
[0235] The term "subject" or "patient" refers to an animal which is the object of treatment, observation, or experiment. By way of example only, a subject includes, but is not limited to, a mammal,including, but not limited to, a human or a non-human mammal, such as a non-human primate, murine, bovine, equine, canine, ovine, orfeline.
[0236] As used herein, the term "effective amount" means an amount of the nucleic acid construct, vector or pharmaceutical composition of the invention, that when administered alone or in combination with an additional therapeutic agent to a cell, tissue, or subject, is effective to achieve the desired therapeutic or prophylactic effect under the conditions of administration.
[0237] The expressions "treating glioma, e.g. glioblastoma” and 'treatment of glioma, e.g. glioblastoma" include methods that produce one or more anti-cancer effects which include, but are not limited to, anti-tumor effects, the response rate, the time to disease progression and the overall survival rate. " Anti-tumor" effects include but are not limited to inhibition of tumor growth, tumor growth delay, regression of tumor, shrinkage of tumor, increased time to regrowth of tumor on cessation of treatment and slowing of disease progression.
[0238] The invention can also be useful in the treatment of a subject having or at risk of having a disease, for example a subject having or at risk of having glioma, in particular glioblastoma.
[0239] “Co-administered,” as used herein, refers to administration of two or more agents, i.e. a nucleic acid construct, vector or pharmaceutical composition of the invention and another agent, such as another anti-cancer therapy, e.g. a chemotherapeutic agent, such that both agents can simultaneously achieve a physiological effect, e.g., in a recipient subject. The two agents, however, need not be administered together. In certain embodiments, administration of one agent can precede administration of the other. Simultaneous physiological effect need not necessarily require presence of both agents in the circulation at the same time. However, in certain embodiments, co-administering typically results in both agents being simultaneously present in the subject.
[0240] " Therapeutically effective amount" means an amount of an agent, i.e. a nucleic acid construct, vector or pharmaceutical composition of the invention that, when administered to a subject for treating or preventing glioma, in particular glioblastoma, is sufficient to effect such treatment for the glioma, in particular glioblastoma. The "effective amount" will vary depending on the severity of the glioma, in particular glioblastoma, treated, the age and relative health of the subject, the route and form of administration, whether the treatment is monotherapy or combination therapy, the judgement of the attending clinician, and other factors.
[0241] As used herein, the term another cancer therapy includes chemotherapy and radiation.
[0242] As used herein, the term "chemotherapy" means the use of one or more chemotherapeutic agent in the treatment or prevention of cancer, for example to kill cancer cells or shrink tumours.
[0243] In one embodiment, at least two nucleic acid constructs as described herein are administered.
[0244] In one embodiment, the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition induces neuronal cell like differentiation of glioma cells.
[0245] In one embodiment, nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition reduces cell plasticity of glioma cells.
[0246] In one embodiment, the glioblastoma is of the classical (CL) subtype, mesenchymal (MES) subtype or proneuronal (PN) subtype.
[0247] In one embodiment, the glioblastoma cell is a progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte- 1 ike (AC-like) and mesenchymal-like (MES-like) cell.
[0248] In one embodiment, the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition is administered by oral delivery, parenteral delivery, intracerebral or intrathecal delivery.
[0249] In one embodiment, parenteral delivery is via intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular delivery.
[0250] In one embodiment, intrathecal delivery is via lumbar injection, cisternal magna injection or intraparenchymal injection.
[0251] In one embodiment, the tumor is resistant to treatment with an anti-cancer therapy, for example a chemotherapy or radiation.
[0252] In one embodiment, an anti-cancer therapy is co-administered, i.e. administered together with, prior or after administration of the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition of the invention. In particular, in some embodiment, an anti-cancer therapy is co-administered when the cancer is resistant to anti-cancer therapy, in particular to a chemotherapy. Such co-administration can modulate the physiological response of a mammalian glioma cell to a chemotherapeutic agent, thereby increasing the efficacy of the chemotherapeutic agent.
[0253] In one embodiment, the anti-cancer therapy is chemotherapy, steroid such as dexamethasone, radiation, and / or surgical resection.
[0254] In one embodiment, the chemotherapy comprises an alkylating or other agent.
[0255] In one embodiment, the chemotherapy comprises temozolomide, lomustine, etoposide, doxorubicin, cisplatin, paclitaxel, carmustine, ceramide or phosphorylcholine or a derivative or a pharmaceutically acceptable salt of any of the recited compounds or a combination thereof, see e.g. Shi et al The Lancet Oncology, Volume 23, Issue 2, February 2022, Pages e62-e74.
[0256] In one embodiment, the anti-cancer therapy comprises the administration of one or more anticancer agent, for example, an anticancer agent selected from: a chemotherapeutic agent and / or a radiotherapeutic agent. For example, in one embodiment, the one or more additional cancer therapy comprises the administration of one or more anticancer agent selected from the anticancer agents listed above.
[0257] In one embodiment, the anti-cancer therapy is a radiotherapy. As used herein, the term "radiotherapy" means the use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors. Radiation may come from a machine outside the body (external-beam radiation therapy), or it may come from radioactive material placed in the body near cancer cells (internal radiation therapy). Systemic radiotherapy uses a radioactive substance, such as a radiolabelled monoclonal antibody, that travels in the blood to tissues throughout the body. The terms irradiation and radiation therapy have the same meaning. In one embodiment, the radiotherapy is external radiation treatment or internal radiation treatment.
[0258] In one embodiment, the one or more additional anticancer agent and / or cancer therapy is selected from the group consisting of: chemotherapeutic agents, immune-modulating agents such as anticancer vaccines, modulators of immune checkpoint proteins, adoptive T cell immunotherapies (for example chimeric antigen receptor T cells (CART cells)), and radiotherapy.
[0259] Temozolomide (TMZ) is the most common chemotherapy for glioblastoma. Thus, in one embodiment, the chemotherapy comprises TMZ or a derivative thereof. In particular, the invention finds use in treating glioblastoma that is resistant to treatment with TMZ. TMZ can be administered together with, before or after a nucleic acid construct, vector or pharmaceutical composition of the invention. Without wishing to be bound by theory, the inventors believe that coadministration of the nucleic acid construct, vector or pharmaceutical composition of the invention and TMZ can alleviate resistance / increase or potentiate the efficacy of TMZ.
[0260] It will also be appreciated by those skilled in the art that a particular method of therapy comprising administering temozolomide (TMZ) or a derivative thereof, or a pharmaceutically acceptable salt thereof, will employ a selected route of administration which will in turn depend on a variety of factors, all of which are considered routinely when administering therapeutics. It will be further appreciated that the optimal course of treatment or prevention, e.g., the formulation and the number and frequency of doses of the temozolomide (TMZ) or a derivative thereof, or a pharmaceutically acceptable salt thereof, given for a defined number of days, can be ascertained by those skilled in the art using conventional treatment tests. According to the method of the present invention, the dosage form of the TMZ or a derivative thereof, or a pharmaceutically acceptable salt thereof and the method of administration thereof are not particularly limited.
[0261] Temozolomide may be commercially available for oral administration and for intravenous injection under the trade name " Temodar®" distributed by: Merck Sharp & Dohme LLC. The person skilled in the art will appreciate that the dose of the TMZ or a derivative thereof, or a pharmaceutically acceptable salt thereof may be varied depending on the age and sex of a patient, and the severity of the glioblastoma. In one embodiment, the TMZ or a derivative thereof, or a pharmaceutically acceptable salt thereof is administered every day, every two days, every three days, every four days, every five days, every six days or once weekly. Standard doses are known to the skilled person (see e.g. Jezierzahski et al Temozolomide
[0262] (TMZ) in the Treatment of Glioblastoma Multiforme — A Literature Review and Clinical Outcomes. Curr. Oncol. 2024, 31, 3994-4002).
[0263] The invention also relates to a method of modulating the physiological response of a mammalian glioma cell to a chemotherapeutic agent comprising administering the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition as above to a patient in need thereof.
[0264] The invention also relates to a method of treating a resistant glioma, in particular glioblastoma, comprising administering the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition as above to a patient in need thereof.
[0265] Tumour specific enhancers
[0266] The inventors have identified nucleic acid sequences that are located upstream of the open reading frame of a tumour specific target gene. The inventors have further identified that these sequences can be used as tumour specific enhancers, for example in gene therapy.
[0267] Thus, in another aspect, the invention relates to an isolated nucleic acid molecule selected from a nucleic acid as shown in Table 1, i.e. a nucleic acid as defined in SEQ ID NO. 31 to 126 or a variant thereof. In one embodiment, the variant has at least 90% or 95% sequence identity with the non-variant sequence. The invention also relates to a nucleic acid construct comprising one or more nucleic acids selected from the nucleic acids as shown in Table 1 or a variant thereof. In one embodiment, the variant has at least 90% or 95% sequence identity with the non-variant sequence. In one embodiment, the nucleic acid construct comprises two nucleic acids selected from the nucleic acids as shown in Table 1 or a variant thereof. In one embodiment, the variant has at least 90% or 95% sequence identity with the non-variant sequence.
[0268] The nucleic acid construct may further comprise a nucleic acid encoding a transcription factor protein useful in the treatment of glioma, for example as described herein.
[0269] In another aspect, the invention relates to the use of a nucleic acids as shown in Table 1 or a variant thereof as a tumour specific enhancer, e.g. for glioma treatment.
[0270] Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. While the foregoing disclosure provides a general description of the subject matter encompassed within the scope of the present invention, including methods, as well as the best mode thereof, of making and using this invention, the following examples are provided to further enable those skilled in the art to practice this invention and to provide a complete written description thereof. However, those skilled in the art will appreciate that the specifics of these examples should not be read as limiting on the invention, the scope of which should be apprehended from the claims and equivalents thereof appended to this disclosure. Various further aspects and embodiments of the present invention will be apparent to those skilled in the art in view of the present disclosure.
[0271] All documents and sequence database identifiers mentioned in this specification are incorporated herein by reference in their entirety.
[0272] "and / or" where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example, " A and / or B" is to be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just as if each is set out individually herein. Unless context dictates otherwise, the descriptions and definitions of the features set out above are not limited to any particular aspect or embodiment of the invention and apply equally to all aspects and embodiments which are described.
[0273] The invention is further described in the following non-limiting examples.
[0274] Examples
[0275] Example 1
[0276] Glioblastoma (GB) is one of the most lethal human cancers, marked by profound intratumoral heterogeneity and near-universal treatment resistance. Cellular plasticity, the capacity of cancer cells to transition between phenotypic states, drives GB progression and resistance. However, the regulatory logic that permits or restricts specific state transitions remains poorly understood. Here, we integrated single-nucleus RNA and chromatin accessibility multi-ome profiles from over one million cells across primary IDH-wildtype GBs and developed scDORI, a scalable deep-learning framework to infer enhancer-driven gene regulatory networks (eGRNs) at single-cell resolution. Our analysis revealed a structured hierarchy of GB cell states governed by distinct regulatory programs, with marked variability in epigenetic plasticity thatenables or constrains transitions. Neuronal-like tumor cells emerge as a low plasticity state that deploys active repression, in contrast to more permissive progenitor-like and astrocytic states. We identified the neuronal-like state-specific repressor MYT1L as a key regulator that silences master transcription factors of alternative states. MYT 1 L gain-of-function in patient-derived GB cells reduced chromatin accessibility, induced neuronal-like identity, and restricted proliferation and invasion in vivo, whereas loss-of-function reactivated plasticity and accelerated malignant features. Our findings delineate the epigenetic architecture and associated transcriptional master regulators that shape GB state trajectories, and establish safeguard repressors such as MYT 1 L as potential therapeutic targets to constrain malignant plasticity.
[0277] Seminal single-cell transcriptomic studies have shown that malignant GB cells occupy a continuum of cellular states resembling developmental progenitors (e.g., OPC-like and NPC-like), as well as astrocytic and mesenchymal-like phenotypes9’10. Patient-derived xenograft models have demonstrated that individual GB cells can give rise to multiple states, implying substantial plasticity1011. However, whether these state transitions follow stereotyped routes or variable trajectories and how they are promoted or constrained by gene regulatory mechanisms remains poorly understood.
[0278] Here, we address these questions by integrating multi-ome single-nucleus RNA and chromatin accessibility (snRNA-ATAC) profiles from over one million cells across spatially mapped regions of primary IDH-wildtype GBs generated in a companion study (de Jong et al.). Through a novel computational approach (scDORI), we decoded enhancer-driven gene regulatory networks (eGRNs) at single-cell resolution and mapped the plasticity landscape across GB cell states. Without relying on predefined annotations, scDORI identified joint transcriptomic and epigenetic regulatory modules that capture the gene regulatory logic underlying cell identity and state transitions in GB.
[0279] Our analysis revealed that cancer cell states are arranged in a clear hierarchy, demarcated by epigenetic “barriers” and “highways” that guide transitions by hijacking neurodevelopmental transcription factors. Neuronal-like cells, in particular, showed strikingly low plasticity and elevated transcriptional repression, acting as a uniquely constrained state in the transition space of GB cells. This repression is orchestrated by state-specific factors such as MYT1L, which actively silence transcription factors governing alternative fates. Experimental perturbation of MYT1L in patient-derived GB cells confirmed its capacity to restrict plasticity, induce neuronal-like morphology, and reduce tumor growth and mortality upon transplantationin mice. These results suggest that manipulating repressors of plasticity may lock GB cells into more benign, less adaptive states and might open new avenues for treatment.
[0280] These findings reveal a universal, epigenetically controlled hierarchy of cell states and transition routes in GB. Our work establishes transcriptional repressors as key regulators of plasticity and underscores the therapeutic potential of targeting the epigenetic foundations of state switching in brain cancer.
[0281] Results
[0282] Glioblastoma Cells Exhibit State-Specific Levels of Epigenetic PlasticityTo characterize the regulatory landscape of glioblastoma, we mined a single-nuclei multi-ome atlas (snRNA-ATAC-seq) generated in a companion study (de Jong et al.), spanning parallel gene expression and chromatin accessibility profiles of over 1 million cells collected across multiple sites (4-15) of 12 isocitrate dehydrogenase wildtype (IDH-WT) primary GB tumors, including peritumoral regions (Fig. 1A). Malignant GB cells exhibited vastly heterogeneous transcriptional profiles, ranging from developmental-like (OPC-NPC-like, OPC-like, OPC-neuronal-like, NPC-neuronal-like, AC-progenitor-like) to glial injury response and hypoxia-associated (AC-gliosis-like, Gliosis-like, Hypoxia) phenotypes, as well as cycling signatures (Proliferative) (de Jong et al.). Expanding cell numbers from previous datasets by more than tenfold10’12-15, this atlas provides the foundation for dissecting the regulatory mechanisms driving GB heterogeneity at an unprecedented scale.
[0283] Drawing on the multi-omic dimension of our dataset, we explored the epigenetic plasticity of GB cells, following the assumption that accessible gene regions without active transcription indicate epigenetic plasticity. Inspired by Burdziak et al.16, we quantified how accessibility profiles of cell state markers can predict transcriptional cell states (Fig. 1B). In this model, cells with uncertain predictions based on chromatin profiles are identified as more epigenetically plastic. Our analysis revealed that malignant cells display greater epigenetic plasticity compared to non-malignant tumor microenvironment (TME) cells (Fig. 1C; p=9.8x10-14, two-sided t-test), with chromatin accessibility in malignant cells often being compatible with multiple transcriptional states (Fig. 1D). Yet, the extent of this plasticity significantly varied across GB cell states (Fig. 1E), with NPC-neuronal-like and OPC-neuronal-like cells standing out as least plastic states (p=6.7x10-6, two-sided t-test). These variations in epigenetic plasticity could not be explained by differences in global coupling between gene expression and accessibility, were robust to differences in cell numbers per state, and were consistently observed acrosspatients (Fig. 1F). This suggests specific regulatory mechanisms underlie GB plasticity and govern cell state heterogeneity.
[0284] Decoding the Gene Regulatory Architecture of Glioblastoma Heterogeneity
[0285] To determine specific gene regulatory processes regulating the observed epigenetic plasticity, we aimed to identify relevant TFs and c / s-regulatory elements (CRE), as well as their interplay across GB states, using enhancer-driven gene regulatory networks (eGRNs). Established eGRN inference methods17-27face limitations that hamper their applicability to a highly heterogeneous single-cell tumor atlas like ours. Specifically, existing methods offer poor scalability to large datasets28, and their reliance on pre-defined cell type annotations means they cannot model continuous and cell state-specific differences of eGRNs. Moreover, previous methods primarily focus on signatures of transcriptional activation, despite the growing recognition of gene repression as a key regulator of cell identity and plasticity in cancer 29,30
[0286] To address these limitations, we developed single-cell Deep multi-Omic Regulatory Inference (scDORI), a computational framework for inferring continuous eGRNs and their relationships across cell populations using scRNA-ATAC multi-ome data (Fig. 2A). Building on autoencoders31, scDORI combines principles of multi-omics dimensionality reduction and Topic modeling to decompose gene expression and chromatin accessibility profiles into gene regulatory modules17’32-37, hereafter referred to as " Topics". Unlike conventional dimensionality reduction approaches that rely solely on correlative signatures, scDORI Topics adhere to regulatory constraints that govern the relationship between TFs, CREs, and target genes. This is achieved by employing multiple coupled decoders that capture established signatures of eGRNs, including peak co-accessibility, TF chromatin binding, CRE-gene linkages, and expression correlations between TFs and their target genes that support activation or repression interactions17-25’38. As a result, individual scDORI Topics represent TF-to-target gene relationships mediated by specific CREs (eGRN) (Fig. 2A, bottom). Because the multi-omic profile of each cell is modelled as a mixture of Topics, scDORI can capture finegrained variation in eGRNs across cell states without relying on predefined annotations (Fig.
[0287] 2A, right). Conversely, a single Topic can be active across multiple cell states, enabling the identification of shared aspects of gene regulation. scDORI scales efficiently to datasets comprising millions of cells, and performs favorably compared to existing eGRN inference methods on benchmarks such as prediction of enhancer-promoter links.
[0288] Applied to our GB atlas, scDORI identified 31 Topics with distinct activity patterns across cells and patients (Fig. 2B-C), each capturing co-accessible chromatin regions c / s-linked to coexpressed genes (Fig. 2D). Notably, despite their mechanistic constraints, scDORI Topics explained the transcriptional variation within tumor cells to a similar or greater degree than conventional dimensionality reduction methods2534. Clustering of transcriptional GB states based on Topic activity patterns revealed four major regulatory states alongside a distinct Proliferative (cycling) population, stratifying developmental states (Neuronal-like and OPC-NPC-like), and AC-gliosis-hypoxia states (AC-like and Gliosis-hypoxia) (Fig. 2C). Topics specific to individual states reflected gene programs characteristic of their developmental counterparts, such as, neurotransmitter release in Neuronal-like cells (Topic 37)39, PDGF signaling in OPC-NPC-like cells (Topic 34)40, and calcium ion homeostasis in AC-like cells (Topic 20)41(Fig. 2E). These programs were also active in corresponding TME cell types, consistent with tumor cells co-opting developmental pathways.
[0289] Beyond GB state-level distinctions, scDORI resolved functional heterogeneity within individual malignant states. For instance, in Gliosis-Hypoxia cells, distinct Topics captured hallmark features such as hypoxic stress (Topics 11)42, cytokine signaling (Topic 19)43, and vascular wound healing (Topic 12)44(Fig. 2E). scDORI also identified “inter-state” Topics (Topic 7, 25, 29, 33, 36, 49) that span multiple GB states, which were enriched for programs linked to fate commitment and differentiation, indicating their potential role in mediating state transitions (Fig. 2C, E). Notably, these Topics were also active in cycling cells, implicating proliferation as a hub for state transitions (Fig. 2C). Finally, scDORI identified Topics that were broadly active across the majority of tumor cells, reflecting core features of GB biology such as postsynaptic signaling (Topic 39)45, inflammatory response (Topic 31)46, and cell adhesion (Topic 18). We tested the robustness of scDORI Topics across multiple model restarts and by confirming consistent mapping across GB patients in our dataset and within an independent single-cell GB atlas10. Moreover, scDORI-derived Topic-specific eGRNs were predictive of differentially expressed genes between GB cells, performing favorably compared to existing approaches2526. Collectively, scDORI Topics redefine GB heterogeneity from a gene regulation standpoint, building the foundation to gain universal insights into how GB cell identity is regulated, shifted, and maintained.
[0290] Mapping the Regulatory Drivers of GB Cell State Transitions
[0291] One of the key open questions in GB biology is whether cancer cells transition according to defined rules, and if so, which TFs govern these transitions9’10. Building on the hypothesis that the activation of master regulators can initiate cell state transitions, we set out to identify keyregulator TFs for each Topic. Using Topic-specific eGRNs from scDORI, we defined “Topic Regulators” (TRs) as TFs with the strongest downstream regulatory influence within each Topic (Fig. 3A). On average, scDORI identified ~9 TRs per Topic. These included known GB cell state regulators, such as ASCL1 in OPC-NPC-like cells (Topic 36), SOX11 in neuronallike cells (Topic 24), and FOSL2 in Gliosis-Hypoxia cells (Topic 19), as well as regulators associated with respective Topic programs such as hypoxia (BACH1, Topic 19), and stress response (ATF3, JUND, Topic 11)10’47’48. TRs of state-specific Topics included lineage-specific TFs, such as SOX6 (Topic 34, OPCs)49, MYT1L (Topic 24, neurons)50, and TRPS1 (Topic 9, astrocytes)51, further supporting that GB cells reutilise developmental TFs and gene programs52. Our analysis also revealed TRs not previously associated with GB (POU2F2, TCF7L2, HNF4G, TFCP2L1), providing candidates for further exploration (Fig. 3A).
[0292] Having identified TRs across GB states, we investigated whether TRs associated with one Topic are either expressed or epigenetically accessible in Topics of a different state, potentially explaining transitions between cell states. While several TRs exhibited expression in at least one other Topic (37 / 87, 43%), only 16% (14 / 87) were expressed in a Topic that marks an alternate GB cell state (Fig. 3B). In contrast, TR accessibility was more widespread, with 54% (47 / 87) being highly accessible in Topics of an alternate GB state, suggesting they are epigenetically primed for activation (Fig. 3B).
[0293] Building on these observations, we developed a framework to systematically quantify the activation potential between cell states, by estimating how readily the TRs of a target Topic can be activated within a different source Topic. This metric, which we term Topic Activation Potential (TAP), integrates three components: (i) the presence of regulatory interactions from TFs in the source Topic to TRs of the target Topic; (ii) the accessibility of target TRs in the source Topic, reflecting epigenetic priming; and (iii) the relative importance of each TR within its Topic (Fig. 3C). All components contributed uniquely to the metric and jointly revealed distinct transition trajectories among GB states (Fig. 3D), each characterized by different driver TFs. While inter-state Topics (33, 36, 49) emerged as connectivity hubs across states, consistent with their enrichment for fate change-related signatures (Fig. 2E), striking differences were observed when examining the core GB states. In particular, OPC-NPC-like (34, 25) and AC-like (9, 44, 20) Topics exhibited strong TAP connections to multiple alternate states, whereas transitions from Neuronal-like (24, 37, 41) and Gliosis-Hypoxia (19, 12, 11) Topics were largely confined within their respective states (Fig. 3D-E). Together, these results highlight marked, state-specific differences in transition potential, likely shaped by distinct epigenetic landscapes and regulatory architectures that govern plasticity across GB states.
[0294] Activation and Repression Jointly Govern GB Cell State Transitions
[0295] Having identified marked differences in transition potentials between GB states based on activation, we next asked whether the absence of activation is reinforced by active repression. To that end, we defined a Topic Repression Score (TRS), conceptually analogous to TAP but considering signatures of repression instead of activation (Fig. 4A). Remarkably, Neuronallike Topics (24, 37) showed the most widespread repression over Topics of alternate GB states (Fig. 4B), driven by the aggregated effects of multiple Neuronal-like TFs. In contrast, other Topics showed repression restricted to specific states (e.g. Topic 2, 20, 36), or minimal overall repression (Topic 9, 44) (Fig. 4B). Similar trends, though less pronounced, were observed when assessing repression of Topic-specific genes and state marker genes.. Notably, total repression exerted by each Topic negatively correlated with the epigenetic plasticity of its associated cells (Fig. 1E and 4B), suggesting that repression is a barrier to epigenetic plasticity and state transitions.
[0296] To assess how activation and repression jointly shape and balance transitions, we defined a net transition score of TAP minus TRS (Fig. 4C). Aggregation of this score at the level of GB states revealed a hierarchy of cell state transition potentials and constraints (Fig. 4D-E), which is consistent with the epigenetic plasticity of each state (Fig. 1E and Fig. 4F). At the top of this hierarchy, OPC-N PC-like and AC-like states exhibited strong overall activating links to other states, reflecting permissive epigenetic configurations conducive to transition. In contrast, Neuronal-like and Gliosis-Hypoxia cells showed limited activation towards alternate states, with Neuronal-like cells further restricting their plasticity with repressive. In general, activation and repression potentials were often asymmetric, i.e. OPC-NPC-like to Neuronal-like and AC-like to Gliosis-Hypoxia transitions were much more likely than their opposite counterparts, highlighting preferential transition directions between states (Fig. 4E). Together, these observations reconstructed a cellular trajectory in GB, offering critical insights into the regulatory logic underlying GB progression.
[0297] To assess to what extent the modelled transition hierarchy can explain tumor architecture, we analyzed the spatial distribution of Topics within matched tumor sections using Visium spatial transcriptomics. This approach is based on the premise that cell states with high transition potential are more likely to occur in close spatial proximity, whereas those separated by regulatory barriers are expected to be spatially segregated (Fig.4G-H) (de Jong et al.). Indeed, Topic pairs with high net transition values (TAP-TRS), such as those between OPC-NPC-like and AC-like cells (Topic 9-25, 44-34, 44-36, 9-19), demonstrated closer spatial proximity (Fig. 4I-J). In contrast, Topic pairs with weak or absent transition links, particularly involvingNeuronal-like and Gliosis-Hypoxia states (Topic 24-19, 24-2, 37-44), exhibited marked spatial separation (Fig. 4I-J).
[0298] We also analyzed transition trajectories across pseudotime-aligned clonal cell populations in our dataset (de Jong et al.), finding that net transition scores (TAP-TRS) aligned with temporal co-occurrence of Topics. Notably, the regulatory logic enabled by scDORI topic-specific eGRNs showed stronger concordance with cell state plasticity, spatial organization, and pseudo-temporal transition patterns when compared to either averaged Topic-specific eGRNs from scDORI or eGRNs inferred through alternative methods, demonstrating the advantage of continuous Topic-resolved modeling. Together, these findings suggest that GB cells transition along structured and spatially coherent trajectories, largely shaped by the regulatory architecture of each state.
[0299] The pseudo-temporal analysis of topic co-occurrence also revealed how Neuronal-like cells, despite their repressive barriers, can transition into other GB states. Across all trajectories (N=60 clones), Neuronal-like cells preceded either Proliferative or OPC-NPC-like cells (Fig.
[0300] 4K). State changes along these transition routes were accompanied by marked changes in the chromatin landscape, whereby TFs from subsequent trajectory stages only become accessible as cells leave the Neuronal-like state (Fig. 4L). Notably, the transition required the shutdown of key plasticity repressors (MYT1L, ST18, POLI2F2, NR3C2) that otherwise silenced transition-initiating TFs (PBX1, S0X4) (Fig. 4M). Silencing these Neuronal-like state-specific repressors, combined with induction of transition-promoting Topics (49, 36, 34), enabled a feed-forward cascade of TF activations driving further state changes (Fig. 4M). This silencing of Neuronal-like state-specific repressors persisted throughout subsequent transition stages, suggesting their continuous suppression is important for GB progression. This analysis indicates that a fine balance between activation and repression dictates whether Neuronal-like state transitions occur, and gives us valuable insights into how this balance could be tilted in either direction.
[0301] The Repressor MYT1L Restricts GB Plasticity and Promotes the Neuronal-like State
[0302] Increased cellular plasticity likely contributes to tumor progression and therapy resistance in GB5354. Given the comparatively low plasticity of Neuronal-like cells and the predicted role of transcriptional repression in restricting GB plasticity in patients, we sought to investigate to what extent we could harness repressors to manipulate GB plasticity (Fig. 5A). Of all scDORI-predicted Neuronal-like repressor TFs, MYT 1 L is the only TF exclusively and highly expressed in over 90% of Neuronal-like cells (Fig. 5B). In addition, MYT1L exhibited the most broad
[0303] predicted repression of alternate GB states among all candidates and was previously described as a safeguard repressor in neurons5055(Fig. 5B), making it a promising candidate to manipulate.
[0304] To test this, we performed MYT1L gain-of-function in patient-derived GB cells (PDGCs; S24) with no detectable endogenous MYT1L expression, which induced major chromatin accessibility rearrangements with >80% of differentially accessible genomic regions closing upon MYT1L overexpression (OE), consistent with a repressive function (Fig. 5C). MYT1L closed regions contained c / s-regulatory and / or coding regions of multiple alternate state TRs and marker genes and were strongly associated with Topics from all non-Neuronal-like states (Topics 9, 19, 25) (Fig.). Conversely, MYT1L loss-of-function in PDGCs (BG5) with endogenous MYT1L expression caused inverse, albeit less pronounced, effects on chromatin accessibility, with >80% of differentially accessible genomic regions opening upon MYT1L knockout, including multiple regions associated with non-Neuronal-like TRs and markers (Fig.
[0305] 5C). Together, this suggests that MYT1L is indeed restricting the epigenetic plasticity of GB cells through transcriptional repression of alternate GB states.
[0306] To determine how MYT 1 L could suppress plasticity and repress such a diverse set of alternate GB states, we identified MYT1L target genes using CUT& RUN sequencing. Out of all differentially accessible genes in MYT1 L-overexpressing PDGCs, 55.5% were directly bound by MYT 1 L, suggesting it directly induces the majority of the observed effects. As predicted by scDORI, MYT1L directly repressed TRs from Topics of all alternate states, including SMAD3 (Topic 19, Gliosis-Hypoxia), TRPS1 (Topic 9, AC-like), TCF7L2 (Topic 2, OPC-NPC-like) and MYBL1 (Topic 29, Proliferative) (Fig. 5D). The smaller fraction of TFs activated by MYT1L was predominantly associated with Neuronal-like Topics (SOX11, ESRRG). At the level of genes, scDORI-predicted MYT1L regulatory effects better than alternative eGRN inference methods, but most notably, 85% of scDORI-predicted TFs downstream of MYT1L were CUT& RUN bound targets. These experiments validate our scDORI-based predictions and show that active suppression of alternate state regulators is a key mechanism by which Neuronal-like cells restrict their plasticity.
[0307] Beyond this marked epigenetic remodeling, MYT1L manipulation also induced broad changes at the transcriptional level. MYT1L loss-of-function in PDGCs (BG5) downregulated several Neuronal-like Topics (Topic 49, 41) and induced genes from alternate state Topics (Topic 44, 19), despite not provoking significant changes in state identity (Fig. 5E). Conversely, MYT1L overexpression in PDGCs (S24 and p3xx) with no endogenous MYT 1 L expression significantly upregulated Neuronal-like state signatures and Topics and caused, to varying degrees,
[0308] downregulation of alternate states (Fig. 5E). Remarkably, induced fates were strongly associated with reduced epigenetic plasticity, while repressed states exhibited higher plasticity, further supporting that MYT1L suppresses plasticity and can shift GB identity towards Neuronal-like states.
[0309] This Neuronal-like reprogramming of PDGCs was accompanied by the upregulation of neuron-associated pathways upon MYT 1 L gain-of-function, including genes related to synaptogenesis and neurite-like outgrowth. To assess if these transcriptional changes translated to functional effects, we assessed characteristic features of the Neuronal-like state upon MYT1L manipulation, such as their low intra-tumoral connectivity and their synapse-driven neurite-like morphology11 56. Indeed, MYT 1 L significantly impacted the formation of interconnected tumour microtubes within PDGC monocultures, as evidenced by their significantly impaired and enhanced formation upon MYT1L gain and loss-of-function, respectively (Fig. 5F). When cocultured with primary hippocampal neurons, MYT1 L-overexpressing PDGCs exhibited a significantly higher number and branching degree of neurite-like projections, suggesting enhanced neuron-to-glioma crosstalk (Fig. 5G)11. Overall, these experiments show that MYT1L-driven epigenetic and transcriptional changes induce functional and morphological shifts in GB cells that promote Neuronal-like features while reducing traits associated with tumour microtube hyperconnected and therapy-resistant states57’58.
[0310] To discriminate induced Neuronal-like phenotypes from those of OPC-NPC-like cells, which share functional characteristics11 56, we analyzed the impact of MYTIL on PDGC proliferation, a feature characteristically higher in OPC-NPC-like cells10. Remarkably, MYT1L gain-of-function halted PDGC proliferation, whereas loss-of-function significantly enhanced it (Fig.
[0311] 5H), suggesting that MYT 1 L uniquely promotes Neuronal-like identity. These effects were also consistent with MYT 1 L directly repressing regulators of proliferative Topics (MYBL1, GLI3), as well as TFs promoting transitions towards Proliferative states (PBX1, S0X4) (Fig. 4M and 5D).
[0312] PDGC spheroid growth within tissue-mimicking extracellular matrices was also significantly reduced upon MYT1L overexpression. Importantly, this reduced proliferation and growth upon MYT1L overexpression was phenocopied when fusing the DNA-binding domain (DBD) of MYT1L to a well-characterized repressor (EnR) and reverted when fused to a well-known activator (VP64) (Fig. 5I). This shows that MYT 1 L can induce Neuronal-like identity and reduce tumor cell plasticity and proliferation by a repressive mechanism.
[0313] Finally, to assess how restricting plasticity through MYT 1 L induction might affect tumor growth in vivo, we followed MYT1L overexpressing PDGCs orthotopically transplanted in the cortex of mice with two-photon live imaging throughout 21 days (Fig. 5J). Notably, MYT1L
[0314] overexpressing tumors exhibit significantly slower tumor cell growth and restricted brain invasion from the original injection site when compared to control PDGCs (Fig. 5J-K).
[0315] Ultimately, this significantly delayed tumor development and improved survival outcomes (Fig.
[0316] 5L). This observation is consistent with previous reports correlating higher MYT1 L expression with better overall patient survival using TCGA data59. These results demonstrate that we can predict and harness state-specific factors such as the plasticity repressor MYT1L to readily promote transitions towards more benign states, opening the door to future therapies targeting epigenetic plasticity.
[0317] Discussion
[0318] Cellular plasticity is a core feature of GB progression, yet the regulatory principles shaping how tumor cells transition between distinct states have mainly remained elusive10’60’61. Leveraging large-scale single-cell multi-omic profiling and a novel computational framework for enhancer-driven gene regulatory network (eGRN) inference, our study delineates a hierarchy of GB cell state plasticity and transition trajectories that are shaped not solely by activation cues but are actively constrained by state-specific repression networks.
[0319] To uncover the regulatory mechanisms underlying GB heterogeneity and transition, we developed scDORI, a deep-learning-based framework that infers continuous eGRNs from paired single-cell RNA and chromatin accessibility data. This approach addresses the limitations of previous methods by offering scalability to large datasets, flexibility beyond predefined cell type annotations, and the ability to model cell state-specific differences in eGRNs, including gene activation and repression19'22'25'26. Applied to our GB multi-ome atlas, we identified several distinct regulatory Topics with unique activation patterns across cells. These Topics correspond to specific gene programs characteristic of their respective cell states, such as neurotransmitter release in neuronal-like cells39and PDGF signaling in OPC-NPC-like cells40. Importantly, scDORI revealed functional heterogeneity within individual GB states, capturing hallmark features such as hypoxic stress and cytokine signaling in gliosishypoxia cells4243. We identified many transcription factors likely driving specific GB cell states and mapped how they regulate one another. This revealed a complex but structured landscape of possible state transitions which correlated with the level of epigenetic plasticity of each state. These findings are consistent with prior reports of state-specific features and developmental-like differentiation programs in GB, yet extend them by mapping the underlying gene regulatory logic and transcription factors that control them.
[0320] Among the most epigenetically confined populations, Neuronal-like cells deploy a distinct mechanism of plasticity suppression. This is orchestrated, at least in part, by MYT1L, a
[0321] transcriptional repressor with a well-established role in neuronal differentiation and development50’55’62. We found that MYT1L binds and represses regulators of all alternate malignant states, including AC-like (TRPS1, STAT3), Gliosis-Hypoxia-like (FOSL2, BACH1), and OPC-NPC-like (ASCL1, SOX10) programs, thereby locking cells in a low-plasticity neuronal-like state. Unlike a passive absence of permissive cues, this repressive architecture actively silences potential transitions, forming a barrier to phenotypic conversion. Functional experiments in patient-derived GB cells validate MYT1L as a key factor in this repressive program. Overexpression of MYT1L induces widespread chromatin compaction, suppresses alternate state regulators, and enforces a transcriptional and morphological shift toward a neuronal-like phenotype, marked by reduced proliferation, loss of tumor microtube connectivity, and an increase in neurite-like outgrowth. Conversely, MYT1L loss leads to chromatin opening and derepression of alternate fate regulators, increasing proliferative capacity and tumor microtube connectivity associated with highly aggressive mesenchymal-like states57’63.
[0322] These findings position MYT1L as a factor suppressing plasticity in GB that can reshape chromatin landscapes, curb tumor growth, and stabilize less aggressive intrinsic states. Upon transplantation in mice, MYT1L overexpression delays tumor progression and prolongs survival in vivo, suggesting a therapeutic relevance for targeting MYT1L. This is supported by TCGA patient data and previous studies showing that MYT 1 L suppresses glioma formation in neural stem and GB cells5964. Critically, we find that the functional effects of MYT1L depend on its repressor activity, as demonstrated by engineered fusions of the MYT 1 L DNA-binding domain with transcriptional repressors and activators, underscoring that repression is the key mode of plasticity control in this context and validating our computational model prediction. The logic of MYT1 L-mediated repression mirrors emerging safeguard mechanisms in development and cancer, where lineage-specific repressors maintain cell identity by silencing alternative fates1 65. These findings highlight how tumor cells can co-opt developmental repressors to fortify stable, low-plasticity phenotypes. From a cancer perspective, similar factors that suppress plasticity by repression have been reported in the liver and colon29’30, suggesting that such factors can be found and manipulated in different tumor contexts.
[0323] Our findings complement and extend our companion study (de Jong et al.), which resolved a conserved spatiotemporal trajectory of glioblastoma cells transitioning from developmental-like to gliosis and hypoxia-associated states across patients. This study mapped cell state transitions by integrating single-cell, spatial transcriptomic, and spatial whole-genome sequencing data. Here, we provide a missing mechanistic layer, showing that GB cell statesdiffer markedly in their epigenetic plasticity and that state-specific eGRNs shape transitions along the spatial trajectory. Importantly, our Topic-based inference framework captures spatial proximity between transcriptionally related cell states and supports the observation that state transitions follow preferred paths rather than arbitrary rewiring. Notably, we validate MYT 1 L as a Neuronal-like state-specific repressor that establishes an epigenetic barrier to plasticity, thereby anchoring cells at one end of the spatiotemporal axis. Together, our studies unify spatial and regulatory dimensions of GB heterogeneity and suggest that epigenetic restriction, as much as permissiveness, is a determinant of tumor architecture and evolution.
[0324] While our study provides significant insights into the regulatory mechanisms of GB heterogeneity, several limitations have to be considered. First, although scDORI offers a robust framework for eGRN inference, its predictions require experimental validation to confirm the functional roles of identified regulators, such as MYT1L. Second, our analysis focused on primary GB samples, but investigating recurrent tumors and their therapy response would provide an exciting future perspective. Third, our findings position the Neuronal-like state as a low-plasticity, more benign GB state, but this may not fully capture its role in the GB ecosystem. Future work is needed to test whether this epigenetically constrained state serves specialized, tumor-promoting functions via non-cell-autonomous mechanisms, such as neuron-to-cancer synaptic or paracrine signaling, or even self-stimulatory cancer-intrinsic neural-like “auto-synaptic or auto-paracrine” interactions1|2.
[0325] Our findings suggest a revised model of GB plasticity in which tumor cells reside in a structured landscape of epigenetic potential, with transitions governed by enabling and constraining forces. The Neuronal-like state could represent a low-plasticity attractor state actively maintained by transcriptional repression and potentially exploitable for therapeutic reprogramming. Future work should explore whether other repressors operate similarly in alternate states and whether their modulation can tip the balance toward benign or therapysensitive configurations. Combining single-nucleus multiome data, plasticity quantification, continuous eGRN inference, and functional validation offers a blueprint for uncovering regulatory bottlenecks in other heterogeneous cancers. Beyond GB, targeting repressors like MYT 1 L may provide a general strategy to stabilize tumor states, suppress malignant evolution, and enhance differentiation-based therapies.
[0326] Materials and methods
[0327] 1. Bioinformatics analysis
[0328] The transcription factors were identified using bioinformatics, benchmarking and statistical methods. Briefly, scDoRI (single-cell Deep Multi-Omic Regulatory Inference) jointly modelssingle-cell RNA-seq and ATAC-seq data to infer enhancer-mediated gene regulatory networks (eGRNs). Unlike methods that handle dimensionality reduction and eGRN inference as separate steps, scDoRI unifies these tasks so that its latent factors naturally capture coordinated changes in gene expression and chromatin accessibility, without relying on predefined cell type clusters. Operationally, scDoRI adopts an Encoder-Decoder design, reminiscent of variational autoencoders like scVI [Romain Lopez et al. Deep generative modeling for single-cell transcriptomics. Nat. Methods, 15(12): 1053-1058, December 2018], wherein an encoder learns a shared low-dimensional representation, and mechanistically constrained decoders map that representation back to observed RNA and ATAC profiles. These decoders are designed to enforce key regulatory logic, such as how open chromatin regions activate nearby genes through enhancer-gene links, and how transcription factors (TFs) act as activators or repressors by binding to regulatory elements. Through this design, scDoRI learns topics: factors that simultaneously group co-accessible peaks, co-expressed genes, and TF regulators into putative TF - gene networks mediated by enhancers. Since scDoRI represents each cell as a mixture of topics (instead of forcing cells into discrete clusters), the model can capture continuous, cell-specific changes in GRNs. Moreover, by processing data in mini-batches, scDoRI is scalable to millions of cells.
[0329] A brief description of the methods is below.
[0330] The scDoRI framework used input matrices derived from paired scRNA-seq and scATAC-seq (multi-omic) data. A key preprocessing step in scDoRI is the computation of signed TF-peak interaction matrices, which serve as a central input for downstream GRN inference. These matrices build upon the “in silico ChlP-seq” framework introduced in [Ricard Argelaguet et al. Decoding gene regulation in the mouse embryo using single-cell multi-omics.bioRxiv, page 2022.06.15.496239, June 2022], which in turn extends DiffTF [Berest et al. Quantification of differential transcription factor activity and multiomics-based classification into activators and repressors: diffTF. Cell Rep., 29(10):3147-3159.e12, December 2019], to estimate the functional binding behavior of TFs at regulatory regions]. The core idea is to capture not just where a TF might bind (via its motif), but also how its expression correlates with the accessibility of those sites across the dataset. Specifically, a positive correlation between TF expression and peak accessibility suggests the TF is associated with opening chromatin when bound — an activator-like signature. Conversely, a negative correlation implies that TF expression is associated with closing chromatin — suggestive of repressive activity. This modeling choice for repressors adapts prior work in DiffTF [van Berest, et al. Quantification of differential transcription factor activity and multiomics-based classification into activators andrepressors: diffTF. Cell Rep., 29(10):3147-3159.e12, December 2019], which treats chromatin closing as a specific signature of repression. We note that while effective, this approach is limited in that it may miss repressive regulatory events that do not involve measurable chromatin closure. To capture these patterns, we integrated three signals:
[0331] 1. Motif match scores that estimate the likelihood of TF binding to a given peak;
[0332] 2. TF-accessibility correlations to determine whether binding tends to open or close chromatin;
[0333] 3. Filtering using a TF-specific background of non-motif peaks to filter false positives
[0334] The scDoRI model consists of an Encoder and a Decoder. The Encoder maps the input data into a shared latenttopic space, while the Decoder reconstructs the observed data modalities and infers GRNs incorporating both activator and repressor components. The Decoder has 4 Modules: 1. ATAC Reconstruction, 2. RNA Reconstruction from ATAC, 3. TF Expression Reconstruction, 4. GRN Inference with Activators and Repressors. Each module captures a distinct aspect of regulatory inference, ranging from raw accessibility and gene expression reconstruction (Modules 1-3) to the final context-aware inference of signed TF-gene regulatory networks (Module 4).
[0335] scDoRI employs several data reconstruction and regularization losses to balance accurate reconstruction with interpretable parameters. Specifically, we modeled ATAC-seq fragment counts using a Poisson likelihood and RNA-seq using a negative binomial (NB) likelihood, which better captures the mean-variance relationship typical of scRNA-seq data, following practices established in scVI [Lopez, et al. Deep generative modeling for single-cell transcriptomics. Nat. Methods, 15(12):1053-1058, December 2018], In all cases, the model predicts the mean of the respective distribution; for NB likelihoods, gene- or TF-specific overdispersion parameters are learned from the data.
[0336] Like a conventional autoencoder, scDoRI is trained using reconstruction-based objectives for each modality. However, because the data are multi-modal and scDoRI integrates multiple, mutually dependent decoders (Modules 1-4), we adopt a two-phase optimization strategy to ensure stable training. Since Module 4 depends on the latent topics and representations learned by Modules 1-3, we first train these core components independently. In the second phase, we introduce the signed GRN module (Module 4) and fine-tune the model to capture TF-mediated regulatory effects, including activation and repression.
[0337] After the training the scDoRI model, additional steps were carried out including:
[0338] 1. Visualizing the scDoRI latent space and aggregating topic usage across cell-states,
[0339] 2. Analyzing the topic-peak matrix (for inspecting co-accesibility patterns of enhancers),3. Computing a topic-gene matrix (using Module 2) and performing gene set enrichment (GSEA),
[0340] 4. Inspecting the peak-gene matrix for enhancer-gene links,
[0341] 5. Building Topic-specific GRNs with empirical permutation-based significance,
[0342] 6. Identifying top activators or repressors per topic (these serve as TRs as used in TAP analysis (Figure 3, 2.5)),
[0343] 7. Computing TF activity at both the cell and topic levels.
[0344] 8. Downstream targets of TFs across topics
[0345] Single-cell technologies that co-profile gene expression (RNA) and chromatin accessibility (ATAC) in the same cell have provided opportunities to infer accurate eGRNs. From these multi-omic data, three key “signatures” can be leveraged for inferring eGRNs:
[0346] 1. TF-Peak Mapping: Identifies which transcription factors (TFs) potentially bind which accessible DNA elements (peaks).
[0347] 2. Peak-Gene Linking: Discovers which regulatory elements (enhancers or promoters) modulate which genes, based on accessibility-expression covariation or proximity.
[0348] 3. TF-Gene Relationships: Connects TF expression / activity to gene expression changes, ideally clarifying which TF is activating or repressing a target gene.
[0349] Many published GRN inference pipelines exploit some (or all) of these signatures, but often do so in a stepwise manner — mapping TF motifs, correlating peaks and genes, then refining TF-gene edges. Meanwhile, a separate class of methods focuses on dimensionality reduction (DR) or factor modeling to jointly embed multi-omic data, typically aiming for a low-dimensional representation that summarizes cellular variation. However, these DR methods rarely impose mechanistic constraints (e.g., binding or enhancer logic) on the learned factors. scDoRI fuses these two paradigms: (1) mechanistic eGRN inference and (2) interpretable dimensionality reduction — within a single deep-learning framework. This fusion enables cells to be represented as combinations of regulatory topics, each corresponding to an interpretable TF-gene program. As a result, scDoRI eliminates the need for precomputed cell clusters, since cells are modeled as mixtures of regulatory programs rather than discrete assignments.
[0350] There are a number of relevant methods that focus on regulatory inference in both arenas, and scDoRI synthesizes the best of each. SCENIC+ was our principal benchmark for multi-omic eGRN inference. We direct readers to a recent review on eGRN inference using sc multi-ome data for detailed descriptions of different signatures and methods [Badia-I-Mompel, et al. Generegulatory network inference in the era of single-cell multi-omics. Nat. Rev. Genet., June 2023]
[0351] Another body of work targets dimensionality reduction (DR) or factor analysis to embed RNA+ATAC data into a low-dimensional space. Such methods typically do not address TF binding or enhancer logic to explain gene-expression directly. By embedding explicit TF binding logic, chromatin accesibility dynamics and peak-gene relationships in the decoder, scDoRI’s latent topics gain a biologically grounded meaning. Instead of generic factors, each topic represents a GRN, connecting sets of peaks and genes under specific TF regulators.
[0352] For benchmarking, we first validated scDORI on semi-synthetic data and compared it against alternative GRN inference methods, adapting a previously proposed benchmarking strategy for GRN inference in Scenic+ [Gonzalez-Blas, et al. SCENIC+: single-cell multiomic inference of enhancers and gene regulatory networks. bioRxiv, page 2022.08.19.504505, August 2022], Specifically, we leveraged simulated single-cell multi-omic profiles (RNA and ATAC) of 4,000 cells derived from 8 distinct ENCODE cell lines. These profiles recapitulate real-world singlecell scenarios, while having additional molecular data (e.g., CRISPR knockouts, Hi-C profiles, and eQTLs) to assess inferred regulatory linkages. We considered 3,068 highly variable genes (HVGs) and 119,662 highly variable peaks. The peaks were chosen from a 150 kbp window around each gene body of the HVGs. Both scDoRI and SCENIC+ were trained on this dataset. To evaluate enhancer-gene link predictions, we used the benchmark introduced by [Moore et al. A curated benchmark of enhancer-gene interactions for evaluating enhancer-target gene prediction methods. Genome Biol., 21 (1): 17, January 2020.]. This resource provides a set of positive enhancer-gene links (validated via CRISPR knockouts, chromatin con- formation assays, or eQTL relationships) alongside a set of negative links. We restricted our analysis to benchmarked cell type-evidence pairs with at least 10 positive enhancer-gene pairs overlapping our data. Both scDORI and SCENIC+ were used to assign peak-gene linkages, and performance was quantified by the Area Under the Precision-Recall Curve (AUPRC).
[0353] For analysis of the GB multi-ome atlas, reads from snRNA-seq and ATAC-seq libraries were aligned to a custom genome combining the 10X Genomics GRCh38 pre-mRNA reference and Cell Ranger-Arc ATAC genome (v1.0.1). Initial quantification and filtering were performed using default parameters of the Cell Ranger-Arc pipeline. RNA data quality control involved filtering nuclei based on gene and UMI counts, as well as mitochondrial read proportions, to exclude low-quality or stressed cells. Doublet detection and removal were conducted using Scrublet [Samuel L Wolock, et al: computational identification of cell doublets in single-celltranscriptomic data. Cell systems, 8(4):281-291, 2019], followed by additional filtering at both the individual cell and cluster levels to refine the dataset.
[0354] ATAC data were processed with ArchR [Granja, et al. Archr is a scalable software package for integrative single-cell chromatin accessibility analysis. Nature genetics, 53(3):403-411, 2021.], applying thresholds on fragment counts and transcriptional start site enrichments to retain high-quality barcodes. RNA quality-filtered barcodes were used to filter the ATAC data, ensuring consistency between modalities.
[0355] This filtering step resulted in 1,025,329 nuclei, which we used for training cell-type label agnostic scDoRI model and obtaining results shown herein. snRNA-seq datasets were integrated using scVI [Lopez et al. Deep generative modeling for single-cell transcriptomics. Nat. Methods, 15(12): 1053-1058, December 2018], incorporating patient ID, tumor site, reaction date, and cell cycle phase as batch covariates. Highly variable genes were identified using dispersion-based methods, and clustering was performed in the scVI latent space. Malignant clusters were further identified using copy number variation profiles (e.g., characteristic gains and losses) inferred with inferCNV [Timothy Tickle, et al. infercnv of the trinity ctat project. Klarman Cell Observatory, Broad Institute of MIT and Harvard, 2019], Clusters were annotated into malignant or tumor microenvironment (TME) populations based on marker gene expression.
[0356] Subclustering of malignant and TME populations enabled more granular annotation. TME cell types were annotated using known human brain marker genes, while malignant subclusters were classified using a combination of gene module scoring (following Neftel et al. [Neffle et al: An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell,178(4):835-849.e21, August 2019]), projection onto a developmental brain atlas [Emelie Braun et al. Comprehensive cell atlas of the first-trimester developing human brain. Science, 382(6667):eadf1226, 2023.], and gene set enrichment.
[0357] Simultaneous measurements of gene expression (RNA) and chromatin accessibility (ATAC) in single cells enable the assessment of the coupling between these two regulatory layers. While chromatin accessibility and transcription are often coordinated, regions of accessible chromatin that are not yet accompanied by active gene expression may indicate a primed state, poised for future transcriptional activation. This decoupling reveals a cell’s latent potential to switch or activate alternative transcriptional programs - a feature we term epigenetic plasticity: the capacity of a cell’s chromatin landscape to support multiple or alternative transcriptional identities. To quantify this phenomenon, we adapted a framework from [Burdzia et al Epigenetic plasticity cooperates with cell-cell interactions to direct
[0358] pancreatic tumorigenesis. Science, 380(6645):eadd5327, May 2023], which leverages a linear classifier trained on RNA profiles but subsequently applied to ATAC-derived gene scores. These gene scores were computed using ArchR [Granja, et al. Archr is a scalable software package for integrative single-cell chromatin accessibility analysis. Nature genetics, 53(3):403-411, 2021.] by aggregating accessibility over promoter regions, gene bodies, and distal regulatory elements weighted by distance. Higher uncertainty or misclassification in the ATAC-based predictions reflects greater chromatin priming and, consequently, elevated epigenetic plasticity (Fig 1B, C).
[0359] To assess epigenetic priming of TRs in GB cells, we examined discrepancies between their expression and chromatin accessibility across the dataset. Due to the high heterogeneity among GB cells, we used topic activation patterns to define finer-grained cell subsets that share similar regulatory dynamics. For each topic, we selected the top 5000 cells with the highest activation scores and computed the average TR expression and accessibility within these cells. TR accessibility was quantified using the Gene Score function from ArchR [Granja, supra], which estimates chromatin accessibility for each gene by aggregating ATAC-seq signal across gene body, promoter, and distance-weighted distal regulatory elements. To enable comparison across topics, both TR expression and accessibility values were min-max scaled across all topics. We defined a TR as epigenetically primed in a given topic-defined substate if its scaled expression was below 0.3 while its scaled accessibility was above 0.5.
[0360] To investigate potential regulatory interactions between scDoRI topics and their effect on state transitions, we developed a computational metric to quantify the Topic Activation Potential (TAP) between pairs of topics. This approach leverages scDoRI’s inferred eGRNs and is motivated by the observation that key topic regulators (TRs) can be epigenetically accessible, even if not currently expressed, in alternate states, suggesting potential for future activation. The TAP provides a quantitative measure of the ease with which cells with a given active topic A can activate a distinct topic B. The core premise of our framework is that activating the TRs of the target topic B is sufficient to drive its respective activation. This concept is analogous to cellular reprogramming strategies, where overexpression of key TFs induces transdifferentiation or pluripotency [Takahashi and Shinya Yamanaka. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4):663-676, August 2006], Two primary scenarios underpin this framework:
[0361] 1. Shared TR Expression: If TRs characteristic of topic B are already expressed in cells with topic A, the transition is facilitated due to the existing expression of critical regulatory factors.
[0362] This scenario is common between transcriptionally similar topic-defined substates (i.e., subset of cells where each topic is active).
[0363] 2. Epigenetic Priming: For transcriptionally distinct states where TRs of topic B are not expressed in cells with topic A, transitions may occur if these TRs are epigenetically primed — that is, their chromatin regions are accessible in cells with topic A. This accessibility lowers the activation barrier, making it easier for these TRs to be expressed upon receiving appropriate regulatory signals.
[0364] To compute the TAP between a given topic pair, we consider three major components: (i) the regulatory influence of TFs in topic A over TRs of topic B, (ii) accesibility (priming) of TRs of topic B within cells with topic A, and (iii) the extent of downstream effects of TRs in topic B (Figure 3C). These components are detailed in the following subheadings.
[0365] We determined the Topic Repression Score (TRS) which mirrors the Topic Activation Potential (TAP) but focuses on quantifying repressive interactions between topics (Figure 4A).
[0366] To gain a more complete view of GB state transitions, we integrated both activation and repression to assess how these opposing forces collectively shape transitions. Specifically, we defined a net topic transition potential as the difference between TAP and TRS values for every pair of topics, reflecting the net effect of all activating and repressing interactions between topics.
[0367] To understand how regulatory interactions between topics drive transitions between cell states, we computed the net influence of all activating and repressing links between pairs of states. The goal is to quantify whether one state promotes or inhibits transitions into another based on the cumulative behavior of its active gene programs. Intuitively, we measure how strongly topics active in one state (State A) activate or repress topics active in anotherstate (State B). We do this by summing all TAP (activating) or TRS (repressing) interactions from topics in A to those in B, weighted by the relative activity of those topics within their respective states (Figure 3D, E).
[0368] Topics were spatially mapped to Visium voxels using Cell2location [Kleshchevniko et al Cell2location maps fine-grained cell types in spatial transcriptomics. Nat. Biotechnol., 40(5): 661-671, May 2022], a method originally designed to map cell types onto spatial transcriptomics data by leveraging reference gene expression profiles for each cell type. In our adaptation, we used the topic-gene matrix as the reference, allowing each scDoRI topic to betreated as a distinct transcriptional program for spatial deconvolution. For each topic, its assignment to a voxel was determined based on two criteria: (1) the inferred abundance of the topic exceeded the median abundance for that topic across all voxels, and (2) the abundance was greater than a baseline threshold of 5. This baseline threshold was chosen to filter out low-signal assignments, ensuring that only biologically meaningful voxel-topic associations were retained. To assess pairwise topic relationships within each tissue section, we computed the pairwise distances between topics. For each section, the distances were summarized by taking the average of the bottom 10th percentile of distances for each topic pair. This approach emphasized close relationships between topics by focusing on their minimum distances, avoiding bias from outlier values. To compare topic spatial organization across the dataset, we first computed pairwise spatial distances between topics within each tissue section. These distances were then averaged across all sections to obtain a single distance value for each topic pair, capturing overall spatial similarity while accounting for variation across sections.
[0369] For selected pseudotime-ordered clonal subpopulations, we reconstructed underlying regulatory interactions based on temporal topic activation patterns. We identified relevant TFs involved in each trajectory as those differentially expressed across respective clonal populations. To highlight temporal variations in their accessibility and expression, we grouped them based on their dominant state of expression and computed the average accessibility and expression of each group along cells in each trajectory. For clarity when plotting, we binned temporally adjacent cells in groups of 50 cells. We separated each trajectory into stages determined by temporal co-activity patterns of topics, and assess the underlying regulatory interactions between these TFs at each stage by merging the GRNs of all co-active Topics.
[0370] 2. TF manipulation in PDGCs
[0371] 2.1 Cell culture
[0372] S24 Patient-derived glioma cells (PDGCs) were derived from freshly dissected glioblastoma (GB) tissue from adult patients after informed consent. PDGCs P3XX and BG5 were kindly provided by Hrvoje Miletic, K. G. Jebsen, Brain Tumour Research Centre, University of Bergen. PDGCs were maintained under stem-like neurosphere conditions and cultured in GBM medium consisting of DMEM F12 (Gibco), 1x B27 supplement (without Vitamin A) (Life Technologies), 5 zg / mL insulin (Gibco), 5 zg / mL heparin (Sigma-Aldrich), 20 ng / mL basic fibroblast growth factor (bFGF, Thermo Fisher Scientific), and 20 ng / mL epidermal growth factor (rhEGF, R& D System). HEK293T (CRL-3216, ATCC) cells were used to produce lentiviral particles. These cells were maintained in growth medium comprising DMEM (Gibco)supplemented with 1x GlutaMAX (Gibco), 1x penicillin-streptomycin (Gibco), 1x MEM non-essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), 0.1 mM ^-mercaptoethanol (Life Technologies), and 10% (v / v) cosmic calf serum (Thermo Fisher Scientific).
[0373] 2.2 Lentiviral Production and Transduction
[0374] Lentivirus was produced through transfection of lentiviral backbones containing indicated transgenes along with third-generation packaging plasmids into HEK293T cells according to the Trono laboratory protocol. Lentivirus was concentrated from HEK293T culture supernatant through ultracentrifugation (69,000g for 2h at 4°C) and stored at 80°C or used immediately. For transduction, single cell suspensions of 1 x 106 human PDGCs were incubated with 10 zg / mL polybrene (Sigma-Aldrich) for 15 minutes at 37 C. Lentiviral particles were then added and incubated for 24 hours. After 48 hours, cells were subjected to selection with 2 zg / mL puromycin, with medium changes every 2-3 days. Cell lines were stably transduced with the following vectors: pLVX-puro, pLVX-puro_hsMYT1 L, pLIX-puro, pLIX-puro_hsMYT1 L, pLIX-puro-FLAG-NLS-MYT1 L-DBD, pLIX-puro-FLAG-NLS-MYT1 L-DBD-VP64, pLIX-puro-FLAG-NLS-MYT1L-DBD-EnR, lentiCRISPRv2-gMYT1L, lentiCRISPR-B3, pSicoR-puro_shCtrl, and pSicoR-puro_shMYT1 L. MYT1 L overexpression was confirmed by Western blot analysis, and MYT 1 L knockout / knockdown was confirmed by qPCR analysis.
[0375] 2.3 ATAC sequencing
[0376] ATAC sequencing was performed on MYT1 L-perturbed PDGCs (S24 & BG5) 3 and 8 days after lentiviral transduction with MYT1L overexpression and knockout vectors, as well as respective non-targeting controls. For each condition, neurospheres from 3 independent transduction batches were dissociated with Accutase, resuspended in ice-cold 1%BSA in PBS and strained through a 70 pm filter. 50,000 cells from each sample were lysed in ice-cold lysis buffer (0.1% NP-40 and 0.01% digitonin in Wash buffer: 10 mM Tris-HCI pH 7.5, 10 mM NaCI, 3 mM MgCI2, 0.1% Tween-20, and 1% BSA in ddH2O) for 3-5 min and subsequently washed with 1 mL of Wash buffer. Equal volumes of tagmentation oligo pairs (Tn5ME + Tn5R1N, Tn5ME and Tn5R2N) were annealed in oligo annealing buffer (10 mM Tris-HCI pH 7.5, 50 mM NaCI, and 10 mM EDTA in ddH2O) by heating them to 95°C (3 min) followed by a ramp down by 1°C to 25°C. Tn5 transposomes were assembled by combining 501 L Tn5 (1 mg / mL stock) with 25 L of each annealed oligo pair. DNA tagmentation was conducted by resuspending lysed samples in tagmentation buffer (38.8 mM Tris-acetate, 77.6 mM K-acetate, 11.8 Mg-acetate, 0.1% BSA, 18.8% dimethylformamide, and 0.12% NP-40 in ddH2O) and adding 5 L of pre-assembled Tn5, followed by a 30 min incubation at 37°C. Tagmented DNA was purifiedwith the MinElute Purification Kit (Qiagen) and pre-amplified with P5 and P7 primers using the NEBNext HF 2x PCR Master Mix (New England Biolabs) in a thermocycler set to 72°C (5 min), 98°C (30 sec), and 5 cycles of 98°C (10 sec), 63°C (30 sec), and 72°C (1 min). A qPCR side reaction was performed with the resulting pre-amplified libraries to determine the necessary additional cycles (5 cycles fewer than those corresponding to 1 / 3 of max fluorescence) for complete amplification. Amplified libraries were subjected to 2-sided size selection with AM Pure XP beads to isolate fragments between 100-500 bp and sequenced on the NextSeq 2000 platform (Illumina).
[0377] 2.4 ATAC data analysis
[0378] Data analysis was performed using the Nextflow ATAC-seq pipeline (Nextflow v23.04.3). Briefly, raw reads were quality-checked with FastQC (vO.11.9), trimmed with TrimGalore (vO.6.7) and aligned to hg38 with BWA(vO.7.17). Aligned reads were cleaned and filtered with samtools (v1.17), bedtools (v2.30.0), and picard (v3.0.0). Peaks were called using MACS2 (v2.2.7.1). Final quality checks were performed with multiqc (v4.7). Differential peak analysis was performed with DiffBind (v3.16.0), adjusting summit sizes to 500bp, and taking all peaks with FDR below 0.05 as significant. We annotated differentially accessible (DA) ATAC peaks by running Homer annotatePeaks.pl on the final set of peaks. Among the set of all DA peaks linked to each gene, we select the closest one to the gene TSS for the volcano plot.
[0379] 2.5 CUT& RUN sequencing
[0380] CUT& RUN sequencing was performed in S24 PDGCs 8 days post-transduction with MYT1L overexpression or control vectors. For each condition, neurospheres from 3 independent transduction batches were dissociated with Accutase, resuspended in ice-cold 1%BSA in PBS and strained through a 70 pm filter. 100,000 cells were collected per sample and MYT 1 L-bound DNA regions were isolated following previously published protocols. Briefly, cells were bound to Concanavalin-A beads (Polysciences), permeabilized and incubated with 1 pg of MYT1L antibody (Millipore #ABE2915) at 4C for 1 hr. Non-specific binding controls were also performed for each sample by incubating with an IgG antibody (Sigma 12-370) instead. Unbound chromatin was digested with protein A-MNase + CaCI2 treatment and undigested DNA was isolated through phenol-chloroform extraction. Libraries were prepared with the NEBNext DNA Library Prep Kit for Illumina (NEB E7645) and sequenced (paired-end, 2x40 bp) on the NextSeq 2000 platform (Illumina).
[0381] 1.6 CUT& RUN data analysis
[0382] CUT& RUN data was analyzed using the nf-core / cutandrun pipeline vl.0.0 with Nextflow v23.04.3. Reads were aligned to hg38. Software versions: bedtools (v2.30.0), bowtie2 (2.4.4), deeptools (v3.5.1), fastqc (vO.11.9), multiqc (v1.11.9), picard (v2.27.4), samtools (v1.16.1), TrimGalore (vO.6.6), ucsc (v385). Consensus peaks were defined with Genrich (v0.6.1)(https: / / github.com / jsh58 / Genrich) using FDR-adjusted p-values below 0.005. Signal intensity of consensus peaks was assessed in MYT 1 L OE and control samples with deeptools. Direct target genes were determined by running Homer annotatePeaks.pl on the final set of peaks and filtering for genes with a peak within a window of -10kb from their transcription start site (TSS) and the end of the gene body.
[0383] 2.7 MYT1L regulon construction
[0384] To reconstruct the regulon of MYT1L in PDGCs, we considered genes directly bound by MYT1L (CUT RUN seq) whose accessibilty changed upon MYT1L OE (ATAC-seq) either at day 3, day 8, or both, post-transduction. Here, a more relaxed DA threshold was considered (FDR<0.25) to capture more subtle changes in regulation. To determine the net differential accessibility of each gene accounting for all linked peaks, we calculated the weighted average fold change of all DA peaks associated to each gene, prioritizing peaks closer to gene TSS as follows:
[0385] Weigh
[0386]
[0387] where FCi is the fold change of peak i, Di is the distance from peak i to the TSS of gene A, and N is the number of peaks associated to gene A.
[0388] We then overlapped DA genes with MYT1 L targeted genes (MYT1L binding within -10kb from TSS and the end of gene body) to obtain a final set of MYT 1 L regulated genes.
[0389] We also used this analysis to assess the precision of scDORI in predicting MYT 1 L downstream targets. For fair comparison, we considered MYT 1 L targets predicted in at least one topic and determined the percentage of these that were (i) truly bound by MYT 1 L and (ii) bound by MYT1L and differentially accessible (either in same or opposite direction). We performed the same analysis with an eGRN inferred with SCENIC+ for comparison.
[0390] 2.8 RNA Sequencing
[0391] Bulk RNA-seq was performed in three PDGC lines (S24, P3XX, and BG5) previously transduced with MYT1L overexpression or knockout constructs, along with their respective controls. Three biological replicates of each line were harvested, and total RNA was isolated using the Direct-zol RNA Miniprep kit (Zymo Research). RNA-seq libraries were prepared
[0392] following the dllTP protocol and sequenced on the NovaSeq 6000 S4 Sequencing System (Illumina). For RNA-seq analysis, raw reads were mapped to the hg38 reference genome using STAR. Differential expression was ascertained with DESeq2 taking an adjusted p-values<0.05. Differentially enriched pathways were assessed with gene set enrichment analysis (GSEA) by comparing all differentially expressed genes ranked by fold change against all gene sets in subcategories H, C2, C5 and C8 from MSigDB database v2023.1. Hs with at least 15 and at most 500 overlapping genes using decoupler (v1.6.0).
[0393] 2.9 PDGC proliferation assay
[0394] Proliferation of MYT1 L-perturbed PDGCs (S24 & BG5) was determined with the AlamarBlue assay (Invitrogen). Neurospheres from 3 independent transduction batches were dissociated at day 7 post-transduction with MYT1L overexpressing (S24), MYT1L knockout (BG5) or respective control constructs with Accutase. 30 wells with 2,000 cells each were seeded per condition in 96-well black plates with clear flat bottom (Corning), pre-coated with Geltrex (1:200 in DMEM: F12, 30 min, 37C), and allowed to attach for 4 hrs. Then, 10 pL of AlamarBlue reagent was added to each well and incubated for 2.5 h at 37 C and 5% CO2. The active compound in AlamarBlue dye, resazurin (7-hydroxy-10- oxidophenoxazin-10-ium-3-one), is a non-toxic redox indicator dye that permeates viable cell membranes and is metabolically reduced from its non-fluorescent, oxidized state, to resorufin, its fluorescent reduced state. Thus, metabolized media was collected in a separate microplate and fresh PDGC growth media was added to PDGCs. The fluorescence intensity of the collected media was measured using a Tecan infinite M1000Pro microplate reader with an excitation wavelength of 535 nm and an emission wavelength of 590 nm. Cells were incubated for 7 more days with periodic measurements upon exposure to AlamarBlue reagent at day 3, 5 and 7, as described above. PDGC proliferation was calculated as follows:
[0395] Proliferation
[0396]
[0397] where FS(t) denotes the fluorescence intensity of sample at day t, FB the background fluorescence of PDGC growth media and FS(tO) the fluorescence intensity of sample at day 0.
[0398] 2.10 PDGC connectivity assay
[0399] To investigate the tumor microtube (TM)-forming capabilities of WT and MYT1 L-perturbed PDGCs, we harnessed a recently developed 2D model that utilizes Matrigel for vessel coating and glucose-supplemented and growth-factor-devoid neurosphere medium, termed high-glucose medium (HGM) hereafter. The combination of these factors was proven to allow both preservation of the transcriptional underpinnings and expression of typical phenotypic features,i.e. infiltrative morphology and TM-network formation, of human primary PDGCs. 96-well imaging plates (#655090, Greiner Bio-One) were freshly coated with growth factor-reduced and phenol red-free Matrigel (#356231, Corning) diluted at a 1:50 ratio with growth-factor-free neurosphere medium (#11330-032, Life Technologies, part of Thermo Fisher Scientific). TdTomato-labeled S24 and BG5 PDGC neurospheres were freshly dissociated with Accutase (#1110501, Thermo Fisher Scientific), rinsed with PBS (#D8537, Sigma) and resuspended in HGM. 5,000 or 7,500 cells TdTomato-labeled S24 PDGCs + / - MYT 1 L OE or TdTomato-labeled BG5 PDGCs + / - MYT1L KO, respectively, were seeded per well. Cells were incubated for 3 days to allow TM formation. PDGCs were incubated with MemGlow560 (4 nM; #MG02-02, Cytoskeleton Inc.) 30 min prior to image acquisition to facilitate visualization of TMs. Subsequently, cells were gently rinsed three times with PBS (#D8537, Sigma, part of Merck). Image acquisition was carried out on a LSM 710 ConfoCor 3 confocal microscope (Zeiss) with a 20x (NA 0.8) dry objective and operated with the Zen black edition v.8.1.0.484 software (Zeiss). We quantified nuclei and TM connectivity using a previously established pipeline. Briefly, stained nuclei and cell bodies were segmented using the llastik v.1.3.2 software, with previous extensive training for this task. The total TM length per region-of-interest (ROI) was estimated as the sum of Euclidian diameter divided by the number of nuclei per ROI, reflecting the mean TM length / viable PDGC per ROI. To correct for differences in nuclei density per ROI, only ROIs with ± 1 standard deviation of the mean nuclei density were considered for further analysis. In order to improve the visibility of nuclei and TMs, Hoechst33342 and TdTomato signals were oversaturated in the displayed maximum intensity projections.
[0400] 2.11 Neuron-PDGC co-culture and morphology analysis
[0401] Primary hippocampal neuronal cultures were isolated from wild-type B6N at P0-1, as described previously. Briefly, the hippocampi from each mouse were carefully dissected in ice-cold HBSS and subsequently digested with papain (2.5 ml HBSS, 2.5 I 0.5 M EDTA pH 8.0, 40 I Papain) for 20 min at 37 °C. After washing twice, hippocampi were resuspended in 1 ml warm neuron plating medium (MEM, Fetal Bovine Serum (5%), 1X B27 Plus Supplement, D-Glucose (0.4%), GlutaMax (1%)) by gentle pipetting. Finally, the cell suspension was filtered through a 70 PXm cell strainer and seeded into 6 wells of a 48-well microplate, previously coated with Matrigel (1:100 in DM EM) for at least 1 hr at 37C. After 1 day, media was replaced with neuron growth medium (Neurobasal-A, 1X B27 Plus Supplement, Fetal Bovine Serum (5%), GlutaMax (1%)) with 25 PXM 5-Fluoro-2’-deoxyuridine (FLIDR). Primary cultures were allowed to become electrically mature for 7 days by replacing half of the media every second day with neuron growth medium, with additional 8 pM FLIDR only on day 3. We confirmed thatprimary cultures effectively form interconnected electrical networks within 7 days by seeding primary cultures on PEI-laminin coated 48-well Multi-electrode Array (MEA) plates (Axion Biosystems) and measuring electrical field potentials overtime with the Maestro Pro multiwell device (Axis Navigator software). On the same day as primary hippocampi isolation, TdTomato-expressing S24 PDGCs were transduced with MYT1L overexpression or control vectors, so that on day 7, they were dissociated with Accutase and seeded onto primary neuronal cultures. PDGCs were seeded at a low density of 5,000 cells per well to prioritize interactions with primary neurons rather than with other PDGCs. Cultures were fixed 7 days later with 4% paraformaldehyde (PFA) for 1 hr at 4C and subsequently washed 3 times with PBS. Fixed cultures were imaged at 10X magnification with a Nikon Ti-HCS inverted microscope using the NIS-Elements acquisition software. Co-cultures were performed with 9 independent primary cultures and 4 independent transduction batches, imaging 1-2 distinct regions of each combination. For all PDGCs in each field of view, the average number of primary branches per cell was determined by counting projections emerging directly from each cell body. Similarly, the average number of total branches per cell was determined by counting all terminal branches from each cell.
[0402] 2.12 Spheroid growth assay
[0403] Growth of MYT 1 L-perturbed PDGC spheroids was assayed by measuring spheroid radius overtime. Single spheroids of S24 PDGCs, previously transduced with doxycycline (DOX)-inducible MYT 1 L overexpression or control vectors, were transferred to the center of a Geltrex containing well (48-well plate, Corning) on ice and subsequently incubated at 37°C for 1 hr. Fresh PDGC growth media supplemented with 2 pg / mL doxycycline was then added to embedded spheroids, which were maintained for 7 days with media change ever 2-3 days. A total of 27-29 spheroids from 3-4 independent transduction batches were assayed for each condition. All spheroids were imaged at day 0 and 7 on a DM IL LED fluorescence microscope (Leica) using the LAX software (4X magnification, brightfield). Fluorescent images were binarized to create a spheroid mask and area was quantified. Spheroid growth was determined as the fold change in spheroid area at day 7 with respect to day 0.
[0404] 2.13 Activator-Repressor Fusion assay
[0405] To assess the predominant function of MYT1L in regulating PDGC proliferation and spheroid growth, S24 PDGCs were transduced with DOX-inducible contructs encoding the minimal DNA-binding domain (DBD) of MYT1L (410-623) fused through its C-terminus with either (i) an activator domain (VP64), containing 4 tandem repeats of the minimal activation domain ofVP16 (amino acids 437-447) from herpes simplex virus, or (ii) the engrailed (EnR) repressor domain (amino acids 1-298) from Drosophila melanogaster. Alamar blue and Spheroid growth assays were performed following 2 pg / mL DOX addition to PDGC growth media, as described above. For spheroid growth assays, 14 (DBD-VP64) and 21 (DBD-EnR) spheroids assayed within 3 independent batches were analyzed. Resulting values from each assay at day 7 were normalized to those of their respective non-induced controls and compared to results obtained with full-length MYT 1 L overexpression.
[0406] 2.14 PDX models
[0407] NMRI nude mice (8-10 weeks old, Charles River) were used to study intracranial tumor growth. Mice were kept in constant housing conditions: temperature 22+ 2 °C, humidity 55 ± 10%, 12 h light / dark cycles). All animal procedures were performed in accordance with the institutional laboratory animal research guidelines after approval of the responsible animal welfare officer (German Cancer Research Center, Heidelberg, Germany) and the regional council (Referat 35, RegierungsprAnsidium Karlsruhe, Germany). For survival studies, 100,000 S24 PDGCs, previously transduced with MYT1L overexpression or control vectors, were resuspended in PBS and intracranially transplanted in the cortex of mice (n=7 or 6, respectively) via stereotactic injection. Tumor growth was monitored with weekly Magnetic Resonance Imaging (MRI). T1- and T2-weighted MRI images were acquired on a 9.4 T horizontal bore MR scanner (BioSpec 94 / 20 USR, Bruker BioSpin) following injection of contrast media (80 I ProHance, 0,5 mmol / kg bodyweight, Bracco). During MRI examinations, mice were anesthesized with 3 - 3.5 % sevoflurane with 0,5 l / min air flow. Mice were scored clinically and euthanized if they reached termination criteria, showed excessive intracraneal fluid accumulation or if tumor volumes exceeded 150 pL. For in vivo two-photon imaging, a chronic cranial window and a titan ring were implanted to allow pain-free fixation of the animals during two photon microscopy. Two weeks after window implantation, 30,000 TdTomato-labeled S24 PDGCs, previously transduced with MYT1L overexpression or control vectors, were resuspended in PBS and intracranially injected in the cortex of mice (n=3 or 2, respectively) at a depth of 500 pm. Intravital two photon microscopy (2-PM) was performed 21 days after PDGC injection with a Zeiss 7MP microscope (Zeiss) equipped with a Coherent Chameleon Ultrall laser (Coherent) on anesthetized mice (4% isofluorane for initiation, 0.5-2% for maintenance of anesthesia). A custom-made aperture was used to allow painless fixation of the head for imaging. For angiograms, 10 mg / ml, TRITC-dextran (500 kDa; 52194, Sigma Aldrich) was injected via tail vein injection. The following wavelengths were used for excitation of different fluorophores: 850 nm (GFP, TRITC-dextran) and 950nm (TdTomato, YFP). Appropriate filter sets (band pass500-550 nm / band pass 575-610 nm) were used. Tilescans were imaged at a depth of 200 and 300 pm, covering an area of approximately 5,000 pm x 5,000 pm at each depth, which included the injection site and regions from both brain hemispheres. Images were analyzed with Fiji. The total number of PDGCs was counted manually after segmentation and summed across both imaging depths. The euclidean distance from each PDGC to the injection site was also measured.
[0408] 3. Statistical Analysis
[0409] Barplots indicate the mean ± s.d. with individual biological replicates shown as dots. Boxplots indicate the median with upper and lower quartiles as box limits and quartile range as whiskers. N represents the experimental replicates performed on separate days. No specific method was used to determine statistical assumption. All statistical details for experiments can be found the corresponding figure legends. Cells for in vitro analysis were randomly selected.
[0410] Example 2
[0411] Proof-of-concept validation of cell-state-specific GBM enhancers in patient-derived glioblastoma cells (reference to Figure 6)
[0412] Materials and methods. Using scDORI, we predicted 96 tumor-specific candidate enhancers from our in-house single-cell multiomic GBM dataset (~1 million cells). To experimentally validate two enhancer candidates (Seq ID 97 and Seq ID 102), each 500 bp enhancer sequence was cloned upstream of a minimal CMV promoter driving GFP in an AAV-compatible reporter backbone. Constructs were delivered by electroporation into patient-derived GBM cells (S24) and by transfection into HEK293T cells. GFP signal was quantified by fluorescence microscopy 72 h post-electroporation (S24) and 48 h post-transfection (HEK293T). A shuffled-sequence construct (E_Shf) and an SV40 enhancer construct (E_SV40) served as negative and positive controls, respectively.
[0413] Results. In S24 cells, the SV40 positive control showed strong GFP expression while the shuffled negative control yielded none, confirming that the reporter system is functional. Both candidate enhancers drove GFP expression in S24 cells, with Seq ID 97 showing markedly higher activity than Seq ID 102. In HEK293T cells, neither candidate enhancer produced GFP signal above the shuffled control, whereas SV40 drove robust expression, confirming efficient transfection. Both enhancers are predicted by scDORI to be specific to the AC-Gliosis-like cell states, which are the predominant states in S24 based on our single-cell RNA-seq.
[0414] Conclusion. scDORI can predict cell-state-specific GBM enhancers, and the two candidates tested here (Seq ID 97 and Seq ID 102) exhibit GBM-context-specific activity consistent withtheir predicted cell-state assignment. This proof-of-concept validates the approach and supports the broader use of scDORI predictions to identify functionally relevant, cell-state-specific regulatory elements that can drive GBM-state selectivity and targeted transgene expression.
[0415] Example 3
[0416] Experimental validation of transcriptional repressors that drive Neuronal-like state in patient-derived glioblastoma cells, (reference to figure 7)
[0417] Materials and methods. Using scDORI, we identified a set of transcriptional repressors in Neuronal-like cells predicted to safeguard Neuronal-like identity by repressing alternate fates. We experimentally tested these predictions by assessing the ability of these factors to (i) induce Neuronal-like identity and (ii) repress alternate-state identities upon overexpression in patient-derived GB cells (PDGCs). Specifically, we overexpressed 8 candidate TFs (MYT1L, ST18, NR3C2, POU2F2, BACH2, SOX4, SOX11, BCL11B) in monocultured S24 PDGCs by lentiviral delivery and performed ATAC- and RNA-sequencing at day 3 post-transduction.
[0418] Results. In monocultured PDGCs, all 8 candidates exhibited repression of alternate-state identities, evidenced by chromatin closure at alternate-state regions and / or negative enrichment of alternate-state programs, with MYT1L showing the strongest and broadest effects. In addition, SOX4 and SOX11 induced upregulation of Neuronal-like programs.
[0419] Conclusions. These experiments support the ability of all 8 scDORI-predicted TFs to safeguard Neuronal-like identity, either by repressing alternate identities or by directly inducing Neuronal-like programs. They provide tunable targets through which GBM cell identity can be redirected towards the least plastic Neuronal-like state.
[0420] Example 4
[0421] Capacity of predicted transcriptional repressors to reprogram patient-derived glioblastoma cells in co-culture with primary neural cells, (reference to figure 8)
[0422] Materials and methods. We performed a pooled TF overexpression screen in PDGCs cocultured with primary neural cells, including 10 candidate TFs (MYT1L, ST18, NR3C2, POU2F2, SOX4, SOX11, EBF1, KLF12, NPAS2, LEF1), and assessed Neuronal-like state induction by single-cell RNA sequencing. TFs were cloned into a barcoded Tet-ON lentiviral system and introduced into three PDGC lines (S24, P3, BG5) at low multiplicity of infection to ensure each cell received only one TF vector. PDGCs were co-cultured with primary cortical neurons to provide an instructive neural niche, induced with doxycycline, isolated by FACS,and profiled by scRNA-seq. Experiments were performed at two seeding densities across three biological replicates per line.
[0423] Results. In co-culture with primary neurons, 4 candidates showed significant induction of Neuronal-like identity (MYT1L, ST18, SOX4, SOX11), even though two of them had shown exclusively repressive effects in the monoculture setting.
[0424] Conclusions. These experiments highlight 4 scDORI-predicted TFs (MYT1L, ST18, SOX4, SOX11) capable of safeguarding Neuronal-like identity in a physiologically relevant neural niche, either by repressing alternate identities or by directly inducing Neuronal-like programs, and identify them as preferred targets for therapeutic GBM-state reprogramming.
[0425] Example 5
[0426] MYT1L plasticity-suppressing activity is retained under chemotherapy and radiation, (reference to figure 9)
[0427] Materials and methods. We assessed the robustness of MYT 1 L activity under therapeutic pressure by comparing OE effects in untreated versus treated cells. S24 PDGCs were transduced with a doxycycline-inducible MYT1L OE lentiviral vector and exposed to ionizing radiation (2 x 2 Gy, 24 h apart) or 300 μM temozolomide for 4 days, under doxycycline-depleted conditions. MYT1L OE was then induced in surviving PDGCs by the addition of doxycycline and maintained for 6 days in co-culture with primary neural cells. PDGCs were isolated by FACS and harvested for ATAC-sequencing. MYT1L OE PDGCs without pretreatment and unmodified PDGCs were handled analogously as controls.
[0428] Results. MYT 1 L gain-of-function consistently closed the chromatin of genes associated with non-Neuronal-like states and opened that of genes associated with the Neuronal-like state, in both untreated and therapy-exposed cells. Differentially accessible genes in pre-treated + MYT1L OE PDGCs largely overlapped with those of untreated MYT1L OE PDGCs, whereas overlap with pre-treatment-only PDGCs was limited. This indicates that the observed effects are predominantly driven by MYT1L OE.
[0429] Conclusions. These experiments demonstrate that MYT1L retains its ability to restrict malignant plasticity under standard-of-care therapeutic pressure, supporting a combinatorial strategy in which enforced plasticity restriction complements conventional treatments.
[0430] References
[0431] 1. Hanahan, D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 12, 31-46 (2022).2. Louis, D. N. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a 706 summary. Neuro-Oncol. 23, 1231-1251 (2021).
[0432] 3. van den Bent, M. J. et al. Primary brain tumours in adults. The Lancet 402, 1564-1579 (2023).
[0433] 4. Verhaak, R. G. W. et al. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 710 17, 98-110 (2010).
[0434] 5. Brennan, C. W. etal. The Somatic Genomic Landscape of Glioblastoma. Cell 155, 462-477 (2013).
[0435] 6. Ceccarelli, M. et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell 164, 550-563 (2016).
[0436] 7. Wang, J. et al. Clonal evolution of glioblastoma under therapy. Nat. Genet. 48, 768-776 (2016).
[0437] 8. Barthel, F. P. et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576, 112-120 (2019).
[0438] 9. Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary 22 glioblastoma. Science 344, 1396-1401 (2014).
[0439] 10. Neftel, C. et al. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell 178, 835-849.e21 (2019).
[0440] 11. Venkataramani, V. et al. Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell 185, 7232899-2917.e31 (2022).
[0441] 12. Couturier, C. P. et al. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nat. Commun. 11, 3406 (2020).
[0442] 13. Wang, X. et al. Single-cell multi-omics sequencing uncovers region-specific plasticity of 727 glioblastoma for complementary therapeutic targeting. Sci. Adv. 10, eadn4306 (2024).
[0443] 14. Wu, H. et al. Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma. Cancer Sci. 114, 2609-2621 (2023).
[0444] 15. LeBlanc, V. G. et al. Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity. Cancer Cell 40, 379- 732392. e9 (2022).
[0445] 16. Burdziak, C. et al. Epigenetic plasticity cooperates with cell-cell interactions to direct pancreatic tumorigenesis. Science 380, eadd5327 (2023).
[0446] 17. Bravo Gonzalez-Blas, C. et al. cisTopic: cis-regulatory topic modeling on single-cell ATAC-seq 736 data. Nat Methods 16, 397-400 (2019).
[0447] 18. Badia-i-Mompel, P. et al. Gene regulatory network inference in the era of single-cell multi-omics. Nat. Rev. Genet. 24, 739-754 (2023).
[0448] 19. Kamimoto, K., Hoffmann, C. M. & Morris, S. A. CellOracle: Dissecting cell identity via network inference and in silico gene perturbation. bioRxiv 2020.02.17.947416 (2020).
[0449] 20. Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083-1086 (2017).
[0450] 21. Berest, I. et al. Quantification of Differential Transcription Factor Activity and Multiomics-Based Classification into Activators and Repressors: diffTF. Cell Rep. 29, 3147-3159. e12 (2019).
[0451] 22. Fleck, J. S. et al. Inferring and perturbing cell fate regulomes in human brain organoids. Nature 746 (2022). 23
[0452] 23. Wang, L. et al. Dictys: dynamic gene regulatory network dissects developmental continuum with single-cell multiomics. Nat Methods 20, 1368-1378 (2023).
[0453] 24. Kartha, V. K. et al. Functional inference of gene regulation using single-cell multi-omics. Cell 750 Genomics 2, 100166 (2022).
[0454] 25. Bravo Gonzalez-Blas, C. et al. SCENIC+: single-cell multiomic inference of enhancers and gene regulatory networks. Nat. Methods 20, 1355-1367 (2023).
[0455] 26. Kamal, A. et al. GRaNIE and GRaNPA: inference and evaluation of enhancer-mediated gene regulatory networks. Mol. Syst. Biol. 19, e11627 (2023).
[0456] 27. Zhang, S. et al. Inference of cell type-specific gene regulatory networks on cell lineages from single cell omic datasets. Nat. Commun. 14, 3064 (2023).
[0457] 28. Badia-i-Mompel, P. et al. Comparison and evaluation of methods to infer gene regulatory networks from multimodal single-cell data. 2024.12.20.629764 Preprint at 759 https: / / doi.org / 10.1101 / 2024.12.20.629764 (2025).
[0458] 29. Lim, B. et al. Active repression of cell fate plasticity by PROX1 safeguards hepatocyte identity and prevents liver tumourigenesis. 2024.09.10.612045 Preprint at https: / / doi.org / 10.1101 / 2024.09.10.612045 (2024).
[0459] 30. Moorman, A. et al. Progressive plasticity during colorectal cancer metastasis. Nature 637, 947- 764954 (2025).
[0460] 31. Rumelhart, D. E., Hinton, G. E. & Williams, R. J. Learning internal representations by error propagation, in Parallel distributed processing: explorations in the microstructure of cognition, vol. 1: foundations 318-362 (MIT Press, Cambridge, MA, USA, 1986).
[0461] 32. Lynch, A. W. et al. MIRA: joint regulatory modeling of multimodal expression and chromatin accessibility in single cells. Nat Methods (2022).
[0462] 33. Zhao, Y., Cai, H., Zhang, Z., Tang, J. & Li, Y. Learning interpretable cellular and gene signature embeddings from single-cell transcriptomic data. Nat Commun 12, 5261 (2021).
[0463] 34. Argelaguet, R. etal. MOFA+: a statistical framework for comprehensive integration of multi modal single-cell data. Genome Biol. 21, 111 (2020).
[0464] 35. Lopez, R., Regier, J., Cole, M. B., Jordan, M. I. & Yosef, N. Deep generative modeling for 24 single-cell transcriptomics. Nat. Methods 15, 1053-1058 (2018).
[0465] 36. Svensson, V., Gayoso, A., Yosef, N. & Pachter, L. Interpretable factor models of singlecell RNA-seq via variational autoencoders. Bioinformatics 36, 3418-3421 (2020).
[0466] 37. Zhou, M. et al. Single-cell multi-omics topic embedding reveals cell-type-specific and COVID 19 severity-related immune signatures. Cell Rep. Methods 3, 100563 (2023).
[0467] 38. Kamal, A. et al. GRaNIE and GRaNPA: Inference and evaluation of enhancer-mediated gene regulatory networks applied to study macrophages.
[0468] 39. Fon, E. A. & Edwards, R. H. Molecular mechanisms of neurotransmitter release. Muscle Nerve - Wiley Online Libr. 24, (2001).
[0469] 40. Zhou, L. et al. Gabi mediates PDGF signaling and is essential to oligodendrocyte differentiation and CNS myelination. eLife 9, e52056 (2020).
[0470] 41. Parpura, V. & Verkhratsky, A. Homeostatic function of astrocytes: Ca2+and Na+signalling. Transl. Neurosci. 3, 334-344 (2012).
[0471] 42. Karsy, M., Guan, J., Jensen, R., Huang, L. E. & Colman, H. The Impact of Hypoxia and 789 Mesenchymal Transition on Glioblastoma Pathogenesis and Cancer Stem Cells Regulation. World Neurosurg. 88, 222-236 (2016).
[0472] 43. Hara, T. et al. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell 39, 779-792. e11 (2021).
[0473] 44. Kim, Y. et al. Perspective of mesenchymal transformation in glioblastoma. Acta Neuropathol. 794 Commun. 9, 50 (2021).
[0474] 45. Taylor, K. R. et al. Glioma synapses recruit mechanisms of adaptive plasticity. Nature 623, 366- 796374 (2023).
[0475] 46. Zhu, V. F., Yang, J., LeBrun, D. G. & Li, M. Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis. Cancer Lett. 316, 139-150 (2012).
[0476] 47. Cooper, L. A. D. et al. The Tumor Microenvironment Strongly Impacts Master Transcriptional Regulators and Gene Expression Class of Glioblastoma. Am. J. Pathol. 180, 2108-2119 (2012).
[0477] 48. Carro, M. S. et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463, 318-325 (2010). 25
[0478] 49. van Bruggen, D. et al. Developmental landscape of human forebrain at a single-cell level identifies early waves of oligodendrogenesis. Dev. Cell 57, 1421-1436. e5 (2022).
[0479] 50. Mall, M. et al. Myt11 safeguards neuronal identity by actively repressing many non-neuronal fates. Nature 544, 245-249 (2017).
[0480] 51. Natarajan, P. et al. Single Cell Deletion of the Transcription Factors Trpsl and Sox9 in Astrocytes Reveals Novel Functions in the Adult Cerebral Cortex. Glia n / a,.
[0481] 52. Davies, M., Boyce, M. & Conway, E. Short circuit: Transcription factor addiction as a growing 810 vulnerability in cancer. Curr. Opin. Struct. Biol. 89, 102948 (2024).
[0482] 53. Yabo, Y. A., Niclou, S. P. & Golebiewska, A. Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma. Neuro-Oncol. 24, 669-682 (2022).
[0483] 54. De Silva, M. I., Stringer, B. W. & Bardy, C. Neuronal and tumourigenic boundaries of 814 glioblastoma plasticity. Trends Cancer 9, 223-236 (2023).
[0484] 55. Weigel, B. et al. MYT1L haploinsufficiency in human neurons and mice causes autism associated phenotypes that can be reversed by genetic and pharmacologic intervention. Mol. Psychiatry 28, 2122-2135 (2023).
[0485] 56. Hai, L. et al. A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1. Nat. Commun. 15, 968 (2024).
[0486] 57. Osswald, M. et al. Brain tumour cells interconnect to a functional and resistant network. Nature 528, 93-98 (2015).
[0487] 58. Weil, S. et al. Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas. Neuro-Oncol. 19, 1316-1326 (2017).
[0488] 59. Melhuish, T. A. et al. Myt1 and Myt11 transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochim. Biophys. Acta BBA - Gene Regul. Meeh. 1861, 983-995 (2018).
[0489] 60. Albiach, A. M. et al. Futile wound healing drives mesenchymal-like cell phenotypes in human glioblastoma. 2023.09.01.555882 Preprint at https: / / doi.org / 10.1101 / 2023.09.01.555882 (2025). 829
[0490] 61. Mathur, R. et al. Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective. Cell 187, 446-463. e16 (2024).
[0491] 61. Mathur, R. et al. Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective. Cell 187, 446-463.e16 (2024).830
[0492] 62. Chen, J. et al. A MYT1L syndrome mouse model recapitulates patient phenotypes and reveals
[0493] altered brain development due to disrupted neuronal maturation. Neuron 109, 3775-3792.e14832 (2021).833
[0494] 63. Hausmann, D. et al. Autonomous rhythmic activity in glioma networks drives brain tumour growth. Nature 613, 179-186 (2023).835
[0495] 64. Hu, J. et al. Neutralization of terminal differentiation in gliomagenesis. Proc. Natl. Acad. Sci. 110, 14520-14527 (2013).837
[0496] 65. Lim, B., Domsch, K., Mall, M. & Lohmann, I. Canalizing cell fate by transcriptional repression. Mol. Syst. Biol. 20, 144-161 (2024)
[0497] Sequences
[0498] SEQ ID NO. 1 >sp|Q9UL68|MYT1L_HUMAN Myelin transcription factor 1 -like protein OS=Homo sapiens OX=9606 GN=MYT1L PE=1 SV=3
[0499] MEVDTEEKRHRTRSKGVRVPVEPAIQELFSCPTPGCDGSGHVSGKYARHRSVYGCPLAKKRKTQDK QPQEPAPKRKPFAVKADSSSVDECDDSDGTEDMDEKEEDEGEEYSEDNDEPGDEDEEDEEGDREE EEEIEEEDEDDDEDGEDVEDEEEEEEEEEEEEEEEENEDHQMNCHNTRIMQDTEKDDNNNDEYDNY DELVAKSLLNLGKIAEDAAYRARTESEMNSNTSNSLEDDSDKNENLGRKSELSLDLDSDWRETVDSL KLLAQGHGVVLSENMNDRNYADSMSQQDSRNMNYVMLGKPMNNGLMEKMVEESDEEVCLSSLECL RNQCFDLARKLSETNPQERNPQQNMNIRQHVRPEEDFPGRTPDRNYSDMLNLMRLEEQLSPRSRVF
[0500] ASCAKEDGCHERDDDTTSVNSDRSEEVFDMTKGNLTLLEKAIALETERAKAMREKMAMEAGRRDNM RSYEDQSPRQLPGEDRKPKSSDSHVKKPYYGKDPSRTEKKESKCPTPGCDGTGHVTGLYPHHRSLS
[0501] GCPHKDRVPPEILAMHESVLKCPTPGCTGRGHVNSNRNSHRSLSGCPIAAAEKLAKAQEKHQSCDVS KSSQASDRVLRPMCFVKQLEIPQYGYRNNVPTTTPRSNLAKELEKYSKTSFEYNSYDNHTYGKRAIAP KVQTRDISPKGYDDAKRYCKDPSPSSSSTSSYAPSSSSNLSCGGGSSASSTCSKSSFDYTHDMEAAH MAATAILNLSTRCREMPQNLSTKPQDLCATRNPDMEVDENGTLDLSMNKQRPRDSCCPILTPLEPMS PQQQAVMNNRCFQLGEGDCWDLPVDYTKMKPRRIDEDESKDITPEDLDPFQEALEERRYPGEVTIPS PKPKYPQCKESKKDLITLSGCPLADKSIRSMLATSSQELKCPTPGCDGSGHITGNYASHRSLSGCPRA KKSGIRIAQSKEDKEDQEPIRCPVPGCDGQGHITGKYASHRSASGCPLAAKRQKDGYLNGSQFSWKS
[0502] VKTEGMSCPTPGCDGSGHVSGSFLTHRSLSGCPRATSAMKKAKLSGEQMLTIKQRASNGIENDEEIK QLDEEIKELNESNSQMEADMIKLRTQITTMESNLKTIEEENKVIEQQNESLLHELANLSQSLIHSLANIQL PHMDPINEQNFDAYVTTLTEMYTNQDRYQSPENKALLENIKQAVRGIQV
[0503] SEQ ID NO. 2 >sp|O60284|ST18_HUMAN Suppression of tumorigenicity 18 protein OS=Homo sapiens OX=9606 GN=ST18 PE=1 SV=1
[0504] MDAEAEDKTLRTRSKGTEVPMDSLIQELSVAYDCSMAKKRTAEDQALGVPVNKRKSLLMKPRHYSPK ADCQEDRSDRTEDDGPLETHGHSTAEEIMIKPMDESLLSTAQENSSRKEDRYSCYQELMVKSLMHLG
[0505] KFEKNVSVQTVSENLNDSGIQSLKAESDEADECFLIHSDDGRDKIDDSQPPFCSSDDNESNSESAEN GWDSGSNFSEETKPPRVPKYVLTDHKKDLLEVPEIKTEGDKFIPCENRCDSETERKDPQNALAEPLDG
[0506] NAQPSFPDVEEEDSESLAVMTEEGSDLEKAKGNLSLLEQAIALQAERGCVFHNTYKELDRFLLEHLAG ERRQTKVIDMGGRQIFNNKHSPRPEKRETKCPIPGCDGTGHVTGLYPHHRSLSGCPHKVRVPLEILA
[0507] MHENVLKCPTPGCTGRGHVNSNRNTHRSLSGCPIAAAEKLAMSQDKNQLDSPQTGQCPDQAHRTSLVKQIEFNFPSQAITSPRATVSKEQEKFGKVPFDYASFDAQVFGKRPLIQTVQGRKTPPFPESKHFPNP
[0508] VKFPNRLPSAGAHTQSPGRASSYSYGQCSEDTHIAAAAAILNLSTRCREATDILSNKPQSLHAKGAEIE
[0509] VDENGTLDLSMKKNRILDKSAPLTSSNTSIPTPSSSPFKTSSILVNAAFYQALCDQEGWDTPINYSKTH
[0510] GKTEEEKEKDPVSSLENLEEKKFPGEASIPSPKPKLHARDLKKELITCPTPGCDGSGHVTGNYASHRS
[0511] VSGCPLADKTLKSLMAANSQELKCPTPGCDGSGHVTGNYASHRSLSGCPRARKGGVKMTPTKEEKE
[0512] DPELKCPVIGCDGQGHISGKYTSHRTASGCPLAAKRQKENPLNGASLSWKLNKQELPHCPLPGCNGL
[0513] GHVNNVFVTHRSLSGCPLNAQVIKKGKVSEELMTIKLKATGGIESDEEIRHLDEEIKELNESNLKIEADM
[0514] MKLQTQITSMESNLKTIEEENKLIEQNNESLLKELAGLSQALISSLADIQLPQMGPISEQNFEAYVNTLTD MYSNLERDYSPECKALLESIKQAVKGIHV
[0515] SEQ ID NO. 3 >sp|P08235|MCR_HUMAN Mineralocorticoid receptor OS=Homo sapiens OX=9606
[0516] GN=NR3C2 PE=1 SV=2
[0517] METKGYHSLPEGLDMERRWGQVSQAVERSSLGPTERTDENNYMEIVNVSCVSGAIPNNSTQGSSKE
[0518] KQELLPCLQQDNNRPGILTSDIKTELESKELSATVAESMGLYMDSVRDADYSYEQQNQQGSMSPAKIY
[0519] QNVEQLVKFYKGNGHRPSTLSCVNTPLRSFMSDSGSSVNGGVMRAVVKSPIMCHEKSPSVCSPLNM
[0520] TSSVCSPAGINSVSSTTASFGSFPVHSPITQGTPLTCSPNVENRGSRSHSPAHASNVGSPLSSPLSSM
[0521] KSSISSPPSHCSVKSPVSSPNNVTLRSSVSSPANINNSRCSVSSPSNTNNRSTLSSPAASTVGSICSPV
[0522] NNAFSYTASGTSAGSSTLRDVVPSPDTQEKGAQEVPFPKTEEVESAISNGVTGQLNIVQYIKPEPDGA
[0523] FSSSCLGGNSKINSDSSFSVPIKQESTKHSCSGTSFKGNPTVNPFPFMDGSYFSFMDDKDYYSLSGIL
[0524] GPPVPGFDGNCEGSGFPVGIKQEPDDGSYYPEASIPSSAIVGVNSGGQSFHYRIGAQGTISLSRSARD
[0525] QSFQHLSSFPPVNTLVESWKSHGDLSSRRSDGYPVLEYIPENVSSSTLRSVSTGSSRPSKICLVCGDE
[0526] ASGCHYGVVTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRLQKCLQAGMNLGARKSK
[0527] KLGKLKGIHEEQPQQQQPPPPPPPPQSPEEGTTYIAPAKEPSVNTALVPQLSTISRALTPSPVMVLENI
[0528] EPEIVYAGYDSSKPDTAENLLSTLNRLAGKQMIQVVKWAKVLPGFKNLPLEDQITLIQYSWMCLSSFAL
[0529] SWRSYKHTNSQFLYFAPDLVFNEEKMHQSAMYELCQGMHQISLQFVRLQLTFEEYTIMKVLLLLSTIPK
[0530] DGLKSQAAFEEMRTNYIKELRKMVTKCPNNSGQSWQRFYQLTKLLDSMHDLVSDLLEFCFYTFRESH ALKVEFPAMLVEIISDQLPKVESGNAKPLYFHRK
[0531] SEQ ID NO. 4 >sp|P09086|P02F2_HUMAN POU domain, class 2, transcription factor 2 OS=Homo sapiens OX=9606 GN=POU2F2 PE=1 SV=3
[0532] MVHSSMGAPEIRMSKPLEAEKQGLDSPSEHTDTERNGPDTNHQNPQNKTSPFSVSPTGPSTKIKAED
[0533] PSGDSAPAAPLPPQPAQPHLPQAQLMLTGSQLAGDIQQLLQLQQLVLVPGHHLQPPAQFLLPQAQQS
[0534] QPGLLPTPNLFQLPQQTQGALLTSQPRAGLPTQAVTRPTLPDPHLSHPQPPKCLEPPSHPEEPSDLEE
[0535] LEQFARTFKQRRIKLGFTQGDVGLAMGKLYGNDFSQTTISRFEALNLSFKNMCKLKPLLEKWLNDAET
[0536] MSVDSSLPSPNQLSSPSLGFDGLPGRRRKKRTSIETNVRFALEKSFLANQKPTSEEILLIAEQLHMEKE
[0537] VIRVWFCNRRQKEKRINPCSAAPMLPSPGKPASYSPHMVTPQGGAGTLPLSQASSSLSTTVTTLSSAV
[0538] GTLHPSRTAGGGGGGGGAAPPLNSIPSVTPPPPATTNSTNPSPQGSHSAIGLSGLNPSTGPGLWWNP APYQP
[0539] SEQ ID NO. 5 >sp|Q96KN3|PKNX2_HUMAN Homeobox protein PKNOX2 OS=Homo sapiens
[0540] OX=9606 GN=PKNOX2 PE=1 SV=2
[0541] MMQHASPAPALTMMATQNVPPPPYQDSPQMTATAQPPSKAQAVHISAPSAAASTPVPSAPIDPQAQL
[0542] EADKRAVYRHPLFPLLTLLFEKCEQATQGSECITSASFDVDIENFVHQQEQEHKPFFSDDPELDNLMV
[0543] KAIQVLRIHLLELEKVNELCKDFCNRYITCLKTKMHSDNLLRNDLGGPYSPNQPSINLHSQDLLQNSPN
[0544] SMSGVSNNPQGIVVPASALQQGNIAMTTVNSQWSGGALYQPVTMVTSQGQVVTQAIPQGAIQIQNT
[0545] QVNLDLTSLLDNEDKKSKNKRGVLPKHATNIMRSWLFQHLMHPYPTEDEKRQIAAQTNLTLLQVNNWF
[0546] INARRRILQPMLDASNPDPAPKAKKIKSQHRPTQRFWPNSIAAGVLQQQGGAPGTNPDGSINLDNLQS
[0547] LSSDSATMAMQQAMMAAHDDSLDGTEEEDEDEMEEEEEEELEEEVDELQTTNVSDLGLEHSDSLE
[0548] SEQ ID NO. 6 >sp|Q9BYV9|BACH2_HUMAN Transcription regulator protein BACH2 OS=Homo sapiens OX=9606 GN=BACH2 PE=1 SV=1
[0549] MSVDEKPDSPMYVYESTVHCTNILLGLNDQRKKDILCDVTLIVERKEFRAHRAVLAACSEYFWQALVG
[0550] QTKNDLVVSLPEEVTARGFGPLLQFAYTAKLLLSRENIREVIRCAEFLRMHNLEDSCFSFLQTQLLNSE
[0551] DGLFVCRKDAACQRPHEDCENSAGEEEDEEEETMDSETAKMACPRDQMLPEPISFEAAAIPVAEKEE
[0552] ALLPEPDVPTDTKESSEKDALTQYPRYKKYQLACTKNVYNASSHSTSGFASTFREDNSSNSLKPGLAR
[0553] GQIKSEPPSEENEEESITLCLSGDEPDAKDRAGDVEMDRKQPSPAPTPTAPAGAACLERSRSVASPSC
[0554] LRSLFSITKSVELSGLPSTSQQHFARSPACPFDKGITQGDLKTDYTPFTGNYGQPHVGQKEVSNFTMG
[0555] SPLRGPGLEALCKQEGELDRRSVIFSSSACDQVSTSVHSYSGVSSLDKDLSEPVPKGLWVGAGQSLP
[0556] SSQAYSHGGLMADHLPGRMRPNTSCPVPIKVCPRSPPLETRTRTSSSCSSYSYAEDGSGGSPCSLPL
[0557] CEFSSSPCSQGARFLATEHQEPGLMGDGMYNQVRPQIKCEQSYGTNSSDESGSFSEADSESCPVQ
[0558] DRGQEVKLPFPVDQITDLPRNDFQMMIKMHKLTSEQLEFIHDVRRRSKNRIAAQRCRKRKLDCIQNLE
[0559] CEIRKLVCEKEKLLSERNQLKACMGELLDNFSCLSQEVCRDIQSPEQIQALHRYCPVLRPMDLPTASSI
[0560] NPAPLGAEQNIAASQCAVGENVPCCLEPGAAPPGPPWAPSNTSENCTSGRRLEGTDPGTFSERGPP
[0561] LEPRSQTVTVDFCQEMTDKCTTDEQPRKDYT
[0562] SEQ ID NO. 7 >sp|Q06945|SOX4_HUMAN Transcription factor SOX-4 OS=Homo sapiens OX=9606
[0563] GN=SOX4 PE=1 SV=1
[0564] MVQQTNNAENTEALLAGESSDSGAGLELGIASSPTPGSTASTGGKADDPSWCKTPSGHIKRPMNAF
[0565] MVWSQIERRKIMEQSPDMHNAEISKRLGKRWKLLKDSDKIPFIREAERLRLKHMADYPDYKYRPRKKV
[0566] KSGNANSSSSAAASSKPGEKGDKVGGSGGGGHGGGGGGGSSNAGGGGGGASGGGANSKPAQKK
[0567] SCGSKVAGGAGGGVSKPHAKLILAGGGGGGKAAAAAAASFAAEQAGAAALLPLGAAADHHSLYKART
[0568] PSASASASSAASASAALAAPGKHLAEKKVKRVYLFGGLGTSSSPVGGVGAGADPSDPLGLYEEEGAG
[0569] CSPDAPSLSGRSSAASSPAAGRSPADHRGYASLRAASPAPSSAPSHASSSASSHSSSSSSSGSSSSD
[0570] DEFEDDLLDLNPSSNFESMSLGSFSSSSALDRDLDFNFEPGSGSHFEFPDYCTPEVSEMISGDWLES
[0571] SISNLVFTY
[0572] SEQ ID NO. 8 SOX11
[0573]
[0574] KIERRKIMEQSPDMHNAEISKRLGKRWKMLKDSEKIPFIREAERLRLKHMADYPDYKYRP
[0575] RKKPKMDPSAKPSASQSPEKSAAGGGGGSAGGGAGGAKTSKGSSKKCGKLKAPAAAGAKA
[0576] GAGKAAQSGDYGGAGDDYVLGSLRVSGSGGGGAGKTVKCVFLDEDDDDDDDDDELQLQIK
[0577] QEPDEEDEEPPHQQLLQPPGQQPSQLLRRYNVAKVPASPTLSSSAESPEGASLYDEVRAG
[0578] ATSGAGGGSRLYYSFKNITKQHPPPLAQPALSPASSRSVSTSSSSSSGSSSGSSGEDADD
[0579] LMFDLSLNFSQSAHSASEQQLGGGAAAGNLSLSLVDKDLDSFSEGSLGSHFEFPDYCTPE
[0580] LSEMIAGDWLEANFSDLVFTY
[0581] SEQ ID NO. 9 >sp|Q8NFU7|TET1_HUMAN Methylcytosine dioxygenase TET1 OS=Homo sapiens
[0582] OX=9606 GN=TET1 PE=1 SV=2
[0583] MSRSRHARPSRLVRKEDVNKKKKNSQLRKTTKGANKNVASVKTLSPGKLKQLIQERDVKKKTEPKPP
[0584] VPVRSLLTRAGAARMNLDRTEVLFQNPESLTCNGFTMALRSTSLSRRLSQPPLVVAKSKKVPLSKGLE
[0585] KQHDCDYKILPALGVKHSENDSVPMQDTQVLPDIETLIGVQNPSLLKGKSQETTQFWSQRVEDSKINIP
[0586] THSGPAAEILPGPLEGTRCGEGLFSEETLNDTSGSPKMFAQDTVCAPFPQRATPKVTSQGNPSIQLEE
[0587] LGSRVESLKLSDSYLDPIKSEHDCYPTSSLNKVIPDLNLRNCLALGGSTSPTSVIKFLLAGSKQATLGAK
[0588] PDHQEAFEATANQQEVSDTTSFLGQAFGAIPHQWELPGADPVHGEALGETPDLPEIPGAIPVQGEVF
[0589] GTILDQQETLGMSGSVVPDLPVFLPVPPNPIATFNAPSKWPEPQSTVSYGLAVQGAIQILPLGSGHTPQ
[0590] SSSNSEKNSLPPVMAISNVENEKQVHISFLPANTQGFPLAPERGLFHASLGIAQLSQAGPSKSDRGSS
[0591] QVSVTSTVHVVNTTVVTMPVPMVSTSSSSYTTLLPTLEKKKRKRCGVCEPCQQKTNCGECTYCKNRK
[0592] NSHQICKKRKCEELKKKPSVVVPLEVIKENKRPQREKKPKVLKADFDNKPVNGPKSESMDYSRCGHG
[0593] EEQKLELNPHTVENVTKNEDSMTGIEVEKWTQNKKSQLTDHVKGDFSANVPEAEKSKNSEVDKKRTK
[0594] SPKLFVQTVRNGIKHVHCLPAETNVSFKKFNIEEFGKTLENNSYKFLKDTANHKNAMSSVATDMSCDH
[0595] LKGRSNVLVFQQPGFNCSSIPHSSHSIINHHASIHNEGDQPKTPENIPSKEPKDGSPVQPSLLSLMKDR
[0596] RLTLEQVVAIEALTQLSEAPSENSSPSKSEKDEESEQRTASLLNSCKAILYTVRKDLQDPNLQGEPPKL
[0597] NHCPSLEKQSSCNTVVFNGQTTTLSNSHINSATNQASTKSHEYSKVTNSLSLFIPKSNSSKIDTNKSIA
[0598] QGIITLDNCSNDLHQLPPRNNEVEYCNQLLDSSKKLDSDDLSCQDATHTQIEEDVATQLTQLASIIKINYI
[0599] KPEDKKVESTPTSLVTCNVQQKYNQEKGTIQQKPPSSVHNNHGSSLTKQKNPTQKKTKSTPSRDRRK
[0600] KKPTVVSYQENDRQKWEKLSYMYGTICDIWIASKFQNFGQFCPHDFPTVFGKISSSTKIWKPLAQTRSI
[0601] MQPKTVFPPLTQIKLQRYPESAEEKVKVEPLDSLSLFHLKTESNGKAFTDKAYNSQVQLTVNANQKAH
[0602] PLTQPSSPPNQCANVMAGDDQIRFQQWKEQLMHQRLPTLPGISHETPLPESALTLRNVNVVCSGGIT
[0603] VVSTKSEEEVCSSSFGTSEFSTVDSAQKNFNDYAMNFFTNPTKNLVSITKDSELPTCSCLDRVIQKDK
[0604] GPYYTHLGAGPSVAAVREIMENRYGQKGNAIRIEIVVYTGKEGKSSHGCPIAKWVLRRSSDEEKVLCL
[0605] VRQRTGHHCPTAVMVVLIMVWDGIPLPMADRLYTELTENLKSYNGHPTDRRCTLNENRTCTCQGIDPE
[0606] TCGASFSFGCSWSMYFNGCKFGRSPSPRRFRIDPSSPLHEKNLEDNLQSLATRLAPIYKQYAPVAYQ
[0607] NQVEYENVARECRLGSKEGRPFSGVTACLDFCAHPHRDIHNMNNGSTVVCTLTREDNRSLGVIPQDE
[0608] QLHVLPLYKLSDTDEFGSKEGMEAKIKSGAIEVLAPRRKKRTCFTQPVPRSGKKRAAMMTEVLAHKIR
[0609] AVEKKPIPRIKRKNNSTTTNNSKPSSLPTLGSNTETVQPEVKSETEPHFILKSSDNTKTYSLMPSAPHPVKEASPGFSWSPKTASATPAPLKNDATASCGFSERSSTPHCTMPSGRLSGANAAAADGPGISQLGEV
[0610] APLPTLSAPVMEPLINSEPSTGVTEPLTPHQPNHQPSFLTSPQDLASSPMEEDEQHSEADEPPSDEPL SDDPLSPAEEKLPHIDEYWSDSEHIFLDANIGGVAIAPAHGSVLIECARRELHATTPVEHPNRNHPTRLS LVFYQHKNLNKPQHGFELNKIKFEAKEAKNKKMKASEQKDQAANEGPEQSSEVNELNQIPSHKALTLT
[0611] HDNVVTVSPYALTHVAGPYNHWV
[0612] SEQ ID NO. 10 >sp|Q9UH73|COE1_HUMAN Transcription factor COE1 OS=Homo sapiens OX=9606
[0613] GN=EBF1 PE=1 SV=2
[0614] MFGIQESIQRSGSSMKEEPLGSGMNAVRTWMQGAGVLDANTAAQSGVGLARAHFEKQPPSNLRKSN
[0615] FFHFVLALYDRQGQPVEIERTAFVGFVEKEKEANSEKTNNGIHYRLQLLYSNGIRTEQDFYVRLIDSMT
[0616] KQAIVYEGQDKNPEMCRVLLTHEIMCSRCCDKKSCGNRNETPSDPVIIDRFFLKFFLKCNQNCLKNAG
[0617] NPRDMRRFQVWSTTVNVDGHVLAVSDNMFVHNNSKHGRRARRLDPSEGTPSYLEHATPCIKAISPS
[0618] EGWTTGGATVIIIGDNFFDGLQVIFGTMLVWSELITPHAIRVQTPPRHIPGVVEVTLSYKSKQFCKGTPG
[0619] RFIYTALNEPTIDYGFQRLQKVIPRHPGDPERLPKEVILKRAADLVEALYGMPHNNQEIILKRAADIAEAL
[0620] YSVPRNHNQLPALANTSVHAGMMGVNSFSGQLAVNVSEASQATNQGFTRNSSSVSPHGYVPSTTPQ QTNYNSVTTSMNGYGSAAMSNLGGSPTFLNGSAANSPYAIVPSSPTMASSTSLPSNCSSSSGIFSFS PANMVSAVKQKSAFAPVVRPQTSPPPTCTSTNGNSLQAISGMIVPPM
[0621] SEQ ID NO. 11 >sp|Q14188|TFDP2_HUMAN Transcription factor Dp-2 OS=Homo sapiens OX=9606
[0622] GN=TFDP2 PE=1 SV=2
[0623] MTAKNVGLTSTNAEVRGFIDQNLSPTKGNISFVAFPVSNTNSPTKILPKTLGPINVNVGPQMIISTPQRLT
[0624] SSGSVLIGSPYTPAPAMVTQTHIAEATGWVPGDRKRARKFIDSDFSESKRSKKGDKNGKGLRHFSMK
[0625] VCEKVQRKGTTSYNEVADELVSEFTNSNNHLAADSAYDQKNIRRRVYDALNVLMAMNIISKEKKEIKWI GLPTNSAQECQNLEIEKQRRIERIKQKRAQLQELLLQQIAFKNLVQRNRQNEQQNQGPPALNSTIQLPF IIINTSRKTVIDCSISSDKFEYLFNFDNTFEIHDDIEVLKRMGMSFGLESGKCSLEDLKLAKSLVPKALEG
[0626] YITDISTGPSWLNQGLLLNSTQSVSNLDLTTGATLPQSSVNQGLCLDAEVALATGQFLAPNSHQSSSAA
[0627] SHCSESRGETPCSFNDEDEEDDEEDSSSPE
[0628] SEQ ID NO. 12 >sp|Q9Y4X4|KLF12_HUMAN Krueppel-like factor 12 OS=Homo sapiens OX=9606
[0629] GN=KLF12 PE=1 SV=2
[0630] MNIHMKRKTIKNINTFENRMLMLDGMPAVRVKTELLESEQGSPNVHNYPDMEAVPLLLNNVKGEPPED
[0631] SLSVDHFQTQTEPVDLSINKARTSPTAVSSSPVSMTASASSPSSTSTSSSSSSRLASSPTVITSVSSAS
[0632] SSSTVLTPGPLVASASGVGGQQFLHIIHPVPPSSPMNLQSNKLSHVHRIPVWQSVPVVYTAVRSPGN
[0633] VNNTIVVPLLEDGRGHGKAQMDPRGLSPRQSKSDSDDDDLPNVTLDSVNETGSTALSIARAVQEVHP SPVSRVRGNRMNNQKFPCSISPFSIESTRRQRRSESPDSRKRRIHRCDFEGCNKVYTKSSHLKAHRR THTGEKPYKCTWEGCTWKFARSDELTRHYRKHTGVKPFKCADCDRSFSRSDHLALHRRRHMLV
[0634] SEQ ID NO. 13 >sp|Q99743|NPAS2_HUMAN Neuronal PAS domain-containing protein 2 OS=Homo sapiens OX=9606 GN=NPAS2 PE=1 SV=3
[0635] MDEDEKDRAKRASRNKSEKKRRDQFNVLIKELSSMLPGNTRKMDKTTVLEKVIGFLQKHNEVSAQTEI
[0636] CDIQQDWKPSFLSNEEFTQLMLEALDGFIIAVTTDGSIIYVSDSITPLLGHLPSDVMDQNLLNFLPEQEH
[0637] SEVYKILSSHMLVTDSPSPEYLKSDSDLEFYCHLLRGSLNPKEFPTYEYIKFVGNFRSYNNVPSPSCNG
[0638] FDNTLSRPCRVPLGKEVCFIATVRLATPQFLKEMCIVDEPLEEFTSRHSLEWKFLFLDHRAPPIIGYLPF
[0639] EVLGTSGYDYYHIDDLELLARCHQHLMQFGKGKSCCYRFLTKGQQWIWLQTHYYITYHQWNSKPEFI
[0640] VCTHSVVSYADVRVERRQELALEDPPSEALHSSALKDKGSSLEPRQHFNTLDVGASGLNTSHSPSAS
[0641] SRSSHKSSHTAMSEPTSTPTKLMAEASTPALPRSATLPQELPVPGLSQAATMPAPLPSPSSCDLTQQL
[0642] LPQTVLQSTPAPMAQFSAQFSMFQTIKDQLEQRTRILQANIRWQQEELHKIQEQLCLVQDSNVQMFLQ
[0643] QPAVSLSFSSTQRPEAQQQLQQRSAAVTQPQLGAGPQLPGQISSAQVTSQHLLRESSVISTQGPKPM
[0644] RSSQLMQSSGRSGSSLVSPFSSATAALPPSLNLTTPASTSQDASQCQPSPDFSHDRQLRLLLSQPIQP
[0645] MMPGSCDARQPSEVSRTGRQVKYAQSQTVFQNPDAHPANSSSAPMPVLLMGQAVLHPSFPASQPS
[0646] PLQPAQARQQPPQHYLQVQAPTSLHSEQQDSLLLSTYSQQPGTLGYPQPPPAQPQPLRPPRRVSSL SESSGLQQPPR
[0647] SEQ ID NO. 14 LEF
[0648] MPQLSGGGGGGGGDPELCATDEMIPFKDEGDPQKEKIFAEISHPEEEGDLADIKSSLVNE
[0649] SEIIPASNGHEVARQAQTSQEPYHDKAREHPDDGKHPDGGLYNKGPSYSSYSGYIMMPNM
[0650] NNDPYMSNGSLSPPIPRTSNKVPVVQPSHAVHPLTPLITYSDEHFSPGSHPSHIPSDVNS
[0651] KQGMSRHPPAPDIPTFYPLSPGGVGQITPPLGWQGQPVYPITGGFRQPYPSSLSVDTSMS
[0652] RFSHHMIPGPPGPHTTGIPHPAIVTPQVKQEHPHTDSDLMHVKPQHEQRKEQEPKRPHIK
[0653] KPLNAFMLYMKEMRANWAECTLKESAAINQILGRRWHALSREEQAKYYELARKERQLHM
[0654] QLYPGWSARDNYGKKKKRKREKLQESASGTGPRMTAAYI
[0655] SEQ ID NO. 15 >sp|Q9C0K0|BC11B_HUMAN B-cell lymphoma / leukemia 11 B OS=Homo sapiens
[0656] OX=9606 GN=BCL11B PE=1 SV=1
[0657] MSRRKQGNPQHLSQRELITPEADHVEAAILEEDEGLEIEEPSGLGLMVGGPDPDLLTCGQCQMNFPL
[0658] GDILVFIEHKRKQCGGSLGACYDKALDKDSPPPSSRSELRKVSEPVEIGIQVTPDEDDHLLSPTKGICP
[0659] KQENIAGPCRPAQLPAVAPIAASSHPHSSVITSPLRALGALPPCLPLPCCSARPVSGDGTQGEGQTEA
[0660] PFGCQCQLSGKDEPSSYICTTCKQPFNSAWFLLQHAQNTHGFRIYLEPGPASSSLTPRLTIPPPLGPEA
[0661] VAQSPLMNFLGDSNPFNLLRMTGPILRDHPGFGEGRLPGTPPLFSPPPRHHLDPHRLSAEEMGLVAQ
[0662] HPSAFDRVMRLNPMAIDSPAMDFSRRLRELAGNSSTPPPVSPGRGNPMHRLLNPFQPSPKSPFLSTP
[0663] PLPPMPPGGTPPPQPPAKSKSCEFCGKTFKFQSNLIVHRRSHTGEKPYKCQLCDHACSQASKLKRH
[0664] MKTHMHKAGSLAGRSDDGLSAASSPEPGTSELAGEGLKAADGDFRHHESDPSLGHEPEEEDEEEEE
[0665] EEEELLLENESRPESSFSMDSELSRNRENGGGGVPGVPGAGGGAAKALADEKALVLGKVMENVGLG
[0666] ALPQYGELLADKQKRGAFLKRAAGGGDAGDDDDAGGCGDAGAGGAVNGRGGGFAPGTEPFPGLFP RKPAPLPSPGLNSAAKRIKVEKDLELPPAALIPSENVYSQWLVGYAASRHFMKDPFLGFTDARQSPFAT SSEHSSENGSLRFSTPPGDLLDGGLSGRSGTASGGSTPHLGGPGPGRPSSKEGRRSDTCEYCGKVFKNCSNLTVHRRSHTGERPYKCELCNYACAQSSKLTRHMKTHGQIGKEVYRCDICQMPFSVYSTLEKH
[0667] MKKWHGEHLLTNDVKIEQAERS
[0668] SEQ ID NO. 16 > NM_001303052.2 Homo sapiens myelin transcription factor 1 like (MYT1L), transcript variant 1, mRNA
[0669] CCTAAGCTACTGCACACTAAACAGTGAGAGAGCTTTTCCCTGCAGTCTTGTTGAAGCACCCCGGG
[0670] TTTTTTGCTCATTGTTGGTGGGTGCATTTTAATTTTTTCATTCCCTGGACTATGGGTTATGATATCCAT
[0671] ACTCACTGAAGACAAAAAGCCACCTTTTCTGCGTCTTGGTGGCATGCATGTGTCTCATCATCCTTT
[0672] CAAACTTGTGGTGGAACAGGGTTTTCTTCCCTGTCTGTGTATTTTGAGCCAGCACAGTTACCAAAA
[0673] TTGAACTTGTCTTTCGCTTGTGAGCGGTTGTGGTCATTGTGAGGGCGGGTCATGAGGAGGCTGTA
[0674] GCCAAGGACGAGGTGTGTGCGGCTGTTGCCTGGACGTTTGTCCAATCCACGTTGACATTTGAGG
[0675] GATCACAGCGTGTGAAAATGAACTCAGAGGAGAATTGGTGAATTCCTATCCAGTGGGCATCTTCAA
[0676] ACCCTGGTCGACGGCGGAAGAATATCAGGTCCTGAGATCACCCACCCGGCGCGGCAACAGTGCA
[0677] GAGTGGCCACATCTGGTGGAAGAAGAAAAAAATGTAGTTATTGAATTCAATCAAGTGTTTGCATCTT
[0678] TCAAGCTATCAACAAAATTCCATCAAGAAAGGTTCCAGTTGGTCTCACAGACGTATGGATATCCGA
[0679] GGAGCCACCTAAAGATGGAGAAATCAAGGCATAGAGAGATTAAGTGACTTTGCCACAGTCACAAG
[0680] CTGGAGAGGACCAGGAGTAGAGCTTAGAGCGAGCCCCTGACTCTGGGCCTGCGTCCTGCCAGG
[0681] AGTCACGCTGCCTCCGTTCCTAGGAGAGAAGACTTCCTGTAAGATGGAGGTGGACACCGAGGAG
[0682] AAGCGGCATCGCACGCGGTCCAAAGGGGTTCGAGTTCCCGTGGAACCAGCCATACAAGAGCTGT
[0683] TCAGCTGTCCCACCCCTGGCTGTGACGGCAGTGGTCATGTCAGTGGCAAATATGCAAGACACAGA
[0684] AGTGTATATGGTTGTCCCTTGGCGAAAAAAAGAAAAACACAAGATAAACAGCCCCAGGAACCTGCT
[0685] CCTAAACGAAAGCCATTTGCCGTGAAAGCAGACAGCTCCTCAGTGGATGAGTGTGACGACAGTGA
[0686] TGGGACTGAGGACATGGATGAGAAGGAGGAGGATGAGGGGGAGGAGTACTCCGAGGACAATGAT
[0687] GAGCCAGGGGATGAGGACGAGGAGGACGAGGAGGGGGACCGGGAGGAGGAGGAGGAGATCG
[0688] AGGAGGAGGATGAGGACGATGACGAGGATGGAGAAGATGTGGAGGATGAAGAAGAGGAAGAGG
[0689] AGGAGGAGGAGGAGGAGGAAGAGGAAGAAGAAAACGAAGACCATCAAATGAATTGTCACAATACT CGAATAATGCAAGACACAGAAAAGGATGATAACAATAATGACGAATATGACAATTACGATGAACTGG
[0690] TGGCCAAGTCATTGTTAAACCTCGGCAAAATCGCTGAGGATGCAGCCTACCGGGCCAGGACTGAG
[0691] TCAGAAATGAACAGCAATACCTCCAATAGTCTGGAAGACGATAGTGACAAAAACGAAAACCTGGGT
[0692] CGGAAAAGTGAGTTGAGTTTAGACTTAGACAGTGATGTTGTTAGAGAAACAGTGGACTCCCTTAAA
[0693] CTATTAGCCCAAGGACACGGTGTTGTGCTCTCAGAAAACATGAATGACAGAAATTATGCAGACAGC
[0694] ATGTCGCAGCAAGACAGTAGAAATATGAATTACGTCATGTTGGGGAAGCCCATGAACAACGGACTC
[0695] ATGGAAAAGATGGTGGAGGAGAGCGATGAGGAGGTGTGTCTGAGCAGTCTGGAGTGTTTGAGGA
[0696] ATCAGTGCTTCGACCTGGCCAGGAAGCTCAGTGAGACCAACCCGCAGGAGAGGAATCCGCAGCA
[0697] GAACATGAACATCCGTCAGCATGTCCGGCCAGAAGAGGACTTCCCCGGAAGGACGCCGGACAGA
[0698] AACTACTCGGACATGCTGAACCTCATGCGGCTGGAGGAGCAGTTGAGCCCCCGGTCGAGAGTGT
[0699] TTGCCAGCTGTGCGAAGGAGGATGGGTGTCATGAGCGGGACGACGATACCACCTCTGTGAACTC GGACAGGTCTGAAGAGGTGTTCGACATGACCAAGGGGAACCTGACCCTGCTGGAGAAAGCCATCGCTTTGGAAACGGAAAGAGCAAAGGCCATGAGGGAGAAGATGGCCATGGAAGCTGGGAGGAGG
[0700] GACAATATGAGGTCATATGAGGACCAGTCTCCGAGACAACTTCCCGGGGAGGACAGAAAGCCTAA
[0701] ATCCAGTGACAGCCATGTCAAAAAGCCATACTATGGTAAAGATCCCTCAAGAACAGAAAAGAAAGA
[0702] GAGCAAGTGTCCAACCCCCGGGTGTGATGGAACCGGCCACGTAACTGGGCTGTACCCACATCAC
[0703] CGCAGCCTGTCCGGATGCCCGCACAAAGATAGGGTCCCTCCAGAAATCCTTGCCATGCATGAAAG
[0704] TGTCCTCAAGTGCCCCACTCCGGGCTGCACGGGGCGCGGGCATGTCAACAGCAACAGGAACTC
[0705] CCACCGAAGCCTCTCCGGATGCCCGATCGCTGCAGCAGAGAAACTGGCCAAGGCACAGGAAAA
[0706] GCACCAGAGCTGCGACGTGTCCAAGTCCAGCCAGGCCTCGGACCGCGTGCTCAGGCCAATGTG
[0707] CTTTGTGAAGCAGCTGGAGATTCCTCAGTATGGCTACAGAAACAATGTCCCCACAACTACGCCGC
[0708] GTTCCAACCTGGCCAAGGAGCTCGAGAAATATTCCAAGACCTCGTTTGAATACAACAGTTACGACA
[0709] ACCATACTTATGGCAAGCGAGCCATAGCTCCCAAGGTGCAAACCAGGGATATATCCCCCAAAGGAT
[0710] ATGATGATGCGAAGCGGTACTGCAAGGACCCCAGCCCCAGCAGCAGCAGCACCAGCAGCTACGC
[0711] GCCCAGCAGCAGCAGCAACCTGAGCTGCGGCGGGGGCAGCAGCGCCAGCAGCACGTGCAGCA
[0712] AGAGCAGCTTCGACTACACGCACGACATGGAGGCGGCCCACATGGCGGCCACCGCCATCCTCAA
[0713] CCTGTCCACGCGCTGCCGCGAGATGCCGCAGAACCTGAGCACCAAGCCGCAGGACCTGTGCGC
[0714] CACGCGGAACCCTGACATGGAGGTGGATGAGAACGGGACCCTGGACCTCAGCATGAACAAGCAG
[0715] AGGCCGCGGGACAGCTGCTGCCCCATCCTGACCCCTCTGGAGCCCATGTCCCCCCAGCAGCAG
[0716] GCAGTGATGAACAACCGGTGTTTCCAGCTGGGCGAGGGCGACTGCTGGGACTTGCCCGTAGACT
[0717] ACACCAAAATGAAACCCCGGAGGATAGACGAGGACGAGTCCAAAGACATTACTCCAGAAGACTTG
[0718] GACCCATTCCAGGAGGCTCTAGAAGAAAGACGGTATCCCGGGGAGGTGACCATCCCAAGTCCCA
[0719] AACCCAAGTACCCTCAGTGCAAGGAGAGCAAAAAGGACTTAATAACTCTGTCTGGCTGCCCCCTG
[0720] GCGGACAAAAGCATTCGAAGTATGCTGGCCACCAGCTCCCAAGAACTCAAGTGCCCCACGCCTG
[0721] GCTGTGATGGTTCTGGACATATCACCGGCAATTATGCTTCTCATCGGAGCCTTTCAGGTTGCCCAA
[0722] GAGCAAAGAAAAGTGGTATCAGGATAGCACAGAGCAAAGAAGATAAAGAAGATCAAGAACCCATC
[0723] AGGTGTCCGGTCCCCGGGTGCGACGGCCAGGGCCACATCACTGGGAAGTACGCGTCCCATCGC
[0724] AGCGCCTCCGGGTGCCCCTTGGCGGCCAAGAGGCAGAAAGACGGGTACCTGAATGGCTCCCAG
[0725] TTCTCCTGGAAGTCGGTCAAGACGGAAGGCATGTCCTGCCCCACGCCAGGATGCGACGGCTCAG
[0726] GCCACGTCAGCGGCAGCTTCCTCACACACCGCAGCTTGTCAGGATGCCCGAGAGCCACGTCAG
[0727] CGATGAAGAAGGCAAAGCTTTCTGGAGAGCAGATGCTGACCATCAAACAGCGGGCCAGCAACGG
[0728] TATAGAAAATGATGAAGAAATCAAACAGTTAGATGAAGAAATCAAGGAGCTAAATGAATCCAATTCC
[0729] CAGATGGAAGCCGATATGATTAAACTCAGAACTCAGATTACCACGATGGAGAGCAACCTGAAGACC
[0730] ATCGAAGAGGAGAACAAAGTGATTGAGCAGCAGAACGAGTCTCTCCTCCACGAGCTGGCGAACC
[0731] TGAGCCAGTCTCTGATCCACAGCCTGGCTAACATCCAGCTGCCGCACATGGATCCAATCAATGAA
[0732] CAAAATTTTGATGCTTACGTGACTACTTTGACGGAAATGTATACAAATCAAGATCGTTATCAGAGTCC
[0733] AGAAAATAAAGCCCTACTGGAAAATATAAAGCAGGCTGTGAGAGGAATTCAGGTCTGAACAGCTGC
[0734] TGTAGTGATGAAACTCTTGCTTAAAAAGGATGCCTCTTGTTTTTTGCTGCTGTAACTTACCAGAAAG
[0735] TGTTCTATATTTATTTCTGTTTGAATTTGAAACAGTGTTATGCTTACAAGACTTCATAATGATTTTATGT
[0736] CTTGCTTTAAAGATAGTACCTGCAGAATAGTTTTTGAATACACCCACATTTTGTACGTTTCCATGTAA
[0737] GCTGACATAGTGTTCTGCCATGTAATGTTTATAGCTGCTGATGTATGCACATTTGGGGGTATATCTATTTCTGAAGAGGTAAGCTGATCAAAATAAATAGAGTGTAAATTCTTTTTAATGCTTTAGTGATTAAATGT
[0738] TTTAGTATTTTGAACTGAAATGGACACACAAACACACACACGCACACACAGACCCACAGCTTTGAA
[0739] TGATCATGTTGTGGCTGAGCAGCCGCTTTTTAGACGTTATCATTTTGCCTCATGTTGGAGGACTTTA
[0740] TGGAATTTAAGAAATACATTTTGTGTGCATATTGTTTCATAGCAAGAATTCGTTGCAAAAATGCTTTAT
[0741] TTTTGAACAATGCTTGGAAATATTATGTGACTTTTTTGTTTGTTTGTTTTAGGAGGATGGTGTATGGT
[0742] GGGGGCAATAAATGAGGTTTTTTGCATTCCAAGGAAATGGCATATGGATTAACTGTAAGAAATGAAA
[0743] TAAGTAATTTATTGTAAGACAACATCAAGCCATGGAAACTTGGCAGAAGATTCAAAGCAGCTTAAAC
[0744] AGCACTTTTAAATTAACTCCTAAGCGTTACATGGTTGTGACTATGGAAACTCCAGTTAAGACAGGAT
[0745] CTTATCAGAGGTGGACAACGTGAAGATTTCCTTTTCCATTTTCAATAAACTTTGGAACAACCTTCTC
[0746] GTATCTCCCCTAGAGTTTCGTGCCCCTCTGAACTGTCTGTTATTGCAATGTAGTTTATCAACAGAAT
[0747] TTGTGTGTTTTCGATTTAAGCTAAAAGATAATTTAAGAACATTTATTTCCCCTTTTCACTTTAAAAAATT
[0748] ATGATTATTCCTATTATTGTTATGAACCTTCTTATTTTACATTTGAGGGATAAAGGCAAATGATTTGTG
[0749] AGTCTTCTAGTTACTGGACCGAGTTTTCTGCTGGATCTGGTGGGAAGGCAGCTCGGTAAAGTTTC
[0750] CCTCCTGCTCCCCCCGCCCGACTTTGACTCTGAATCAGCATTTGGTCCTATTCAGAGGACTCTTAC
[0751] CACGACGTTTCTGTTCTACACTTGGGTGGAGACCAGTTGACCATAGAGCATTTGCAGAGCCTCATT
[0752] GTTTGATTTCTTGTGACTATTCTAAGAATGAATGCAATCAGATTTTAAAAGTAACTAAATATACTTCAG
[0753] CACTTTTTTGCTTTAAACTAGATCATCTTAGACTTGTTTATACCTTCCAGATTTGATTGTTTTACTCCC
[0754] AATGACTGCACTATATGTATGCATAAGACCACTTTTGAGCGCTGTGTTCCCCCTTCTGAGTAGTCCT
[0755] TTGACGACGTGTTGTGTTTTCTGATGTTGACTTGAGTTCCATTTAGTAGCATCTCTTCCTTCCATGT
[0756] CTTGATGTTATGCAGGAAGTACAGACGTACTTTAAATTTTTGTTATGAAATAAAAAAAAGATGGGTTT
[0757] TGTAAAAATAAAAAAAAAATATTTTTAGCAGAACAGGACTTACAGGGTCATTGTCCCCACAATGTGC
[0758] CAGTCGACTATTTGCACTTACCTTGTCCTATATATCCGTACGGAGGTGTGCAATTCCTCGTGTCAGT
[0759] AGCCTTGTGACACTGAACCTGGATGGATTATAGAGGAGCCCTCACGGCTGATCAATAATGTTGCAA
[0760] AGGGAGACTACAGGGATCTCACGACGAATATTCTGATACAATACTCAACCTCGGTATATATATATGTG
[0761] TATAAATATATGTATATCCCAGCGGCACTTTATACTGTTCACTGTACAAAAGCTTACAGTTTTCCACAA
[0762] GGACTTTAATAACTAGCTGGGAAAAGACGATGTAATTATTTCGGGGCTCTGCGGAACCTTCTCTGT
[0763] ACAGCGCCCCCTTTCTGTTGTGCTATTGGTTGCAGCTGCCATGCTCAGAATGCGTTTTGAGAGCT
[0764] GAAGCAAGGTGCTTGCAGTCACCTGAGGCCGTCCGTGTGGCCCAGGGCCCCAGCTGCCTTTAG
[0765] GGCCCCCATTGTTCATAACAGCATATGCATTTCCCCACCGCGTTGTGTCTGCAGCTTCTTTGCCAA
[0766] TATAGTAATGCTTTTAGTAGAGTACTAGATAGTATCAGTTTTGGATTCTTATTGTTATCACCTATGTACA
[0767] ATGGAAAGGGATTTTAAGCACAAACCTGCTGCTCATCTAACGTTGGTACATAATCTCAAATCAAAAG
[0768] TTATCTGTGACTATTATATAGGGATCACAAAAGTGTCACATATTAGAATGCTGACCTTTCATATGGATT
[0769] ATTGTGAGTCATCAGAGTTTATTATAACTTATTGTTCATATTCATTTCTAAGTTAATTTAAGTAATCATTT
[0770] ATTAAGACAGAATTTTGTATAAACTATTTATTGTGCTCTCTGTGGAACTGAAGTTTGATTTATTTTTGT
[0771] ACTACACGGCATGGGTTTGTTGACACTTTAATTTTGCTATAAATGTGTGGAATCACAAGTTGCTGTG
[0772] ATACTTCATTTTTAAATTGTGAACTTTGTACAAATTTTGTCATGCTGGATGTTAACACATCTTACTCTA
[0773] AATAAACAAGGTGTTGCCACATTTGTAGCACGAAGGATCTCTAA
[0774] SEQ ID NO. 17 > NM_014682.3 Homo sapiens ST18 C2H2C-type zinc finger transcription factor (ST18), transcript variant 1, mRNA
[0775] GATTCTATGGAACCTTTTTGTAGGGAGAAGGGCAGGATGTTTTTAACTGAATGTGACCTCAGGGGA
[0776] ATACTAGAGAAAATAATAAAATTTCTGAATGGGGCAGCGTGGAGAAATCCTAAGAGAAATAGCATAA
[0777] GAGCATTTTGGAACACATCCAGGAAAAGATAACTTTCGACACACCTGTAGACGTTCGCCAGGTAAA
[0778] GGAGTGATGGAAACTCTCCAGTTCAGATCCAGTAGCTTTTAGGGAAGGAACTACAGTTGCTGACTT
[0779] AAGTTGAAGAAGCATCTATTTAATGTCTGGTCAAATCCTACAAGAAACACAGAAATCTATGATTAAAA
[0780] AGCTGAGCACTTTGATATACTGCAAAGGGTAGAGAAGGCAGGACGGTAGAAATTTTCTGCAAGAAA
[0781] GAATGAATTTCAGGATTTATCACTAAATAAGACAAAGTCATTTATTTAGTCCCCCTGACACAGCAGG
[0782] GCAAACTGAGTTGACATACAAGTTACCTGGAGAAAAAGAGAGCAATTCCAGGACTTCCTCTTCAGC
[0783] CTAAAAGAAGGTACCAGATCTGTGCACTGGGGCGATGTGGAAGAGACCTGCTTATTGCCCCTGAT
[0784] GTAAGCTCCAGTAAGAAAAGACGTCAAGTACAAGTACTAGGAAATCACTTTATACATCTGTTTATAG
[0785] GAATGACCTCAGGACTTTGTGTTCATGTTATAGATGGATGCAGAGGCTGAAGATAAAACGCTGCGT
[0786] ACTCGCTCTAAAGGAACCGAGGTGCCAATGGATTCACTAATCCAGGAGCTCAGTGTTGCCTATGAT
[0787] TGCTCCATGGCAAAGAAGAGAACAGCTGAAGATCAGGCTTTGGGGGTTCCAGTCAACAAAAGGA
[0788] AATCCCTGCTAATGAAGCCCCGACACTACAGCCCAAAAGCAGACTGCCAAGAAGACCGCAGTGAC
[0789] AGGACAGAGGACGATGGCCCCTTGGAAACACATGGTCACTCTACCGCAGAGGAAATCATGATAAA
[0790] ACCTATGGATGAAAGTCTTCTTTCAACTGCACAAGAAAACTCCAGTAGGAAGGAAGACAGATACTC
[0791] TTGTTATCAAGAGCTCATGGTCAAGTCTTTAATGCACTTGGGGAAATTTGAAAAAAATGTATCTGTT
[0792] CAGACTGTAAGTGAAAATTTAAATGACAGTGGCATCCAGTCTTTAAAAGCAGAGAGCGATGAAGCA
[0793] GACGAGTGCTTTCTGATTCATTCTGATGATGGAAGAGACAAGATTGATGATTCTCAGCCACCCTTC
[0794] TGCTCCTCTGATGACAATGAAAGTAACTCTGAAAGTGCAGAAAATGGCTGGGACAGTGGCTCCAA
[0795] CTTCTCAGAAGAAACCAAACCACCTAGAGTCCCAAAGTATGTTTTAACAGATCATAAAAAAGACCTA
[0796] TTGGAAGTTCCTGAAATAAAAACTGAAGGTGACAAATTTATCCCTTGTGAGAACAGGTGTGATTCT
[0797] GAAACAGAAAGGAAAGACCCGCAGAATGCTCTCGCAGAACCCCTGGATGGCAATGCCCAGCCCT
[0798] CATTCCCTGACGTTGAGGAGGAAGATAGCGAGAGCCTGGCAGTAATGACGGAAGAGGGTAGTGA
[0799] CCTGGAAAAGGCCAAGGGGAATTTAAGTTTGCTGGAGCAGGCAATTGCTCTGCAGGCTGAGCGA
[0800] GGTTGTGTTTTCCATAACACCTACAAAGAGCTGGATAGGTTCCTGCTGGAGCACCTAGCAGGGGA
[0801] AAGGAGGCAAACCAAAGTTATCGACATGGGTGGAAGACAAATCTTTAACAATAAACATTCACCAAG
[0802] GCCTGAAAAGAGGGAGACCAAGTGCCCGATCCCTGGATGTGATGGCACGGGACACGTGACAGG
[0803] GCTCTACCCGCACCACCGCAGCCTTTCGGGGTGCCCCCACAAAGTGCGGGTTCCCCTGGAAATT
[0804] CTTGCCATGCATGAAAATGTGCTCAAGTGTCCCACGCCGGGATGCACAGGAAGGGGTCATGTGAA
[0805] CAGCAACCGCAACACCCACAGGAGTCTTTCTGGTTGTCCAATTGCTGCAGCTGAAAAATTGGCAA
[0806] TGTCCCAGGATAAAAATCAGCTTGATTCTCCCCAAACTGGGCAGTGTCCTGACCAGGCCCACAGG
[0807] ACAAGTTTGGTGAAGCAAATTGAATTCAATTTCCCGTCACAAGCCATCACCTCTCCCAGAGCCACA
[0808] GTGTCAAAAGAACAAGAGAAGTTTGGAAAAGTACCATTTGATTATGCCAGTTTTGATGCCCAAGTTT
[0809] TCGGTAAACGCCCTCTCATACAAACAGTGCAAGGACGAAAAACACCACCATTTCCTGAATCAAAGC
[0810] ATTTTCCAAATCCAGTGAAATTTCCTAATCGACTGCCTAGTGCAGGCGCCCACACCCAGAGCCCTGGCCGTGCCAGCTCTTATAGCTACGGTCAATGTAGTGAAGACACCCACATAGCAGCAGCTGCTGCC
[0811] ATCCTGAACCTTTCCACCCGCTGCAGGGAAGCCACAGACATCCTCTCCAACAAGCCACAGAGTCT
[0812] GCATGCCAAGGGAGCCGAAATAGAAGTGGATGAAAATGGCACATTGGACTTAAGCATGAAAAAAA
[0813] ATCGAATCCTGGACAAGTCTGCACCCCTAACTTCCTCTAACACTTCTATTCCAACTCCTTCCTCTTC
[0814] CCCATTCAAAACAAGCAGCATTCTGGTCAATGCAGCATTCTATCAGGCTCTTTGTGACCAAGAGGG
[0815] CTGGGACACTCCTATCAACTATAGCAAAACTCACGGGAAGACAGAGGAGGAGAAAGAGAAAGACC
[0816] CAGTGAGCTCTCTAGAAAATTTAGAGGAAAAAAAGTTTCCTGGAGAGGCCTCTATACCAAGCCCTA
[0817] AACCCAAGCTTCATGCAAGAGATCTCAAAAAGGAACTAATCACCTGTCCAACACCAGGATGTGATG
[0818] GAAGTGGCCACGTGACAGGAAACTATGCATCTCATCGCAGTGTTTCTGGATGTCCTTTAGCAGATA
[0819] AGACTCTAAAATCCCTCATGGCTGCCAACTCTCAGGAGCTTAAGTGTCCAACCCCAGGCTGCGAT
[0820] GGCTCGGGGCACGTGACTGGAAACTATGCTTCCCACAGAAGCTTGTCCGGATGCCCTCGTGCAA
[0821] GGAAAGGTGGTGTCAAAATGACCCCTACCAAGGAAGAAAAAGAAGACCCTGAACTGAAATGTCCT
[0822] GTGATAGGGTGTGATGGCCAAGGTCACATATCAGGTAAATACACATCACACCGCACAGCTTCTGGC
[0823] TGTCCTCTGGCTGCCAAGAGACAGAAGGAGAATCCTCTCAATGGAGCCTCCCTCTCCTGGAAACT
[0824] GAACAAACAAGAGCTACCACATTGTCCCTTGCCAGGCTGCAATGGGCTGGGCCATGTAAATAATGT
[0825] TTTTGTCACCCACCGAAGCTTATCTGGATGTCCTCTCAATGCACAAGTTATCAAAAAGGGCAAGGT
[0826] TTCTGAAGAACTCATGACCATCAAGCTCAAAGCAACTGGGGGAATAGAGAGTGATGAAGAAATTAG
[0827] GCATTTGGATGAAGAAATAAAGGAACTGAATGAATCCAACCTTAAAATTGAAGCAGATATGATGAAA
[0828] CTTCAGACCCAGATCACATCTATGGAGAGCAACTTAAAGACGATAGAGGAGGAGAACAAACTCATA
[0829] GAACAGAACAATGAAAGTCTGCTGAAAGAGCTGGCAGGTCTAAGCCAAGCTCTCATTTCAAGCCT
[0830] TGCTGACATCCAGCTTCCACAGATGGGACCTATCAGTGAGCAGAATTTTGAAGCATATGTAAATACA
[0831] CTCACAGATATGTACAGCAATCTGGAACGGGACTATTCCCCGGAATGCAAAGCTCTACTGGAAAGT
[0832] ATCAAACAGGCAGTGAAGGGTATCCATGTGTAGGATCACAGCGCTGCCGGGCAACAGAAGTTACC
[0833] AACAGCAGTAAACTCCAGATGGATCTGTTAGAGGTTCATGTACTGCTAAGGCGTGGAGGTTGCCG
[0834] TACTGCATTTACAATTTGCAACATTGCACTAATTTTATTTTCCCCAGCTGATATAAAAAGGAAAGAAA
[0835] AACTATGATAGACTTCTTGGATTAAAAGCAATGCAGTCAATTATTAGATCTTATTTATTTTCATATGTTT
[0836] TTCTTTTATTTCTTCATTGTACTCTTTTTTTTTTTGTAAAGTATATGTAAAATAAATGTGACATTTTTATA
[0837] ATTTATTTATTACTAATCAAAGAGTTTTTTATCTTTTAACTGCATTTTGAAGTCTGCCGTATTTTTACAA
[0838] GTGTGTTTATTAATTTATTTTCCAATAGGATTTAAATAGAAATGCTATTCTCAAGTCATCTTTCTTGCTG
[0839] GGTTTTAATGAGGAAACAGGAAAGGGTGAAGGAAATCCTTGTCTAAGGACTGCACTATAGTTGAGT
[0840] TTGATTTTTATTGCACACTTCTTCCCCCACCTTTCACTGATTTTTGTATTTATAAATGAATTTGCGGTA
[0841] AGGTGAGCTGCACGGAAGGAATAAGAAGACAAATGGCGCCCACTAGTGGGGAATCCGCACTCAC
[0842] AAAAGCACAGGATGCTGGAAAACAGCCTGCTCAGAATTTGTTAGCAATAATTAAATATAGCAATCAG
[0843] CAAAGTATTCGACTTGGCTGGACGGTTTTCGTTAATATGAATTATTTATTTGAAATGTTTTAAAGAAA
[0844] CATAAGCCTTTTTAGTGATGCAGATTTGTCTGTTTGTTTTTCAAGTCATATCAGATCGTTGGCAACTC
[0845] GTATCCCAAGATGAAAAATAAGACTTGGTGTGACCAGCCAGGCTTTCCTGCCATATGTTGGTACAA
[0846] TATACAAGTGACAATATTGGTGTAGATTTGTACTTAGCAAATACAAACACATCCAAATGAAAAATTTTG
[0847] TAGATACCATATCCCCTGAAATAGCATTTATCTTACTGGGTTGACTGGAAAGGAATGGAAAATATAGT
[0848] AACACATGAAAAAATGCTACTCCAATCTGAATGATTACTTCAAACACTGGCACCTTGGGTCTCACCCACCATAGGAAACAAGACAACATTCAATTTGATAGAAATCTTGCCACAAAACTTCAAATGCTACAAAAT
[0849] ATACACACACACTCACACACACAGGCATACTCACACACAGACACACACACACACACACACACAGA
[0850] CTCATCCACACTTCAAATTGAGCCCACAATCTTGAATTTCTGAACGGATCAGAGTTTCATAGTTTCT
[0851] ATAGTAAAGGCAATGTCTATTTCAGGGATTGTAAAGTAGTTAAGCATTGTTTCAAAAGTTTTTTTATAT
[0852] TTATTTTTTTTAAGGAAAAGGTATAGACAACCAGCTAAACTGCCTTTTTGGTGTGCACACACATTTCA
[0853] TGTGCAGACGTGCCTCTGTGTAAATGTACACATGAACTTCATGTGGGCTTAATTTTCTGTGCTATAA
[0854] ACAAAAGTGTTTATTTTTTATTAACCTCATGGATATTTAGATGGAAAGTGATGGCATTCACAGGCTTG
[0855] ATGTATTCCACTGTTATTACTGTTACCTGCACAAATGAAAAACAATACTCAACAGTAATTCCACTCCC
[0856] ATGAAACTTTGGTCATTGTTATGCATTAAGTGGGGCTTATCTTTGGTTTGGAGTTCATTTGAACTCTT
[0857] GAACCTTAGTTTAGTGAAGATGAACTGTCTGTTCTTAGGTAGAAACGGTGTTTATTTAAAAATCAGTT
[0858] TTAAAAAATGAGCTACCATATGTGCTGTCTATTATAAATGGGACACCAAACAAAATTTTCTATTACAGT
[0859] TGTGTACTTGCAAACATTTTGCTATACAGTACTTCATAGATGCATACAAATGAGCTCACTTATTACAAA
[0860] GACAAACGTTTAATTTGCTAAATATTTTAACAAGTTTGTTATATATTTTATTTAATTTAAAAGAAATCTCT
[0861] TACCAACCTACATATTTATTACTATAATTTGCTATGACTTCAGGTTAATTTATTTGTGTTTGCATAGTTT
[0862] GAGCAGGATGTTTTGTGAAGTATGTTTGTATTTATTTGCCTACTTTGTACTTGATGTGTTTTGTAATG
[0863] TGCACTGAATTTGTTTTCTTTTCAACTATGTTAATGATCAATACTGTAAATTGGGTCTTTTGTAAACAA
[0864] AAAGGCAATGATGTATGCATTTTTTTTAATTTGAGGTAGTTTGTTTGTATACTGTTTCTCCAAACACTT
[0865] AATATTTCTTACATCAAAGCAACAAAATTGTGTTCAGTGCTGTACATTTGGTGTATGGTAGGAAATAA
[0866] AAATTGATAACGA
[0867] SEQ ID NO. 18 > NM_000901.5 Homo sapiens nuclear receptor subfamily 3 group C member 2 (NR3C2), transcript variant 1, mRNA
[0868] CTCTCAGCCCCTCCGCGCCCGGGGTGTCATTGGGCCCGGGAGACGGGAGCCAACTTCAGGCTG
[0869] CTCAGAGGAAGCCCGTGCAGTCAGTCACCTGGGTGCAAGAGCGTTGCTGCCTCGGGCTCTCCC
[0870] GCTGCAGGGAGAGCGGCACTCGCTGGCCTGGATGTGGTTGGATTTAGGGGGGCTCCGCAGCAG
[0871] GGGTTTCGTGGCGGTGGCAAGCGCTGCAACAGGTAGACGGCGAGAGACGGACCCCGGCCGAG
[0872] GCAGCGATGGAGACCAAAGGCTACCACAGTCTCCCTGAAGGTCTAGATATGGAAAGACGGTGGG
[0873] GTCAAGTTTCTCAGGCTGTGGAGCGTTCTTCCCTGGGACCTACAGAGAGGACCGATGAGAATAAC
[0874] TACATGGAGATTGTCAACGTAAGCTGTGTTTCCGGTGCTATTCCAAACAACAGTACTCAAGGAAGC
[0875] AGCAAAGAAAAACAAGAACTACTCCCTTGCCTTCAGCAAGACAATAATCGGCCTGGGATTTTAACA
[0876] TCTGATATTAAAACTGAGCTGGAATCTAAGGAACTTTCAGCAACTGTAGCTGAGTCCATGGGTTTAT
[0877] ATATGGATTCTGTAAGAGATGCTGACTATTCCTATGAGCAGCAGAACCAACAAGGAAGCATGAGTC
[0878] CAGCTAAGATTTATCAGAATGTTGAACAGCTGGTGAAATTTTACAAAGGAAATGGCCATCGTCCTTC
[0879] CACTCTAAGTTGTGTGAACACGCCCTTGAGATCATTTATGTCTGACTCTGGGAGCTCCGTGAATGG
[0880] TGGCGTCATGCGCGCCGTTGTTAAAAGCCCTATCATGTGTCATGAGAAAAGCCCGTCTGTTTGCA
[0881] GCCCTCTGAACATGACATCTTCGGTTTGCAGCCCTGCTGGAATCAACTCTGTGTCCTCCACCACA
[0882] GCCAGCTTTGGCAGTTTTCCAGTGCACAGCCCAATCACCCAGGGAACTCCTCTGACATGCTCCCC
[0883] TAATGTTGAAAATCGAGGCTCCAGGTCGCACAGCCCTGCACATGCTAGCAATGTGGGCTCTCCTC TCTCAAGTCCGTTAAGTAGCATGAAATCCTCAATTTCCAGCCCTCCAAGTCACTGCAGTGTAAAATCTCCAGTCTCCAGTCCCAATAATGTCACTCTGAGATCCTCTGTGTCTAGCCCTGCAAATATTAACAAC
[0884] TCAAGGTGCTCTGTTTCCAGCCCTTCGAACACTAATAACAGATCCACGCTTTCCAGTCCGGCAGC
[0885] CAGTACTGTGGGATCTATCTGTAGCCCTGTAAACAATGCCTTCAGCTACACTGCTTCTGGCACCTC
[0886] TGCTGGATCCAGTACATTGCGGGATGTGGTTCCCAGTCCAGACACGCAGGAGAAAGGTGCTCAA
[0887] GAGGTCCCTTTTCCTAAGACTGAGGAAGTAGAGAGTGCCATCTCAAATGGTGTGACTGGCCAGCT
[0888] TAATATTGTCCAGTACATAAAACCAGAACCAGATGGAGCTTTTAGCAGCTCATGTCTAGGAGGAAAT
[0889] AGCAAAATAAATTCGGATTCTTCATTCTCAGTACCAATAAAGCAAGAATCAACCAAGCATTCATGTTC
[0890] AGGCACCTCTTTTAAAGGGAATCCAACAGTAAACCCGTTTCCATTTATGGATGGCTCGTATTTTTCC
[0891] TTTATGGATGATAAAGACTATTATTCCCTATCAGGAATTTTAGGACCACCTGTGCCCGGCTTTGATG
[0892] GTAACTGTGAAGGCAGCGGATTCCCAGTGGGTATTAAACAAGAACCAGATGATGGGAGCTATTACC
[0893] CAGAGGCCAGCATCCCTTCCTCTGCTATTGTTGGGGTGAATTCAGGTGGACAGTCCTTCCACTAC
[0894] AGGATTGGTGCTCAAGGTACAATATCTTTATCACGATCGGCTAGAGACCAATCTTTCCAACACCTGA
[0895] GTTCCTTTCCTCCTGTCAATACTTTAGTGGAGTCATGGAAATCACACGGCGACCTGTCGTCTAGAA
[0896] GAAGTGATGGGTATCCGGTCTTAGAATACATTCCAGAAAATGTATCAAGCTCTACTTTACGAAGTGT
[0897] TTCTACTGGATCTTCAAGACCTTCAAAAATATGTTTGGTGTGTGGGGATGAGGCTTCAGGATGCCA
[0898] TTATGGGGTAGTCACCTGTGGCAGCTGCAAAGTTTTCTTCAAAAGAGCAGTGGAAGGGCAACACA
[0899] ACTATTTATGTGCTGGAAGAAATGATTGCATCATTGATAAGATTCGACGAAAGAATTGTCCTGCTTG
[0900] CAGACTTCAGAAATGTCTTCAAGCTGGAATGAATTTAGGAGCACGAAAGTCAAAGAAGTTGGGAAA
[0901] GTTAAAAGGGATTCACGAGGAGCAGCCACAGCAGCAGCAGCCCCCACCCCCACCCCCACCCCC
[0902] GCAAAGCCCAGAGGAAGGGACAACGTACATCGCTCCTGCAAAAGAACCCTCGGTCAACACAGCA
[0903] CTGGTTCCTCAGCTCTCCACAATCTCACGAGCGCTCACACCTTCCCCCGTTATGGTCCTTGAAAA
[0904] CATTGAACCTGAAATTGTATATGCAGGCTATGACAGCTCAAAACCAGATACAGCCGAAAATCTGCTC
[0905] TCCACGCTCAACCGCTTAGCAGGCAAACAGATGATCCAAGTCGTGAAGTGGGCAAAGGTACTTCC
[0906] AGGATTTAAAAACTTGCCTCTTGAGGACCAAATTACCCTAATCCAGTATTCTTGGATGTGTCTATCAT
[0907] CATTTGCCTTGAGCTGGAGATCGTACAAACATACGAACAGCCAATTTCTCTATTTTGCACCAGACCT
[0908] AGTCTTTAATGAAGAGAAGATGCATCAGTCTGCCATGTATGAACTATGCCAGGGGATGCACCAAAT
[0909] CAGCCTTCAGTTCGTTCGACTGCAGCTCACCTTTGAAGAATACACCATCATGAAAGTTTTGCTGCT
[0910] ACTAAGCACAATTCCAAAGGATGGCCTCAAAAGCCAGGCTGCATTTGAAGAAATGAGGACAAATTA
[0911] CATCAAAGAACTGAGGAAGATGGTAACTAAGTGTCCCAACAATTCTGGGCAGAGCTGGCAGAGGT
[0912] TCTACCAACTGACCAAGCTGCTGGACTCCATGCATGACCTGGTGAGCGACCTGCTGGAATTCTGC
[0913] TTCTACACCTTCCGAGAGTCCCATGCGCTGAAGGTAGAGTTCCCCGCAATGCTGGTGGAGATCAT
[0914] CAGCGACCAGCTGCCCAAGGTGGAGTCGGGGAACGCCAAGCCGCTCTACTTCCACCGGAAGTG
[0915] ACTGCCCGCTGCCCAGAAGAACTTTGCCTTAAGTTTCCCTGTGTTGTTCCACACCCAGAAGGACC
[0916] CAAGAAAACCTGTTTTTAACATGTGATGGTTGATTCACACTTGTTCAACAGTTTCTCAAGTTTAAAG
[0917] TCATGTCAGAGGTTTGGAGCCGGGAAAGCTGTTTTTCCGTGGATTTGGCGAGACCAGAGCAGTCT
[0918] GAAGGATTCCCCACCTCCAATCCCCCAGCGCTTAGAAACATGTTCCTGTTCCTCGGGATGAAAAG
[0919] CCATATCTAGTCAATAACTCTGATTTTGATATTTTCACAGATGGAAGAAGTTTTAACTATGCCGTGTA
[0920] GTTTCTGGTATCGTTCGCTTGTTTTAAAAGGGTTCAAGGACTAACGAACGTTTTAAAGCTTACCCTT
[0921] GGTTTGCACATAAAACGTATAGTCAATATGGGGCATTAATATTCTTTTGTTATTAAAAAAACACAAAAAAATAATAAAAAAATATATACAGATTCCTGTTGTGTAATAACAGAACTCGTGGCGTGGGGCAGCAGCT GCCTCTGAGCCCTCGCTCGTCCACGGTCTTCTGCATCACTGGTATACACACTCGTTAGCGTCCATT
[0922] TCTTATTTAATTAGAATGGATAAGATGATGTTAAATGCCTTGGTTTGATTTCTAGTATCTATTGTGTTG
[0923] GCTTTACAAATAATTTTTTGCAGTCTTTTGCTGTGCTGTACATTACTGTATGTATAAATTATGAAGGAC
[0924] CTGAAATAAGGTATAAGGATCTTTTGTAAATGAGACACATACAAAAAAAATCTTTAATGGTTAATAGG
[0925] ATGAATGGGAAAGTATTTTTGAAAGAATTCTATTTTGCTGGAGACTATTTAAGTACTATCTTTGTCTAA
[0926] ACAAGGTAATTTTTTTTTGTAAAGTGCAATGTCCTGCATGCATAATGAACCGTTTACAGTGTATTTAA
[0927] GAAAGGGAAAGCTGTGCCTTTTTTAGCTTCATATCTAATTTACCATTATTTTACAGTCTCTGTTGTAA
[0928] ATAACCACACTGAAACCTCTTCGGTTGTCTTGAAACCTTTCTACTTTTTCTGTACTTTTTGTTTTGTT
[0929] CTTGGTCTCCCGCTTGGGGCATTTGTGGGACTCCAGCACGTTTTCTGGCTTCTGCTTCATCCTGC
[0930] TCCATCGGGGAATGACACACTGCGGTGTCTGCAGCTCCTGGAAGGTGTCATTTGACAACACATGT
[0931] GGGAGAGGAGGTCCTTGGAGTGCTGCAGCTTTGGGAAAGCTGCCTCGTTTCCCTTTTCCTCTAG
[0932] AAGCAGAACCAGCTCTACGAGAGTGAGACTGGGAACTTGATGGCTCAGAGAGCATCTTTTCCTCC
[0933] CATTTTAGAAAATCAGATTTTCTCCTGTGGGAAAAAAAAATTCCATGCACTCTCTCTCTGTTAAAGAT
[0934] CAGCTATTCCCTTCTGATCTTGGAAAGAGGTTCTGCACTCCTGGAACCGGTCACAGGAACGCACA
[0935] GATCATGGCAGGATGCGCTGGGACGGCCCATCTTGGCAAGGTTCAGTCTGAATGGCATGGAGAC
[0936] CGGGAGATAGAGGGGTTTTAGATTTTTAAAAGGTAGGTTTTAAAAATAAGTTTTATACATAAACAGTT
[0937] TTGGAGAAAAATTACAGATCATATAAGCAAGACAGTGGCACTAAAATGTTTAATTCATTAATCTGTTT
[0938] GTTTGGCACTGATGCAATGTATGGCTTTTCTCTTGCCCCAAATCACAAACATATGTATCTTTGGGGA
[0939] AACTAACAATATGATTGCACTAAATAAACTACTTTGAATAGAGGCCAAATTAATCTTTTAAAAATGATG
[0940] ATAATCATCAGGTTTACTCAGTGAAATCATATTAATTATTTTCCAAAATCTAAAAGCTGTAGCTGGAGA
[0941] AGCCCATGGCCACGAGGAAGCAGCAATTAATTAGATCAACACTTTTCTCCAGGGTTCACCATGCAG
[0942] GCAACATTACCTTGTCTTTCAAAAGACACCTGCCTTATGCAAGGGGAAACCTGTGAAAGCTGCACT
[0943] CAGAGGGAGGAGTTTTTCTTACATAATTTGCAATTTCAGGAATTTAATTTATAGGCAGATCTTTAAATA
[0944] CAGTCAACTTACGGTGCACAGTAATATGAAAGCCACACTTTGAAGGTAATAAATACACAGCATGCAG
[0945] ACTGGGAGTTGCTAGCAAACAAATGGCTTACTTACAAAAGCAGCTTTTAGTTCAGACTTAGTTTTTA
[0946] TAAAATGGGAATTCTGACTTACTTAACCAGGTTTGGGATGGAGATGGTCTGCATCAGCTTTTTGTAT
[0947] TAACAAAGTTACTGGCTCTTTGTGTGTCTCCAGGTAACTTTGCTTGATTAAACAGCAAAGCCATATT
[0948] CTAAATTCACTGTTGAATGCCTGTCCCAGTCCAAATTGTCTGTCTGCTCTTATTTTTGTACCATATTG
[0949] CTCTTAAAAATCTTGGTTTGGTACAGTTCATAATTCACCAAAAGTTCATATAATTTAAAGAAACACTAA
[0950] ATTAGTTTAAAATGAAGCAATTTATATCTTTATGCAAAAACATATGTCTGTCTTTGCAAAGGACTGTAA
[0951] GCAGATTACAATAAATCCTTTACTTTAATCA
[0952] SEQ ID NO. 19 > NM_001207025.4 Homo sapiens POU class 2 homeobox 2 (POU2F2), transcript variant 1, mRNA
[0953] ACAGTTGTTCCCCCAGCCCTGGCGGGGCGGGCAGCATGGTTCACTCCAGCATGGGGGCTCCAG
[0954] AAATAAGAATGTCTAAGCCCCTGGAGGCCGAGAAGCAAGGTCTGGACTCCCCATCAGAGCACACA
[0955] GACACCGAAAGAAATGGACCAGACACTAATCATCAGAACCCCCAAAATAAGACCTCCCCATTCTCC GTGTCCCCAACTGGCCCCAGTACAAAGATCAAGGCTGAAGACCCCAGTGGCGATTCAGCCCCAGCAGCACCCCTGCCCCCTCAGCCGGCCCAGCCTCATCTGCCCCAGGCCCAACTCATGTTGACGGG
[0956] CAGCCAGCTAGCTGGGGACATACAGCAGCTCCTCCAGCTCCAGCAGCTGGTGCTTGTGCCAGGC
[0957] CACCACCTCCAGCCACCTGCTCAGTTCCTGCTACCGCAGGCCCAGCAGAGCCAGCCAGGCCTG
[0958] CTACCGACACCAAATCTATTCCAGCTACCTCAGCAAACCCAGGGAGCTCTTCTGACCTCCCAGCC
[0959] CCGGGCCGGGCTTCCCACACAGGCCGTGACCCGCCCTACGCTGCCCGACCCGCACCTCTCGCA
[0960] CCCGCAGCCCCCCAAATGCTTGGAGCCACCATCCCACCCCGAGGAGCCCAGTGATCTGGAGGA
[0961] GCTGGAGCAATTCGCCCGCACCTTCAAGCAACGCCGCATCAAGCTGGGCTTCACGCAGGGTGAT
[0962] GTGGGCCTGGCCATGGGCAAGCTCTACGGCAACGACTTCAGCCAGACGACCATTTCCCGCTTCG
[0963] AGGCCCTCAACCTGAGCTTCAAGAACATGTGCAAACTCAAGCCCCTCCTGGAGAAGTGGCTCAA
[0964] CGATGCAGAGACTATGTCTGTGGACTCAAGCCTGCCCAGCCCCAACCAGCTGAGCAGCCCCAGC
[0965] CTGGGTTTCGACGGCCTGCCCGGCCGGAGACGCAAGAAGAGGACCAGCATCGAGACAAACGTC
[0966] CGCTTCGCCTTAGAGAAGAGTTTTCTAGCGAACCAGAAGCCTACCTCAGAGGAGATCCTGCTGAT
[0967] CGCCGAGCAGCTGCACATGGAGAAGGAAGTGATCCGCGTCTGGTTCTGCAACCGGCGCCAGAA
[0968] GGAGAAACGCATCAACCCCTGCAGTGCGGCCCCCATGCTGCCCAGCCCAGGGAAGCCGGCCAG
[0969] CTACAGCCCCCATATGGTCACACCCCAAGGGGGCGCGGGGACCTTACCGTTGTCCCAAGCTTCC
[0970] AGCAGTCTGAGCACAACAGTTACTACCTTATCCTCAGCTGTGGGGACGCTCCACCCCAGCCGGAC
[0971] AGCTGGAGGGGGTGGGGGCGGGGGCGGGGCTGCGCCCCCCCTCAATTCCATCCCCTCTGTCAC
[0972] TCCCCCACCCCCGGCCACCACCAACAGCACAAACCCCAGCCCTCAAGGCAGCCACTCGGCTATC
[0973] GGCTTGTCAGGCCTGAACCCCAGCACGGGCCCTGGCCTCTGGTGGAACCCTGCCCCTTACCAG
[0974] CCTTGATGGCAGCGGGAATCTGGTGCTGGGGGCAGCCGGTGCAGCCCCGGGGAGCCCTGGCCT
[0975] GGTGACCTCGCCGCTCTTCTTGAATCATGCTGGGCTGCCCCTGCTCAGCACCCCGCCTGGTGTG
[0976] GGCCTGGTCTCAGCAGCGGCTGCGGCTGTGGCAGCCTCCATCTCCAGCAAGTCTCCTGGCCTCT
[0977] CCTCCTCATCCTCTTCATCCTCATCCTCCTCCTCCTCCACTTGCAGCGAGACGGCAGCACAGACC
[0978] CCTGGAGGTCCAGGGGGGCCCGAGGCAGGGTCCAAACCTGAGTGAGGGCCAGCCATGCCTCC
[0979] CCTCCCATTCCTCTGGTCCCTGCCTTGGTCCCTTGCCTGGGAAGAGGGCGAGGAGGCCAGTGGT
[0980] GGGGACGCAGAGGGTCCTCAGAGCAGGAGTGACAAGGGAGGAAAGACCAAAAAAACAACCAAC
[0981] CAAAAAAAAAAAAAAAAAGGAAAGAAACTAACCAACAAAAGAGAAAACCAAAAATAATCACAACAG
[0982] AAACCAGCTGCCCCAAAGGAACCAGAGGTGAAAAACAAACAAAAAAAAACCAAAAACAAACCAAA
[0983] AAAAAAAAAAACCCACAAAATCAAACAAACCAAAAAACCAGTCGCGAGCCAGACCTCAGCGTGCT
[0984] CACCCTCACTGCTACGACGCCAAATAAAAACCCCAGCCAGGGGCGGAGAAGCCTCCAGCAGGTC
[0985] AGACCTCATGCCACCGAGCCCTGGCTGTGGGACCAACCCCCAACCCTGCCTCCCCCGTGGGGG
[0986] CTACAGAAGGAAAAAGAGAAGATGCCAGCTTCCTAATCCCAGCCCCCAGCCCTGGGCCAGCGAA
[0987] GACAGGGCACAGCCTGGGCAGATGGGCTGGGGCTTAGCACCACCCACCAAATGTTCTTTTCCAG
[0988] AAGGTGAAAGAGAAAGGGCCTGAACAACCTTACACCAAATATTCAGTAGCTTCATCCAAAGGATGT
[0989] ACAGAATTTTTAGCATTGTGCTCAACAGAATGTGTCCCTACCATGTGTCCCCTTCTCCCCTGGCCC
[0990] CCAGCTCTCCCCACCTGGGCAGGGGGTCTTGCTTTAACCTCCTCCCTCCCCCCAGCAGGGGAGA
[0991] GTTCAAGGGAAGGCCTGCGGACAACTTTTCATCCCCTGTTCCTCCCTCTTTTCCCCTTTGAAGGG
[0992] TGGGCTAGGCCATTTTGCCAAGTTCTAGCTCTCACAAGTCCCTCCTCAACCCTGTCACCCTCCTCT
[0993] GCTCTGGAACTGACTCCCTCCCCAGCCTATGGGAAGGTGGAAATTTCAGGCAAGAGGGGATGAAGACATTCAGTTGAGGGCATTCAGTTGTCTTTTTCCATCCTGTCTGTTTCCCTGAAAAAAAAAAAAAT
[0994] TCATATTCCAGTGCCTATCCGTGGGATCCTTCACGTTCTTTGACATTAACCAGAAACCAAAAAGAGA
[0995] ACTCACCTCGCTTTTCCCACCCTGTGCCCCTCTGGTACTGGCGAATGCCTCTCCCTCCCCCCACA
[0996] TGCACGCACGCACACACCCCAGTGGTGGGGTTCCTCGAGATGGCATCCCCATCAGGGTCCATGT
[0997] GGTGGGGACAGTGCCACAGCCTGTGGTCCCCATCTGAGAGGGCGCGGTGGTGGCCACCACTCC
[0998] CACAAGACCTCCACAACTCTTGGCTGGACCCTGTGTTTGACCAGCCCCGGACACGTCTCCACTG
[0999] ACGACGGACAGAGGAGAGACACCACTGGGAGCCACCCTGCCCTCCTGCTATTGTGGAGGCCAAC
[1000] AAAGTTTTGAACCGAAAACCAAAAAAACAGAAACAAACAAACAATAAATTTAAACTAGAAAAAAAATT
[1001] TATATATATATATAAACATATATATATATATATATATAAAAGGGAAAGAAGATGAGGACTCTTCAAGAATAA
[1002] GATGGAACCGCGAGGCGGAGCCAAGCCCCTGCACCGGTGGTCCAGGCCCTTGTTCCCCAAGGC
[1003] GGATGGAAGGACGGATGCTTCTTTCTCTTCACAAATACCTCATGGACGTTGTCTTTGGGAAAGCCG
[1004] GAGGGGGCGGCTGGGGCAGGGCCTGTCCCTCGGCCAGGGCAGATGGAAGCGGGTGGGCGGG
[1005] GCTGAGAGAGGGTATCAGGGACAGGGGTGAAGAGCCCCAAACTCCCCTCCCAAATCAACTGAAA
[1006] AAGCTTTAAAAAAAGACAGGAAAAAAAGGAGTAAGAAAGCAAAAAGAACAGATGAAGGAAAACTTA
[1007] ACAACTTTTGGGTGGTTTGATTCCTCCTTTGATTTCTTTTTCGGTTCTCTTTTGTCTGACCTCTCTC
[1008] CTCCCCTCCTTCCTCTCTCCTCCCCTCCTTCCTCTCTCCTCTCCTCCTTCCTGTCTCCTCTCTCTC
[1009] CCTTTGCTCTCCTCTCTTCTCTCTCAATCTTGTTCTTTCTGTGTCTCTCCTCAAACCAAAGTGTTGC
[1010] AGTGAAGGACACGAGCCATTGAAATCAGGGTGGGGCCTGACAGCCGTAGTGTGGCCCCTGCCCC
[1011] TTGTTGGGCAGGAGCAGAGAGAGAGGAGAGCCCTGAGACCGCAGGGCTTTGGCCTGGGCAGCT
[1012] TCCACTTTCTGCCGGACACTCTGAGGAGAGGCAGATGGAGCTCCAGGCCTCAGCGTTCTCTTTTT
[1013] TCCTTGTCTCCCTTCTCCCACCCGGGAAATGAAACTGTTGGGCTGGGCGACGGAGGCAGCAGAG
[1014] ACTCGGCCATTGCAGGGGCCTCTGGGTGCCTTGTCCGGGCAGTGGTGAAGTAGCCGCCCCTCC
[1015] CACCCCGGCACGATGGGGCCTGGCACCTCGTCTACCCAACCTCACCGGAATGTAAGCATCTCCG
[1016] CTGAACGACTCCCTGCCCTTACCCTACCTCTGAGTTTGTCCATGTTTATTTCCTGAAGAGAGAAGG
[1017] GACTGGCAAGAGGGCTTGGGCCCCAGCCCAAGGGTGGAGAGGGGGCCAAGGGCTCCTGACCA
[1018] AATAGGAAGGACATTTGAGCAGAGCAAAATGAAAGGAATTACAACCAAAAACCCCCTCCGAGAAG
[1019] ACAGGCAGCATGGAAGGCATGGTGGAGATGACTCAAACAAAAACTATGATTCTAGACCAAAAAGG
[1020] AAAAAAAAAAAAAAAAAAGGAAAGAAAATCCAGGACTCACCACCACCCACTTCATCCTGCTTCCTC
[1021] CCCATCAAGTCCCACCACCTGGGACCTCTCCCCACCCCAGTATGTGGGAGTGGGGTAAAGAGGA
[1022] GAGGAGGAGCAGGGGGCAGGGATGGGGCAGATGCCCTGATGTTGGTGGAGGGACCCCTGTGCA
[1023] GCCGGGGGTGCTGGGGACCCTCCCCATCCAACCCTCACACCTAGGAAAAGAAAAACAAGAAAAA
[1024] AAAATTCCTGGGAGGGGGAAAAATAACCAAATCCCAAGCTTTAACTACAGCTGTGAAACCAAATATT
[1025] GGGAAGGGGGTAGGAGGGAGGGAGGGGCAGGTGAGCCCCAGGTCTCCCCCTGGGCCCCCCTC
[1026] CCCTGAGGACTCGAGATAAGGCACCAAATACCTCATAGAACTTTAATGTTAAAAAAAGGAAACCAAA
[1027] TATCGTTGGCTGGGGGCCAGCCAGGGCAAGGGGCTGGGGGGCTGGAGGGAGCCAGGGTTGGG
[1028] AAGGTGATGGGGGAATTCATGCCCCCCACCCCCATCTGCCCCTTACACTCTGGTCCCCCGTCTCG
[1029] ACTCCGGGAAACAAAACTATCTCATCGTTTTTATTTTGTGGTCTGTACAGAGCCTGTGTCCGTGTGT
[1030] CTGTGTATGAGCGAGAGAGTTGGAGGGCTGGGGAGCTTTATGTGGGGGATGGGGAGGGCAACC
[1031] CCAGGCTAGGCTATGGGCTAGGTTAGATGTCCGAGGTTGGGGGCCAAGGGCCTGGGCTAGAAAGAGAGGAGAGATGAGTGGGTTGGAGCAGTGGGGAGCCCTCTGAATTTCTCTTCTCCCCAACCCTG
[1032] ACCTCCTACTTAAGGGAGGGACAGAGACTGGGTCTACCCTAATGGTGGGCCTTTTCATTGTGCCA
[1033] AAAAAAAAAAAAAAAAAATTGATGCCAGTAACTAAACCACCTCTCTCTGTTCTCTTCTGGGGGGTG
[1034] GGGTGGGTGTGTGTGTGGGGGTGGGTAGGGATGGGGAACCCAAGCCCCAGTAGGAGTTGGGGC
[1035] TGAGATCAGGAGGAGGGGAAGGATATGAGTTTTCCATCCATCTCCCTGGAGAAGGCCATGACGGG
[1036] CTCTCCAAGCCCTGGGGAGATCTGGCGAGGGACTAGCCAAGTCAGGGTGACCTCTTGACCTGAC
[1037] TAGTTTTTCTAACCCACATGAACACCAGGGTGCCTCTCTCTTCCTCTAGCCCAGGGTAGGGGGAC
[1038] CTGAGTGAGAGAGAGAGTGAGACAGACAGCAAGATTGAGACACGCGGGCCCCCACTGGTCTCT GAGTGGGAAAGGCAAGTGCGAGAGATAAAGGCCTCCAAGAGAAAAAAGAAACAAACCAAAGATTT
[1039] AACCATTTAAAAAAAAAAAAAAACCCACAGACAACTCCGCTACCTTTTTATATGTTGGAAAAAAAGT
[1040] GAAAAAAAATTAAAAATAAAAATAAAAAAAAATACACAAAAACTCCAAGCCGCAAGTCCTTCATGCG
[1041] GTTTAAACTTTGACCTCAGCAGTCTCCAAAGCAAGACGACGATGACAAAGGCGGAAACAAAGAAA
[1042] AAATAATGTATATTTTTAAGTATTTGTCCTTGAATTGTTAGCTCCTTGTTAAACAAACAAAAGGAGAGA
[1043] AAAATCCAGAGAGAAGTGTTGCTGGGATGGAGACAACTATTTACTATGTCTGTGACCCCTCCCTTC
[1044] TGCCTCCCTCCCCTTCCTCTCTTTCCTGTCCTCTATCCTTGCTGCCCCTCCCCCAATATGTCCCCC
[1045] AAACCCAGGGGCTCAGTATTTATTTATTTATATAATTGCAGGGTGACTGGGGGCCTCTCTCGGCAAC
[1046] TCGTAGAGAGCCTTTGGATAATGGCAGGGTGGGGAATGGGCGAGGAGTCTTTGGGAAGAGCAGG
[1047] GGCCTGAACTTTCAACTCCTTTCTGGCCTCTTGTCCCACTGCTTCCACCATCACCTTCCAAATCCA
[1048] GGGCTGCACTAGGGCAAGGTGACCACCCTACTTGGTAAAGACCTGATTGGCGCAGCCCATTCTG
[1049] GTGTGGGTGTCTTTCACCACCCAGAATGACCAGGTTGGAATGGGGGTGGGTGAAGTTGGAGGGG
[1050] GTGGCAAGTACAAGGCAAGGGTGCCCAGGAACCGGCATCCAGAAATCAGCCCTGGAGTAGACCT
[1051] GCCTTTCCTCCATCCTTACCAAGTTAGCCTCCCTTTCAGTTCCGTCTGACCCCTGTGTTGGTAGCC
[1052] CCTTCCTTCCCTTCCTGTACCCCCTCCGTCTCTTCTCGTGGTAGCGGGTTAGTGTTTCAGTGTTCT
[1053] TAACTCCAATCTGCTTGTTCATTGTACAATGTGCTTCTTTTAAGGCCCCATTTTTGTAACTTGAGTGT
[1054] GTCATTCATCTGAACAACAAACATCAAAAAATAAAAAATTAAAAACTGTACAGAGAGAAATGA
[1055] SEQ ID NO. 20 > NM_001382323.2 Homo sapiens PBX / knotted 1 homeobox 2 (PKNOX2), transcript variant 1, mRNA
[1056] GTCAGTCTGATGAAGATTGGCATCAGGTGAAGTCTGGAGCAGGACTTCTGAGGCTTTCTATCCTC
[1057] CATGCTGCTCACTAGAAAAGGGGCTGTGAACTGTGCTTTGGCTCTAGCAGACAGGAAGAAATTCT
[1058] GGCCCAGCTGGAAGTAGAAAGAGGGGAGTGAGTCTCCTGAGGACCATCTCAGAGGCCCCGGGA
[1059] TCACCCGAACAGTCCTCCATGTGAATCAATCCCATGATGCAACATGCCTCCCCAGCCCCCGCTCT
[1060] GACGATGATGGCCACGCAGAATGTCCCGCCCCCACCCTACCAGGACAGCCCACAGATGACGGCA
[1061] ACCGCCCAGCCACCCTCCAAGGCCCAGGCTGTCCACATCTCTGCCCCCTCAGCTGCTGCCAGCA
[1062] CACCTGTGCCCAGTGCCCCCATCGACCCCCAGGCCCAGCTGGAGGCTGACAAGCGAGCTGTATA
[1063] CAGGCACCCTCTTTTCCCGCTCCTGACGCTGCTGTTTGAGAAATGTGAACAGGCCACCCAGGGC
[1064] TCTGAGTGCATCACCTCCGCCAGCTTTGATGTGGACATCGAGAACTTTGTCCACCAGCAGGAACA
[1065] GGAGCACAAACCCTTCTTCAGCGATGACCCAGAACTGGACAATCTGATGGTGAAGGCAATCCAGG TCCTGAGAATCCACCTGCTGGAGCTGGAGAAAGTCAATGAACTCTGCAAGGACTTTTGTAACCGT
[1066] TACATCACCTGCCTCAAAACCAAGATGCACAGCGACAACCTGCTCAGGAATGATCTAGGGGGGCC
[1067] CTACTCCCCCAACCAGCCCTCCATCAACCTTCACTCACAGGACCTCCTGCAGAATTCCCCCAATTC
[1068] CATGTCCGGAGTCTCCAATAACCCCCAGGGGATTGTGGTCCCAGCCTCAGCGCTCCAGCAGGGC
[1069] AACATCGCCATGACAACCGTCAACTCACAAGTTGTGTCAGGTGGAGCCTTATACCAACCGGTTACC
[1070] ATGGTAACCTCCCAGGGTCAGGTGGTCACCCAAGCAATCCCCCAGGGAGCCATCCAGATCCAGA
[1071] ACACACAGGTTAACCTTGACCTCACCTCCCTCCTGGACAATGAGGATAAGAAGTCCAAGAACAAA
[1072] CGAGGAGTCTTGCCCAAGCATGCCACCAATATAATGCGTTCTTGGCTCTTCCAGCATCTCATGCAC
[1073] CCCTACCCCACGGAGGATGAGAAGAGGCAGATCGCAGCCCAGACCAACCTCACCCTCCTGCAAG
[1074] TAAACAACTGGTTCATCAATGCCCGGAGGCGCATCCTGCAGCCCATGCTTGATGCCAGCAACCCA
[1075] GATCCTGCCCCCAAAGCCAAGAAGATCAAGTCTCAGCACCGGCCCACCCAAAGATTCTGGCCCA
[1076] ACTCCATCGCTGCGGGGGTGCTGCAGCAGCAGGGCGGTGCCCCAGGGACAAACCCCGATGGTT
[1077] CCATCAACTTGGACAACCTGCAGTCCCTGTCCTCAGACAGTGCCACCATGGCCATGCAGCAGGCT
[1078] ATGATGGCTGCACACGATGACTCATTGGATGGGACAGAAGAAGAGGATGAGGATGAGATGGAAGA
[1079] GGAGGAGGAGGAGGAGCTGGAGGAGGAGGTCGACGAGCTGCAGACGACAAATGTCAGCGACCT
[1080] GGGCTTGGAACACAGTGACTCCCTGGAGTAGTCGGGCAGCCCAGATGGCACTGATCACTGAGCA
[1081] GGAGAGGAGTGTCGCCGGGAGGCCTTCAGGGTGGGGGGGAAGGGGACATGGGCAGGAAGCAC
[1082] CGAGGGAGTTGGGCCCTAGCTTCCCCAAATCAGTAGCTTGAAGAAAGGCAAAGGAGACACCTGT
[1083] TCCTTCCCAACCACCGAGCTTCAATGAGGACCCCAGCCCCACTTCCCTGGAACTGCCGAGGACT
[1084] CTGTTTGGCGGGGCCAGTCGAGCAGCCTGTGTGGAAAGACAGGAGTGAGATCTGGACTCACCAA
[1085] ATCCCTGAGGATAGATGGCACCCATGGCCCCCACCCACGGAAGGACTTGAGTTGTTTACAAGCCC
[1086] TGCACTGAGGCAGATTGGTGCTGTTCGCAGAGTAGGCCTTTGCCCGGGGGCAGACTTAGAAGGA
[1087] AGGGGAGAGACAAAGGGGGACTGAGTTTCATCCCCAGAAGTTTCTCAGCTCCTTTGACAGACATT
[1088] CAAGGGCAGGAGGGAGCCCCAAAGCATAACCAGTGGCCAGAGGAGTGGGAGGGCCTGAGGCAT
[1089] CACATCTTGCAGATCAGAATGGGATGGAATCCACCAGGCTCCAGCTCATCCCTCCAAGGCCCTGT
[1090] CTCTGCGCACAGCAACCATGGACATGGGAGAAAGGGATGGGAGCCACAGTGCCCTTCACTCTCT
[1091] CCTGGAAACCAACTGTAAGCTGGTGGGCTCAACCTGTGGGAGGTTAAGAGGAGTCCCTTCTGGG
[1092] TTGACTCCAAGAGCCAAGGAGATGGCAGACCCTGGGCTAGGAACCATATGGAGGTGACTTTGAG
[1093] GCCACAGCTGTCCCTAGGTGATCACAGAACTTAGCTCCTTTAACAACAGGACAATGGTTTTTTACC
[1094] CTAGATGTTCCCACCTTCAGTGCTCCACGCCCTCCATAGACCTTCAGAGAAGGTGAAACCAGGTT
[1095] ATCTGGGAATCTTTCCAGCCCGCAGGTCGCCACGGCCATCCCTTTGCTCCCAGCCTGGCTCCATC
[1096] AGCCTCCAGCTTCCTTTCTTCATTCTGTCCTTCAGGGAAGGCAGAAGAAACATTGGAAAGCATCTA
[1097] GTCCAGTGGGAAGCCAGGGGTTGGAGAAGGTGCTACATCCCTCTTCCCATCAATATCCTAAATGT
[1098] GGGGGAGGGCCCAGAGAATGGCACCCAAGAGCCTGCGGGGATGCCCATCCCACACACCCCACC
[1099] CAGCTGTTCTAACCCTGCTATCCACAGCCCTGGAGGAACTGGGGCTCCTGGAAGGAGGAGGAGG
[1100] CTCTCCACTGTCCACCCTAACACATACCCTCCCACCCACCTTCCAGACCCCCTTGGTTGGCACCC
[1101] TCTCCTCCGGTTCCCTCTCACCCCATGGCTGTGAATGACAGGACAGGTCACACGTGTGTTTTCCA
[1102] TTGGGTTTAATTTAATGGACGTGCAGTTTCATTTGTAAATTGTGCATTGGCCACCTCCTTCAGTGGC
[1103] AGGATGTGAGTGGCTACCTGGCTCAACTGGAGGGGACCCCTTGGGCCCTCTGGGGCTTCCCCTC
[1104] CCCCACCTGGTTGGGGTAGAGCAAAAGGATGGTCACTCTTCCGAGGTCTCCCTGAAATGAATGTATTTCTCCCCCAAAAGAGCTGATATTTAATGTTTTAATAAGGATTTTTGAGAAACAAATAACCTTATTTA
[1105] TAATCTGGGTGATCCAATCATTTTTTACTCCCTTTTGATGCCATACATAGAGGAAAGTCTAGCTTTTT
[1106] TGGCGTGAGACTTTTGCAATGTGCAGTGGGATAAAATGCATTTCCTTTTCTGGTTCGTTTTTCTTGT
[1107] TAACACGCGCACACAGACACACACACACACCGTTCCACTCACCACCTGGACAGGCGTCCCCCAG
[1108] CACGGACACACTGGCACACAGGTGCCCACATCTCTTCCTCTCAGCCCCTCCACCTGCCTAATGTT
[1109] ATGCAACCTCCTTCTGATGTATCCACCAAACCAGTACTGAATGTGGCCGAGACGTTTTCAGTAAAT CTTATTACCTACCGTAA
[1110] SEQ ID NO. 21 > NM_021813.4 Homo sapiens BTB domain and CNC homolog 2 (BACH2), transcript variant 1, mRNA
[1111] AAACAGCGCCGAGCCGCCGCCGCCTCAGCAGCAGCAGCAGCAGCAGCAGCGGCAGCAGCGGC
[1112] CGTGCACGCCCGGGCTGCGGTCGCACAGCGCTAACGTGAGCGGCCGCCGCCCTCGCCACCCC
[1113] GCCTGCCCACTCCCGCCGCCGCCCCGCTCTCGCTTTCCCCCCGGCCTCCCCTCGCCCCTTCCC
[1114] CTCCCCCTTCCCGGCGCACTCGGGGGGCTGGGAACGAGCTGCCATGTGATGCGCGTCCCCTCC
[1115] GCGAGCTTTCGGTGACCCACGAACTGCCCACCTCGCCGGCTGCCGGGAGGGGGCTGCGAGCC
[1116] GGGAAGACGCGGGGAAGAGGAGGCGGAAAAGGACGCAAAGTTCTCCGGCGAGCGCGTTCGTTC
[1117] ACATAGCTCCCAGTTTTAACATTTCGCCACCTACTGAAGACATCATTTGGGACCAAGCTGATGAGC
[1118] CCTTGAAGCACAGCAGATAAGAGTGTTGCTGTTGATCATCTTTGCCTGGGAAGTTGAATGATAAAG
[1119] CCAGAAGAAAGCATGCTTTCTGATCATTTGCAGCTGTCTGCTTCAGAAAGTGAGGGCTCCAGGAA
[1120] TGAGGAGAATCTTCAAGAACTTCCTCGCACTGTGACATGTCTGATCCCTTGCTCCCATCCCTGCAG
[1121] CATGAACAAGGTGGACACTCACTGACCTGTCACAAGGTTGCCCCACAAAACTTTGGGGTCCATGT
[1122] CTGAATGGATTGCCAGAGCCTTCTCATCTCTCCCTTCGCCCAGTTCCCTGCATCCTAAGACTCGAA
[1123] GGCAGCACAGGACCTGGAAAAATTACATGGTGTGAACGGCATGTCTGTGGATGAGAAGCCTGACT
[1124] CCCCCATGTATGTGTATGAGTCCACAGTCCACTGCACCAACATCCTCCTGGGCCTCAATGACCAG
[1125] CGGAAAAAGGATATTCTCTGTGACGTGACTTTGATCGTGGAGAGGAAGGAGTTCCGGGCCCACC
[1126] GGGCTGTGCTGGCCGCATGCAGTGAATATTTTTGGCAGGCGCTGGTTGGACAGACAAAAAATGAT
[1127] TTGGTGGTCAGCTTGCCTGAGGAGGTCACAGCCAGGGGCTTTGGGCCGCTGTTACAGTTTGCCT
[1128] ACACTGCCAAGCTGTTACTCAGCAGAGAAAACATCCGCGAGGTCATCCGCTGTGCTGAGTTCCTG
[1129] CGCATGCACAACCTGGAGGACTCCTGCTTCAGCTTCCTGCAGACCCAGCTCCTGAACAGTGAGG
[1130] ATGGCCTGTTTGTGTGCCGGAAGGATGCTGCGTGCCAGCGCCCACACGAGGACTGCGAGAACTC
[1131] TGCAGGAGAGGAGGAGGATGAAGAGGAGGAGACGATGGATTCAGAGACGGCCAAGATGGCTTG
[1132] CCCCAGGGACCAGATGCTTCCAGAGCCCATCAGCTTTGAGGCCGCCGCCATCCCCGTAGCAGAG
[1133] AAGGAAGAAGCCCTGCTGCCCGAGCCTGACGTGCCCACAGACACCAAGGAGAGCTCAGAAAAG
[1134] GACGCGTTAACGCAGTACCCCAGATACAAGAAATACCAGCTTGCATGTACCAAGAATGTCTATAATG
[1135] CATCATCACACAGTACCTCAGGTTTTGCAAGCACATTCCGGGAAGATAACTCTAGCAACAGCCTCA
[1136] AGCCGGGGCTTGCCAGGGGGCAGATTAAAAGTGAGCCGCCCAGTGAAGAGAATGAGGAAGAGA
[1137] GCATCACGCTCTGCCTGTCTGGAGATGAGCCTGACGCCAAGGACAGAGCGGGGGATGTCGAGAT
[1138] GGACCGGAAACAGCCCAGCCCTGCCCCTACCCCCACGGCCCCAGCTGGGGCCGCCTGCCTGGA
[1139] GAGATCCAGGAGCGTGGCCTCGCCCTCCTGCTTAAGGTCTCTGTTCAGCATAACGAAAAGTGTGG
[1140] AGCTGTCTGGCCTGCCCAGTACATCTCAGCAGCACTTTGCCAGGAGTCCAGCCTGCCCTTTTGAC
[1141] AAGGGGATCACTCAGGGTGACCTTAAAACTGACTACACCCCTTTCACAGGGAATTATGGACAGCC
[1142] CCACGTGGGCCAGAAGGAGGTGTCCAACTTCACCATGGGGTCGCCCCTCAGGGGGCCTGGGTT
[1143] GGAGGCTCTCTGTAAACAGGAGGGAGAGCTGGACCGGAGGAGCGTGATCTTCTCCTCCAGCGCT
[1144] TGTGACCAAGTGAGCACCTCGGTGCATTCTTATTCTGGGGTGAGCAGTTTGGACAAAGACCTCTC
[1145] TGAGCCGGTGCCAAAGGGTCTGTGGGTGGGAGCCGGCCAGTCCCTCCCCAGCTCGCAGGCCTA
[1146] CTCCCACGGTGGGCTGATGGCCGACCACTTGCCAGGAAGGATGCGGCCCAACACCAGCTGCCC
[1147] GGTACCAATCAAAGTCTGCCCTCGCTCACCCCCCTTGGAGACCAGGACCAGGACTTCCAGCTCC
[1148] TGCTCTTCCTATTCCTACGCGGAGGACGGGAGCGGGGGCTCACCCTGCAGCCTCCCTCTCTGTG
[1149] AGTTCTCCTCCTCGCCCTGTTCCCAGGGAGCCAGATTCCTTGCCACAGAACATCAGGAACCAGGC
[1150] CTGATGGGAGATGGAATGTACAACCAAGTGCGGCCCCAAATTAAATGTGAGCAGTCTTATGGAACC
[1151] AACTCCAGTGACGAATCCGGATCGTTCTCGGAAGCAGACAGTGAGTCGTGTCCTGTGCAGGACA
[1152] GGGGCCAGGAGGTAAAACTTCCTTTTCCTGTAGATCAAATCACAGATCTTCCAAGGAACGATTTCC
[1153] AGATGATGATTAAAATGCACAAGCTAACCTCAGAACAGTTAGAGTTTATTCATGATGTCCGACGGCG
[1154] CAGCAAGAACCGCATCGCGGCCCAGCGCTGCCGCAAAAGGAAACTGGACTGTATTCAGAATTTAG
[1155] AATGTGAAATCCGCAAATTGGTGTGTGAGAAAGAGAAACTGTTGTCAGAGAGGAATCAACTGAAA
[1156] GCATGCATGGGGGAACTGTTGGACAACTTCTCCTGCCTTTCCCAGGAAGTTTGCCGAGACATCCA
[1157] GAGCCCCGAGCAGATCCAGGCCCTGCATCGGTATTGCCCTGTCCTCAGACCCATGGACTTGCCC
[1158] ACGGCCTCCAGTATTAACCCTGCGCCCTTGGGTGCTGAGCAGAACATTGCGGCCTCCCAATGCG
[1159] CAGTGGGGGAAAACGTGCCCTGCTGCTTGGAGCCAGGCGCGGCTCCCCCCGGACCCCCCTGG
[1160] GCACCCAGCAACACCTCCGAGAATTGTACCTCTGGGAGGAGACTAGAAGGCACTGACCCGGGAA
[1161] CCTTCTCAGAGAGAGGACCTCCTCTTGAACCCAGGAGCCAAACAGTGACCGTGGACTTCTGCCA
[1162] GGAAATGACTGATAAGTGTACAACTGACGAACAGCCCAGGAAAGATTATACCTAGTGACTCGGCTC
[1163] TGCCTCCCAGTCCGCACACCTCTCCCATCCAGGCGTTCTTCAGTCAGCCTGTGGCACTGTTCATC
[1164] TGCTGTCCCGAAGAAACCGAGAACACATTTGGTGCACACTACAGCGGTCTTAGCAGCAATACTGT
[1165] TCCGAAGTATCCTCTCCTCTTCTCGAGCAGGAGTGATAGTTACCTTCACAATGGTGCTACCCCTTG
[1166] CCCAGGCAAGGAAAGACAGCAGTGATGACACTGTCTGTCTGTGGCTCAATTTCAGTCTTCACAGG
[1167] GATAGACTACAACACCTCTAGGCCCCAACCACGGATTTTTTTTCTCAGTGGCCCATGTCACAAACC
[1168] CTATCTCAGGAATTTCTTCTGAATGTTCAATTTTTTTCATTGAAGACAGCTTCTATACACATCAAAGTT
[1169] TTATAGCTAGACTGTACATATTATATATAATATATATATAAAATATATATATATATATATATATATCCATATGCA
[1170] AAAGTCCTGCATGCCTCAACTTTCTCATCCTAAAACTGGAAACTTATTTCTCATTTAGAAACAGGTT
[1171] CCAACATTCCTCTTCTTTTGTCTCTGATGCTAGAACTAGTTTGGTAACTGTTAACATGGTCATTTTTC
[1172] TTGCTTCACAGTTCAATTTTCAATTCGTACTTATTTATGGACAAAATTCAGTGTTGGAAGCTTTTTCC
[1173] CAAGGTTTTATTTCAGATTTCTTTTTCGTTTGGTTTGGTTTTGGCACCTCCAAGTGGTGTCATTTGA
[1174] GCATTGTAGGTTTGTTTTTTGTTTGTTTGGGGGGTTTTGTTTGTTTTTGTTTTTGTTTTTGTTTTCCT
[1175] TGCAGATACTGTACAGTAATGGTCAACTTTGCCACTTGCACTGAGTTTTGGGTCAAACCTATTTTCT
[1176] TAAATGAAGTTGTAACTTCGGTATAACTCAAGTATACTGTATATTCTTTGCTTTTAGTTAAAAAAGTAA
[1177] AACATTTTAGCTAATTAAAAAGCACTCAGGTGATAATTATGTAGGAAAAACAATCTTGCCAAATAATG
[1178] AATTCATCCTAGGATGTGTAGACAATAATCTGCTTGAATATTTTTATATTTCACCTCCTCCCCACCTTTCCCTAAGCAAAGTTTAAACGCAGATAGAGAGTTCAGAGTTGATGCTGGATGTTCAGATTCCTAAGT
[1179] GGGGAGAGAGTTTGGACATCTCACTCAAAAGTACATCAGAAAAACAGGAATCCGTGATTTTATACC
[1180] AGAACTCAGCAGGCATTGGCTCCTAGAAATCAAGTTAGAAAGTTTTCACCCAGGGAGTAAGTCCCA
[1181] TTCATTTCAACACGTCCTGAGGCCTCGGCTTGCTCTTGGAAGTGTTGTGCAGTAGGACCTGCTCC
[1182] CCTGAAGGACGGGGCCAACCAGCCACTGGCTTTCCTGCCCAGGCTTGGCCTCCCAGGACATCTG
[1183] GCCTGAGGGGATTTGAATCACAGCCCCGAAGGTCCTGCCTTCACCCCATTGGGAGAGAGCAGGG
[1184] CATCCTGGCATCTGCGATCCATCCCTGACACAGGCTGACACATTCTTTCTCCTTTCCTTCTCCAAA
[1185] GGCTTGGAGTTTTCTTCTGAGGTTTTTCTGCCAGTGTCTTGTCTGAAGGCAGACTTCATTCTGAGG
[1186] CTTTGGACAAGCTATCACCGGGAACCCTCCCTGTCCCCTTCCCGAATCACACACATACCCTACCCT
[1187] CACCTGATGATAATTTTCTCTTCTTGCTGCAAAACTGGTTGGCTTGCAACCCAGAGAGAGCAGCTT
[1188] CCCTTGGCTCTGGGGCCGTGTTGGCCCCAGCCACGTTTACAGGAAGGTGTGCCCCAGAGGAGG
[1189] AGGAATCAGCTCCCTCGCTCCAGTGGCCTTGGGTCCGGGTCTCACTGAGCAGCCCGAGGGCCA
[1190] CTCCAGCCCGGCTGGGGAAGAGAGTCCTGAACGGTTTGATGTGGGGATGGGGTGGTGGGCAGT
[1191] GGGGAATAGATGGTTGACTTTGTTTCTTTATTTGTGCCATTGTTTGGACAATATTAAAGCTGCATGTA
[1192] AAAGGGGAAATTAGTATATGATGTAGGCTAAAAGTGAAATCATAGTAACATATGTTTTAGTATTATTAA
[1193] CTTTTTTCTGTACAAATATTAGCACTAAATGTTTAAATATGTATGAATGCCAGAAATTTGTCAGTTCAT
[1194] GCAGTAGGATAAAAAAAAAAAAAAAAAAAAAAAAAAGGCTTTTCTTTTTAAACAGTTCCACTTTTAAA
[1195] ACCTGCCTCTGGGTTTTTGTTTTTTCTTGTTTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT
[1196] GTGTGTGTGTGTGTGTCTGAAACAGATCTTGATAAAGCTCTGTGTTGGAGCTGCTGGTTTTTGTTA
[1197] TGGTTGTTGGAATTTCTTGGCCTACTAGGACAGTTCTGTGCTTCACCATGAGGTTTGCCTTTGTGG
[1198] AAAACTGGTGACAGTGAGAATATAAACTCAATGTGAATCACGTGATACTTCGCAGGCGTGTGTTAC
[1199] AGTGGAGTCAGCTGACAGTATTTTGCTTTTTAACTCTATTGTTGCCTTTCCAAGTGACCTCTCCTCT
[1200] TCTTTTAAAAAAAGAACACTTTCTGCTCATATCATAACCAGGTCCAACCCAGCTTCTTGGCATGAGG
[1201] TTTACCCTGGTAACAACTCATGTGCAACTGGTAGTCTTGACCACATTCCATCCATTTCCTCAGGTTT
[1202] CTGTGGTTCAGTAGCCCAGACCTGTTTGGCAGCCATTTCTAGCAGGGGCGGGGCCTCTTTATTTC
[1203] TCTCCACCCTAACTCAGACCTCACCTTCCTCCCACCCACCCCTGCCTTGCTTTTCTTCCTCTTCCC
[1204] CCAACCTAACTTCTGCCATGGGAACTGGTTAAAAACACTGCTCTAAAAACCATCTTCCAATTTCATA
[1205] GAGATTTCTCACAAGTTATTTCATTCATAATCCACCATGAACAGTGACTAGCTTCGTGCAGTTGTTC
[1206] ATGTGATGTGTGTGTGTCTTTTCCTATTCAGAACTATGTGCTTGTCAAAATTATTTCTGGGTTGATTC
[1207] AAAGGGAGGACTTGCTGGGGACCAGAATCCAAACGGCCTCAAGTGGAATTTTAAAACCTAGCCTG
[1208] TCTCTTTTCCCTGGGATCCCTCTGTCAACCCCACGCCTTTTAGGAAAAAGAAAAGTGAGTGAACAG
[1209] CAAGGAAGAGTGTTTGCACAGTACAGTAACATTTGGTTGTTCTTAAGGCTCTTTTCTTACAAAAATA
[1210] AGAGACCCTCCAACCACGGGCTGTTTAGGAGGATGCCTGCTTGGGTCTCCAAATGGCTGGGGTA
[1211] GGAATGGTTGTTGGGGCAGAGCCAGTGGAGGTGAGTGACCCTGAGACTAATGAACATCCCACCT
[1212] AAATCCAGTCCTCCCCTTGGATCTGCCTTTGTCCTGCTTGTGTATCCAGGCAACCTCTTTTCAAGT
[1213] TGGTCAGGCTTTGGACAGGTGAGTGATTTGCTGTATGTGTTTGTTTCTCTGCGTTACCTGGGGGT
[1214] GCCTTGATTAAAATCGAACTTTATTACATACTGATTCTGGAACAAAACAGTTAGAAAAACTTTAAAAA
[1215] AAAAAAAACCGACAAAGTTACGAGGCCATCCTGCTATTTATCTTCTGAGTTCCCAGCAATGACTCA
[1216] GGCATCAGAGATGATGCTGCAGTGGAAAACCTGACTCTGTGTGTCTGCAACTGAATGTTGTGCGAGTAATTTATTAACTGTCTTTCTAAAGGTTTGCTGCTTTTAAGATGCACTATAATTCGGGATGTAATCCT
[1217] TACATTGCTTTTCCAAGGAAGGGAACAAAAGTCTAGTGATTAGTATGCCAACTGCCACTACTCCTTC
[1218] AAAAGGAGCCAGGACCAGCGACAAGACTCATGAGAGGACTGGCTAAAGTGAAGTGTGCACAGTG
[1219] TGAAGTTTAATGCTGTTGTCAAGAGGCCTAAACCCACATTTTCTCTTTTAATATTTTATGATTGCCAT
[1220] CAAAGAAGAAGAAAAAGAAGGAACAGACAAAGGTTTGAAAATGATAAGCCTGTTAAGACACCAAAA
[1221] ACTCCTGTCCCGTGAAGCTGCTTGACATCCTGTGGAGTAGCATAATCCTCTCAAAATGAGGAAGAG
[1222] CTGCCTGCAAAGCTTTCTCAAGTCCCTATTTGGCTACCTACTTCTCTACATTATGCCCCATTTAAACT
[1223] AGGAGCTGTCTTAGAAATGACTTCAAACTGCTTCACTATTGCTTACAGTTTAGGAGGAGTCTCAGAT
[1224] CCAGAAGGAGCAAGAATCAAGTTTGGTCCTCAAATGACTGTAAATAGACTAAAGAACAAGGTGTTT
[1225] TTTGTTTTTGTTTTTGTTTTCTAAGAATAAAGCTGTTCGTTGTATCATGAGTTAGTGTTTCTTCCCCA
[1226] AACTGAAGACTGTGTTGGAAGTGCAATTTCTGGTGAGTCAGTCCACAATACAATGCCCTGTGTGG
[1227] AGTTGGTATTCATACAGGAAATCTGTGTGCACGAGGCATTGTGTGTTGAAAGTGTATGTTTATAGTA
[1228] CTGCCTGAGCCATCTCATGACCCCAGCGTCCAAAACCGATGCTGTAGAACAGAACATATCTGTACA
[1229] CAAATAGTGTGTGCAAATAGCATTTGTACATAGAAAAGTCTCATTGTGGCAGATTGAGCATAAATTAT
[1230] TCAACTGACGGTGCAAAAACATTACTTGCAAAGAAAAGTTTATAGTATTTTCCTACACTCCACCCTG
[1231] GGAGATGATATTTCTATCAAATGAATATCAGTGCATTTTAAATGTAATATGAAAACGATGCTGCCATTT
[1232] TGTGAAGAATACCCACTTGGTTGCAGAGGCCAACTTTCATAGCTTTGATTTAATGTTGTGACACGG
[1233] TGTATGCATTTTGCTGTCAAGCAATGGATAAACAGCTCTGACTTTCATTCTCATTCCAGTTTATTGAC
[1234] CTCAGATAAAACACTGGCCCTTCTTAGAAGCAGAAGTGTGCACCAAGACCATTCATTTCAGGTAGA
[1235] CTCACATTCAGTGCCAAGTGCTCCCATGGGAATAATCAGACGCATATGTTGCGAAAGAGTGAAGG
[1236] GACTTGGACAAAGAGGGGTTTTCCTACAGATGGATGCTCAGTCTTCTACCAAAACATGTTTGGAGG
[1237] CAGAACTATGACCTCCCCTTAAGTCCTAACAATGTATTTTGTGTGTGCAAATCCTGGGATGCCCGTT
[1238] TCACGCTCTGACATAAAGACATGGCACCTCTAGTGAGTGATCAGGAAGATTCCATATGCATTTGGG
[1239] AGCTTCAGGTGCTTGTTAGACACAGTGAGCCATTCAAGGCAAGCACCACCTTTGCTAGTGAGGCC
[1240] AAGAGAGCCTGTGACAATTTGACAATTTGTTCCAGAACCAGTCTGATGCAAGTGCACCTCTAATATA
[1241] TGCCTTACAAACTCCAGAGGCCATATTCAAAACAGGGTCTTCTCAGTGTATGCAAGGGGCTGCAG
[1242] CCCCTCTTCTCTTCCTCCCCAGGTTGAACAATACGGACAGTTTTCACACATATCTACCTGTATAACC
[1243] CTCTGTACCTCTCATAACTGGTCAACGACTGTAACAGGTTACATCAGGTGTTTTTCTACATACTTTTT
[1244] ACACAGATTCTATGCGATTAATGTAATTTAATTCAATGCATCATTTTATTGTACTAGTTCTTAGGCTTGT
[1245] CCTTATTTTTTTCTAAGTGATTGTGGTTTTTCTCGTGGTTTTTATTGTAAAAAATGAAAGGCTGTTGAT
[1246] GCTTATTCTCTGTAACTAAGAATTTTTACCTTTTGGGGGAAAAAAGCATTGCTATGAACTAATGAATT
[1247] GAAACTTCATTTACTCATTGTAAATACACTATTGTGCAAAAAAAGTTTTCACTCAATTGAATTGCTAGT
[1248] GTTAACTGAATTTTGTCTAGACACCATTTCTGTTGATGAAATAAAGACATATCATTATGCATTGTAAAC TGA
[1249] SEQ ID NO. 22 > NM_003107.3 Homo sapiens SRY-box transcription factor 4 (SOX4), mRNA
[1250] GCTCTAAGCTGCAGCAAGAGAAACTGTGTGTGAGGGGAAGAGGCCTGTTTCGCTGTCGGGTCTC
[1251] TAGTTCTTGCACGCTCTTTAAGAGTCTGCACTGGAGGAACTCCTGCCATTACCAGCTCCCTTCTTG
[1252] CAGAAGGGAGGGGGAAACATACATTTATTCATGCCAGTCTGTTGCATGCAGGCTTTTTGGCTTCCTACCTTGCAACAAAATAATTGCACCAACTCCTTAGTGCCGATTCCGCCCACAGAGAGTCCTGGAGC
[1253] CACAGTCTTTTTTGCTTTGCATTGTAGGAGAGGGACTAAGTGCTAGAGACTATGTCGCTTTCCTGA
[1254] GCTACCGAGAGCGCTCGTGAACTGGAATCAACTGCTTCAGGGAAAAAGAAAAAAAAAAAAAAAAG
[1255] ACTTGCCTGGGAGGCCGCGAGAAACTTGCATTGGAAGCTTCAGCAACCAGCATTCGAGAAACTC
[1256] CTCTCTACTTTAGCACGGTCTCCAGACTCAGCCGAGAGACAGCAAACTGCAGCGCGGTGAGAGA
[1257] GCGAGAGAGAGGGAGAGAGAGACTCTCCAGCCTGGGAACTATAACTCCTCTGCGAGAGGCGGA
[1258] GAACTCCTTCCCCAAATCTTTTGGGGACTTTTCTCTCTTTACCCACCTCCGCCCCTGCGAGGAGTT
[1259] GAGGGGCCAGTTCGGCCGCCGCGCGCGTCTTCCCGTTCGGCGTGTGCTTGGCCCGGGGAACC
[1260] GGGAGGGCCCGGCGATCGCGCGGCGGCCGCCGCGAGGGTGTGAGCGCGCGTGGGCGCCCGC
[1261] CGAGCCGAGGCCATGGTGCAGCAAACCAACAATGCCGAGAACACGGAAGCGCTGCTGGCCGGC
[1262] GAGAGCTCGGACTCGGGCGCCGGCCTCGAGCTGGGAATCGCCTCCTCCCCCACGCCCGGCTCC
[1263] ACCGCCTCCACGGGCGGCAAGGCCGACGACCCGAGCTGGTGCAAGACCCCGAGTGGGCACATC
[1264] AAGCGACCCATGAACGCCTTCATGGTGTGGTCGCAGATCGAGCGGCGCAAGATCATGGAGCAGT
[1265] CGCCCGACATGCACAACGCCGAGATCTCCAAGCGGCTGGGCAAACGCTGGAAGCTGCTCAAAGA
[1266] CAGCGACAAGATCCCTTTCATTCGAGAGGCGGAGCGGCTGCGCCTCAAGCACATGGCTGACTAC
[1267] CCCGACTACAAGTACCGGCCCAGGAAGAAGGTGAAGTCCGGCAACGCCAACTCCAGCTCCTCGG
[1268] CCGCCGCCTCCTCCAAGCCGGGGGAGAAGGGAGACAAGGTCGGTGGCAGTGGCGGGGGCGGC
[1269] CATGGGGGCGGCGGCGGCGGCGGGAGCAGCAACGCGGGGGGAGGAGGCGGCGGTGCGAGTG
[1270] GCGGCGGCGCCAACTCCAAACCGGCGCAGAAAAAGAGCTGCGGCTCCAAAGTGGCGGGCGGC
[1271] GCGGGCGGTGGGGTTAGCAAACCGCACGCCAAGCTCATCCTGGCAGGCGGCGGCGGCGGCGG
[1272] GAAAGCAGCGGCTGCCGCCGCCGCCTCCTTCGCCGCCGAACAGGCGGGGGCCGCCGCCCTGC
[1273] TGCCCCTGGGCGCCGCCGCCGACCACCACTCGCTGTACAAGGCGCGGACTCCCAGCGCCTCGG
[1274] CCTCCGCCTCCTCGGCAGCCTCGGCCTCCGCAGCGCTCGCGGCCCCGGGCAAGCACCTGGCG
[1275] GAGAAGAAGGTGAAGCGCGTCTACCTGTTCGGCGGCCTGGGCACGTCGTCGTCGCCCGTGGGC
[1276] GGCGTGGGCGCGGGAGCCGACCCCAGCGACCCCCTGGGCCTGTACGAGGAGGAGGGCGCGG
[1277] GCTGCTCGCCCGACGCGCCCAGCCTGAGCGGCCGCAGCAGCGCCGCCTCGTCCCCCGCCGCC
[1278] GGCCGCTCGCCCGCCGACCACCGCGGCTACGCCAGCCTGCGCGCCGCCTCGCCCGCCCCGTC
[1279] CAGCGCGCCCTCGCACGCGTCCTCCTCGGCCTCGTCCCACTCCTCCTCTTCCTCCTCCTCGGGC
[1280] TCCTCGTCCTCCGACGACGAGTTCGAAGACGACCTGCTCGACCTGAACCCCAGCTCAAACTTTG
[1281] AGAGCATGTCCCTGGGCAGCTTCAGTTCGTCGTCGGCGCTCGACCGGGACCTGGATTTTAACTTC
[1282] GAGCCCGGCTCCGGCTCGCACTTCGAGTTCCCGGACTACTGCACGCCCGAGGTGAGCGAGATG
[1283] ATCTCGGGAGACTGGCTCGAGTCCAGCATCTCCAACCTGGTTTTCACCTACTGAAGGGCGCGCA
[1284] GGCAGGGAGAAGGGCCGGGGGGGGTAGGAGAGGAGAAAAAAAAAGTGAAAAAAAGAAACGAAA
[1285] AGGACAGACGAAGAGTTTAAAGAGAAAAGGGAAAAAAGAAAGAAAAAGTAAGCAGGGCTGGCTT
[1286] CGCCCGCGTTCTCGTCGTCGGATCAAGGAGCGCGGCGGCGTTTTGGACCCGCGCTCCCATCCC
[1287] CCACCTTCCCGGGCCGGGGACCCACTCTGCCCAGCCGGAGGGACGCGGAGGAGGAAGAGGGT
[1288] AGACAGGGGCGACCTGTGATTGTTGTTATTGATGTTGTTGTTGATGGCAAAAAAAAAAAAGCGACT
[1289] TCGAGTTTGCTCCCCTTTGCTTGAAGAGACCCCCTCCCCCTTCCAACGAGCTTCCGGACTTGTCT
[1290] GCACCCCCAGCAAGAAGGCGAGTTAGTTTTCTAGAGACTTGAAGGAGTCTCCCCCTTCCTGCATCACCACCTTGGTTTTGTTTTATTTTGCTTCTTGGTCAAGAAAGGAGGGGAGAACCCAGCGCACCCC
[1291] TCCCCCCCTTTTTTTAAACGCGTGATGAAGACAGAAGGCTCCGGGGTGACGAATTTGGCCGATGG
[1292] CAGATGTTTTGGGGGAACGCCGGGACTGAGAGACTCCACGCAGGCGAATTCCCGTTTGGGGCTT
[1293] TTTTTTCCTCCCTCTTTTCCCCTTGCCCCCTCTGCAGCCGGAGGAGGAGATGTTGAGGGGAGGA
[1294] GGCCAGCCAGTGTGACCGGCGCTAGGAAATGACCCGAGAACCCCGTTGGAAGCGCAGCAGCGG
[1295] GAGCTAGGGGCGGGGGCGGAGGAGGACACGAACTGGAAGGGGGTTCACGGTCAAACTGAAATG
[1296] GATTTGCACGTTGGGGAGCTGGCGGCGGCGGCTGCTGGGCCTCCGCCTTCTTTTCTACGTGAAA
[1297] TCAGTGAGGTGAGACTTCCCAGACCCCGGAGGCGTGGAGGAGAGGAGACTGTTTGATGTGGTAC
[1298] AGGGGCAGTCAGTGGAGGGCGAGTGGTTTCGGAAAAAAAAAAAGAAAAAAAGAAAAAAAAAGAA
[1299] AAAAAAAAGATTTTTTTCTTCTCTTAATCGGAATCGTGATGGTGTTGGATTATTTCAATGGTGGGGTT
[1300] AATATAGCATGTTATCCTGTCTATCTTTTAAAGATTTCTGTATAAGACTGTTGAGCAGTTTTTAAAATA
[1301] GTGTAGGATAATATAAAAAGCAGATAGATGGCGCTATGTTTGATTCCTACAACGAAATTATCACCAGC
[1302] TTTTTTTCATTCTTAACTCTTTAAAGGATTCAAACGCAACTCAAATCTGTGCTGGACTTTAAAAAAAC
[1303] AATTCAGGACCAAATTTTTTCTCAGTGTGTGTGTTTATTCCTTATAGGTGTAAATGAGAAGACGTGTT
[1304] TTTTTCCTTCACCGATGCTCCATCCTCGTATTTCTTTTTCCTTGTAAATGTAATCAGATGCCATTTTAT
[1305] ATGTGGACGTATTTATACTGGCCAAACATATTTTTTCTTTTGTCCCTTTTTTTCTTTCCTTTCTTTTTA
[1306] CTTCCTTTATTTCTTTATTCCTTCCTTTTCCTTTTTTTCTTTTTTTTTTCTTTTTTTTTTTTTTTTTTTGG
[1307] TAGTTGTTGTTACCCACGCCATTTTACGTCTCCTTCACTGAAGGGCTAGAGTTTTAACTTTTAATTTT
[1308] TTATATTTAAATGTAGACTTTTGACACTTTTAAAAAACAAAAAAAGACAAGAGAGATGAAAACGTTTG
[1309] ATTATTTTCTCAGTGTATTTTTGTAAAAAATATATAAAGGGGGTGTTAATCGGTGTAAATCGCTGTTTG
[1310] GATTTCCTGATTTTATAACAGGGCGGCTGGTTAATATCTCACACAGTTTAAAAAATCAGCCCCTAATT
[1311] TCTCCATGTTTACACTTCAATCTGCAGGCTTCTTAAAGTGACAGTATCCCTTAACCTGCCACCAGTG
[1312] TCCACCCTCCGGCCCCCGTCTTGTAAAAAGGGGAGGAGAATTAGCCAAACACTGTAAGCTTTTAA
[1313] GAAAAACAAAGTTTTAAACGAAATACTGCTCTGTCCAGAGGCTTTAAAACTGGTGCAATTACAGCAA
[1314] AAAGGGATTCTGTAGCTTTAACTTGTAAACCACATCTTTTTTGCACTTTTTTTATAAGCAAAAACGTG
[1315] CCGTTTAAACCACTGGATCTATCTAAATGCCGATTTGAGTTCGCGACACTATGTACTGCGTTTTTCA
[1316] TTCTTGTATTTGACTATTTAATCCTTTCTACTTGTCGCTAAATATAATTGTTTTAGTCTTATGGCATGAT
[1317] GATAGCATATGTGTTCAGGTTTATAGCTGTTGTGTTTAAAAATTGAAAAAAGTGGAAAACATCTTTGT
[1318] ACATTTAAGTCTGTATTATAATAAGCAAAAAGATTGTGTGTATGTATGTTTAATATAACATGACAGGCA
[1319] CTAGGACGTCTGCCTTTTTAAGGCAGTTCCGTTAAGGGTTTTTGTTTTTAAACTTTTTTTTGCCATC
[1320] CATCCTGTGCAATATGCCGTGTAGAATATTTGTCTTAAAATTCAAGGCCACAAAAACAATGTTTGGG GGAAAAAAAAGAAAAAATCATGCCAGCTAATCATGTCAAGTTCACTGCCTGTCAGATTGTTGATATA
[1321] TACCTTCTGTAAATAACTTTTTTTGAGAAGGAAATAAAATCAGCTGGAACTGAACCCTAAA
[1322] SEQ ID NO. 23 SOX11 > NM 003108.4 Homo sapiens SRY-box transcription factor 11 ( SOX11 ), mRNA
[1323] GCAGAAGGAGCGCGCGCGCCTGGGAGAGCTCGGGGTCCGGCGCTTGCGGTAGGAGCCACGAGCCGGAGAG
[1324] AGGGGTCCCGGGCTGCCTCGACCGCCGTCGCCACCGCCTCTCCTGTCGCGACCGCAGCTCCCACCGCGCC
[1325] GGCGGCCGTCGTCGCCGAAGCCACCACAGCCGCTGTGTGCAGCCTGGAAGGGGGGGCGGGGGGGAGGGGG
[1326] GGAGCCGCGAAAGCGGGGTGCCGAGGACTTTGCAACTTGCCCAGGAAGGTGGAGGGGTGGGAGGGGGAGGGGGACCTCCGCACGAGACCCAGCGGCCCGGGTTGGAGCGTCCAGCCCTGCAGCGGATCATGGTGCAGCAG GCGGAGAGCTTGGAAGCGGAGAGCAACCTGCCCCGGGAGGCGCTGGACACGGAGGAGGGCGAATTCATGG CTTGCAGCCCGGTGGCCCTGGACGAGAGCGACCCAGACTGGTGCAAGACGGCGTCGGGCCACATCAAGCG GCCGATGAACGCGTTCATGGTATGGTCCAAGATCGAACGCAGGAAGATCATGGAGCAGTCTCCGGACATG CACAACGCCGAGATCTCCAAGAGGCTGGGCAAGCGCTGGAAAATGCTGAAGGACAGCGAGAAGATCCCGT TCATCCGGGAGGCGGAGCGGCTGCGGCTCAAGCACATGGCCGACTACCCCGACTACAAGTACCGGCCCCG GAAAAAGCCCAAAATGGACCCCTCGGCCAAGCCCAGCGCCAGCCAGAGCCCAGAGAAGAGCGCGGCCGGC GGCGGCGGCGGGAGCGCGGGCGGAGGCGCGGGCGGTGCCAAGACCTCCAAGGGCTCCAGCAAGAAATGCG GCAAGCTCAAGGCCCCCGCGGCCGCGGGCGCCAAGGCGGGCGCGGGCAAGGCGGCCCAGTCCGGGGACTA CGGGGGCGCGGGCGACGACTACGTGCTGGGCAGCCTGCGCGTGAGCGGCTCGGGCGGCGGCGGCGCGGGC AAGACGGTCAAGTGCGTGTTTCTGGATGAGGACGACGACGACGACGACGACGACGACGAGCTGCAGCTGC AGATCAAACAGGAGCCGGACGAGGAGGACGAGGAACCACCGCACCAGCAGCTCCTGCAGCCGCCGGGGCA GCAGCCGTCGCAGCTGCTGAGACGCTACAACGTCGCCAAAGTGCCCGCCAGCCCTACGCTGAGCAGCTCG GCGGAGTCCCCCGAGGGAGCGAGCCTCTACGACGAGGTGCGGGCCGGCGCGACCTCGGGCGCCGGGGGCG GCAGCCGCCTCTACTACAGCTTCAAGAACATCACCAAGCAGCACCCGCCGCCGCTCGCGCAGCCCGCGCT GTCGCCCGCGTCCTCGCGCTCGGTGTCCACCTCCTCGTCCAGCAGCAGCGGCAGCAGCAGCGGCAGCAGC GGCGAGGACGCCGACGACCTGATGTTCGACCTGAGCTTGAATTTCTCTCAAAGCGCGCACAGCGCCAGCG AGCAGCAGCTGGGGGGCGGCGCGGCGGCCGGGAACCTGTCCCTGTCGCTGGTGGATAAGGATTTGGATTC GTTCAGCGAGGGCAGCCTGGGCTCCCACTTCGAGTTCCCCGACTACTGCACGCCGGAGCTGAGCGAGATG ATCGCGGGGGACTGGCTGGAGGCGAACTTCTCCGACCTGGTGTTCACATATTGAAAGGCGCCCGCTGCTC GCTCTTTCTCTCGGAGGGTGCAGAGCTGGGTTCCTTGGGAGGAAGTTGTAGTGGTGATGATGATGATGAT AAT GAT GAT GAT GAT GGT GGT GTT GAT GGT GGCGGT GGTAGGGT GGAGGGGAGAGAAGAAGAT GCT GAT G AT AT T GAT AAGAT GT C GT GAG GCAAAGAAAT T GGAAAACAT GAT GAAAAT T T T GGT GGAGT T AAAGT GAA ATGAGTAGTTTTTAAACATTTTTCCTGTCCTTTTTTTGTCCCCCCTCCCTTCCTTTATCGTGTCTCAAGG TAGTTGCATACCTAGTCTGGAGTTGTGATTATTTTCCCAAAAAATGTGTTTTTGTAATTACTATTTCTTT TTCCTGAAATTCGTGATTGCAACAAAGGCAGAGGGGGCGGGGCGGGGGAGGGGAGGTAGGACCCGCTCCG GAAGGCGCTGTTTGAAGCTTGTCGGTCTTTGAAGTCTGGAAGACGTCTGCAGAGGACCCTTTTGGCAGCA CAACTGTTACTCTAGGGAGTTGGTGGAGATATTTTTTTTTCTTAAGAGAACTTAAAGAACTGGTGATTTT TTTTTAACAAAAAAAGGGACCATTGCAACTTTTGTTAATTTAATTTTTTTTTTTTTTTTTTTTTTTTTTT TTTTTGGAGGGAGAAAACTGATGTCTTCTATGCATCCGATTCTTAACAAAACTGCAGGGAGCTTGAAAAA ATGCAGACTGTACAAACGCTTACAAAAAAAAAAACTGTGAACTGACTTAAGATCAGAGTTTACTTTTCAG ATCAAATTGTTTATGGTTTTACAAATGTGATTTCTACTTGCCAACTTTTTTTTTGTAACTTGTTCCCTTA TACCTCCTTGATTGAATACCAGACAGCCTAGACCTCAGTACAAAAGGTATTGAAACATTTTTGATACATA ACAGACCTCAGTCTTTTTTAAAAATTAATATATTTTCAGGCGTATTTTTGTACAGTGAAAAGGGAACATT CTTGCTGTGTTTTTTCAGTAAGACTTTCAGGCACTTCTTCCCTTTTGATTTCTTTTTTTTCCTCTGTTTT TTAGCATGCAAGTATGTTGGTACGTTATGTCCTGGTTTAAAAAGGATTAAAATTTTAAAATAATCCTTGC ATCTAAAGGCCTTGTGGTTTAAAAAAAAAAAGCAAACTTTTTTTTGTACAGCTATAGTAGAGATTTGTTC AATATTTGTAGGTAAAGATTTATTGAAAATGGTGATATAGACCTCAGAGCTGTTATCTTAGTTTAAAGAT TGTATATGTACTGTACTATAGTAGGACTTTATGTATCTCATACGCTGTGATGTGGATGGGGCCCCAGATG GAAGGTTTGAAACTGGATTCTCGATTTTTAGCAAAAAAGAAAAAAAAAAGGCACATAGTTTAAAAAGTTT CTCATTTTGTGCAATATAATCTAAATAAAGTACAGACCATCTGCATATTTTGTAGCAAATGGTGGCAAAG CAGACTCAATGCACTGTCGACATCATTGCCTGTTTTTTTTTTTTTTTTTTTGTGCTGGAAGTCTGTATCT TGACAATTTTAATAAATCAGCTGGAACTGATAGAAACTCGCATCGCCAATAGTCTCTATGGAAGTCAAAC TGGAGGTCCTGTTGTCGCAGAGCATTCGGTGGTGAGGCTGTTGTGTGCGCGGATGAGGGGAGGTGGCAGG AGAGAATTCTACATTTAGGGGGTTAGGCTGAAAAGTGTTCAATTAGCAGGCTGATTTCTTTTTCCTCTTC CGCTAGTTGTGAAAGACAGGGGAAGGGTGTTCTTTCTCTCTGCCCTCCCTTTCCATCTCCAGCTCCCCAT TTCCTTTCTCACCTCCTCCTCCACTCCCTGCCTCTTCTCCCCACCCATCCTGGCGGGCGGGCTGCGCGGA GGCTCGGGAGCTGGCCGGGGAGGGGCGGATGGAGGGGCCTGGGTTGCCAGCTCCCTTGGTCGGGGTCCTG CTCGCTGGGGCTTGTGTGTTCTCTGCGGCGGGCCGCGTCCCCGCTGAGCCTCGCGGTGACAGCCGCCTTT GGCAGCGAGCGCTCGGGGCACTTCTATCCCCGCCTCTCAAAGGGTGGGGACAGCCGTTTCCAGATTTGAA TTTTTTCTGTTCTTTATTTTTAACGCTGCATCTTCGCGTGTGCTCAGAGGTGGTTGTTGGCGGAGAACGC CGCCGCAGTGTTTGACCTCTAGCGGTGAAGGGGGAAGGGGAAGAGGAAAGGAGAGAAGTGGTCGGTGTCT GTTTCCTTCTGTCCCCCGGGGCCGTGGAGCTGTCGGAGGGAAGGAGGACGGTGCGGGGCCGCAGGGGGCG CGGGGCGCGGCGGGACCCAGGCTACGAGCGGGAGGGAGGCGGGAGTCGGGGGAAGACGCGGCAGGCCGGC CGAGGGCACCCCGAGGAACATGGCATGGCCTCTGTGCGATCCGAGTCGCGGTCTCCGGGGTGCCTGGGAG GGCCGAACCACTGGTGAGGGCGTGGGGAGCAGGGGGTGGCAGAGGGCACCCGGGCGGTAGTCCGGGACGC GCAAGGCAGAGCCCTGACGCTCCGGGTCCCCGTGCCTGGCTCTTCTTGCCTCGCCACCGCGTGCTCCTGG GCGCGCCCCGCCGCGGGCCCTTGAGGCGCGCGGAGACACCAGCGCTGGCTTCCCGGGCCCGCGGGCCGGG GAGGGAAGCCTCGGGGCTGCGGGGTGAGAGGAAGAAAGCAAACCCGGGGAGCAGGCGGCTGCCGCACCCG
[1327] CGCACCCCGGGCCCTCACCACGCCCTCCCCGCGCGCCGGCTCAGGGGCTGCCCCGGAATCAGCTCCCCGG GGCCGCCGCAACGAAGGTGGATCCGCATCTTGATTGTTCTCCGGGAGCCTCCTGGGGGCTCCGGCGGCGG CGCGGGCGCGACCCATCCCGCTGGCGCTCCCCGCTCGCTGAACCCCGTTTGCCTGTCCACACCCCCTCGC TCCCCACCATTTTTCCTGACCGGCCTGTGTCCCCGAGCCCTCGCGGCAGGCCCGAGCAGGCGATCGCGGC CGGGCACGCGCGCCCCGGGCTCCCGCCCCCCTTCCGAGCATCCGCCGCCTCTTTTCTGCTGGGTCTGGGA GGAGGGAGGCTGGGAGGCCGCTCGGGGCCCAGCGTGCCAGCCCCGGAGTTCAGCCTCCCGAGCTGCGGCG CCCGCAGCGGAGGAGGTTTTCAGTGGCTGATTGAAACTCACTGCAAAATCACCACGACTCTTTCACCTAC TGAGATGATTGACCGAGGTTTGGCCTTCCATTTTTACTGAGATTTGGCGAGACCGAATGGAAGCGTCCGC ACAGTAACTGCAGCTGCTAGGCCAGAGGGGCCCCGGCGCCCTTCCCGCCTCCCCTCCCGCTTGCTTTTGC CTTACTCGATCTTACCACCACCCCTCCCCCGGCCCCCCGACTGAGAACTCGGGCCTCTCACCCGCCCCCC AGCCTCCCGCTCTGGGCGAGCCTCCTCCCCAGCCCCCACCCCTGGGATGCGAAGCCAGCAAGCTTTTGCT GCAGATGGACAGGTTTCTTTTCTGTGGCTTTTTCCTTTCGATAAACCATCAGATTTCAGTAGTACATTTG GGAAAAGAAGGGGCTGATGGCGTTAACCAGGTTCTCAATATAGAACTGGATTTCTGGAGTTGTTTACCTT ACCCCACACCCCCTCAACATGTAGACTAATGCAGCCATTGGTGGTACATTTATTTTAGCCACGGATAATT GAACCAGCGGTTTACAATTGACACGTGCTCCGTGCTGGTGATTTTATGTGGCAGCCCTCTGCTGCAGTTC CGAAACTTGTTGGCAACGTAAACCCATTGATAGGCTGATCTATGTATTTTGAAAGCCTGAAAACTTGGCA TGTCTTTTCTGTTTTAATCATAGATGAATCTTGGACATTTTCTGTGGTGAGGTGGAAACTTTAAGTAAAT TAGTAAAGTAATAATTTGGCTTCAGAATGGGAAGAGATAGTCAAGATTTTTTTTTTTTAAAGCCATGTGG CCTAACTTGATACAAAAATAAAAGTAATTGTTTGGCAATCTAAATTTAAAACCTGTTAGAACTCAGGACA GGCGCTTCAATGCGCTTTTTAACAATATTTAAGGCTGTTTTGATGAGTGCGTTGTGAGAATCATCTTAAT GAATTCTTTATTGAGTGTCTAAAACATAGTATAATACACATGGTATTCTTGCCACTGGATAGTCTTCAAT AAAAGTTTAATTGATTTTTTTTTGTTGGTCTCTTAAGTAAGTCTTATTTTTAACTAAGCATTGACAGAAT ATCTTAAAATGGTAACCTGGGGGTGGCGGGTGGGTGCTGTGTGCACGGCAGCCTAGCCAGTGGGGATCCT GCTGTTTATTATAAGTAGTTCACAGACTCTGATGGCATTTTGGTAAGCTTTCCATCTTTAAGAAATTGAA CCAGCATTCTCTTATTAATTCTTTAAACTGTGGAAGTAATTTCCAGTTCTTACACTCTGATACGCATCCC TTTTATTTAAAAAAAAAAAAAATGCTAATAAAAGGCAGTGTACTTAAACTGTGCTTTGCAAATATTGTGT ATGTTATGAATGACTACAGACACTGGGCAAATTATTTGTAGAATGATTATCCTTTAGCTAGAGAAAGAAA TCATTACAACTCTTTTGGGCAGAGATGTTTCTTTTTAATGTTAATCAAGGGGAAGTGATTTAAATATGCA TAAATGTAGCAGTCAGGGTGATTTAGTTGCTTTTTTCATGAAAGAAAAAGACTCAAAAGACAAGACTTAT TTTTCTCTTCTGGGACTTGAAATCATAATCATCTGATATTAGTACAGTACAAGAAATTTACATTTGTTTT TTACTTCAGAATTTAAGTGACTTTTGCCCAAGGAATTTGAGAAATAAGGCAAATAAGTTGCTCTATTTTA AAGT AGT CAT T C AAT AT AAAT AT AT TAT AT C AAT CTTAACTTTTTTATTCTCT GAT AT GAT T AAT AAT AT GTATATTCTTACTTTTCTTCTAATGGGCATATGTATCCTTGTGGACACTTTGAGAGAGGTTTTCTTGGAC TCTCCCATTTATAGAATCTTTATACTCTTTTACTGTGTGGTTCCCTGCTTTTAACAGATTTCTGAGGCAA ATATATTTGTGCTTTTTTCTTATGTAGGAAGACCAGCGAAAATAGTTTACTGAGTTGTCAATTTTATCAG TAGATAAGAAACTTTCTTTATTACAGTTTCAGGGAAGATTTTTTCAGGATATTTCTCAGTTATTCTAAGG GCCAAATTTTGTAAAATTTCCATTAGGAATGTCAGTTTCAAATACCCTTTGTATAGCCTAAGCCTGTGAG GATAACAAGAATGAGCCTTACCTATCCTAACACAGGGATTTACAAGTTCCCAAAGTAACCGTCTCCATGT AACTCTTGACATACTTTTCTGAGATTTGGCTTATTTTTATTATTGGTTATTTCTCACTGTTCATTCTATT TGATTTATTCTACAACATCCCCTTTTATTTAATGATCTGGAAAATTCTGCTCTTTGATAACAACTCAGGA TTTTTTTGTTCAGTTTTGGTTTTTGCCCCTTCCTGTGGAGCCTACATTTTCAACCACAATAAAGATGAAA CAAAATTTATGAAACTGAGCTCTCTTCCATTTTACTTACTGCTGGCTTTTTTTTTTTTTTTTTTCCTTGA TTCCTACCATACCTTCGTTTTTTTCATTGTACTTTTTTAACACTACCTATATCCATTAGCTGCCTAATTA GT T T TAT CT GT T C CAT GT GGAT GCAGT GAGT T T AT AAGAGAAT T T CACAAACAAGT AGT T T T T T AGT GAA CTTAAAATAAACAGAATTTTAAAGGAGACCTATTTTTATACTCAATAAAAGCACAAAAGTGCAGAAAGTA TAAAACGGCTTACAAAGGGAGACACAAGCTCATAATGTTCCATGTATAAAAGTAATAACTTTATTGGGTA GAGATATTCTTACAAGATCTAGCACCTCTGCCAGTGCACAGATAGGACTGTTTTAAATGATTTGGGAACT TTTGGTTGCCTGCAGTTGTGAACAGAGAACTTCTCTACAGAGAAACAAACCACTAAAAGCAATATGACCG AGTTGAGATGTGGTTTCCAATGAGCAATTGGTGAATTTAAGCAACCTGGATGTGCATATGTGGAGGCTCC CGTCTCACTGTTTGATCAAACTTCTTTTATGTAGTCACGTAGACTTGATTTTTTCTGCTGTGAAAATGAA AAAATAAAGCAATATGACAAAAAGTTTAAAAATGCATAAAAAATAGGATTTCCTCTAGGCTCCTCGAAGA GATTTTTTTAATATGATGCTTGTCTTACTTTCTTAGACACGTTACATTTCCCCTTCCAAAAAAAAAAAAA AGGACAACTGGAAGTAATTTATCATATAAAGAATTTTGATCAAATAGATATTGACAAAGGGCCCTCTGTC ACATTTTTCTTCATCCAGCTTTTGTTCAAAAACAGTATGCCTCCTCCCTTGAATCACATAGGGAGAAACG TTATACTCCATTCTCATTAATTTCCCATTTTGTCTACTTTTACTCTTGTACATATGTTGTGGGTTTAAGA GTCTTTTGCATTTGTTCTGTGACACCTTTTTTTGAATTGACTGTTTTAAAACGGAGGCCTATTTTTTCCG GTTTGGGACTCCTAGTGGTTATGGCATCCCATAATGCTTCGTGACGGCCACCAGGACAGAACCACCTGAT GTTTTAGAGCAGTTTTCAGCATGACACTGTTAACAAGTGTGTATTTTCCAAGGCCACATGAAACTTACTT TCTTAGCCACTCCAGGTTTGGGAGCAGAAAAGCTGAAAAACCCTTTTGTGTAGAAGTCTGAGTGGTTTGT
[1328] GGGGGGGACCTTTTTTAGAGTTTGCATGCCAGCGCACGGCCTATTGCTGTGAAACAGAGAGAAGGTAAAG CTACCTGAGGCAGTGCGCTGGAGGATGAAGTGTTTGATAGCACTAGGGGGGAAAGAAAATGCATGGCAAA GTTTCGTCTTCTCGTAGACTATCTAGCATGCAGAGTGTAGTGTGTTGAAACGGTGTATGACATTGCTGTA T CAAAGT T GT AAAAT T AAGCAT TAT T TAT T GAAAACT AT GT AT T T T T T T GT AAAAAC CT GAT CACAT AGA GAATATCAGTGGCTTGTGCTTGTGCTTCGATCTAACCAGCTTCTTGACCCACCCCCCCTTGGTATGCAGT GTTAATGCTCAGGGTTGAAAATAGTACACTCCAATGTCTCTTTTGCAAGAGTTTTTCACAGAGGATTACA T T T GT T C AAAAGAC T C TAAT AAAAT T GT GT GAT C AAT C T T C A
[1329] SEQ ID NO. 24 > NM_030625.3 Homo sapiens tet methylcytosine dioxygenase 1 (TET1), transcript variant 2, mRNA
[1330] ACTCCCTGAGGTCTGTCCTGGGGAGACACTGCTGCTCCGGGGGGCTGACCTGGCGGGGAGTGG
[1331] CCGCGCAGTCTGCTCCGGCGCCGCTTTGTGCGCGCAGCCGCTGGCCCCTCTACTCCCGGGTCT
[1332] GCCCCCCGGGACACCCCTCTGCCTCGCCCAAGTCATGCAGCCCTACCTGCCTCTCCACTGTGGA
[1333] CCTTTGGGAACCGACTCCTCACCTCGGGGGCTCGGGCCTTGACTGTGCTGGGAGCCGGTAGGC
[1334] GTCCTCCGCGACCCGCCCGCGCCCCTCGCGCCCGCCGGGGCCCCGGGCTCCAAAGTTGTGGG
[1335] GACCGGCGCGAGTTGGAAAGTTTGCCCGAGGGCTGGTGCAGGCTTGGAGCTGGGGGCCGTGC
[1336] GCTGCCCTGGGAATGTGACCCGGCCAGCGACCAAAACCTTGTGTGACTGAGCTGAAGAGCAGTG
[1337] CATCCAGATTCTCCTCAGAAGTGAGACTTTCCAAAGGACCAATGACTCTGTTTCCTGCGCCCTTTC
[1338] ATTTTTTCCTACTCTGTAGCTATGTCTCGATCCCGCCATGCAAGGCCTTCCAGATTAGTCAGGAAG
[1339] GAAGATGTAAACAAAAAAAAGAAAAACAGCCAACTACGAAAGACAACCAAGGGAGCCAACAAAAA
[1340] TGTGGCATCAGTCAAGACTTTAAGCCCTGGAAAATTAAAGCAATTAATTCAAGAAAGAGATGTTAAG
[1341] AAAAAAACAGAACCTAAACCACCCGTGCCAGTCAGAAGCCTTCTGACAAGAGCTGGAGCAGCAC
[1342] GCATGAATTTGGATAGGACTGAGGTTCTTTTTCAGAACCCAGAGTCCTTAACCTGCAATGGGTTTA
[1343] CAATGGCGCTACGAAGCACCTCTCTTAGCAGGCGACTCTCCCAACCCCCACTGGTCGTAGCCAAA
[1344] TCCAAAAAGGTTCCACTTTCTAAGGGTTTAGAAAAGCAACATGATTGTGATTATAAGATACTCCCTG
[1345] CTTTGGGAGTAAAGCACTCAGAAAATGATTCGGTTCCAATGCAAGACACCCAAGTCCTTCCTGATA
[1346] TAGAGACTCTAATTGGTGTACAAAATCCCTCTTTACTTAAAGGTAAGAGCCAAGAGACAACTCAGTT
[1347] TTGGTCCCAAAGAGTTGAGGATTCCAAGATCAATATCCCTACCCACAGTGGCCCTGCAGCTGAGAT
[1348] CCTTCCTGGGCCACTGGAAGGGACACGCTGTGGTGAAGGACTATTCTCTGAAGAGACATTGAATG
[1349] ATACCAGTGGTTCCCCAAAAATGTTTGCTCAGGACACAGTGTGTGCTCCTTTTCCCCAAAGAGCAA
[1350] CCCCCAAAGTTACCTCTCAAGGAAACCCCAGCATTCAGTTAGAAGAGTTGGGTTCACGAGTAGAAT
[1351] CTCTTAAGTTATCTGATTCTTACCTGGATCCCATTAAAAGTGAACATGATTGCTACCCCACCTCCAGT
[1352] CTTAATAAGGTTATACCTGACTTGAACCTTAGAAACTGCTTGGCTCTTGGTGGGTCTACGTCTCCTA
[1353] CCTCTGTAATAAAATTCCTCTTGGCAGGCTCAAAACAAGCGACCCTTGGTGCTAAACCAGATCATC
[1354] AAGAGGCCTTCGAAGCTACTGCAAATCAACAGGAAGTTTCTGATACCACCTCTTTCCTAGGACAGG
[1355] CCTTTGGTGCTATCCCACATCAATGGGAACTTCCTGGTGCTGACCCAGTTCATGGTGAGGCCCTG
[1356] GGTGAGACCCCAGATCTACCAGAGATTCCTGGTGCTATTCCAGTCCAAGGAGAGGTCTTTGGTAC
[1357] TATTTTAGACCAACAAGAAACTCTTGGTATGAGTGGGAGTGTTGTCCCAGACTTGCCTGTCTTCCT
[1358] TCCTGTTCCTCCAAATCCAATTGCTACCTTTAATGCTCCTTCCAAATGGCCTGAGCCCCAAAGCAC
[1359] TGTCTCATATGGACTTGCAGTCCAGGGTGCTATACAGATTTTGCCTTTGGGCTCAGGACACACTCC
[1360] TCAATCATCATCAAACTCAGAGAAAAATTCATTACCTCCAGTAATGGCTATAAGCAATGTAGAAAATG
[1361] AGAAGCAGGTTCATATAAGCTTCCTGCCAGCTAACACTCAGGGGTTCCCATTAGCCCCTGAGAGA
[1362] GGACTCTTCCATGCTTCACTGGGTATAGCCCAACTCTCTCAGGCTGGTCCTAGCAAATCAGACAGA
[1363] GGGAGCTCCCAGGTCAGTGTAACCAGCACAGTTCATGTTGTCAACACCACAGTGGTGACTATGCC
[1364] AGTGCCAATGGTCAGTACCTCCTCTTCTTCCTATACCACTTTGCTACCGACTTTGGAAAAGAAGAA
[1365] AAGAAAGCGATGTGGGGTCTGTGAACCCTGCCAGCAGAAGACCAACTGTGGTGAATGCACTTACT
[1366] GCAAGAACAGAAAGAACAGCCATCAGATCTGTAAGAAAAGAAAATGTGAGGAGCTGAAAAAGAAA
[1367] CCATCTGTTGTTGTGCCTCTGGAGGTTATAAAGGAAAACAAGAGGCCCCAGAGGGAAAAGAAGCC
[1368] CAAAGTTTTAAAGGCAGATTTTGACAACAAACCAGTAAATGGCCCCAAGTCAGAATCCATGGACTA
[1369] CAGTAGATGTGGTCATGGGGAAGAACAAAAATTGGAATTGAACCCACATACTGTTGAAAATGTAAC
[1370] TAAAAATGAAGACAGCATGACAGGCATCGAGGTGGAGAAGTGGACACAAAACAAGAAATCACAGT
[1371] TAACTGATCACGTGAAAGGAGATTTTAGTGCTAATGTCCCAGAAGCTGAAAAATCGAAAAACTCTG
[1372] AAGTTGACAAGAAACGAACCAAATCTCCAAAATTGTTTGTACAAACCGTAAGAAATGGCATTAAACA
[1373] TGTACACTGTTTACCAGCTGAAACAAATGTTTCATTTAAAAAATTCAATATTGAAGAATTCGGCAAGA
[1374] CATTGGAAAACAATTCTTATAAATTCCTAAAAGACACTGCAAACCATAAAAACGCTATGAGCTCTGTT
[1375] GCTACTGATATGAGTTGTGATCATCTCAAGGGGAGAAGTAACGTTTTAGTATTCCAGCAGCCTGGC
[1376] TTTAACTGCAGTTCCATTCCACATTCTTCACACTCCATCATAAATCATCATGCTAGTATACACAATGAA
[1377] GGTGATCAACCAAAAACTCCTGAGAATATACCAAGTAAAGAACCAAAAGATGGATCTCCCGTTCAA
[1378] CCAAGTCTCTTATCGTTAATGAAAGATAGGAGATTAACATTGGAGCAAGTGGTAGCCATAGAGGCC
[1379] CTGACTCAACTCTCAGAAGCCCCATCAGAGAATTCCTCCCCATCAAAGTCAGAGAAGGATGAGGA
[1380] ATCAGAGCAGAGAACAGCCAGTTTGCTTAATAGCTGCAAAGCTATCCTCTACACTGTAAGAAAAGA
[1381] CCTCCAAGACCCAAACTTACAGGGAGAGCCACCAAAACTTAATCACTGTCCATCTTTGGAAAAACA
[1382] AAGTTCATGCAACACGGTGGTTTTCAATGGGCAAACTACTACCCTTTCCAACTCACATATCAACTCA
[1383] GCTACTAACCAAGCATCCACAAAGTCACATGAATATTCAAAAGTCACAAATTCATTATCTCTTTTTATA
[1384] CCAAAATCAAATTCATCCAAGATTGACACCAATAAAAGTATTGCTCAAGGGATAATTACTCTTGACAA
[1385] TTGTTCCAATGATTTGCATCAGTTGCCACCAAGAAATAATGAAGTGGAGTATTGCAACCAGTTACTG
[1386] GACAGCAGCAAAAAATTGGACTCAGATGATCTATCATGTCAGGATGCAACCCATACCCAAATTGAG
[1387] GAAGATGTTGCAACACAGTTGACACAACTTGCTTCGATAATTAAGATCAATTATATAAAACCAGAGG
[1388] ACAAAAAAGTTGAAAGTACACCAACAAGCCTTGTCACATGTAATGTACAGCAAAAATACAATCAGGA
[1389] GAAGGGCACAATACAACAGAAACCACCTTCAAGTGTACACAATAATCATGGTTCATCATTAACAAAA
[1390] CAAAAGAACCCAACCCAGAAAAAGACAAAATCCACCCCATCAAGAGATCGGCGGAAAAAGAAGCC
[1391] CACAGTTGTAAGTTATCAAGAAAATGATCGGCAGAAGTGGGAAAAGTTGTCCTATATGTATGGCACA
[1392] ATATGCGACATTTGGATAGCATCGAAATTTCAAAATTTTGGGCAATTTTGTCCACATGATTTTCCTAC
[1393] TGTATTTGGGAAAATTTCTTCCTCGACCAAAATATGGAAACCACTGGCTCAAACGAGGTCCATTATG
[1394] CAACCCAAAACAGTATTTCCACCACTCACTCAGATAAAATTACAGAGATATCCTGAATCAGCAGAGG
[1395] AAAAGGTGAAGGTTGAACCATTGGATTCACTCAGCTTATTTCATCTTAAAACGGAATCCAACGGGA
[1396] AGGCATTCACTGATAAAGCTTATAATTCTCAGGTACAGTTAACGGTGAATGCCAATCAGAAAGCCCA
[1397] TCCTTTGACCCAGCCCTCCTCTCCACCTAACCAGTGTGCTAACGTGATGGCAGGCGATGACCAAA
[1398] TACGGTTTCAGCAGGTTGTTAAGGAGCAACTCATGCATCAGAGACTGCCAACATTGCCTGGTATCTCTCATGAAACACCCTTACCGGAGTCAGCACTAACTCTCAGGAATGTAAATGTAGTGTGTTCAGGTG
[1399] GAATTACAGTGGTTTCTACCAAAAGTGAAGAGGAAGTCTGTTCATCCAGTTTTGGAACATCAGAATT
[1400] TTCCACAGTGGACAGTGCACAGAAAAATTTTAATGATTATGCCATGAACTTCTTTACTAACCCTACAA
[1401] AAAACCTAGTGTCTATAACTAAAGATTCTGAACTGCCCACCTGCAGCTGTCTTGATCGAGTTATACA
[1402] AAAAGACAAAGGCCCATATTATACACACCTTGGGGCAGGACCAAGTGTTGCTGCTGTCAGGGAAA
[1403] TCATGGAGAATAGGTATGGTCAAAAAGGAAACGCAATAAGGATAGAAATAGTAGTGTACACCGGTAA
[1404] AGAAGGGAAAAGCTCTCATGGGTGTCCAATTGCTAAGTGGGTTTTAAGAAGAAGCAGTGATGAAG
[1405] AAAAAGTTCTTTGTTTGGTCCGGCAGCGTACAGGCCACCACTGTCCAACTGCTGTGATGGTGGTG
[1406] CTCATCATGGTGTGGGATGGCATCCCTCTTCCAATGGCCGACCGGCTATACACAGAGCTCACAGA
[1407] GAATCTAAAGTCATACAATGGGCACCCTACCGACAGAAGATGCACCCTCAATGAAAATCGTACCTG
[1408] TACATGTCAAGGAATTGATCCAGAGACTTGTGGAGCTTCATTCTCTTTTGGCTGTTCATGGAGTATG
[1409] TACTTTAATGGCTGTAAGTTTGGTAGAAGCCCAAGCCCCAGAAGATTTAGAATTGATCCAAGCTCTC
[1410] CCTTACATGAAAAAAACCTTGAAGATAACTTACAGAGTTTGGCTACACGATTAGCTCCAATTTATAAG
[1411] CAGTATGCTCCAGTAGCTTACCAAAATCAGGTGGAATATGAAAATGTTGCCCGAGAATGTCGGCTT
[1412] GGCAGCAAGGAAGGTCGTCCCTTCTCTGGGGTCACTGCTTGCCTGGACTTCTGTGCTCATCCCC
[1413] ACAGGGACATTCACAACATGAATAATGGAAGCACTGTGGTTTGTACCTTAACTCGAGAAGATAACC
[1414] GCTCTTTGGGTGTTATTCCTCAAGATGAGCAGCTCCATGTGCTACCTCTTTATAAGCTTTCAGACAC
[1415] AGATGAGTTTGGCTCCAAGGAAGGAATGGAAGCCAAGATCAAATCTGGGGCCATCGAGGTCCTG
[1416] GCACCCCGCCGCAAAAAAAGAACGTGTTTCACTCAGCCTGTTCCCCGTTCTGGAAAGAAGAGGG
[1417] CTGCGATGATGACAGAGGTTCTTGCACATAAGATAAGGGCAGTGGAAAAGAAACCTATTCCCCGAA
[1418] TCAAGCGGAAGAATAACTCAACAACAACAAACAACAGTAAGCCTTCGTCACTGCCAACCTTAGGG
[1419] AGTAACACTGAGACCGTGCAACCTGAAGTAAAAAGTGAAACCGAACCCCATTTTATCTTAAAAAGT
[1420] TCAGACAACACTAAAACTTATTCGCTGATGCCATCCGCTCCTCACCCAGTGAAAGAGGCATCTCCA
[1421] GGCTTCTCCTGGTCCCCGAAGACTGCTTCAGCCACACCAGCTCCACTGAAGAATGACGCAACAG
[1422] CCTCATGCGGGTTTTCAGAAAGAAGCAGCACTCCCCACTGTACGATGCCTTCGGGAAGACTCAGT
[1423] GGTGCCAATGCAGCTGCTGCTGATGGCCCTGGCATTTCACAGCTTGGCGAAGTGGCTCCTCTCC
[1424] CCACCCTGTCTGCTCCTGTGATGGAGCCCCTCATTAATTCTGAGCCTTCCACTGGTGTGACTGAG
[1425] CCGCTAACGCCTCATCAGCCAAACCACCAGCCCTCCTTCCTCACCTCTCCTCAAGACCTTGCCTC
[1426] TTCTCCAATGGAAGAAGATGAGCAGCATTCTGAAGCAGATGAGCCTCCATCAGACGAACCCCTATC
[1427] TGATGACCCCCTGTCACCTGCTGAGGAGAAATTGCCCCACATTGATGAGTATTGGTCAGACAGTG
[1428] AGCACATCTTTTTGGATGCAAATATTGGTGGGGTGGCCATCGCACCTGCTCACGGCTCGGTTTTG
[1429] ATTGAGTGTGCCCGGCGAGAGCTGCACGCTACCACTCCTGTTGAGCACCCCAACCGTAATCATCC
[1430] AACCCGCCTCTCCCTTGTCTTTTACCAGCACAAAAACCTAAATAAGCCCCAACATGGTTTTGAACTA
[1431] AACAAGATTAAGTTTGAGGCTAAAGAAGCTAAGAATAAGAAAATGAAGGCCTCAGAGCAAAAAGAC
[1432] CAGGCAGCTAATGAAGGTCCAGAACAGTCCTCTGAAGTAAATGAATTGAACCAAATTCCTTCTCATA
[1433] AAGCATTAACATTAACCCATGACAATGTTGTCACCGTGTCCCCTTATGCTCTCACACACGTTGCGG
[1434] GGCCCTATAACCATTGGGTCTGAAGGCTTTTCTCCCCCTCTTAATGCCTTTGCTAGTGCAGTGTATT
[1435] TTTTCAAGGTGCTGTTAAAAGAAAGTCATGTTGTCGTTTACTATCTTCATCTCACCCATTTCAAGTCT
[1436] GAGGTAAAAAAATAATAATGATAACAAAACGGGGTGGGTATTCTTAACTGTGACTATATTTTGACAATTGGTAGAAGGTGCACATTTTAAGCAAAAATAAAAGTTTTATAGTTTTAAATACATAAAGAAATGTTTCA
[1437] GTTAGGCATTAACCTTGATAGAATCACTCAGTTTGGTGCTTTAAATTAAGTCTGTTTACTATGAAACA
[1438] AGAGTCATTTTTAGAGGATTTTAACAGGTTCATGTTCTATGATGTAAAATCAAGACACACAGTGTTAA
[1439] CTCTACACAGCTTCTGGTGCTTAACCACATCCACACAGTTAAAAATAAGCTGAATTATTATTTCATGG
[1440] TGCCATTGTTCCAACATCTTCCAATCATTGCTAGAAAATTGGCATATTCCTTTGAAATAAACTTATGA
[1441] AATGTTTTCTCTCTTAAAATATTTCTCCTGTGTAAAATAAATCATTGTTGTTAGTAATGGTTGGAGGCT
[1442] GTTCATAAATTGTAAATATATATTTTAAAAGCACTTTCTATTTTTAAAAGTAACTTGAAATAATATAGTAT
[1443] AAGAATCCTATTGTCTATTGTTTGTGCATATTTGCATACAAGAGAAATCATTTATCCTTGCTGTGTAGA
[1444] GTTCCATCTTGTTAACTGCAGTATGTATTCTAATCATGTATATGGTTTGTGTTCTTTTACTGTGTCCTC
[1445] TCACATTCAAGTATTAGCAACTTGCAGTATATAAAATAGTTAGATAATGAGAAGTTGTTAATTATCTCTA
[1446] AAATTGGAATTAGGAAGCATATCACCAATACTGATTAACATTCTCTTTGGAACTAGGTAAGAGTGGT
[1447] CTCTTCTTATTGAACAACCTCAATTTAGTTTCATCCCACCTTTCTCAGTATAATCCATGAGAGGTGTT
[1448] TCCAAAAGGAGATGAGGGAACAGGATAGGTTTCAGAAGAGTCAAATGCTTCTAATGTCTCAAGGTG
[1449] ATAAAATACAAAAACTAAGTAGACAGATATTTGTACTGAAGTCTGATACAGAATTAGAAAAAAAAAATT
[1450] CTTGTTGAAATATTTTGAAAACAAATTCCCTACTATCATCACATGCCTCCCCAACCCCAAGTCAAAAA
[1451] CAAGAGGAATGGTACTACAAACATGGCTTTGTCCATTAAGAGCTAATTCATTTGTTTATCTTAGCATA
[1452] CTAGATTTGGGAAAATGATAACTCATCTTTTCTGATAATTGCCTATGTTCTAGGTAACAGGAAAACAG
[1453] GCATTAAGTTTATTTTAGTCTTCCCATTTTCTTCCTATTACTTTATTGACTCATTTTATTGCAAAACAAA
[1454] AAGGATTACCCAAACAACATGTTTCGAACAAGGAGAATTTTCAATGAAATACTTGATTCTGTTAAAAT
[1455] GCAGAGGTGCTATAACATTCAAAGTGTCAGATTCCTTGGGAGTATGGAAAACCTAATGGTGCTTCT
[1456] CCCTTGGAAATGCCATAGGAAGCCCACAACCGCTAACACTTACAATTTTGGTGCAAAAGCAAACAG
[1457] TTCCAGCAGGCTCTCTAAAGAAAAACTCATTGTAACTTATTAAAATAATATCTGGTGCAAAGTATCTG
[1458] TTTTGAGCTTTTGACTAATCCAAGTAAAGGAATATGAAGGGATTGTAAAAAACAAAATGTCCATTGAT
[1459] AGACCATCGTGTACAAGTAGATTTCTGCTTGTTGAATATGTAAAATAGGGTAATTCATTGACTTGTTT
[1460] TAGTATTTTGTGTGCCTTAGATTTCCGTTTTAAGACATGTATATTTTTGTGAGCCTAAGGTTTCTTATA
[1461] TACATATAAGTATATAAATAAGTGATTGTTTATTGCTTCAGCTGCTTCAACAAGATATTTACTAGTATTA
[1462] GACTATCAGGAATACACCCTTGCGAGATTATGTTTTAGATTTTAGGCCTTAGCTCCCACTAGAAATTA
[1463] TTTCTTCACCAGATTTAATGGATAAAGTTTTATGGCTCTTTATGCATCCACTCATCTACTCATTCTTCG
[1464] AGTCTACACTTATTGAATGCCTGCAAAATCTAAGTATCACTTTTATTTTTCTTTGGATCACCACCTATG
[1465] ACATAGTAAACTTGAAGAATAAAAACTACCCTCAGAAATATTTTTAAAAGAAGTAGCAAATTATCTTCA
[1466] GTATAATCCATGGTAATGTATGCAGTAATTCAAATTGATCTCTCTCTCAATAGGTTTCTTAACAATCTA
[1467] AACTTGAAACATCAATGTTAATTTTTGGAACTATTGGGATTTGTGACGCTTGTTGCAGTTTACCAAAA
[1468] CAAGTATTTGAAAATATATAGTATCAACTGAAATGTTTCCATTCCGTTGTTGTAGTTAACATCATGAAT
[1469] GGACTTCTTAAGCTGATTACCCCACTGTGGGAACCAAATTGGATTCCTACTTTGTTGGACTCTCTTT
[1470] CCTGATTTTAACAATTTACCATCCCATTCTCTGCCCTGTGATTTTTTTTAAAAGCTTATTCAATGTTCT
[1471] GCAGCATTGTGATTGTATGCTGGCTACACTGCTTTTAGAATGCTCTTTCTCATGAAGCAAGGAAATA
[1472] AATTTGTTTGAAATGACATTTTCTCTCATAAAA
[1473] SEQ ID NO. 25
[1474] > NM 024007.5 Homo sapiens EBF transcription factor 1 (EBF1 ), transcript variant 2, mRNA
[1475] CCTGCTTCTTCAAGTGAAGGGTACCTCTACAAAAGGAAACTCCAGCCCCTCCTGTCCTCCACCGGCCTGT GAT CAT T AC AAAAAAAAAAAAAAAAAAG C AAAAAAAAAAAAAAAG C AC C C AAAC C AAAAAT C AAC C AAC C AAACAACCCCCAACAGCCAAGCATACATCTCTAATTTTATTATTTTGGTCTTTTCGTTGGATTTTCCCTT TCTTCTTTTTTTCGGGTTATCGCTCAGTTTTGAGCAGAGGTTTACATTTTTTAAAAATTTGCTTTCCAGC CCGCCTTGATCTTCTAAGTGCGAGTTCATCGTCTGAGAAAAAAAAAAATCTCTGGTTGGCGTTTTTGTTT CTTTTCTTTTCTTTCTTTTCTTTCCTTTTTTTTTTTTTTTAATTTTTTTCAAGGGGGAGGAGATTTTCCA CAAGAAAAGGTTGTTTTCATGTTTGGGATTCAGGAAAGCATCCAACGGAGTGGAAGCAGCATGAAGGAAG AGCCGCTGGGCAGCGGCATGAACGCGGTGCGGACGTGGATGCAGGGCGCCGGGGTGCTGGACGCCAACAC GGCGGCGCAGAGCGGGGTGGGTCTGGCCCGGGCTCACTTTGAGAAGCAGCCGCCTTCCAATCTGCGGAAA TCCAACTTCTTCCACTTCGTCCTGGCCCTCTACGACAGACAGGGCCAGCCCGTGGAGATCGAGAGGACAG CGTTTGTGGGGTTCGTGGAGAAGGAAAAAGAAGCCAACAGCGAAAAGACCAATAACGGAATTCACTACCG GCTTCAGCTTCTCTACAGCAATGGGATAAGGACGGAGCAGGATTTCTACGTGCGCCTCATTGACTCCATG ACAAAACAAGCCATAGTGTATGAAGGCCAAGACAAGAACCCAGAAATGTGCCGAGTCTTGCTCACACATG AGATCATGTGCAGCCGCTGTTGTGACAAGAAAAGCTGTGGCAACCGAAATGAGACTCCCTCAGATCCAGT GATAATTGACAGGTTCTTCTTGAAATTTTTCCTCAAATGTAACCAAAATTGCCTAAAGAATGCGGGAAAC CCACGTGACATGCGGAGATTCCAGGTCGTGGTGTCTACGACAGTCAATGTGGATGGCCATGTCCTGGCAG TCTCTGATAACATGTTTGTCCATAATAATTCCAAGCATGGGCGGAGGGCTCGGAGGCTTGACCCCTCGGA AGGTACGCCCTCTTATCTGGAACATGCTACTCCCTGTATCAAAGCCATCAGCCCGAGTGAAGGATGGACG ACGGGAGGTGCGACTGTGATCATCATAGGGGACAATTTCTTTGATGGGTTACAGGTCATATTCGGTACCA TGCTGGTCTGGAGTGAGTTGATCACTCCTCATGCCATCCGTGTGCAGACCCCTCCTCGGCACATCCCTGG TGTTGTGGAAGTCACACTGTCCTACAAATCTAAGCAGTTCTGCAAAGGAACACCAGGCAGATTCATTTAT ACAGCGCTCAACGAACCCACCATCGATTATGGTTTCCAGAGGTTACAGAAGGTCATTCCTCGGCACCCTG GTGACCCTGAGCGTTTGCCAAAGGAAGTAATACTCAAAAGGGCTGCGGATCTGGTAGAAGCACTGTATGG GATGCCACACAACAACCAGGAAATCATTCTGAAGAGAGCGGCCGACATTGCCGAGGCCCTGTACAGTGTT CCCCGCAACCACAACCAACTCCCGGCCCTTGCTAACACCTCGGTCCACGCAGGGATGATGGGCGTGAATT CGTTCAGTGGACAACTGGCCGTGAATGTCTCCGAGGCATCACAAGCCACCAATCAGGGTTTCACCCGCAA CTCAAGCAGCGTATCACCACACGGGTACGTGCCGAGCACCACTCCCCAGCAGACCAACTATAACTCCGTC ACCACGAGCATGAACGGATACGGCTCTGCCGCAATGTCCAATTTGGGCGGCTCCCCCACCTTCCTCAACG GCTCAGCTGCCAACTCCCCCTATGCCATAGTGCCATCCAGCCCCACCATGGCCTCCTCCACAAGCCTCCC CTCCAACTGCAGCAGCTCCTCGGGCATCTTCTCCTTCTCACCAGCCAACATGGTCTCAGCCGTGAAACAG AAGAGTGCTTTCGCACCAGTCGTCAGACCCCAGACCTCCCCACCTCCCACCTGCACCAGCACCAACGGGA ACAGCCTGCAAGCGATATCTGGCATGATTGTTCCTCCTATGTGAAAGAATTGCCTTGAAGAATTGTATTA ATGAAGAGGTTGGATTCTGCTACAGAGAGTAATCTGATACAAGTCCCAGAGTGGAACTTTTAACTCAGGC CTTTTTAAGAGGAATCACAATAACTGCAGATTTTTAAACAAACAAAATCACCGACCTTGCAAATACTGAA ATTGGAAGAGGGATCTGCAAGTGCAGGGTGTTGGTTAAAGTTGTACCTCCCAAGTATTTGGGGGATATAT TTATTCTGTATTGACAAAAGCAAATCCACTTTTTCTTTTTCTTTTTTTTTTTTAAGCTTAATTCTGCAAT CATTTGTCTTTTATAAACCGTAAAGCTCTATACAAGGGACACTATAAATAAGACTCCATGTTTTAATTTA T GAT GT T T T T AAAGCT GT GT AAAGGAAGAAT GAAGT GGT GAT AT T T ACAAAAAAGT AAAAAAAAAAAAAA AGAAAAAAAGGAAAAAAAAAAAAGCTTGTATGGGACAGAATAGGAATGCCAGTTAGATTTTTTAGAAAAA CTAAGGGTCGGCTTTTGCGCCTTAAAGCATATCAAATGGTAGTTAGCTCAGACAGTGCATTTTCAATATC TAACTTAACATGCCACCCCTTAGCAGTGCAAGCTTATTTATCTCTTTTGTATTGTTGTCTTAAGCAACTG TGTAAATAAATGCAGCCTGGAAAGTTAAAACGCGATGTAAGTGATCACATTTTTCCCTCTACTCGAAAAT CCAGTGCCTCTAGACAGATTGTTAAAACTGCATATTTAAATCTGATCTCATTCTCTCCTTTTACTTAAGT CAGTTTCTTCTGAAGCCGATGGCCTCTCGAGAGCTTGGTGGCACACATACTGTGTGAGAATCTCCTTTGA GACTTCATGGAACAGGGTCCAGGCACAGAATTCCACACTCTGCCCTCCAGTTAACAAGCCAAAACCTCAC GTACGCTCCCCCATTTGCAAGTTTAAAGTTTACTCGTCCTAAATGCAGACTTCATACCTATCTTCCAAAA GTTGATAAAAGCAACGTGGCAGGTATTTTCGATTTTCCCATTCCAGATACTGCCTCTATCAGTCGACCCT TACCATTTGTAACATAATAGATTGAAACAACAGGTTAAGTGCTTTGGAATTAAGAGTTAAAGGGAACCGG GGGTGGAGAAAGGAAAAGAAGGTTGAGACCTCCAAAACATAGTTTTCTGTTCTATGGGAATTTTTGCTCT CATTATCTGGGAAGTGTTCTTAAAAATAAGAATTAATAGCAAAGATGCAGCAAAGCTCTGAGGATGCATT TGCCTGATATTTTTTTCTTTGCTCTTGTGTTTTTGTATGTAGTTATAAATACTGTAGATTTTTTTTTTGT GAT T T T T T GC CAAAGT T GT T GT T CT AT T T AT ACAT T T T AAT GT CT T AAGACAT T T T T T CAAT AT CACAAA AAGATTTTACTGCGTATTTTGCAAAGAAAAAAAGCTCACTACCTTTAGCTTGCACATACTTGCAAAGTTA ATTAAAAGGCTTTTTGTTTTAAAGGGGATTTTGTAAAATATCCATATAAATAATGTATTTATCTTTCGAA TTTGTACATTGCTTTTCCCTTCTTCCTCTTCCTTCCACCCCCAATTTATTTTATTGTGTATGTTTGCTAC GTGAAAAGTGCGTATTTGTTTGGTCACCTACACTTGTATTAGCTGTTTCAATGTGATTTTTAAACATTTC AT T T AT AGT TAT T T T T AGT AT T GT TAT AAAC CAT GCT T CAGT T T T T T T AAT T T C CAC C CAAAAGT CAT T GT CT AT T T T T GT AT TAT T T GT AAGT T AAGAAGT T T T T T C CAAT AT AT GGCAAAAAAAAAAAAAT AGT AGCA TATTATTCTTGTAGTATTTAGTTCAGTAGATTTAAAAAAAAATGTATCCTTTGCTTTGGAAGCTTACAAA ACAACCCTAATGCTGTTTTACTCTATTAATATGCATGGAATCTCTCCCTTTGGAGTGACGCATTTTGTGC ATTAAATTCTAGGGAGAAACTTCATAGAAATCAATGAACATACTTTCTTTCTTAAGTCTGCTTGTATATT TCCTCTGTCTTTCACATAAATATAAACCAGCAGATTGGATGCCTTAACAATGCAAATCATATTCATTTCA CTT GTACATT GTAACT GT GCACCAGAACT GT CAGT CAT CACTAACATT CTAAGAAAAAAGAAAAAGAAAA AAAGAAAAAAAAAAAAAC AAAGAAAT C GAAAAG C AC AAAAGAAC TGTTTTGTTACCT T AAGAC AAT GT AA CTTTTTCTAGTAGAGCAAGAAATCATTTACAACAATGCTGCAACTGTGCATGCCCCCATATGGATTTTGC AATGGTTTTCACTAGGCTGTCAAGAGTGCGATTTTTATGGGTTGGGGTGGGTGGGGGAGGGGAGTTGTGG GAGGGTAGGGGAGGGAGGAAAGCT GTTTTT CAT GGT GAGAAATAATAAT GAT GACTAATAATAATAAAAA AAACTGGAAAATGTAAGCAAGGTGGACGCATTGCTTCTCGGTACTCAGAAAGGTTATCTGAATTTGCGTG GTAAGCGCTGGCCTGAAGATGTACACAAGTTAAAGCCATATTTTATCTGGTGAGCCCCTTAACTGTTTCT GAAGGAATGAACGGTCAGCCGGGAAGGTGTCCGGCTTAGACCTTGACAACAGACACTACCCATCTGTCAG CCATGTGCAGTGGTTAGAACTCTTCTTGAAAGTCCAAAGAGCCTTTAAAATGTGTATAATTTGTGTTTTG TTGCTTCTATTTCTATTGATTAGATGAAAAGACATTCTGGCCCTCTGATCCTCTTTCTTCTCCACAAAAG T T T T AC AAAT AAAAGAT GT T C C C C T AAAT AC AGAAT AT G G C T T T AAGAAGAAAAT GAAAT GAAGAAT T AA ATTAAGATTTCAGTGTTGGGGGAAAAAATACAGCTTCTGGATGACTGGATTGCATAACATTGCCCTGGCC TCACATTGTACTAGGATGCAGCTTAAATGAAGTCATCTCTAAATCTACTAACCTTTCACCTTCTTATCAA AACTTTTTGAATAGACACACACTGTACAGTTCAATTGTTAGAGAACCTAACTACTGTAGAGATTGTTAAA TTTTTTTTTTTTTTTTGCAAAAATTCAAGCTGTAAAAACTTTTCAACTTTCACAATATTTAATTAAAGTT ACTTCCTGTCTGTGA
[1476] SEQ ID NO. 26 > NM_001178139.2 Homo sapiens transcription factor Dp-2 (TFDP2), transcript variant 3, mRNA
[1477] GCGCACTGTGCTGCTCCGCCGCCAAAGCTCGCGCGGGGGAAGCGGGGCTGTAGCTGGGCAGG GAGAGGGCGGACGAAATCGGTAGCGATCTCGGCTGCGGCGCTGCCGCAGCTGCCCGGCCCGC
[1478] GGGGCGCGCCCTGACCCTTCATCTTTGGGCAGGCTCGAGGGCGCGCGCACGGTTGGCGTTCTG GGGCCTCAAACTCCTGGGCCTTGACCGGGCAGGCCGCGTCTCCCCGGGTGTGAGTCCACCGGG ACCCGGCCGCCGCCTAAGCGCGGGCGCCACAGAAGCGGCGGCGCCCGAAGACGCGCTCCTGG
[1479] CTCGGCCCGACAGCCTCGCTTGGCCGCCAGTTCTTCTGCAGCCGAAGGCGGTTGTTCTTTTAAA
[1480] GAATTATTGAAGACGAAGGTTTTTTTCTTTTTATTTTTTTAATGGCTTTACAGAATCTTAAATAGAATAC AGTTTGACATGACGGCAAAAAATGTTGGTTTGACTTCCACAAATGCAGAAGTAAGAGGATTTATAGA
[1481] TCAGAATCTCAGTCCAACAAAAGGCAACATTTCATTTGTTGCATTTCCAGTTTCCAATACCAACTCA CCTACAAAGATTTTACCAAAAACCTTAGGACCAATAAATGTGAATGTTGGACCCCAAATGATTATAAG
[1482] CACACCACAGAGACTAACCAGTTCAGGAAGTGTTCTGATTGGGAGTCCATATACCCCTGCACCAG CAATGGTTACTCAGACACACATAGCAGAAGCTACTGGCTGGGTCCCTGGTGATAGAAAACGGGCT
[1483] AGAAAATTTATAGACTCTGATTTTTCAGAAAGTAAACGAAGCAAAAAAGGAGATAAAAATGGGAAAG GCTTGAGACACTTTTCAATGAAAGTGTGTGAGAAAGTTCAACGAAAAGGTACAACATCGTACAATG
[1484] AAGTCGCTGATGAGCTGGTGTCAGAGTTCACCAATTCAAATAACCATTTGGCTGCTGATTCGGCTT ATGATCAGAAGAACATTAGGCGAAGAGTTTATGATGCTTTAAATGTGCTAATGGCAATGAACATAATT
[1485] TCAAAGGAAAAAAAAGAAATCAAGTGGATTGGCCTGCCTACCAATTCTGCTCAGGAATGTCAGAAT CTGGAGATAGAGAAGCAGAGGCGGATAGAACGGATAAAGCAGAAGCGGGCCCAGCTGCAAGAAC TTCTCCTACAGCAAATCGCTTTCAAAAACCTGGTACAGAGAAATCGACAAAATGAGCAGCAAAACC
[1486] AGGGCCCGCCGGCTCTGAACTCTACCATTCAGCTGCCATTCATAATCATCAATACAAGCAGAAAAA CAGTCATAGATTGCAGCATCTCCAGTGACAAGTTTGAGTATCTTTTCAATTTTGACAACACCTTTGA
[1487] GATCCATGATGACATAGAAGTACTAAAGCGGATGGGAATGTCGTTTGGCCTGGAGTCAGGCAAATG
[1488] CTCTCTGGAGGATCTGAAACTTGCGAAATCCCTGGTGCCAAAGGCTTTAGAAGGTTATATCACAGA
[1489] TATCTCCACAGGACCTTCTTGGTTAAATCAGGGACTACTTCTGAACTCTACCCAATCAGTTTCAAAT
[1490] TTAGACCTGACCACTGGTGCCACCTTACCCCAGTCAAGTGTAAACCAAGGGTTATGCTTGGATGCA
[1491] GAAGTGGCCTTAGCAACTGGGCAGTTCCTGGCCCCAAACAGTCACCAGTCCAGCAGTGCGGCCT
[1492] CTCACTGCTCCGAGTCCCGAGGCGAGACCCCCTGTTCGTTCAATGATGAAGATGAGGAAGATGAT
[1493] GAGGAGGATTCCTCCTCCCCAGAATAAAGACAAGAGAAAGCCTACGTTTCAATATGTGATGCTCAT
[1494] GTGTGTTTGTAGTGTGAGCTCTTGTTTTTGAAATGATTGCTTCAGTCTTTGCCTTTGTTTGCACTGT
[1495] GTGTTCAGTGAAAACTAGAGAAACACAATAAGCAAATCACATGAAGGCTGAGATGATTGAGATGAA
[1496] AGTTAACATAGTGTGAATGAAAGTCTGGCCAACAGAGCAGTAGATGATATAACAAAGAAAGCATGC
[1497] TTTCTGAGGAGATAGTGGGGATAATCCCTGAAGAGTTGGCAGTGTGAGTGCAACTCATTTATCTTC
[1498] TGTGAGGTGGGATTTTTGTGTTCCTCACACCCATGTAATTATTCTTAGAATTGAGATTGCTACACGG
[1499] AGCAGTCCTTGACGATCGTGTTTCTGACGTTTCTCTTCCTTGCCTGGACTGCCTTTGACAAGGCA
[1500] GAAATGAACATGAAAAGTCCCCAGGAGAGGGGAGCTGTGTAGTGAGGGATACTGAGGGCAGTCC
[1501] TGTGGCTGAGGGGCACAGATTGAACTGCTGAACTAGTTGGAGGTCTAGATGAGGTGCTTTACGCA
[1502] TCAGCTGCCTTAGACAGCTTCTAGAAAGGAGCGAGCGCTACTTCTTAAGTACTTAAGTGACATTTA
[1503] GATAATTTATAGTAAAACTGAAATTATTATTAGCCAATGCATTGGTGCATAGAATTTACTAGGGCTACT
[1504] TCTGGAAGCCAAAATAGAATAGCATTTCCATGTGCATTAAATACTTTGCCAGCACTGCCTTTGCCAG
[1505] CATCCTAAATCTGGAGTTTTACAAAGAAGGAAACTGTATCTTTAGGTTAATCAAAGCTATGCATTTCA
[1506] TATAGCTTTTTCATTTAAAACAAGACAAAGAAACAAATTCCTATGACCAAATTGCTTGCCTACAGTTC
[1507] CCTGCAGTAATTGTATGATCTCACCCAGTGTGCAATTTGTGAAAATGAACCAAATGTCATTACTTTT
[1508] GTCTTAAAGAAAAGTCTATTTCAAGAATATGAACAGCAGTGTTTCCTTGTACATGTCACCTTTTTTCA
[1509] CATTTTCATTAATCAGAATGACCTTATTGAGCCTACTCCTGGGGTCAATTGCATTTCAAACTAATCCA
[1510] ATATTTAGTGTTTCACAGAAACACTAGAAAACGTTGAACACTCCTACTGCCTGGATATATGGTAGTG
[1511] CAGTTATGTTGTTTATGGCTCAAGATGTCATTAGAAATACTGCAGTGGTGTATTCACAGCTGCTCCT
[1512] TCTCTGAATGAAAGAGTGTAGGGACACCTGCCACCATGGCCAGACCCTGACTGAATTTCACATTAA
[1513] GGCTTTGGAAAGGAGCAAATAATAATGGGAGAATTAACTCCAAAACTTTGACCTGAATCATGTGGAT
[1514] TTGTCCCAAGATTATGCTAGATGCACCAAGCATGGCCCAAATTGGTTCTTTTTTAAATCCCATGGGG
[1515] GAAGTGCAGGCTCCTTCCTGTGGTGCCTCTTTATAGCCTCACCACCATGCTAACACTGAGCATGGT
[1516] GAGGAGGAGGAAGCTTTGGCTAGCTAAACATGTTTAATAAGGCCATAAAAACTGAGAAAGAAAAAC
[1517] ATTCAACTTTAGCTGAAGCTCCTTTGATACAAAAGTTTCATTCTGTCAGAAATAAGCCATAGTACAGA
[1518] CTCAGAGATAGAGGCAGTTTCTAGAGAACTCGGTCTTATCGTGGGTTCTGGAGCACACCTCTCAG
[1519] ACCAGTCAGGAACACTGGGGAGGTGACAGCAGGTCCCCAGGGGCCTGCAGGGAATCTTTCAGC
[1520] TGCACGGATTGGGATTTCCCTCCAAACCAAACTGTCCTTTAAGGGGCAGCCTCCTCTTTTACTAAC
[1521] TCCACCCTTTCTCATCTCTGGGACCCAGCAGGGACCTGGAGAGGCCAACAGCCACTGCTACCTTT
[1522] GTAGTCTTCAAAATATTGAACTGCAGGTCCCAAGATGCATTTCAGGATTTAAGACAGGTGCACTAAT
[1523] GATAACCATTCCTTCACCAAGTAGCAACATTCTTGCCAGAGTTCTTGGGAAACCTGTTTTTTTCTCT
[1524] ACTCTCCATCTCTGCTGCTCTCATGCTTTAAATTGATAAAATATGGGCTCAAAAAAAGAAAGCCGCC
[1525] AAAGACTCTTATCCTTATTGGTGCCCCATCATTGGCCACCCCAGCCATAGGTGTGTGCTGTTGGTGGGAAATGGTCTCCTTCCTCAGCGTTGTGTTTGGGTTACTGGTGAGGCCAGCTCACAGAGTGACAT
[1526] CATGGTCACCAGTACATGTCGCTGGAGTAAAATCTTGCCTTTAGAAACTAGGTTGAGCTGTTCAGA
[1527] AAGGTCAATTCTCTTCTGTATTCCCCCTCAACATTTATCTGGGTCTAAAGCTCAGCACTGAGTCACA
[1528] ATTTCACACAAGATCAAAGTGAGGCAGTGTTAGGAAACCATGGGCTGGGTGCAGTGCCTCTCGCC
[1529] TGTAATCGTAGCACTTTGGGAGGCCGAGGCGGGCACATTGCTTGAGCTCAGGAGTTCAAGACCA
[1530] GCCTGGGCAACATGACAAAACCCTGTCTCTACAAAAATACAAAAATTAGCTGGGTGTGGTGGGGC
[1531] ATGCCTGTAGTCCTGGCTACTCAAGAGGCTGAGGTGGGAGGATTGCTTGAGCGCAGGAGGCGGA
[1532] GGTTGTAGAGCCAAGATCACACCACTGCACTCCAGCCTGGGTGACAGAGCAAGACCCTGTCTCA
[1533] AAAAAAAAAAAAAAAAAAATGGAAGTTGTGGTCACAATGCCCAGGCTTCTTTGTTATAGTGGCACG
[1534] CTGGGTTACTTGCCACACACAGATCACTCCTCCCAGGGCTGCTGGCACACACTGATTGTGGGGA
[1535] GTTCAAGAGGCCTTTTCCCCTTGAGGGTGTGGCTGTCCCCCTTTCAGGCGTGTGGCGTCATTCAT
[1536] GGAGGAAGTGCTGGCTCTACTTAGCACACGCACAGTGGCACTAGGACCTGCGTGCCTGGCCCTC
[1537] AGTGGGTAGGGCGGTGCTGCCTAGGCACACAGCAGCGCTTACGGGCCCCAGGTGCCTACTAGG
[1538] CTGCCTTCCTCTTCCCCGCTGTCAGTCTGTGTCCTCCACGTGCTTATTTCCTGTGGTGAGAGCAG
[1539] TTGTGGTGTTTGTATACCTTGTGCCTTATGATCAAGGTGGGCCTTGGAGGAGGGCGGGAAAGGAG
[1540] CGACCAACATGGCGGTCCTCCACCCCTCAGCGACACCCACCGCCCGAGAAACTACAGACAATGG
[1541] CCACAAGTTTGGCGTCCTTCAATTTAATTCTTTAAAGAAGTGCTGGGAAGAAAAAGCTATGTGGTTT
[1542] CTACCATTTTAGCAGGATAAAGAGGATAACTCCTTCCATTAGCAAATTTTACAGTTGTTAACAGTACT
[1543] CTGCCATATTTGAAAAATAATGCCAGAGTCAGTCCTTGAAAACAAGGTAGCTCCTATCAGAATTCAA
[1544] ATGGAAATTTTTTTTTTTTTTTTTTTTTTTTTTGAGACTGAGTCTCGCTCTGTTGCCCAGGCTGGAGT
[1545] GCAGTGGTGATCTCGGCTCACTGCAAGCTCCGCCTCCCGGGTTCACGCCATTCTCCTGCCTCAG
[1546] CTGGGACCATGCCTGGCTAATTTTTTTTGTATTTTTAGTAGAGACGGGGTTTCACCGTGTTAGCCAG
[1547] GATGGTCTCGATCTCCTGACCTTATGATCCACCCCTCTCGGCCTCCCAAAGTGCTGGGATTACAG
[1548] GCGTGAGCCACCGCACCCGGCCTCAAATGGAAATATTTCACAGAGGAGTGGTTCAGTTTAGCCCT
[1549] GCAAGACATCTATAACTTGACTGTTTGCTAAACCACAACTCTTTTTGGCTACTTGGGTCATAGAGAC
[1550] AGCAGAGTTGCTCCAAGTATAAATGTGACTTAGGCTCCCTCCAGCACACAGTGTGTATGTTGGAGG
[1551] GAGTGTGGATTAGCAGAGAATGAGAACTACCTCAGCTATTCCTGCCATAACCACACTGAGAGAGG
[1552] GGGGCACGGTGGGGAGCCTATTTAGCTTTTTTTTTTTTTTGAGACGGAGTCTTGCTCTGTCGCCA
[1553] GGCTGGAGTGTAGTGGCGCAATCCCGGCTCACTGCAACCTCTGCCTCCCGGGTTCAAGCGATTC
[1554] TCCTGCCTCAGCCTCCCAAGTAGCTGGGATTATAGGCGCATGCCGCCACACCCGACTAATTTTTTG
[1555] TATTTTTAGTAGAGTCAGGGTTTCACCGTGTTGCCCAGGCTGGTGTCGAACTCCTGACCTCAGGT
[1556] GATCTGCCCACCTCAGCCTCCCGAAGTGCTGGGATTACAGGTGTGAGCCACCGCACCCGGCTCT
[1557] ATTTAGCTTTTTAAAAATTATTTCCTTTCAAGGGCCCTTTAATATCTATCAAGCTCCCTCCCCTAACAA
[1558] AATGGGCTGTCCCTGCCCAACAAGTCTGAAATAGACCTTAAAACTGTGCTGCCTTAGTGGTAAGTA
[1559] AGGGGTGGGGGTTGGACAGTGAATCTTAAGATTTCATCCTTCATTCAGTAAGCATTTGAGTACCTA
[1560] CTGTGAGCAGGCATTGGGGCGGAGCAGCGAGAGCCCTGCCGATGTTGGGTTCTCCTCCTATTGG
[1561] GGAAACTTGATCACAGATGGAACACGTGCAGATTGATTGATGAGTGCTGTGGAGAAAGCAGCAGC
[1562] GTAGCGGGACCGTTTGGGAAAGGCTACTTTGGCTGGGGGTGGCTGGGAAAGGCCCCTCTGGGA
[1563] AAGAGACAGTTTTACTGAGTCAGATGGTGGAAAGACAGATGTCTCTATACTTTCTTAACAAGCCACTCTGTCCCATAACATGCACTTGGAATCTCTCCTAAGTTCCAGAGGCCCCACTGTTCCAGTTTCAAGC
[1564] CTTCATTTTGGAGTCTGTTTGGGAACTTTTAAGACTTCAAAGCAAAGTTAGCTACCAGCAATTTCTG
[1565] TAAACCAAGAGAAGATTGTCACAAAGATTCACTACTTTCCAACTGAATCTATGCAGTAGAAAAATCA
[1566] TTAGAAAATACAAAAATTAGCCGGGCGTGGTGGCACATGCCTGTAGTCCCAGCTACTCGGGAGGC
[1567] TGAGGCAGGAGAATCACTTGAACCCAGGAGGCGGAGGTTGCAGTGAGCCAAGATCCCGCCACTG
[1568] CACTCCAGCCCAGGTGACAGAGCAGGACTCTGTCTCAAAAAAAGAAAAAAGAAAGAAAGAAAAAT
[1569] GATTAGAAATTGAGAACTATTTTACGTGTTTCTAAGTTGTTGGCTACATCAAAGAGATCATCTGTATT
[1570] CTGCATATGGGCTGGCTTTGGTGAAGCTGATGACTGGACTTCTAAGAACCGTTTTCCCAAATGGGT
[1571] TCCCATATTCATGCACCCAAAGCAATGGTCCCCAAGCACTGATGAAAACTAATATGCATTTCCCAAA
[1572] GACCCACACTATGTATCAGGAGCCTGCACCATGCCATTTGAATGACCCTCAGCAATGTGCCTCCCT
[1573] GCCCTCAAATTCCCAGTTGATAACAGTGTTTGATTAAATTTCCACTCAAGCCAAACATGGTTACTAA
[1574] GAAGAGAAAAACCTGATGTTTGCATAATATTTTTTTTCCCCTCGAGATGGAGTCTTGCTCTGTTGCC
[1575] CAGGCTGGAGTGCAGTGGCATGATCTCAGCCACTGCAACCTCTGCCTCCCGGGTTCAAGCGATT
[1576] CTTCTGCCTCAGCCTCCCAAGTAGTTGGGATTACAGACATGTGCCACCACGCCTGGCTAATTTTTG
[1577] TATTTTTAGTAGAGACAGGGTTTCACCATGTTGACCACACTGGTCTTGAACTTCTAACCATGTGATC
[1578] TGCCTGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCTTGAGCCACCACGCCCAGCCTAAGAT
[1579] TTTATGATTAAAAAAAATTCAAGCTCAATACCCACATAAATTATAACGTTTCTCAGGAAGTAGTCCCTT
[1580] AACCAAAACGTCTCTGAGAAGTGATGCTTAGGTAATCTCTGGGATCCGATTTTCCCACATGTCTCA
[1581] CTCCACAGTATGCTAAAGAAGAAAAAGTGAGTGGGCACAACACTTTGACCCTCTGGCTAAGCCCT
[1582] GGGAGTCCCTGACAGGTCCAGAAACTTCTCTGACACCCATTCACCAGGGTGCTGAGATAGGAGA
[1583] AAGTGCTCATTTATAATGTGTATTCTGTGCAGCTGTTCTCAGACAAGACCGGATCTTGTCATCTTAC
[1584] CTTTTGCTTTACAAAAAAGGCCTGTTGAAGTCAATGCTGTCTTGCCCCTTGCTGTTTCAGCAGGTT
[1585] AGACTTTGGTCTTCACTGCTTATAGCTGCATTGGAGGCCAACGTAGCTGATGCTCAGGGTCAGGC
[1586] CTCGCCCCTTCGCCGCAGGTCTCAGGATCGGGGATAACATCGCTCCCACCCTGCTCATTTAGAGA
[1587] TGGGAAACAAGCAAGAGCTTGACTTGCCTCCCATCCCTCAGCCTGTCTGTGGCAGAGCCTGCAC
[1588] CAAAACCCAGAGCTTCTTCCCTCCGTGAGGGCCACGCTGTCACCACAGTCCTCCCAGATGGGTT
[1589] TTGGATTAGCATCAGTCCTGTGTCACCAAGTGCCAAACAGCTGAGGGGTAGAAGTGGGACTCCTT
[1590] TCCCGAGCCCCAGCATGAGGCTGTGGTGTCAGGTTTAGGCCTCTCTCAAGTCAGAAAACCCCGG
[1591] GCTGAGACCTCCACAGACAAGGGCTCCCCATGCTGGCCATTGGCAGGGGCCCAAGAAGTTCAGT
[1592] GACCAACTGGTCCTTCCACACCACACCAGCTGGTGCTGCCCATGTCTGTCGAATCATAACGGAAA
[1593] ATTCCCCAGATCACGTTTGGATTTAAAAACTCATCCCTTGTCGTGCTTCAATGCATGCCATTTGTCA
[1594] CTTACCATACTTCACCATGGCCGAGCTTCATGTCACATGGCCTGGCGATTGTGCTTGTTCACACTG
[1595] GGGCCAGGATTTTCATACTAAAACGTCACTGACAATGGGGCTACTTTTCTCCTGAATAGCTCCTCT
[1596] GGGCTTGTTGCAGTTCTAGTTTTCCCAGTAGTTCCATGGCAGGTTCAACCTCTCAGTGTCCTGAAA
[1597] AATGGAACCACCCACTAACCATATGCACTGGCTGCCCAGGTGGCTGCACTCCGGGGATCACGTTT
[1598] CAGTACTGAGTTCCTTCACGCACTTGGTTCACCACCATCACTCTTGAGTTTTGGACAAAAGAGGTG
[1599] GGTATGCCAGGCACAGTGGCTCACGCCTGTGATCCCAGCACTTTGGGAGGCCGAGGCGGGCGG
[1600] ATCACCTGAGGTCGGGAGTTCGAAACCAGCCTGACCAACATGGAGAAACCCTGTCTCTACTAAAA
[1601] ATATAAAATTAGCCGGGTGTGGTGGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCTCTTGAACCCAGGAGGCAAAAGTTGCAATGAGCTGAGATCGTGCCATTTGCACTCCAG
[1602] CCTGGGCAACAAGAGCGAAATTCCATCTCAAAAAAAAAAGGTGGGTAAAGGGCCATGAGCCCAAA
[1603] CCACTAGGTTGTTCACCTTTTCATCTGAAAATGCTTTACTCTGACTATGTGCTATTGGGTTTTATTTC
[1604] CAGAAAATATAGTTCTCCTTTTTTCTGCATGAAGGATACATCGTGGTGCCACATGCTTTAAGCAATTT
[1605] AAACAAGAGAGATAAGAGGAAAATGCAACCACCACATCTGACTTGCCCAATGTAGACTTTCCTTTAT
[1606] TAGATTGAAGTACACAACCTAATATGATATATTATTTTGTAGTATCTCAGACTTTGTAAATAAATGCCAT
[1607] TATTTTTATATGGAAATTTTATAGAAGAGCTATTTCTGTATACGTAATTACTCCTGATTTTCTGAAATTG
[1608] CTTCTGGTAGATAACAGACAAGTCCTAAGCAGTGTTCCACTAAGGGTGGTTCCAGGCCTGCCTGC
[1609] CGTGGAGTTGACTGGGGGAATTTTACAGTTTTGCGATCCTAGGATGCGTCCCAGACGCTCAGTCA
[1610] GAAGTGCTGGAGGTGGGGCCTGGGAAGCTGTATTTGTAATGAACTCTGGTGTTTTTTGTCCATTAA
[1611] AGTGTATCTTTGTCCATCCTATAAGATTAAAGGAAAGAAAAAGCATCTCAAATGAGTGTAAGTTGTTC
[1612] TTGAGAAAAAAATGTATCAGACTTTTATGATTTGAATGAAATGTATTATAGAAAAAAATAAACACTTTA
[1613] AAATAA
[1614] SEQ ID NO. 27 > NM_007249.5 Homo sapiens KLF transcription factor 12 (KLF12), transcript variant
[1615] 2, mRNA
[1616] ATTCATTTCCTGAGAACTGCAGAGAGCCGCTGAGAGGCTCTGCGTGTGCGTGTGCGCGGGTGAC
[1617] GCCGTGTGTGTGCGAGTGTGTGTGTGTGTGTGCGCGCGCGCGTGTGAGAGAGAGAAAGGGAGA
[1618] GAGAGAGGGGGACTCTGTGTGAGGGAAAGAAAACAATTTCTCCTGCTCTGCAGCTTCTGTTCAG
[1619] GATCAATGTGACTCTAAGAACAAATGGATGAATGAATATCCATATGAAGAGAAAAACAATAAAGAATA
[1620] TCAACACCTTTGAGAACAGAATGTTAATGCTTGATGGGATGCCGGCAGTCAGAGTCAAAACAGAG
[1621] CTTTTGGAATCTGAACAAGGGTCTCCAAACGTCCACAACTATCCCGATATGGAAGCCGTTCCCCTG
[1622] TTGCTAAATAATGTGAAAGGGGAGCCCCCGGAGGACTCGTTATCTGTAGATCACTTCCAAACACAA
[1623] ACTGAGCCAGTGGACTTGTCAATAAACAAAGCCAGGACGTCCCCTACTGCCGTTTCATCCTCCCC
[1624] AGTTTCCATGACAGCATCTGCCTCCTCACCTTCTTCAACTTCAACCTCTTCATCGTCTTCTAGTCGT
[1625] CTAGCCTCATCCCCAACTGTTATCACATCAGTATCTTCAGCGTCATCTTCGTCAACAGTATTAACTC
[1626] CAGGGCCCCTTGTGGCCTCTGCATCTGGTGTTGGAGGCCAGCAGTTTTTGCACATTATCCATCCC
[1627] GTACCGCCTTCAAGTCCCATGAATTTACAGTCTAACAAACTGAGTCATGTTCACCGCATCCCCGTG
[1628] GTGGTACAGTCGGTGCCTGTTGTCTACACAGCTGTAAGGTCACCTGGAAATGTGAACAACACTATT
[1629] GTCGTGCCGCTTTTGGAGGATGGGAGAGGCCATGGCAAAGCACAAATGGACCCCCGAGGCCTAT
[1630] CTCCCAGACAAAGTAAAAGTGACAGTGATGATGATGACCTGCCAAATGTGACCTTAGATAGCGTTA
[1631] ATGAAACTGGATCTACGGCCCTTTCCATAGCCAGAGCAGTACAAGAGGTACATCCGTCCCCAGTAT
[1632] CAAGGGTCCGGGGCAATCGAATGAATAATCAAAAGTTTCCTTGTTCAATTTCACCATTTAGTATTGA
[1633] GAGCACAAGACGCCAGAGACGGTCTGAATCCCCAGACTCCAGAAAACGGCGTATCCACAGATGT
[1634] GATTTTGAGGGATGCAACAAAGTGTACACAAAAAGTTCTCACCTGAAGGCTCACCGGAGGACACA
[1635] TACAGGAGAGAAACCTTACAAGTGTACCTGGGAAGGCTGCACCTGGAAGTTCGCTCGTTCAGATG
[1636] AACTGACGAGGCATTACCGCAAACATACGGGAGTGAAGCCATTCAAGTGCGCGGACTGTGATCGC
[1637] AGCTTTTCCCGGTCAGATCATTTGGCCCTGCACCGCCGGAGGCATATGTTGGTGTGAGGAATGCT
[1638] ACCTGTCCAGCTGAGCGTAAGAGCTGGATCTCTTAGCGGCACCCAATTCAGCAGGGCTGAATCCC
[1639] CTTCACAGTGTTAACACAAAAGGGCATCACCATCCCACGATGTCTGAAACCAGAGCAGGAAAAAG
[1640] AAGGCACACTTCTTTTGGTCTGAAGGTAACCCCCATCATGACTAGACGAGAACCGTCTTTACCCGG
[1641] GCCTGGGAGCTCAGTGACATAAATGCTGAAGAGACAGGCATTGTTTTCCGTGCTGTGTCCTCTGC
[1642] CATTTAAAGATGTTTGTAGCTTGTACATTTTCTGAGCTGTCAGACATTTTGTTATTGATACCTTAAAG
[1643] GTCACCTACCACAAATTGATGGCTAGAGCAAGACCTTTTAAATTTGGATGAATCTCCCATCATCCCA
[1644] TCCCTTAACCCCTTTTTACAGAAATTTTAGTTACAATCTGAGTAAGCTAGAACACACATCCAATCTGT
[1645] TACCAGCAAGCAGCATGAAAGTAGAAACGAAGAAGCAGATGGAGAGGTCCCATTACCTGCAAAGA
[1646] AAGGGCACTCAGGCAGCCCTTTGCAATCGCGATGGCAGCCACTAGATATCACTCTCAACTTGTCAT
[1647] TCTGCCATGCCCTGAAGAAAACCAACATTGAATCTTTCATTTGTTTGTCGTTGATTGTTTTTGTTTTG
[1648] TTTCGATTCTGTTTTGTTCATCTGTTCGAGCAGAGGGGCAGTTGAAGTCTCGTCCTGGTCTCTGCC
[1649] CTGGCATGGACTGGCACAGAGGTGTTCTGTAGTTGAATAGGAAGAGCCTGTCTAAAAAACTACTG
[1650] CCCCACTTCAAATTGCAGTGTTCTGTCACCTAGGCATCATCTCTTCCTGCCCCTAGTATTTGATTAC
[1651] AAGGAACCAGGGGAAAAAAACTTTCTTAGACACACTGGCACCAAGGTAAGAGGTGGGGCTGCCC
[1652] AGGCAAAGTCAGTGAACATGAAAACTCAGACAAAGCAGAGATGGAAATAATGCGCCTCTTGAGGA
[1653] GAAAAGCAATAATGAATAAAAGGACTTTCCTACAATAACTTCACTGAGGACTCACGTTACCAATTTT
[1654] CATACTTACTAAAGGGATTGTAAAAAACACCCCAGCATTTTAGGTGTCTTGGTTCCATTTACAGCAC
[1655] TGAGGTAATCTTTCTGCTGTTTGTTGTCCTGCTTGGTTGAGTACCACAATTAAAGATTATGCTCCCC
[1656] TTTTCTTGTTTGAAAACAGTTATTTGGTGACTAGAAAGGCAAGGGAGGCATAGCCGGGAATTAACT
[1657] CTTCGGTTAATGGGTCAGTTCTCCTTGGAACTGAATCAGTGGAAAGAGAATGCTTCCCATAGAAAG
[1658] CCCGACATGGTGCTAGTTTCCTCTCTTGGAGAGCCAAGGATAAGTGACTCTCCAATAGGTTCTTCT
[1659] ATACCGATTTCATTTTCTAAACTGTATCAGGACCCAGGTGTCCTGCATTGGCATCTGCAGGGATATT
[1660] GAACCCACTCATCCTGTGCAGAGGATGAGAGGAAGGTGTTAGTTCCATCAGCCCCATAAAATTATG
[1661] AACCTTTTTGCAACTAGGAACATATACAGTAAACAAGCAATACATCACCAACGAGCATTCTTTCAGA
[1662] AAAATTACCATATTTTTGTCCCCACCACAAGCTGGGTTTTTTTCCAGCTTTCTGTGGCTGAGGGGC
[1663] TGGTGAGATTTTTTGTTGTTATTGTTGTTGTTGCTAGAATTTTTTATAGCTTAGATATAAAAGGTCTCC
[1664] AACAAAGACCTTTGCAATATATTTTAATTACAAACACTTGATTTTGGGAATTGCACATATTAACCTCAC
[1665] AATATTACTAGCTCATTTTTAAATGTCTGGACATTCTGAAATAATTTCCGGTTACAGAATTACCCTTTT
[1666] TAGGATCATCTTCTAATTCAGATAATCTTATTCTGATGAAGCGAGAACTATGAACGTTGAAACAAGGA
[1667] CAATTTGTGTTGGATGGTATTCAAAAGGAATTTTTTAAAACATTAAGCAACAGTGTAATGATTTTCAG
[1668] GTCAAATTATGGCTTCACAAATATGTGCTCTATATTGTCTGCCAGGTCTCAAAAATTCATCAAGCAAT
[1669] TTCCCTCCAACAAGGGCTGCAGTTCTAGTGATAAATAGCATCTTTAGCTGCACAGTCTACTACTCAT
[1670] CAACCAGTGGGTTTTTTTTAGCACCTGGAAAGTTTTTTTGTACTATATGCAACTCCTACTTCACATTG
[1671] CCTGTGACCATTCAGAATAGAAAAAGGTCTGTTGATGCATGCCAGTGCTGGTTACTAGTCAGTGAC
[1672] AGAGAACACAGAGAGGGACAAACACAGCCATGAACCCCCTGGCACTAGTACCAGCACCTAGTTG
[1673] GCAAGTAGTGGGTGCATCTCTCAAGTGAAGTGTAGATTTGTATTTAGTCCTGCTTGCTCTCATAAAA
[1674] AGAGCCAGTTCTTTTCTCTGCTGAAAGATGTCTTGAGAGTATTACAGGTAGACTTGGTTTTTAGAAT
[1675] TCATAAAACTGACAGGCAGGGGAATCTTCCTGAGTGACAGCTTGGTTTAAATTTAGCACAGAACTA
[1676] GATGAGTTGCACTTTTCTAATAACATAGGATGGATTTGGGGAAGGGAACATTTTCCCTCATCCTCTG
[1677] AAAGTGGAAACCAGACTGAGATGGTAAGTTAACTGATAAAACCTGTCAGCATTCCATCATTTTCCCCTTTTGACGTATCAGTACTTCTAAGAAGGGATCTAAGCACAATTAAGTGAATTGAGTCCCTGGTCTAG
[1678] CCTCAGGAACTGAAACTTCTTTGGGGCTTGTCTTGAGACGTGGCAAATTCTCCTTGGTGAGTTTTC
[1679] TAAAAGTATTTCCCCATGGAAAGGAGAAAGTGGTTTGGGACAGAAAGAAATGGAATGTCTTCAGTC
[1680] ATGGAAGAGCCTCCATTTCATCTCATGTCCATTTCTAGCCTCTTTCAAAAAGCACAGTGCATCATGA
[1681] GCAACAGAAAAGCAGTAGAATCCTAAAGGACATAACAGTTGTTCCGTAACTAGAAGCATTCTTTGAT
[1682] TTTAAATTTGAAGCTGTTCAGTTTGCAGCTGGGGATATGTGCATGGTTGGGAACTTATACACATAGA
[1683] GCCATTAACTACTTAAGCAGCTGCAGTAGACCTGATTTTCTGTTTGCAGTATAGAGATTGATTTCAA
[1684] GGGAGTTACATTATTTGAAAAGTTATGACTTTCAGCCTTTGAGGTTTTAAGAATCCCTTTTCATGGTC
[1685] TGATCTTAAGTTGTTTGAAAAAAGATTCACGCTTCTGCATCCACCTCTGCCCTCATTCTGTCAATTG
[1686] TGTGTGGACTCTGAGAAGCCTGCTTGATAACTTGTCTTAAGTTCTATTAAGGCAGTTAGACTGAGAT
[1687] TTCTAATGACTTCACCATAAAGATTATACTTCTGCCTGGCGTCGTTTCTATAAAACACTATAGGACAT
[1688] TTGTTTTCAAAAGCAGTTGAGTAACAGCAACATAAACCACATTTTTTAAAAAAATGAGCACTTTTCAT
[1689] TCACTTGAAAGCTTAAGTGGGAAAAAGGAAGATGATTGTCAGGGGAAAAACTTACAAAATGCTACA
[1690] GTGTTTACAAATGCCAGTTCCAGGTGATTAGAAAGGCCGTTTTCATTATGGTTCAGATTTGGAATAG
[1691] CTTATGCAAAGATTGTGTTCATTTTTATACAATTCTTTTTAACTTTAAATTGCCATCTGTGTTTTAAACA
[1692] TAATTCTGCACTTTGGAATCAGTTCATTAGAATGATAACATTTATATGGATAAAGATGCAGTATTCCTT
[1693] ATTCTGTACTTGATTTATTATACTTACCAAAGCTGCAACTGAATAAATCTGGTGAGGTGAGGCCTTCA
[1694] AAATGTATTAATACGCCTTTGTTATGTTGTTATGACTGCTTAGAAATGTAGCCATGATGTTGTTCTAAA
[1695] GATGTCTTAACATTTATAGTGAGGATTGACAGAAATTAAGCAGTGTTAAGAATACCAGCATCCATGTT
[1696] ACAGTCTGCGTATAAGGGACTGAATGTGAGGTAACTCTTATGAATCATAATAGGCCCAGAAAGCCTT
[1697] AATATTCATAGTTCATAATCCAGTCTCAGATTTTGCTCTTCAATGTTGCCTGTAAACTTAGCAGGTAA
[1698] ATGTATTCTAGTATAAAACATCATTGACCAAATCTCTTCCTTTAGTTTTTCTGAGGTAGTGCATCCCAT
[1699] TAAAAAAGTCTCTTCAATTAGATTTGGCTTTAGTTTAGAAAGGGGTTTGGTAAGTCATGTCTTCCATA
[1700] TGACATTTCTACTCATCCCCACACTGCCTTCCACTTAACCTGTACAGACAGCCCCAACACATGCAC
[1701] ATGTGTGTACACAACTGTATATGCAGCAGCCAGTGGGCTAACAAATATCAGCAAAGAACTTTTTTAA
[1702] AAAGAATTTGTAATAATCCGTGCTGTCTAGAAATGTGAGTTACTTACCTTATTAGGAAACCGGCTTAT
[1703] AATACTATATATGACTCTGCCTGCATTTTATAGTTAAGAAATGTACATAAAAATTGCTATATTTTCACAG
[1704] TTTCATTATAATGTCTGTTTAGTAACCCATGTCCACTGATACTTTAAATATGCTAATTACTGAGCAATT
[1705] GCAATAGAAATCCAGATTTTCATAAGAAAATGAAATAGAAGGATACTGCATCTTTAAAAAATAGAGTG
[1706] AAGATATTTTACTGTATTCGTAACATATGTGATAGTGGAAAAAGTATTTTCAAACTCACAAATTTTACA
[1707] GAGGTTGTAAATAGTTTGATGAAGTATGTTGGGAAAGAGAGCTTCTAGTTTTCATCACAATAAAAAG
[1708] AAAAAACTTGTTCAGATATGCCTTGTATATCTTACACACAATGAGTGAAATTGCCATGGGAACTCTGT
[1709] CCAACTTTGTCAGAGCATGCTCTTCGTGTTCTGTTCAAAATAGAGTGGCCACTTGTCATGGTTTAG
[1710] CCAGGATGGTTTAAAATATAATGAAGTCATTTTAAGTTGCAGACAACTGATTCCAAACTAGTAATGTC
[1711] TTTTCCTGAAAAGGGCAAAACAGCTGCACAGGATTTTGCTTGTACTAAAGAGGAGCATCTTACAAT
[1712] TGTTCTCTTTTCTCAGTTATCTCCCTCCTCAACAGAGTGTGAACAACCATACAGGTGTTTATTCTTG
[1713] TTTTATTCCAGGGAGACTGCTTTTAGGTATAACTACATGTTGACAAGATTAAGTGCTGTGGATATGG
[1714] CCACGTGTTAAAGGAATCTATACTCGCAATAGGAATAAGCTAATGCCCATTTTCAGAAATAAATTAAA
[1715] TGCTGAAAGTGCCTGTCAGTAAACCTTATGACCAATGAGATATTCCTATACTTTTACACAGCAATAATTCTTAATAAGACTGGGTTTTTTCCTGCACATGTGAACACACACACACATACACACAGAGAGAGTAAA
[1716] TACATACACATAGTAAATCAAATCTGTTCACATGCCCACAAAAAACGCTTTTATAGCTTTCAAATATAC
[1717] CTAATCTTGTTTACATTAACATTTCTTAATTTGATCTTTCTAACTTGCAGAACGTTAAGAACACAAATC
[1718] TGAACATTAAGTTTATCTTCAGTGAACACTATTGCATATGGTAATTATAATTTCCAGATAAAAAGTTGA
[1719] CTGTCATTTGCCCCAAACTTATGAAACAGTATGTATGATTCAAAAAGTTTTGCTCAGTTAAAAACACC
[1720] AATTTATTTGGCGCAAAAGACTGAAGGATATTTGTTTGCTTGTTCATTTTATCCACTCATATCAAACG
[1721] CACAAATTCATCTTTACATTTCTTCATTCCCCTTTCCCCTAATATTTCCTATTATCATCTTAAGAATCAT
[1722] TTTGGAATGAATATTGACAGAATCATTTCTCCCCAAAAAGTCTGTTGAAGTACCACTGACACTTAGT
[1723] AAGCCTAGCCTTTAACCATCTTTGCAGTTAGTCCTAAAAATTACCAGATGCACATTCAGAAGCTCAC
[1724] AGGTTTTTTCCTGTAATTACTGTACTGCTAAAAGTGGAGTCATGGATAGAAATATACAATGAGACTAT
[1725] ATGAATAGACATGAACCCTGGAAATTCTCCAACCCTGCCATCTCAGAGCACAAATTCACCCAAACA
[1726] AGCTACTGAGGCTATCAGTAAAATTATACTCATGGAGAGTCACACATCGGGTAAGGGCAATTTTAAA
[1727] AGTAGGACTGTGATTAAACATTCAGGCTTTAGACTTCCATGATGGACTCAGACCACAGGCCTCAAA
[1728] AAAACATCCACTGTTTTCTCCTCCCAATGTTAGAAAGAAGAAAAGGGAGACGGAAATGTACCAGGA
[1729] TAAGGGGGTAAAATAACCAATTAAGTGTCAAAGGAAAGCTGCTGGGTTCCTTAATCTCACTGAAGT
[1730] CAAGTCTTCTGACTGGGCTTCTTACCATGTGTTGTCTGAAAAAACTAAAGTACCTTGAAAGGTTACA
[1731] CATTCAGCAAACCATGAAGATAATAGCTATTCTTTATTAAACACTGTGTGCCAAGCAATAGACTAGGC
[1732] AATTTTTAGATACGTTACCTGCAACCTGTACAACATTTCTACACTTTATGGATGGGAAACGGAGACAT
[1733] GGGAAGTGTGGCTGAGTTGTTCATGGATGTAGAAATAGTAAACGGCAGAGTAGGAAAGTGAAACC
[1734] GCCTATCTCTGACCTGGAGGTCTGCCTGTATCTTTCCCACTCCACCACACTGCACGTGGGTGTCC
[1735] CGAAACCACCTTCCCAGATTCCTGACTCTCAGTAATTTTATTATGGACAACATGCATGAGTAGTCAT
[1736] CATATTTTTCAAGTGAAATATCGGGACATGATATAACACATGACTTAACAATGGTACTGAATATTTGAA
[1737] ATCAGGCCTTTCCCGGAAAATCATGCATGAAGGATCATTATAAACAAACAATAGCAACCAGTTGTCT
[1738] CCCCGAACTTGTCACTTTTCTCATAAATGTCTGGCCTGGAGCTCCAAAATCATCCAAATACTTAGTA
[1739] GCATTTTAGCCTGAGTACACTTTCTCAGTTCCTCAACTCTTTGTATACCTTTCCACCAATATAGACAT
[1740] TCTAGAATCTGCTTCAGATGCATTTGAAATTTTCACCCCCATGGAACTAGTGATTAATATCAGAGCC
[1741] CACTCTTGCAGTTGGTAATGGGGTGGCAATCAAACGTTCAGATGATGATAAAGGAGAGATAATGGA
[1742] TAATTCTTTTTCAGAGTTCTCACTTAACAGCTCTGTTGTGGAATGTTTTAAATAGTCTTATAAATAATT
[1743] TGTTTATAGTATTGTTGTTAGTTTAATTGAATTTTATGTAAGAAGCTGTCCAACATCAGAGAAATGAAA
[1744] TTCCTCCCACTTTCTGTGTAGAACAAGGTCTCTGACAGTATTGATTCATGGAAGTACTAATGGACTT
[1745] AGAAAACATTAAGAGAATGTCATTTCTCATAGTGTTTCTGTTTCTGAAAATGAATCTCCTGAATTATTA
[1746] TCTTTCTCCCTGTTACTTGGCTGGGGAAAGAGATAGAAGCTGTATAAACAAATTCTCTTCCATGCTC
[1747] AAAGCAAGTGTTCCATGTGCACAACCTGCTGCAGACTGGGGCCCTTCTCAGTTAATTGGGTTTCA
[1748] CAAGCAATAATTTCTCCACAACAAAAACCACAACTTGAAGTGAGTTGAAAAGAGATCAATAGTGGA
[1749] AACAGTCGCCTCAGTACTTTTTCTTTCTGGATTTCATCTCTAGAAATTTGAAGTGTTTGAGACAGAG
[1750] TCCACCCTTTGTGCAAGGCGAGAACCAATGAATGGACTCCTTGTGTGAATTATTGCATCTTCTTCC
[1751] AAAGCAGGTTCATCAAGACTTTCACAGAGATTCATTTTTGTTGAGAAGTAAGGGTTAATAGGAGGAT
[1752] AGAATTTGGATCCAAATCTAGTGATAAAAGTGTCCAAGCAATCAAAAAGTAAGATATTTTAGGGACAT
[1753] ACCAACATCTTCCCTTTCTGCTAATTTCATGCTCCAAAGATATGGCAAAAAAAAAAATCATAAAAAGTGCTTTTGCCCTACTTGTGTTCTAGTTTTCCCATGGCAGAATTTTGTAATTACATCCAGAATATAGTGT
[1754] ATATTTTGTTCCTCAAACTTTATTACATTGGATGGATATTGTTGAACTGGGGCACTGGTGCCTATATT
[1755] CAAGGCTCTTTCCTATCAACGTGTCTGTCCACGATTTGTTGTGTTTAAAGCTTCATTTTGAAAAATC
[1756] ACTGTCCCCCTGTGGGGTAGTGACTGTATTGTTTTGTTCATGTCTATGTGGGACACATTGCATCAC
[1757] ATGGCAAACCAACTCTCTGTGGATGTGAGATAAGTACTTATAAAACCAGCTTGAAAACATCGTCTTA
[1758] TGTATTATGTCATCCTGCATCATAATGCAATTATGTGTATCATAACATGCTCATTTAAAAAAAGAGAAA
[1759] CCAGCAAATTCATGTTTGTCCATAGAAGAATGTACTCAGAACTTTGTGTTGTGAAACGATGAGAACA
[1760] GACCACCTTTAAGATACCCACCTGCCACTTAAAATGACTTAGTTATAATTAGTAGTAGTCTAGACGTT
[1761] GTTCTTGGTGTGTGGGGGTCAATTCTAACGTCATGTTCTTTTGAATAAATCTCTCAGTCATATTTGAA
[1762] AAAAAAATACATGGGAATAAAGAAAAATATCATCTTTGGCCAAATCAAGCAGGCATCTTTTTTCTTTT
[1763] CCTTGACGTTTAGCTCATTATACGTGGTGATTGGATCACGAGATCTGTCCGTGTGAAAATACAGAAA
[1764] CATCCTTTAGTTTACAAAACAGTTATTCTAGGCTTGAAGCCTCTGAACAGCAAATTGAATAGATGGG
[1765] CTGCATCTGATTTGCTTTATGGATGTAATTTTACAAAACACTCTTGGGTCTCTGACCCCAGGGAGTT
[1766] AAGAGTGCCCAGAGGAGGTCCTACACATTAAAGGATAAAGCCCCCCAGTGATGCTGGCAAGCAAA
[1767] TGTGTTGAGTTCTTAAATCTTCATTTGGTTTTCTGTTCAGGATTTTAATTGCAAATGAATTTATTTCTC
[1768] CAGTTTATCTAAAGACCTAATTTCCCAATAGTTTCCTCTGCATTTATATACTCTGTAGTGTTTAGGCAA
[1769] CCCTGTTATAAGTTTATTAATATTATGTAAGTGTTGTTCTTGTATTTATGTATAGTGTATGTATTGTAAAT
[1770] ATACTCAGAGCTTTTTTCCTTTTACTGTAAAATGGTGATTTTTTTGCCCTATGATAATGTAAAGGGAG
[1771] ACCCTCCTAATGAGATTCTCTCAGAGGATGATTATTCCAGTCTATTCTCAGAGATTTAAATGAACAAG
[1772] TGTTATTGTTTTTAATGGTGTCTCAGACATATTCTGTTGGTGCATTGCTTTTCTGTATTCAACTTTCCT
[1773] ATGAATTGAGCTGTGAACTGAAATAGAGTTTAAACCTTTAACTGTATGCATTTGTATAATTATCTGAAT
[1774] GAAGGCATGAAGGTTAAATAAAGCATTTTGTATGGAACAAAA
[1775] SEQ ID NO. 28 > NM_002518.4 Homo sapiens neuronal PAS domain protein 2 (NPAS2), mRNA
[1776] GCGTGCGGAAGAGTTTGCCGCGCGAGCAGCCGGCCTCTCGCAGGAGCCGAGGGACCCGCGCG
[1777] GCTGCGGCCCAGGAGCGGCGGCCGCGGAGCCCGGAGACCCGCAGCCGCGGCGGCGGCGGCG
[1778] GCGGCGGCAGCAGCTAGAGCAGCGCCTCCCGCCGCCGCCCGGGAGGAGCTCGCCGCGCCCGC
[1779] TCGCCGCCTCGTCTCCCAGCGGCGGCGGGAGGCGCGTCTCCCCGGCCCAGTCCGCGCCCGGC
[1780] CCCGCGGGGCCGCTCCGGCCCGCTCCGAGGAAAAACTGCATAGAAAATCTAATGGATGAAGATG
[1781] AGAAAGACAGAGCCAAGAGAGCTTCTCGAAACAAGTCTGAGAAGAAGCGTCGGGACCAGTTCAA
[1782] TGTTCTCATCAAAGAGCTCAGTTCCATGCTCCCTGGCAACACGCGGAAAATGGACAAAACCACCG
[1783] TGTTGGAAAAGGTCATCGGATTTTTGCAGAAACACAATGAAGTCTCAGCGCAAACGGAAATCTGTG
[1784] ACATTCAGCAAGACTGGAAGCCTTCATTCCTCAGTAATGAAGAATTCACCCAGCTGATGTTGGAGG
[1785] CATTAGATGGCTTCATTATCGCAGTGACAACAGACGGCAGCATCATCTATGTCTCTGACAGTATCAC
[1786] GCCTCTCCTTGGGCATTTACCGTCGGATGTCATGGATCAGAATTTGTTAAATTTCCTCCCAGAACAA
[1787] GAACATTCAGAAGTTTATAAAATCCTTTCTTCCCATATGCTTGTGACGGATTCCCCCTCCCCAGAAT
[1788] ACTTAAAATCTGACAGCGATTTAGAGTTTTATTGCCATCTTCTCAGAGGCAGCTTGAACCCAAAGGA
[1789] ATTTCCAACTTATGAATACATAAAATTTGTAGGAAATTTTCGCTCTTACAACAATGTGCCTAGCCCCT
[1790] CCTGTAATGGTTTTGACAACACCCTTTCAAGACCTTGCCGGGTGCCACTAGGAAAGGAGGTTTGCTTCATTGCCACCGTTCGTCTGGCAACACCACAATTCTTAAAGGAAATGTGCATAGTTGACGAACCT
[1791] TTAGAGGAATTCACTTCAAGGCATAGCTTGGAATGGAAATTTTTATTTCTGGATCACAGAGCACCTC
[1792] CAATCATAGGATACCTGCCTTTTGAAGTGCTGGGAACCTCAGGCTATGACTACTACCACATTGATGA
[1793] CCTGGAGCTCCTGGCCAGGTGTCACCAGCACCTGATGCAGTTTGGCAAAGGGAAGTCGTGTTGC
[1794] TACCGGTTTCTGACCAAAGGTCAGCAGTGGATCTGGCTGCAGACTCACTACTACATCACCTACCAT
[1795] CAGTGGAACTCCAAGCCCGAGTTCATCGTGTGCACACACTCGGTGGTCAGTTACGCAGATGTCC
[1796] GGGTGGAAAGGAGGCAGGAGCTGGCTCTGGAAGACCCGCCATCCGAGGCCCTCCACTCCTCAG
[1797] CACTAAAGGACAAGGGCTCAAGCCTGGAACCTCGGCAGCACTTTAACACACTCGACGTGGGTGC
[1798] CTCGGGCCTTAATACCAGTCATTCGCCATCGGCGTCCTCAAGAAGTTCCCACAAATCCTCGCACA
[1799] CAGCCATGTCAGAACCCACCTCCACTCCCACCAAGCTGATGGCAGAGGCCAGCACCCCGGCTTT
[1800] GCCAAGATCAGCCACCCTGCCCCAAGAGTTACCTGTCCCCGGGCTCAGCCAGGCAGCCACCATG
[1801] CCGGCCCCTCTGCCTTCCCCATCGTCCTGCGACCTCACACAGCAGCTCCTGCCTCAGACCGTTC
[1802] TGCAGAGCACGCCCGCTCCCATGGCACAGTTTTCGGCACAGTTCAGCATGTTCCAGACCATCAAA
[1803] GACCAGCTAGAGCAGCGGACGCGGATCCTGCAGGCCAATATCCGGTGGCAACAGGAAGAGCTCC
[1804] ACAAGATCCAGGAGCAGCTCTGCCTGGTCCAGGACTCCAACGTCCAGATGTTCCTGCAGCAGCC
[1805] AGCTGTATCCCTGAGCTTCAGCAGCACCCAGCGACCTGAGGCTCAGCAGCAGCTACAGCAAAGG
[1806] TCAGCTGCAGTGACTCAGCCCCAGCTCGGGGCGGGCCCCCAACTTCCAGGGCAGATCTCCTCT
[1807] GCCCAGGTCACAAGCCAGCACCTGCTCAGAGAATCAAGTGTGATATCAACCCAGGGTCCAAAGC
[1808] CAATGAGAAGCTCACAGCTAATGCAGAGCAGCGGCCGCTCTGGAAGCAGCCTAGTGTCCCCGTT
[1809] CAGCAGCGCCACAGCTGCGCTCCCGCCAAGTCTGAATCTGACCACACCTGCTTCCACCTCCCAG
[1810] GATGCCAGCCAGTGCCAGCCCAGCCCAGACTTCAGCCATGATCGGCAGCTCAGGCTGTTGCTGA
[1811] GCCAGCCCATCCAGCCCATGATGCCCGGGTCCTGTGACGCAAGGCAGCCCTCGGAAGTCAGCA
[1812] GGACGGGACGGCAAGTCAAGTACGCCCAGAGCCAGACCGTGTTTCAAAATCCAGACGCACACCC
[1813] CGCCAACAGCAGCAGCGCCCCGATGCCCGTCCTGCTGATGGGGCAGGCGGTGCTCCACCCCAG
[1814] CTTCCCTGCCTCCCAACCATCGCCCCTGCAGCCTGCACAGGCCCGGCAGCAGCCACCGCAGCA
[1815] CTACCTGCAGGTACAGGCACCAACCTCTTTGCACAGTGAGCAGCAGGACTCGCTACTTCTCTCCA
[1816] CCTACTCACAACAGCCAGGGACCCTGGGCTACCCCCAACCACCCCCAGCACAGCCCCAGCCCCT
[1817] ACGTCCTCCCCGAAGGGTCAGCAGTCTGTCTGAGTCGTCAGGCCTCCAGCAGCCGCCCCGATAA
[1818] TGCCCCGGCACTGAAGTCGGGACACAATCAGCTTTAACCAATGGATGAGGGGGGTGGCCACAGG
[1819] AGATGGGGAGAGGAGTCTGAACTAAACCCCTGGCTTTTGTGCACACTGCATACGTTTCAGAACTC
[1820] CTGGATGGTAACCATCTCTGGAGTGCAGCGCTTGCTGCAGTGGAAATGATCAGGAATACTGACCG
[1821] TGTTTCTCTTGCCTCCGAGGTTCTTGGGCACACTCTATAGCCATACTGGACAGGAACCAGGTGCC
[1822] CCGTGTAGGCATCGTCGGTCGGTTTGCCGTCAGAGATGGCGCATCTCGCTGCATCCCCCGAGAG
[1823] TACACCGGTTGCTCTAGCCACCTGCGGCCCGCCCATCTGCGCTAGCTGGCCTTCACGCTCTTGAT
[1824] CGTCTTTCCTTTGTATTGGAGAAGGACTGGGTCAGAGATCTGTTGGAGAGAGAGAATAAAGAGATT
[1825] ATTTTTCATTATTTTTAAATGGTTGTTTTTGTTTTAATTTGCACAGCTACACAGAGGAAATAACTTAGG
[1826] CACTTTCTGTTTTTTTTAAAAAAATAATAAGGTCTCATGGCTTCATTTAGAGACCACAGTAACAACAG
[1827] CAGCCCACCAATCAGAGAAGCTGGTTGTTATTAACCAAGCTACAGATTCACACTTTCTGGCCTAAA
[1828] CCCTAATGGGATGAGGCTTTTCACCCCAGGCCATGCTGGTGGTGATTTTTTAGCCCCTAAATAAAACACTGGACTATTTCCTGTTTACTTCATTGATTGCAACTACAAAGGTGGACTCAAAGCAAAGCACAAT CATGCCAGCCAACATTCCAGAATTCTGCTGAGAACTCCAAGTCTGTGAGGGGAGAGGTTTTACAA
[1829] GCCAGACAGGCCTGGGGGACTGCAGTCCCCAAGGAGACCCTGCCACATGCTGGCCCTTTGAGT
[1830] GAGAATGCTGCATCTTTCTACATATCTTCATGAGAATACTGAGAATTGGATTTTCCTTTTCAAAATGC
[1831] ACTTTGCTTTTTTTGTATGTTTTGTTATGTTGAGATGTTTCTAAAGAAAAGATTTTATGTAATTATAAGA
[1832] TGAAGCGTAGTGAATTGTACAGCTGTTGTAATAATGACCTATTTCTATATAAAATAAAATTGTATGGCT
[1833] TATGTGTAAATTATTTTGTATCTGAGATACCAGTTCCTTTTCCCAAATATAAAAGTATAAAAGTTTTCTT GTGTTTTTCTGTGAGTGAAAATTTTGTAATAAATTAACAAATTTGTACAATT
[1834] SEQ ID NO. 29 LEF > NM_001130713.3 Homo sapiens lymphoid enhancer binding factor 1 (LEF1), transcript variant 2, mRNA
[1835] GAGAAGCAGTGGGGAGGCGCAGCCGCTCACCTGCGGGGCAGGGCGCGGAGGAGGGACCCGG GCTGCGCGCTCTCGGGCCGAGGAACCAGGACGCGCCCGGAGCCTCGCACGCGGCCAAGCTCG GGGCGTCCCCTCCCCTCGGCCGGGCGAACTCAAGGGGCGCAGCTCTTTGCTTTGACAGAGCTG GCCGGCGGAGGCGTGCAGAGCGGCGAGCCGGCGAGCCAGGCTGAGAAACTCGAGCCGGGAAC AAAGAGGGGTCGGACTGAGTGTGTGTGTCGGCTCGAGCTCCGGGCAGAGGCATTTGGGCCCGA GGCCCCCGCTGTGACTCCCCGAGACTCCGCAGTGCCCTCCACTGCGGAGTCCCCGCGCTTGCC GGCAAAAACTTTA...
Claims
Claims1. A nucleic acid construct comprising a nucleic acid encoding one or more polypeptide selected from MYT1L (SEQ ID NO. 1) or a fragment thereof or a sequence having at least 90% sequence identity thereto, ST18 (SEQ ID NO. 2) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NR3C2 (SEQ ID NO. 3) or a fragment thereof or a sequence having at least 90% sequence identity thereto, POLI2F2 (SEQ ID NO. 4) or a fragment thereof or a sequence having at least 90% sequence identity thereto, PKNOX2 (SEQ ID NO. 5) or a fragment thereof or a sequence having at least 90% sequence identity thereto, BACH2 (SEQ ID NO. 6) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX4 (SEQ I D NO. 7) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX11 (SEQ ID NO. 8) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TET 1 (SEQ I D NO. 9) or a fragment thereof or a sequence having at least 90% sequence identity thereto, EBF1 (SEQ ID NO. 10) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TFDP2 (SEQ ID NO. 11) or a fragment thereof or a sequence having at least 90% sequence identity thereto, KLF12 (SEQ ID NO. 12) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NPAS2 (SEQ ID NO.13) or a fragment thereof or a sequence having at least 90% sequence identity thereto, LEF1 (SEQ I D NO. 14) or a fragment thereof or a sequence having at least 90% sequence identity thereto and / or BCL11B (SEQ ID NO. 15) or a fragment thereof or a sequence having at least 90% sequence identity thereto.
2. The nucleic acid construct according to claim 1, wherein the nucleic acid comprises one or more of SEQ ID NO. 16-30 or a sequence having at least 90% sequence identity thereto.
3. The nucleic acid construct according to claim 1 or 2 further comprising one or more nucleic acid encoding a tumour specific enhancer optionally selected from a sequence as shown in Table 1.
4. A vector or plasmid comprising a nucleic acid construct according to any preceding claim.
5. A vector according to claim 4, wherein said vector is viral vector.
6. A vector according to claim 4, wherein said vector is a recombinant adeno-associated vector (rAAV) or lentivirus.
7. The rAAV according to claim 6, wherein the rAAV is an AAV2, AAV5, AAV8 or AAV9 serotype.
8. The vector according to claim 5, wherein said vector is a recombinant oncolytic virus.
9. The vector of claim 8 wherein the oncolytic virus is a herpes simplex virus, a polio virus, a vaccinia virus, a measles virus, a vesicular stomatitis virus, an orthomyxovirus, a parvovirus, a maraba virus or a coxsackievirus.
10. A rAAV comprising a nucleic acid construct according to any of claims 1 to 3.
11. An oncolytic virus comprising a nucleic acid construct according to any of claims 1 to 3.
12. A host cell comprising a nucleic acid construct according to any of claims 1 to 3, a vector or plasmid according to any of claims 4-9, a rAAV according to claim 10 or an oncolytic virus according to claim 11.
13. A pharmaceutical composition comprising a nucleic acid construct according to any of claims 1 to 3, a vector or plasmid according to any of claims 4-9, a rAAV according to claim10 or an oncolytic virus according to claim 11 and a pharmaceutically accepted carrier.
14. A nucleic acid construct according to any of claims 1 to 3, a vector or plasmid according to any of claims 4-9, a rAAV according to claim 10, an oncolytic virus according to claim11 or a pharmaceutical composition according to claim 13 for use in the treatment or prevention of glioma, in particular glioblastoma.
15. The nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition for use according to claim 14 wherein the tumor is resistant to treatment.
16. The nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition for use according to claim 14 or 15 further comprising administering chemotherapy, radiation, and / or surgical resection to the subject.
17. The nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition for use according to claim 16 wherein the chemotherapy comprises temozolomide, lomustine, etoposide, doxorubicin, cisplatin, paclitaxel, carmustine, ceramide or phosphorylcholine or a derivative or a pharmaceutically acceptable salt of any of the recited compounds or a combination thereof.
18. The nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition for use according to any of claims 14 to 17 comprising administering at least two nucleic acid constructs each nucleic acid construct comprising a different nucleic acid encoding a different protein selected from MYT1L(SEQ ID NO. 1) or a fragment thereof or a sequence having at least 90% sequence identity thereto, ST18 (SEQ ID NO. 2) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NR3C2 (SEQ ID NO. 3) or a fragment thereof or a sequence having at least 90% sequence identity thereto, POLI2F2 (SEQ I D NO. 4) or a fragment thereof or a sequence having at least 90% sequence identity thereto, PKNOX2 (SEQ ID NO. 5) or a fragment thereof or a sequence having at least90% sequence identity thereto, BACH2 (SEQ ID NO. 6) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX4 (SEQ ID NO. 7) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX11 (SEQ I D NO. 8) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TET1 (SEQ ID NO. 9) or a fragment thereof or a sequence having at least 90% sequence identity thereto, EBF1 (SEQ ID NO. 10) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TFDP2 (SEQ ID NO. 11) or a fragment thereof or a sequence having at least 90% sequence identity thereto, KLF12 (SEQ ID NO.12) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NPAS2 (SEQ ID NO. 13) or a fragment thereof or a sequence having at least 90% sequence identity thereto, LEF1 (SEQ ID NO. 14) or a fragment thereof or a sequence having at least 90% sequence identity thereto and / or BCL11B (SEQ ID NO. 15) or a fragment thereof or a sequence having at least 90% sequence identity thereto.
19. The nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition for use according to any of claims 14 to 17, wherein the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition induces neuronal cell like differentiation of glioma cells.
20. The nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition for use according to any of claims 14 to 20, wherein the nucleic acid, vector, plasmid, rAAV, oncoloytic virus or pharmaceutical composition reduces cell plasticity of glioma cells.
21. The nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition for use according to any of claims 14 to 20, wherein the tumor is of the classical (CL) subtype, mesenchymal (MES) subtype or proneuronal (PN) subtype.
22. The nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition for use according to any of claims 14 to 21, wherein the glioblastoma cell is a progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte- 1 ike (AC-like) and mesenchymal-like (MES-like) cell.
23. The nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition for use according to any of claims 14 to 22, wherein the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition is administered by oral, parenteral delivery, intracerebral or intrathecal delivery.
24. The nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition for use according to claim 23, wherein the parenteral delivery is via intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular delivery.
25. The nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition for use according to claim 24, wherein the intrathecal delivery is via lumbar injection, cisternal magna injection or intraparenchymal injection.
26. A nucleic acid construct according to any of claims 1 to 3, a vector or plasmid according to any of claims 4-9, a rAAV according to claim 10, an oncolytic virus according to claim 11 or a pharmaceutical composition according to claim 13 for use in a method to reduce the resistance of glioma, in particular glioblastoma, to treatment with a chemotherapy, induce neuronal cell like differentiation and / or reduce cell plasticity of glioma cells.
27. A combination therapy comprising a nucleic acid construct according to any of claims 1 to 3, a vector or plasmid according to any of claims 4-9, a rAAV according to claim 10, an oncolytic virus according to claim 11 or a pharmaceutical composition according to claim 13 and a chemotherapeutic agent.
28. The combination therapy of claim 27 wherein the chemotherapeutic agent is temozolomide, lomustine, etoposide, doxorubicin, cisplatin, paclitaxel, carmustine, ceramide or phosphorylcholine or a derivative or a pharmaceutically acceptable salt of any of the recited compounds or a combination thereof.
29. A method of treating or preventing glioma, in particular glioblastoma, comprising administering a nucleic acid construct according to any of claims 1 to 3, a vector or plasmid according to any of claims 4-9, a rAAV according to claim 10, an oncolytic virus according to claim 11 or a pharmaceutical composition according to claim 13 to a patient in need thereof.
30. A method of inducing neuronal cell like differentiation and / or reducing cell plasticity of glioma cells comprising administering a nucleic acid construct according to any of claims 1 to 3, a vector or plasmid according to any of claims 4-9, a rAAV according to claim 10, an oncolytic virus according to claim 11 or a pharmaceutical composition according to claim 13 to a patient in need thereof.
31. The method according to claim 29 or 30 wherein the tumor is resistant to treatment.
32. The method according to any of claims 29 to 31 further comprising administering chemotherapy, radiation, and / or surgical resection to the subject.
33. The method according to claim 32 wherein the chemotherapy comprises temozolomide, lomustine, etoposide, doxorubicin, cisplatin, paclitaxel, carmustine, ceramide or phosphorylcholine or a derivative or a pharmaceutically acceptable salt of any of the recited compounds or a combination thereof.
34. The method according to any of claims 29 to 33 comprising administering at least two nucleic acid constructs each nucleic acid construct comprising a different nucleic acidencoding a protein selected fromfrom MYT1L (SEQ ID NO. 1) or a fragment thereof or a sequence having at least 90% sequence identity thereto, ST18 (SEQ ID NO. 2) or a fragment thereof or a sequence having at least 90% sequence identity thereto, NR3C2 (SEQ I D NO. 3) or a fragment thereof or a sequence having at least 90% sequence identity thereto, POLI2F2 (SEQ I D NO. 4) or a fragment thereof or a sequence having at least 90% sequence identity thereto, PKNOX2 (SEQ ID NO. 5) or a fragment thereof or a sequence having at least 90% sequence identity thereto, BACH2 (SEQ ID NO. 6) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX4 (SEQ ID NO.7) or a fragment thereof or a sequence having at least 90% sequence identity thereto, SOX11 (SEQ I D NO. 8) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TET 1 (SEQ ID NO. 9) or a fragment thereof or a sequence having at least 90% sequence identity thereto, EBF1 (SEQ ID NO. 10) or a fragment thereof or a sequence having at least 90% sequence identity thereto, TFDP2 (SEQ ID NO. 11) or a fragment thereof or a sequence having at least 90% sequence identity thereto, KLF12 (SEQ ID NO. 12 or a fragment thereof or a sequence having at least 90% sequence identity thereto, NPAS2 (SEQ ID NO. 13) or a fragment thereof or a sequence having at least 90% sequence identity thereto, LEF1 (SEQ ID NO. 14) or a fragment thereof or a sequence having at least 90% sequence identity thereto and / or BCL11B (SEQ ID NO. 15) or a fragment thereof or a sequence having at least 90% sequence identity thereto..
35. The method according to any of claims 29 to 34 wherein the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition induces neuronal cell like differentiation of glioma cells.
36. The method according to any of claims 29 to 35 wherein the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition reduces cell plasticity of glioma cells.
37. The method according to any of claims 29 to 36 wherein the tumor is of the classical (CL) subtype, mesenchymal (MES) subtype or proneuronal (PN) subtype.
38. The method according to any of claims 29 to 37, wherein the glioblastoma cell is a progenitor-like (NPC-like), oligodendrocyte progenitor-like (OPC-like), astrocyte- 1 ike (AC- like), and mesenchymal-like (MES-like) cell.
39. The method according to any of claims 29 to 38, wherein the nucleic acid, vector, plasmid, rAAV, oncolytic virus or pharmaceutical composition is administered by oral delivery, parenteral delivery, intracerebral or intrathecal delivery.
40. The method according to claim 39, wherein the parenteral delivery is via intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular delivery.
41. The method according to claim 39, wherein the intrathecal delivery is via lumbar injection, cisternal magna injection or intraparenchymal injection.
42. A method of modulating the physiological response of a mammalian glioma cell to a chemotherapeutic agent comprising administering a nucleic acid construct according to any of claims 1 to 3, a vector or plasmid according to any of claims 4-9, a rAAV according to claim 10, an oncolytic virus according to claim 11 or a pharmaceutical composition according to claim 13 to a patient in need thereof.
43. A method of treating a resistant glioma, in particular glioblastoma, comprising administering a nucleic acid construct according to any of claims 1 to 3, a vector or plasmid according to any of claims 4-9, a rAAV according to claim 10, an oncolytic virus according to claim 11 or a pharmaceutical composition according to claim 13 to a patient in need thereof.
44. A kit comprising a nucleic acid construct according to any of claims 1 to 3, a vector or plasmid according to any of claims 4-9, a rAAV according to claim 10, an oncolytic virus according to claim 11 ora pharmaceutical composition according to claim 13 and optionally instructions for use.
45. A nucleic acid construct comprising a nucleic acid as defined in SEQ ID NO. 31 to 126.
